<SEC-DOCUMENT>0001485003-22-000063.txt : 20220509
<SEC-HEADER>0001485003-22-000063.hdr.sgml : 20220509
<ACCEPTANCE-DATETIME>20220509080259
ACCESSION NUMBER:		0001485003-22-000063
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220509
DATE AS OF CHANGE:		20220509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sesen Bio, Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		22903313

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-444-8550

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sesn-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:543d6d7e-07fa-4fa5-80cd-d905631091cd,g:997a4fa6-361a-4df1-8bb3-52045b6d76b9,d:5c128332a7fc4e0a80e34b1a19796bcf--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:sesn="http://www.sesenbio.com/20220331" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sesn-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF81LTEtMS0xLTU3MzM3_30560051-477c-436d-acfb-bff8c2cc8e50">0001485003</ix:nonNumeric><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF82LTEtMS0xLTU3MzM3_32260a81-7ccb-4b89-aec3-f64f884c36d2">Dec 31</ix:nonNumeric><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF83LTEtMS0xLTU3MzM3_05630365-f4e3-41a0-adbc-eb82bf7fe5d4">2022</ix:nonNumeric><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF84LTEtMS0xLTU3MzM3_bcf8896d-52ff-4790-8ce0-ccde3ac0936a">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF85LTEtMS0xLTU3MzM3_063a7201-046f-47bb-a281-9dc3fb4b2019">false</ix:nonNumeric><ix:nonNumeric contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_70e2c78d-7000-4550-b39c-7708486d9514">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_a608af25-a8c3-43f1-bc13-bde655007b13">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_257c3c35-2b5f-4801-99d1-da6db072ebc5">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_870e15ab-96b9-4644-93c8-e07c8cee8f3a">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i63ed6a9dc3044356a0f726f687f89398_D20220101-20220331" name="sesn:ShortTermLeaseRenewalFrequency" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIxOTkwMjMyNTg5Mjc_107f62f1-7e63-49b3-8b18-5cce5a5aebdc">P6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sesn-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i9f552561389a4839b36955112414fddd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46864a0b0016476db02fe2e892f7cef9_I20220502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ic3755f1139a340e2aade3663223c8a7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i96da131196c74762907df64863032814_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f5e4b9652d54e48bf163ae90b636a83_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d598df14f84452c822d3e02466c66f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d886c640194c0d8d40f577a2a0b6da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65986cee0a3f47009f98ae26909e02e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bac899f8bff4b5e9d817fa13e651697_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60cbef6e654745cab2772e4470b57220_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ff0b9c4e94c4ca3a50ec38953dae726_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i267ce3744e594084b9adfe990aefe17d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58548d968bce4d57bbbe97f3173fb16e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i801045fc75394914ab13f94f4ae1394c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796d93487eea41168a8fd66cd90a9db5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40fdf0d0baf64a318b375f964064207f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d094d92f884dde854fd3394639b343_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4281f2dc82c64e5bb1ce03499a4ff7dd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia555869172ce4586aed28eb0644e17ac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfb59442f67a48209291031525080d0a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df4db59df3a4f2399c13d3d26fe2f52_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i782b68f9a89b4a16b35f3ff27087d813_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bf8f5ab2d074836afe2b1f523782410_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3c390b4af0e43b2adb9e8e3c0f80caf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9953df45c3614a88bc336cd3adb59e66_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i715f0bbb32d5441aa4c0c66f57e6c15d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idef1618b7f7c4e21924ddb1ad216ec24_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e13475210e4b4f8ded7256b0146395_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>sesn:patient</xbrli:measure></xbrli:unit><xbrli:context id="i526122db789843438c15c6cda35ca7ab_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1fa9d23ba6f4ab397f6863c899cf391_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ie71051d6bdb042b9928263d050777b62_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5b79e7ff7b4732bf5be21b5ad315e9_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia625ecc78ac34ee7b9442e7a9ee6c67a_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c08d92ea854817ba5024a4619ebab0_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie49f04215a514ffe9aa6de52f1449f7c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29f65186d8914b83bd3a931c1ddffbf4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i487e4fc22ff1483fa5e2a198b37ce024_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf2fde291dcd4b11bca4ee8ea8be676d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i352f1de5f4fc4ed299dd42039cae4d43_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9d6eda91c70472c97ddbcf9c27c26f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id856a959b0b243f28a91153f115b51d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f177ca553484a5e816e4b2458b15d0e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff3dd7d4481c4276acefb438f635d714_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37b667a740a14082b1c2a0e4fe06a99d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777b729b56654272aecb76e84444d371_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85202389e8f434f9771578dd1116186_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6c8bda95fde40828c577fa8789c7d3f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied03436a4b954153b51104e07b4308a5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c3d72e64284343ad41bbaabad2492e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0974e9a0eac4b9a943068d81c400af6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4024043b56ba43449e39178a89ef2a79_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5defd37759486088c2d5f6a80ad271_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc5ad7341ef44d9e9d0eb812d5d6aef7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i789b708b5a4b4f70b35c83d05b643756_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5b7224c57a349dd8417b26074fdfea8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37a86bcaa5c4400cb485d8e214b15877_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4d8a28b63694dfca536772f228dfd1f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc771771ec447eb817fedfab04c5064_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:GermanVATRecoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i545bec4894b147faa5be77fb0ce698df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf4f0077ab4d4c7e8baa7cd8eac1afbe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5e2f3183009408a88a2121d2f8320de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9c6211a35774d058c2bc34135cd81cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if355f8cd711e40d5bb37354a4ec90cf0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie489efabccd5453ea2dc7e35706cfaa4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>sesn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ie0b15da2342248bf8f341d5a7661bd17_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="term"><xbrli:measure>sesn:term</xbrli:measure></xbrli:unit><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i63ed6a9dc3044356a0f726f687f89398_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91a2e679410d42bd9b578b3fe11ffb4a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i145c98efedcf4ac6a1bfc225996ebb5c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4acdf8e88564bcaa3b39b640d7f099c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4321e3e7de5f473b81eb3f2fa81fef3b_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38aea9f975c9437f993d25b7b3b9c71b_D20210601-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb19d0c9c4ac4cbaac6c9dc28bf97c0d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc89768d7574532a2c9411e20751c77_D20211129-20211129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-29</xbrli:startDate><xbrli:endDate>2021-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad87f2a2e4064dc8babf6447190779eb_I20210502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6a9e7c16bd84278a88fc26407cd68a3_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21ceb143543841428ec32f3c9ad4b0be_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe2c623a9d74a7389296573a31bbb22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3baa1439c0ea43b08add2b44f358ac2d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i221c8962daf4444ebdf4d3c88988461b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2d1253ec7414a4b84ffbe87119b85ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id98165c78fa5475887c60e7c8804b011_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3c6c33e3cf54dd39de56d11701d0b0d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefba41b22eac4b17ad9b01a9511c163f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b8342820bc14fc18dcb66343e2d8dbb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60a06969725e4e0ab841501477d0ab94_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46b9def9cc834e2e9e98a5e65496e75a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>sesn:vote</xbrli:measure></xbrli:unit><xbrli:context id="i874e45992d94489c9ad7c98356670dc7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i900115e3ca494438812c53a74b2e941e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie30fcbf9c3814ac980e2533dce4fe035_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3779abea087b4610ba82ce1d85f2bf38_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2a61ca27ef84e2aa470147840bc3c1a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c1ad53e5a84769a79cc00b7c419f7f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1240079e3b784011876aef3004337651_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2db8bf0bb154bf988c5f0cbf4b1fa14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8543e2bf0407481b92ce314c98882350_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b139b5a19b94648b6cd590da2967190_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0474ce6e41f94994aa5166f4cef01656_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i491f8467f7ff45e0b2e6a6bc33dabb45_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad7b614817843a2a51daa8dac6c033e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1d7e92567284313b0215206d23cf138_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01f86ee5c7454a6daf1539b8ff9154fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1313b2a80c4a2b83d39bef2b31ff64_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6df6b49ba9af4253b2980614997544b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i442503d958e94d1cbb92a12c86bfd18d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638a4bc304a64fefb58743f705706eb0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb83446dcd9e42a599260539ad1c0a9e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08791a0aa370455b99495a2b83190943_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b72109f9aee425d9d32f4948d46c658_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i548c92c454ec4c8eb027f6787d1601b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064bfd4b1d304882b1628ad085b4d6c2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf9f504438bf430eb66685abf363cbbe_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id04c1f00c3054d6b86cd44222571b020_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ed5641b729d40d8b652fe7425a4c97c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3414053ba29c49659486e8317c638717_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3644a46ac29a4cd088a111e400276c65_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i843c8c42b555485e8edc0700629c070d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5fbafca91d4ed69dc2dd77e2c3d271_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i070828932cb7457b89a6d3428bf1884e_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe0c595a8b504aa7a9ef9bed9511cc7c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20b6c5aa1a3c4bd7a85f15364a9f7f10_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8efee58bbcb34cfeb4ebe4d44af7870e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a6dde7845004b009c604f58eaaf54f2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14ad2e265e504b4994de4346a904f964_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i721f2630aa8b4812af090675ea7c48d8_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6795b392d224fd1958f431310a8ae42_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c321cdcae954377903223a91776e0b9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41cd54bf6e0e43108d5f54b38cbcef44_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9646b6fad074c349a38b736d334913f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if180a9498a6049c5a369d46136508c69_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i249eb5f45f4a43748f1453177c588a6e_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia471201fe4bb48848f6167bcc65d599c_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015e286376344c4c9c156e22c95fc9c6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i703ddc2f34bf4c4fa0e273c40ad0142a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1448067179f94f71ac95826b8ee7a5be_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i719e07b970f244aaa770a65739f6261a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75fda142f1274858950bc952a648690a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id114c77b04144d64bd3d93db2ab92506_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e725e6c9c5548a683b0b8cd8414f46c_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f0b7b32437649f0aebbff5cb5bced22_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i3170a4ca7c3743c2af7e5c8f5d4ce2eb_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8e64e250af4d2790f73c3b79426507_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5115ded926c24cf0bfdc639b4a65bd23_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35b7f963b9974be1ae64730ce05532ff_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f201162abfc475998aec36e2f378832_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860ae1f5203e49a08aa91ee83b20d7e5_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aab7a1843994c3488d3876ab37fc007_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i425a0d3a4bfe493e99909f42b47fd556_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide74b46daaba4a75ad68f84d5d0e6d0f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i607e98a9eea546b983ca1b261b279229_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aafe20143b64883857f4e9a3c846e12_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05e3cb0224f54a1186393da585df2efb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fba7eecc61a49598234f514785e0ed0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ec8b79f17f43bbb84e97e2a5566d46_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b8e98722c2b4cdcb4f305e34994b6e7_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id273db7a5ed6402bb34a4872220bae45_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17d89aea5f0f47dd8400fd0b5a4720c9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf94f20a694b4bee91f6f6da52f38a93_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:IL6Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>sesn:period</xbrli:measure></xbrli:unit><xbrli:context id="iea001a4f9d934dd893e45269b2383c74_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f42a6de33704f62b0e682799149f0e6_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8142289592f45f3ac1543eeb3a12d8f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd649cc1b18c474ab1dd1aab76c6641c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ad5cac1a07b45d6ba8c79753fc4a02f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc08ea5943f404b9c1b2ff1c2b62d78_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6380f74d6af34e0fb121780679e0dbd2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab08b81f1a8468bb8602311426ac4a5_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0473c8cf700e465d8a8670d029d1a17e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d312124644e44a09f50ee532d536d0c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2dcc52dfed04067b81a5e2472d5ab8d_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2f514ca47c14bcc81a567e7c8ee3089_D20210805-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ea7fa933c347ecacaa65b87757c77a_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35e5be36237a414280b903dade9eff3e_D20210830-20210830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>sesn:position</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjQx_f3b09cd7-0830-4cc6-82aa-c0c0c41e96ce">10-Q</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6MWM4MDkxODZiNDg0NDkyYzhhNGZiNDc4ZDM1OWQyZmIvdGFibGVyYW5nZToxYzgwOTE4NmI0ODQ0OTJjOGE0ZmI0NzhkMzU5ZDJmYl8wLTAtMS0xLTU3MzM3_a0c595e7-462c-4fea-8b86-bd66ebdecc2b">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8xMzE_5064e231-3bf3-48ad-8e26-5f7392406969">March&#160;31, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6MWRkMzU0MzY3ODJjNGRlZGIwNmJkZjgxMzcxZTdkMzkvdGFibGVyYW5nZToxZGQzNTQzNjc4MmM0ZGVkYjA2YmRmODEzNzFlN2QzOV8wLTAtMS0xLTU3MzM3_9a29744d-e8a1-4cd8-8fae-daa6e8663fc3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from _____ to _____</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjQy_6788a3e2-510d-4da5-90e3-668ba7db8983">001-36296</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjM1_19b43f81-b448-4a2e-b36e-2b7555908b39">Sesen Bio, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6MzQwNjllZTA2NDkwNDZjODgzMjAxODFlNGI2YmNhZWQvdGFibGVyYW5nZTozNDA2OWVlMDY0OTA0NmM4ODMyMDE4MWU0YjZiY2FlZF8wLTAtMS0xLTU3MzM3_9664fafa-56d5-423a-a67f-f585744c63fb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6MzQwNjllZTA2NDkwNDZjODgzMjAxODFlNGI2YmNhZWQvdGFibGVyYW5nZTozNDA2OWVlMDY0OTA0NmM4ODMyMDE4MWU0YjZiY2FlZF8wLTEtMS0xLTU3MzM3_ab40d022-45f7-4788-b738-e67e85e4b464">26-2025616</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTAtMS0xLTU3MzM3L3RleHRyZWdpb246MmMzZGVhOWMzNGVmNGMzZGE0MGNlY2E1OWI4NTg3ZjJfNA_eb686097-96b1-4686-a506-440550cf8e13">245 First Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTAtMS0xLTU3MzM3L3RleHRyZWdpb246MmMzZGVhOWMzNGVmNGMzZGE0MGNlY2E1OWI4NTg3ZjJfOA_221867cc-fa47-4ff0-9718-a6f3b16ae3fd">Suite 1800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTAtMS0xLTU3MzM3L3RleHRyZWdpb246MmMzZGVhOWMzNGVmNGMzZGE0MGNlY2E1OWI4NTg3ZjJfMTE_d46954b2-8474-41b9-b2ff-55b2ce9ab33d">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTAtMS0xLTU3MzM3L3RleHRyZWdpb246MmMzZGVhOWMzNGVmNGMzZGE0MGNlY2E1OWI4NTg3ZjJfMTU_f2319aa3-c773-4e95-8e62-8fca946f17fc">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTEtMS0xLTU3MzM3_f0747755-fe50-4fe1-bcc3-e042fcb32b39">02142</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zNTE_b423a194-a35a-4bb0-8966-5fa225459e34">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjM2_e2a63062-a65e-4037-aa5f-1709c395019e">444-8550</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.472%"><tr><td style="width:1.0%"></td><td style="width:43.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6NjBlNmY0NzVlNWRhNGRlZThmNmM1N2RmYmJkNjU1YjEvdGFibGVyYW5nZTo2MGU2ZjQ3NWU1ZGE0ZGVlOGY2YzU3ZGZiYmQ2NTViMV8xLTAtMS0xLTU3MzM3_80d75d9e-0278-4529-8366-9bd64904aaa9">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6NjBlNmY0NzVlNWRhNGRlZThmNmM1N2RmYmJkNjU1YjEvdGFibGVyYW5nZTo2MGU2ZjQ3NWU1ZGE0ZGVlOGY2YzU3ZGZiYmQ2NTViMV8xLTEtMS0xLTU3MzM3_b2c13e4d-4453-4844-97d0-a5bc4483bc17">SESN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6NjBlNmY0NzVlNWRhNGRlZThmNmM1N2RmYmJkNjU1YjEvdGFibGVyYW5nZTo2MGU2ZjQ3NWU1ZGE0ZGVlOGY2YzU3ZGZiYmQ2NTViMV8xLTItMS0xLTU3MzM3_2e898299-f31f-450f-95d4-f750e7514ea1">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjM3_702de1b0-be9a-4d19-bf2d-4e7ba8bd1f6b">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjM4_85f4d6ff-554f-496e-a40a-13fb32ca45a9">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer," &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.166%"><tr><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6YTU0MjBlMTI3YjNlNGMzM2EzYmU0OGYwN2FlZmVhM2IvdGFibGVyYW5nZTphNTQyMGUxMjdiM2U0YzMzYTNiZTQ4ZjA3YWVmZWEzYl8wLTAtMS0xLTU3MzM3_6e109ac7-fc0f-4723-bc5b-a7dd3602cd08">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6YTU0MjBlMTI3YjNlNGMzM2EzYmU0OGYwN2FlZmVhM2IvdGFibGVyYW5nZTphNTQyMGUxMjdiM2U0YzMzYTNiZTQ4ZjA3YWVmZWEzYl8wLTMtMS0xLTU3MzM3_fd217707-c97e-4356-ae11-ae12a3982fbb">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6YTU0MjBlMTI3YjNlNGMzM2EzYmU0OGYwN2FlZmVhM2IvdGFibGVyYW5nZTphNTQyMGUxMjdiM2U0YzMzYTNiZTQ4ZjA3YWVmZWEzYl8xLTMtMS0xLTU3MzM3_c1e43590-31a5-44a6-82e0-09cd17f28e38">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjQ1_1676b058-d548-467f-96b8-3b366e16e1b2">&#9746;</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="i46864a0b0016476db02fe2e892f7cef9_I20220502" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8yNzg1_f7a33ee3-7707-4bcf-978e-ffcdb418d366">199,463,645</ix:nonFraction> shares of the registrant's common stock outstanding as of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May&#160;2, 2022</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Report on Form 10-Q for the Quarterly Period Ended March&#160;31, 2022</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I - FINANCIAL INFORMATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_64">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March&#160;31, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_67">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three Months Ended March&#160;31, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_70">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the Three Months Ended </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;31, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_76">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_79">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_1230">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_1358">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_1353">39</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II - OTHER INFORMATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_1371">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_19">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities and Use of Proceeds.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_1445">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_1445">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_1445">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_1445">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_49">42</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i5c128332a7fc4e0a80e34b1a19796bcf_55">SIGNATURES</a></span></div></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1203"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_64"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except share and per share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNC0xLTEtMS01NzMzNw_e5548060-e185-4db9-bc19-524b5d64dc96">169,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNC0zLTEtMS01NzMzNw_70e96ce7-6f8c-4846-9740-b3085b23a50f">162,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNS0xLTEtMS01NzMzNw_62a63408-e3d3-4ca3-90c2-3e51a9d46cbe">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNS0zLTEtMS01NzMzNw_86a05a23-8d72-4ad3-8a3f-7dc1ed695887">21,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNi0xLTEtMS01NzMzNw_cd2dfe2b-7158-4a8f-bc04-0795e5ea2ebe">1,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNi0zLTEtMS01NzMzNw_2640699c-fed4-4013-92c1-890645267a6b">3,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNy0xLTEtMS01NzMzNw_18fe83cf-93d1-4a61-a415-3952de31563c">8,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNy0zLTEtMS01NzMzNw_876b46ad-8af7-436d-a62e-3853ce287720">18,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfOS0xLTEtMS01NzMzNw_13675fec-4a90-4d34-bf3a-032bf76f1475">180,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfOS0zLTEtMS01NzMzNw_c346bb85-2f0e-4a16-89aa-0647f307ed28">205,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTItMS0xLTEtNTczMzc_e99822a8-ba43-4c6f-b290-0f1eae8da215">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTItMy0xLTEtNTczMzc_dbcd9d9d-bff2-4270-bb52-2bbda85c67ab">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTMtMS0xLTEtNTczMzc_825b908f-7301-485d-9a7b-0450d357b9b7">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTMtMy0xLTEtNTczMzc_54e46161-e460-4dc6-9eba-0dfb91c43fb1">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTQtMS0xLTEtNTczMzc_562d9104-62ee-429e-92e0-0663da46c4b7">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTQtMy0xLTEtNTczMzc_bb932bcf-b0fb-41b6-b88e-a1777ba378b8">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTUtMS0xLTEtNTczMzc_581546e3-4339-4cbb-a937-f349b09d2665">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTUtMy0xLTEtNTczMzc_ee783ca2-83f5-4a80-a23d-b605efbd788c">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTYtMS0xLTEtNTczMzc_24d15e3c-e39b-46c1-9a9e-d9aeaca1cefd">17,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTYtMy0xLTEtNTczMzc_9e8c9d94-45ca-4d87-a431-6b6897887437">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTctMS0xLTEtNTczMzc_9bf54941-bb10-4ed8-bf3e-3ac0294785b4">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTctMy0xLTEtNTczMzc_b021ea10-846d-4e72-b5d5-617673000b06">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTgtMS0xLTEtNTczMzc_9210ddc0-1c3d-41a4-9c24-fb7515d34b77">45,203</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTgtMy0xLTEtNTczMzc_bd8587d6-c444-434b-85c8-9b460706fb1f">35,142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTktMS0xLTEtNTczMzc_79c10e92-c79c-4112-903a-de8b51eaa8c1">225,840</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTktMy0xLTEtNTczMzc_69f53e6c-c6c4-4b2f-89b9-f30d946c5b30">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjMtMS0xLTEtNTczMzc_b9123f93-5ada-492c-b53d-b3ee9a084058">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjMtMy0xLTEtNTczMzc_8a5bfc72-25c4-4ebd-a14a-67e4f86659d9">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjQtMS0xLTEtNTczMzc_2fc662e2-3352-417e-8a57-91249c2f578f">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjQtMy0xLTEtNTczMzc_8577eb7a-db3c-47ac-bb3b-d6b434a096af">8,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjctMS0xLTEtNTczMzc_25192d9e-68b6-4dae-8038-1f39deea3d8f">530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjctMy0xLTEtNTczMzc_faae3845-f457-4a63-bb75-2e28bb33d37c">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjgtMS0xLTEtNTczMzc_7e9e9823-a46c-4554-8ab3-f5041d344482">8,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjgtMy0xLTEtNTczMzc_71f5d354-9edc-4a7b-8cd0-5bae45a98dc5">11,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzEtMS0xLTEtNTczMzc_2f16ed32-e614-4c62-bdfd-761a69c879f0">39,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzEtMy0xLTEtNTczMzc_e3fe1285-4910-4551-b2e1-3c1662f7c68b">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzItMS0xLTEtNTczMzc_d5272d13-537e-46de-93fe-c0354d89debf">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzItMy0xLTEtNTczMzc_8998d6fe-3339-4e5f-9545-dec34f8bf21d">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzMtMS0xLTEtNTczMzc_5f85f69f-fd29-4653-8cdc-f6c9e3faf9f7">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzMtMy0xLTEtNTczMzc_1c8630b5-826c-438e-8efe-5c968782ae7e">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzUtMS0xLTEtNTczMzc_d6cc7723-bfac-4a5e-ac2c-9fed9204da2f">44,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzUtMy0xLTEtNTczMzc_dd7992c6-8ec7-4c3a-a2af-089d0ea54564">57,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzYtMS0xLTEtNTczMzc_0bfc871c-494b-45f2-beae-c9de56dacaff">53,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzYtMy0xLTEtNTczMzc_94185446-7b35-4465-b68a-c955da3a3c06">69,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN18yMQ_5cc46fee-8b75-41d3-bff6-9a53c2d0f210"><ix:nonFraction unitRef="usdPerShare" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN18yMQ_aaa691c4-794f-4a31-b0d9-824b122d10f4">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN180NQ_a2ee158d-7983-43a9-b51f-5aa47efa0cdb"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN180NQ_d94a625c-6e13-46f8-af64-d5a2593b42fb">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN185OA_66bda149-1205-43bc-baab-8d3fb7db6b04"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN185OA_a6e34bd8-c089-4deb-b21b-9cb6c3259184"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN185OA_aafb27e6-21cd-455b-9d29-6d7f1759ad68"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN185OA_d5da9766-bde3-4691-a714-876c187a9ad3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMS0xLTEtNTczMzc_a5d1283c-94ac-4158-8d49-c1aad668d0f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMy0xLTEtNTczMzc_b1bc4713-ee91-47ef-850b-44c4c80dfb8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xOA_06b46a3d-5ecb-4487-ad81-0366d2c37fd1"><ix:nonFraction unitRef="usdPerShare" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xOA_719e92d4-47c1-4a67-9b75-5cec05ec24fb">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV80Mg_3f10894c-4d6d-4c30-84af-9ac3c4676536"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV80Mg_b81a0aae-b3d4-4d53-9f6f-1f5f3855886f">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xMDE_111b222e-3a07-4bba-b32f-77382a1d6d3c"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xMDE_161906aa-69c8-4ff1-8354-9b7c6339cf08"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xMDE_20961428-0725-43f9-914c-d696cb22de4b"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xMDE_2fc36e55-f4e0-4fc6-93bf-abe175b50117">199,463,645</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMS0xLTEtNTczMzc_33086369-3fa4-4de5-92ef-25cc64b74562">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMy0xLTEtNTczMzc_ce0e3c7b-6cf9-41df-8841-07d1cd66fd0d">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDEtMS0xLTEtNTczMzc_2b3c5a7c-3260-44da-a8a6-4663420e5761">489,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDEtMy0xLTEtNTczMzc_f454f251-aa11-4da5-b57f-14117579aad9">487,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDItMS0xLTEtNTczMzc_47a2b5ea-58b6-4403-bf8c-de0878d9480f">317,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDItMy0xLTEtNTczMzc_2469d2f4-5eb9-4e65-9c05-4631f046fa69">316,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDMtMS0xLTEtNTczMzc_4fcfc894-dae1-4e85-99f3-0b803d6b0f5f">172,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDMtMy0xLTEtNTczMzc_d05e10ed-0d48-4541-8497-38ebe2fb8cc3">171,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDQtMS0xLTEtNTczMzc_17d12d3e-6d97-42ac-a0b2-82573fb31a2b">225,840</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDQtMy0xLTEtNTczMzc_4fff433d-82f1-4f9a-a083-d51e018eece5">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96da131196c74762907df64863032814_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfNC0xLTEtMS01NzMzNw_deb93049-ef0c-407e-9af4-e32f34a9cd72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5e4b9652d54e48bf163ae90b636a83_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfNC0zLTEtMS01NzMzNw_e335b44a-a452-44e5-832b-f2e76c74cdba">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfNS0xLTEtMS01NzMzNw_8335e648-e3b8-4d25-9c30-f4798caa4d9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfNS0zLTEtMS01NzMzNw_69a74ab4-6355-4cd8-88da-fde6a94c23cc">4,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfOC0xLTEtMS01NzMzNw_180df177-8772-45ac-88af-46dba954a3f8">4,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfOC0zLTEtMS01NzMzNw_ffca905d-3743-4987-8501-dfa4b2e47614">6,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfOS0xLTEtMS01NzMzNw_0f395886-87af-444e-a7eb-afcb56dbc1f0">8,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfOS0zLTEtMS01NzMzNw_d7c1d42f-147b-46ea-9bd0-dc0ace85421e">5,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTItMS0xLTEtNTczMzc_ba71d98b-8fd8-4fa9-ba90-8eafb31b5995">12,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTItMy0xLTEtNTczMzc_c45cd241-ae4a-47db-acb7-f95d62682722">48,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTMtMS0xLTEtNTczMzc_396fbebd-923e-456a-8ac2-fda9896abb03">835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTMtMy0xLTEtNTczMzc_3e79547c-72b9-4a09-9f6c-6b92dd377483">59,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTUtMS0xLTEtNTczMzc_445ad8e4-a5a6-4774-be46-edb46baf98d7">835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTUtMy0xLTEtNTczMzc_2f6ee948-73c8-4533-a312-10e6bba2906a">55,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTYtMS0xLTEtNTczMzc_e7f3d8a8-9668-467f-9d51-2a9c4bf26a73">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTYtMy0xLTEtNTczMzc_85abd35a-ab4c-4015-9e32-d7fe7b1a6c36">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTctMS0xLTEtNTczMzc_85c76de3-c230-4da7-8c08-339440f1d974">807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTctMy0xLTEtNTczMzc_cf7284ae-216c-4511-b3ee-20f656c66d11">55,224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTgtMS0xLTEtNTczMzc_e27aa945-476f-4790-9e86-c262a030da12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTgtMy0xLTEtNTczMzc_8d9c5771-1bec-4601-8499-efd876f09c33">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss and Comprehensive Loss After Taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTktMS0xLTEtNTczMzc_59d03f74-4a64-49fc-a7ac-a742bca96e14"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTktMS0xLTEtNTczMzc_a0b86604-55f8-4358-b1c3-9663a4fc036a">807</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTktMy0xLTEtNTczMzc_63bdf2f6-ee7f-49dc-9e6e-5c12e090f624"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTktMy0xLTEtNTczMzc_880d1fa1-b49e-4d3c-9b13-3010702f59c0">55,512</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjMtMS0xLTEtNTczMzc_962d12b4-8d3f-4f2e-87a3-e1e1254afd03"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjMtMS0xLTEtNTczMzc_e2683da8-3ceb-4e2a-8a48-a50be3d5386e">807</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjMtMy0xLTEtNTczMzc_3865bc2f-cd1a-4c76-8616-4c3440ec52bb"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjMtMy0xLTEtNTczMzc_54799d24-da33-415b-9941-e3fd3474c823">55,512</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjQtMS0xLTEtNTczMzc_8e525fcd-54e4-4fbb-84b7-105b145f35a9"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjQtMS0xLTEtNTczMzc_91a81c08-67b6-4f4c-9873-f2409c9a69b2">0.00</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjQtMy0xLTEtNTczMzc_c1e788ef-be6d-4214-81c0-912f27503de4"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjQtMy0xLTEtNTczMzc_fdbbb918-3832-4a24-a2c8-8ef30fc3877c">0.35</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjUtMS0xLTEtNTczMzc_79f96683-d8cd-4a31-b19d-77aab21ac3ef"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjUtMS0xLTEtNTczMzc_b6722d95-b8bb-4c60-820e-b6807b4c8f91">199,464</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjUtMy0xLTEtNTczMzc_b3e2728a-d859-4d4b-ab36-9dc0f088f08e"><ix:nonFraction unitRef="shares" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjUtMy0xLTEtNTczMzc_e5496eb3-2642-4fe9-8e91-5eeefe39763c">157,033</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.528%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d598df14f84452c822d3e02466c66f4_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi0xLTEtMS01NzMzNw_22ca032d-5d66-49ce-abf7-c63d985b087f">199,463,645</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d598df14f84452c822d3e02466c66f4_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi0zLTEtMS01NzMzNw_0511f059-98d8-4ab9-9dcf-eea293fbe33f">199</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9d886c640194c0d8d40f577a2a0b6da_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi01LTEtMS01NzMzNw_3e19cf53-866c-4f40-b95f-da809c48ee29">487,768</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65986cee0a3f47009f98ae26909e02e4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi03LTEtMS01NzMzNw_570b4f2b-9873-4f3e-bb6c-034ebbae07a7">316,257</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi05LTEtMS01NzMzNw_ddb757b3-a24b-4331-b739-5d11550573f1">171,710</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3bac899f8bff4b5e9d817fa13e651697_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMy03LTEtMS01NzMzNw_fbe7343e-6fe9-42d4-987a-53c941187867">807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMy05LTEtMS01NzMzNw_00fbdc62-bece-4184-9388-dd398c10d854">807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60cbef6e654745cab2772e4470b57220_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfNC01LTEtMS01NzMzNw_c756e4d7-dc1b-4cc9-85d0-4932cc13d51b">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfNC05LTEtMS01NzMzNw_05724157-9e20-42ba-908d-4ad3c5c60275">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ff0b9c4e94c4ca3a50ec38953dae726_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtMS0xLTEtNTczMzc_c80a3310-7061-46bd-af55-2b6a5479099e">199,463,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ff0b9c4e94c4ca3a50ec38953dae726_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtMy0xLTEtNTczMzc_494d7881-c50f-431a-9e3e-c6a739a1414d">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267ce3744e594084b9adfe990aefe17d_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtNS0xLTEtNTczMzc_f33503c9-3f27-40aa-9a6d-81a51779d12c">489,662</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i58548d968bce4d57bbbe97f3173fb16e_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtNy0xLTEtNTczMzc_11cf214e-bf43-4be9-9b01-f78bab6aff4a">317,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtOS0xLTEtNTczMzc_895dab63-b55b-4f89-80ef-9eef8d682065">172,797</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:38pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 7pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i801045fc75394914ab13f94f4ae1394c_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctMS0xLTEtNTczMzc_d4ea3dda-93ec-4e7f-ab08-a5fbaaee9a13">140,449,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i801045fc75394914ab13f94f4ae1394c_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctMy0xLTEtNTczMzc_5cf2fe09-9001-4698-b80b-578030090fd5">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i796d93487eea41168a8fd66cd90a9db5_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctNS0xLTEtNTczMzc_7e5b255a-40a4-4193-a8e6-eb72246fb033">306,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40fdf0d0baf64a318b375f964064207f_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctNy0xLTEtNTczMzc_bcfe5feb-e52c-4133-af4f-ca038649312d">315,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40d094d92f884dde854fd3394639b343_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctOS0xLTEtNTczMzc_ed684b61-3908-4442-8cd4-0298c59af531">9,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4281f2dc82c64e5bb1ce03499a4ff7dd_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTgtNy0xLTEtNTczMzc_d2a850e6-dcbe-410a-94d3-31922e3cbecf">55,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTgtOS0xLTEtNTczMzc_fffa8bda-1789-4fa1-8db1-b7ebbcf75cd1">55,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia555869172ce4586aed28eb0644e17ac_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTktNS0xLTEtNTczMzc_11efbada-c707-473b-b176-bcc25cd81e9a">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTktOS0xLTEtNTczMzc_77cc05b8-9a41-46c9-a816-99d36be55b55">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfb59442f67a48209291031525080d0a_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjAtMS0xLTEtNTczMzc_1e285121-5fea-4a14-b3d8-f2f7c75c97c0">30,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia555869172ce4586aed28eb0644e17ac_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjAtNS0xLTEtNTczMzc_6d30c26c-3122-4109-a561-a0a6f54a8387">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjAtOS0xLTEtNTczMzc_b20f29a8-4aab-4dd0-b9ef-85df56225974">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibfb59442f67a48209291031525080d0a_D20210101-20210331" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjItMS0xLTEtNTczMzc_912571a4-0530-40d2-9d8c-1b9165daa292">852,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfb59442f67a48209291031525080d0a_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjItMy0xLTEtNTczMzc_b4b35bac-a55a-4ada-9d0a-bcd5a15aa54e">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia555869172ce4586aed28eb0644e17ac_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjItNS0xLTEtNTczMzc_8d0403d9-f6ac-4207-86dd-cf3b9ecaf691">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjItOS0xLTEtNTczMzc_14136856-c9fd-4ada-b299-279052b716fd">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo3NmRjNDliNTA1OWM0Zjc0OTcxNTJkMWNkNjY4NjFhYV83NA_8175de32-79a5-4b23-8460-0abd7f870137">2.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8df4db59df3a4f2399c13d3d26fe2f52_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtMS0xLTEtNTczMzc_4feccc91-a392-47e0-be25-f1ccb456c65b">30,645,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df4db59df3a4f2399c13d3d26fe2f52_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtMy0xLTEtNTczMzc_4790823b-dbe3-4243-8ed0-acdff4e10f2f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i782b68f9a89b4a16b35f3ff27087d813_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtNS0xLTEtNTczMzc_bc1f0a78-ebd9-432c-ae03-872719c15583">72,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bf8f5ab2d074836afe2b1f523782410_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtOS0xLTEtNTczMzc_36b4c3b9-d36d-4700-8619-35e098f9f47a">72,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3c390b4af0e43b2adb9e8e3c0f80caf_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtMS0xLTEtNTczMzc_8eda3102-9069-426b-9069-ae5d6dadc8ec">171,978,799</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3c390b4af0e43b2adb9e8e3c0f80caf_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtMy0xLTEtNTczMzc_b13bc8cb-691e-4eef-aad3-254d92069235">172</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9953df45c3614a88bc336cd3adb59e66_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtNS0xLTEtNTczMzc_3b470845-4e01-4593-ba83-caf21134e082">380,531</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i715f0bbb32d5441aa4c0c66f57e6c15d_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtNy0xLTEtNTczMzc_c378a3a8-9edd-4493-930e-2d5662f57cb2">371,433</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef1618b7f7c4e21924ddb1ad216ec24_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtOS0xLTEtNTczMzc_cac96922-6ed2-417f-8617-16a4c6d0db69">9,270</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMy0xLTEtMS01NzMzNw_4833a359-2ee3-4a30-ab27-947bc7b47ec8">807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMy0zLTEtMS01NzMzNw_7a0d278c-5afe-47cf-a1a2-0790d0802522">55,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNS0xLTEtMS01NzMzNw_3eaa1752-dfbd-4820-9622-756a5afb6b56">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNS0zLTEtMS01NzMzNw_69646cae-76c2-4c69-9edb-e4d8169f975d">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNi0xLTEtMS01NzMzNw_e9a271bf-adc5-47d4-89c3-12c6081b69a4">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNi0zLTEtMS01NzMzNw_8e3e62c6-7a30-4c74-925f-abdb076c12b0">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNy0xLTEtMS01NzMzNw_ba71d98b-8fd8-4fa9-ba90-8eafb31b5995">12,900</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNy0zLTEtMS01NzMzNw_c45cd241-ae4a-47db-acb7-f95d62682722">48,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTEtMS0xLTEtNTczMzc_f4e6c9ec-cf14-4086-b69c-493958c72142">20,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTEtMy0xLTEtNTczMzc_5e14a35d-06b3-4b64-8b04-7c6063256322">2,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTItMS0xLTEtNjUxNDk_3f2cf2c9-a9b2-4db3-b8a9-ecba5471ab72">2,441</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTItMy0xLTEtNjUxNDk_e07ee806-fe64-4833-bc2a-d1716efb338e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTItMS0xLTEtNTczMzc_37e0394c-2ed5-469c-85ce-3863e805a506">9,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTItMy0xLTEtNTczMzc_9b56b297-6ad3-4101-8e9f-7fdb06d38887">6,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTUtMS0xLTEtNjk0NTk_d676ea96-fada-4e20-9b58-a206f9b82113">10,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTUtMy0xLTEtNjk0NzM_056038a1-707e-47c2-9178-283f48a4bca3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTYtMS0xLTEtNjk1Mzg_129b9d28-c53c-4e9b-879a-b45f367da9fe">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTYtMy0xLTEtNjk1Mzg_41890140-f6ce-4ec5-8a0c-044eab742129">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTQtMS0xLTEtNTczMzc_2927abf7-5971-4262-89ed-5879a98fb4dd">2,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTQtMy0xLTEtNTczMzc_88e67860-f8aa-4d08-92ff-2baf3cb9efe5">1,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTUtMS0xLTEtNTczMzc_bd0d37dd-910c-4932-8c62-6d6d5ed28fad">908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTUtMy0xLTEtNTczMzc_eb14df53-e74f-4ea8-b241-2cf482dfcd2a">468</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTYtMS0xLTEtNTczMzc_307a904d-7d6f-470e-825a-1e858636df90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTYtMy0xLTEtNTczMzc_c799d0b6-7d0e-4468-8915-aa49d4c05354">1,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash provided (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTctMS0xLTEtNTczMzc_e04424f9-8743-4a92-a82a-88383c0c848f">7,154</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTctMy0xLTEtNTczMzc_ef6c2a4c-f7ea-4e07-aade-1fa816c2fd6f">18,475</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjAtMS0xLTEtNTczMzc_f125e1bd-ce76-496c-bfb2-eb50800eb85c">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjAtMy0xLTEtNTczMzc_72c6be55-96ac-4d3b-9c28-7aff318b275e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjMtMS0xLTEtNTczMzc_53f3396b-7472-47e2-a2b7-cf25d9cb810c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjMtMy0xLTEtNTczMzc_264d4ae2-41c4-4aff-add0-3969718291e8">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM Offering, net of<br/>issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjQtMS0xLTEtNTczMzc_f79c876c-b60a-4386-bd3b-a91633c891ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjQtMy0xLTEtNTczMzc_8e204ef4-a1d8-46a2-aa46-9b2a06e18b74">72,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjUtMS0xLTEtNTczMzc_ae5720d9-008f-4c2c-981e-93e178a42d57">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjUtMy0xLTEtNTczMzc_4fccef20-3788-4450-ab68-481260d9217d">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjctMS0xLTEtNTczMzc_200735f8-21ea-4c8f-bea7-999c5a060ca9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjctMy0xLTEtNTczMzc_0a649c49-3409-4074-ac78-09c23e9ec1d2">73,051</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjgtMS0xLTEtNTczMzc_7970160c-669e-4d9f-ab34-bb3d7143a59c">7,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjgtMy0xLTEtNTczMzc_090fbd79-e421-4143-9397-35c0f30b27cf">54,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjktMS0xLTEtNTczMzc_3278e0d6-043b-4408-8ed7-6b9078d11b03">162,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40d094d92f884dde854fd3394639b343_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjktMy0xLTEtNTczMzc_e6cbcea4-8507-4b7a-ba0a-3b3135a7d748">55,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMzAtMS0xLTEtNTczMzc_3b95125f-080a-4f76-a817-1bcd6bb9e332">169,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef1618b7f7c4e21924ddb1ad216ec24_I20210331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMzAtMy0xLTEtNTczMzc_131c5c19-4dbd-45d0-ab32-f96be640ca6a">109,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental cash flow disclosure:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMzktMS0xLTEtNTczMzc_5e69866e-5680-4304-9b99-2d604e350d7b">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMzktMy0xLTEtNTczMzc_7270342b-d3f5-4185-9696-480d3f7a003f">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span><br/></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_82"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfMTY1NDM_f06e5032-3d48-4d64-8e3c-f9617d2b2eb1" continuedAt="i3838d6d0dc894fd0b2c3ec540ecc75fe" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="i3838d6d0dc894fd0b2c3ec540ecc75fe" continuedAt="i2bdffbe5c288430ba8643c6dff061744"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). The Company is in the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bacillus Calmette-Gu&#233;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of <ix:nonFraction unitRef="patient" contextRef="i04e13475210e4b4f8ded7256b0146395_I20180430" decimals="INF" name="sesn:NumberOfPatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfOTA2_60b6e027-f626-4234-bc36-81ab28e3bf3e">133</ix:nonFraction> patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#8220;CMC&#8221;) issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued <ix:nonFraction unitRef="shares" contextRef="i526122db789843438c15c6cda35ca7ab_D20160901-20160930" decimals="-5" name="sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNDI0Ng_d3012cbc-1ed8-42a4-9834-118ac07c5fb5">4.0</ix:nonFraction> million shares of its common stock to the Selling Shareholders, which at that time represented approximately <ix:nonFraction unitRef="number" contextRef="ib1fa9d23ba6f4ab397f6863c899cf391_I20160930" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNDM1MA_f626b25f-65ea-4ace-bb1b-e296545b8c8e">19.9</ix:nonFraction>% of the voting power of the Company as of immediately prior to the issuance of such shares.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2bdffbe5c288430ba8643c6dff061744">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ie71051d6bdb042b9928263d050777b62_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNDkxNA_b03c3774-850f-4627-9398-96322fde12e1">12.5</ix:nonFraction> million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i3e5b79e7ff7b4732bf5be21b5ad315e9_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTA0Mw_4226aeac-22b5-49fe-bc0d-4eb33b2c82cc">7.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="ia625ecc78ac34ee7b9442e7a9ee6c67a_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTE4OQ_55daadd2-7068-4afe-ba36-e4152c76ef87">3.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to <ix:nonFraction unitRef="number" contextRef="if0c08d92ea854817ba5024a4619ebab0_D20160901-20160930" decimals="2" name="sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTMwMQ_6d23f7f5-936b-4106-a879-0f6f8633ff1a">2</ix:nonFraction>% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) <ix:nonNumeric contextRef="i526122db789843438c15c6cda35ca7ab_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTU2OA_14fe9375-9d56-49df-9ded-60f5eb46a39a">fifteen years</ix:nonNumeric> after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first <ix:nonNumeric contextRef="i526122db789843438c15c6cda35ca7ab_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTg4Mw_c98eb497-adca-4d96-9412-9789a0dfd9ca">seven years</ix:nonNumeric> following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of March&#160;31, 2022, none of these individuals are active employees or members of the Company's board of directors.</ix:continuation> </span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84NS9mcmFnOjY5MjM0ZTllY2I2NTQzZjlhNmZiNGMwOWUyMjkxYzc4L3RleHRyZWdpb246NjkyMzRlOWVjYjY1NDNmOWE2ZmI0YzA5ZTIyOTFjNzhfMjM2MA_fd57e6a1-7375-4d0c-88f7-3bef56068c47" continuedAt="ib4a71e8d791b44cbb04217db2ca853b3" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="ib4a71e8d791b44cbb04217db2ca853b3"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84NS9mcmFnOjY5MjM0ZTllY2I2NTQzZjlhNmZiNGMwOWUyMjkxYzc4L3RleHRyZWdpb246NjkyMzRlOWVjYjY1NDNmOWE2ZmI0YzA5ZTIyOTFjNzhfMjM2MQ_56c1a99a-cbc2-4a8d-b5c0-4097db759f6e" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84NS9mcmFnOjY5MjM0ZTllY2I2NTQzZjlhNmZiNGMwOWUyMjkxYzc4L3RleHRyZWdpb246NjkyMzRlOWVjYjY1NDNmOWE2ZmI0YzA5ZTIyOTFjNzhfMjM2Mg_0a10c04d-e655-468b-a340-5b765b2fc142" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84NS9mcmFnOjY5MjM0ZTllY2I2NTQzZjlhNmZiNGMwOWUyMjkxYzc4L3RleHRyZWdpb246NjkyMzRlOWVjYjY1NDNmOWE2ZmI0YzA5ZTIyOTFjNzhfMjM2Mw_09546163-7fab-4ec9-9d11-affa81dce2a1" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div></ix:nonNumeric></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_88"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84OC9mcmFnOjMzZTkwNzU2ZjY2ZTRkNmM5OTgzMjVmNzdkYTI5ZDc0L3RleHRyZWdpb246MzNlOTA3NTZmNjZlNGQ2Yzk5ODMyNWY3N2RhMjlkNzRfMjgwMjc_809220bf-d163-4eba-b703-b3c6d4443d12" continuedAt="if9f2d2c559434140b69d3c1d8cf86f00" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if9f2d2c559434140b69d3c1d8cf86f00">The Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.</ix:continuation></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_91"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85MS9mcmFnOjBkZDQwZGJhMjExOTRhOTliNmUwM2JjNDUxZmFhYTY3L3RleHRyZWdpb246MGRkNDBkYmEyMTE5NGE5OWI2ZTAzYmM0NTFmYWFhNjdfOTM1_3b740a41-9880-4ca3-a9af-b5e2fd5c0719" continuedAt="ib25309e1aadd4358a8e26fc5fffdaa8a" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="ib25309e1aadd4358a8e26fc5fffdaa8a" continuedAt="i75047d70702a48228b98a7b339a9798d"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85MS9mcmFnOjBkZDQwZGJhMjExOTRhOTliNmUwM2JjNDUxZmFhYTY3L3RleHRyZWdpb246MGRkNDBkYmEyMTE5NGE5OWI2ZTAzYmM0NTFmYWFhNjdfOTM3_cc6a704d-9022-4900-93bf-dcf1c03734d9" continuedAt="id47eadc9b78a41f9bd8bc29e97492535" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i75047d70702a48228b98a7b339a9798d"><ix:continuation id="id47eadc9b78a41f9bd8bc29e97492535"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div></ix:continuation></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_94"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNjAyNQ_f6cc6dd8-f9bf-461e-ab5d-570213bba97a" continuedAt="if77ec9d91f5643e88bfe394560b33d45" escape="true">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="if77ec9d91f5643e88bfe394560b33d45" continuedAt="i829d709a19eb4b1fbee4b0b5477c7a29"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNjAyNg_a4c30958-ffd0-4461-a1b2-90147dbd46fe" continuedAt="id51aa0f1ba914090a2fc94664359f8ba" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of March&#160;31, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:continuation id="id51aa0f1ba914090a2fc94664359f8ba" continuedAt="i4987578cf4bf4de4979e8d7fb3bbcc49">Level 3</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4987578cf4bf4de4979e8d7fb3bbcc49">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.</ix:continuation> </span></div><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNjAyNw_089a6db5-cff7-45a3-8754-069360e19d0c" continuedAt="i23e0d9747cac4be2a44a8cf310fadb78" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49f04215a514ffe9aa6de52f1449f7c_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC0xLTEtMS01NzMzNw_a9c3d085-4407-41c5-b2de-a9a591becaf0">16,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f65186d8914b83bd3a931c1ddffbf4_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC0zLTEtMS01NzMzNw_2dbc649f-ef77-42ba-b5f5-24fb18268af2">16,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487e4fc22ff1483fa5e2a198b37ce024_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC01LTEtMS01NzMzNw_aceb5f96-47a8-4cf7-b20b-ea67f6b4198f">16,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2fde291dcd4b11bca4ee8ea8be676d_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC03LTEtMS01NzMzNw_a648e4a7-0dc8-4edb-b576-3e1c7a2d114a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352f1de5f4fc4ed299dd42039cae4d43_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC05LTEtMS01NzMzNw_364fb145-1b6a-4415-801d-fccc25424d3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie49f04215a514ffe9aa6de52f1449f7c_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy0xLTEtMS01NzMzNw_cbdb6874-f359-4c03-9ea1-93f23630074e">39,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29f65186d8914b83bd3a931c1ddffbf4_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy0zLTEtMS01NzMzNw_3ca80efe-dbd6-4c92-b2fe-dbf7f68ec460">39,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i487e4fc22ff1483fa5e2a198b37ce024_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy01LTEtMS01NzMzNw_ab80364f-1277-4ae3-9327-0f1d20243fec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf2fde291dcd4b11bca4ee8ea8be676d_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy03LTEtMS01NzMzNw_6608c209-ed80-498a-8557-a0fb851d692d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i352f1de5f4fc4ed299dd42039cae4d43_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy05LTEtMS01NzMzNw_2db040c7-841d-4f8e-9d61-29f176a97d7e">39,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i829d709a19eb4b1fbee4b0b5477c7a29" continuedAt="iaefc8d604e73460983ce9e20e592b234"><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i23e0d9747cac4be2a44a8cf310fadb78"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6eda91c70472c97ddbcf9c27c26f9_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC0xLTEtMS01NzMzNw_6538b298-dd92-4b33-b5fa-8059e75f6ef1">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id856a959b0b243f28a91153f115b51d1_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC0zLTEtMS01NzMzNw_5bc6b6b5-1847-44e9-aa45-7f41fa2db43c">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f177ca553484a5e816e4b2458b15d0e_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC01LTEtMS01NzMzNw_72986ccd-6860-467a-b8d7-bd6028c0c84a">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3dd7d4481c4276acefb438f635d714_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC03LTEtMS01NzMzNw_0a32a024-4a17-423e-9283-42feaf77448d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b667a740a14082b1c2a0e4fe06a99d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC05LTEtMS01NzMzNw_e6abe676-62d3-4720-8275-6ebdcd37b595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9d6eda91c70472c97ddbcf9c27c26f9_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy0xLTEtMS01NzMzNw_7d672c0d-d303-4c68-9832-05c99fe89824">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id856a959b0b243f28a91153f115b51d1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy0zLTEtMS01NzMzNw_43a77027-1361-4c3d-9f3c-e0a0d05ff888">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f177ca553484a5e816e4b2458b15d0e_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy01LTEtMS01NzMzNw_f2fd42f7-1b69-464a-9f22-e73a5aaeff10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff3dd7d4481c4276acefb438f635d714_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy03LTEtMS01NzMzNw_f1b22661-a830-49f7-a184-662b09c7174b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b667a740a14082b1c2a0e4fe06a99d_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy05LTEtMS01NzMzNw_195c4973-27d1-43ef-8577-1c5b5297a3b9">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the quarter ended March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from <ix:nonFraction unitRef="number" contextRef="i777b729b56654272aecb76e84444d371_I20220331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMTA5OTUxMTYyOTcwMjU_3a477643-ac3b-4361-87ec-ce612884f5db">9.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia85202389e8f434f9771578dd1116186_I20220331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNzY5NjU4MTQxMjUyNQ_3dfac151-c911-4a23-9088-10861975294f">9.7</ix:nonFraction>% as of March&#160;31, 2022 and <ix:nonFraction unitRef="number" contextRef="ia6c8bda95fde40828c577fa8789c7d3f_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNzY5NjU4MTQxMjQzOA_807fc940-06bc-4431-b9d6-149102eabf94">8.0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ied03436a4b954153b51104e07b4308a5_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNzY5NjU4MTQxMjQ0NA_9bebe03b-6eed-41e2-b695-68ee1ea4735e">9.3</ix:nonFraction>% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the three months ended March 31, 2022. </span></div><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNjAyOA_690e30de-e7ab-4591-a7b8-915301c71eda" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the quarter ended March&#160;31, 2022, (in thousands).</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c3d72e64284343ad41bbaabad2492e_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjQyOWRlODdhMTdmMjQxYWZhYTUxYzk5MTExMjRjYmFmL3RhYmxlcmFuZ2U6NDI5ZGU4N2ExN2YyNDFhZmFhNTFjOTkxMTEyNGNiYWZfMC0xLTEtMS01NzMzNw_7ed169d0-0997-4e8d-9b7d-9e048219e274">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0974e9a0eac4b9a943068d81c400af6_D20220101-20220331" decimals="-3" sign="-" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjQyOWRlODdhMTdmMjQxYWZhYTUxYzk5MTExMjRjYmFmL3RhYmxlcmFuZ2U6NDI5ZGU4N2ExN2YyNDFhZmFhNTFjOTkxMTEyNGNiYWZfMi0xLTEtMS01NzMzNw_9299d79d-24e4-45b3-9964-63667a0877d3">12,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4024043b56ba43449e39178a89ef2a79_I20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjQyOWRlODdhMTdmMjQxYWZhYTUxYzk5MTExMjRjYmFmL3RhYmxlcmFuZ2U6NDI5ZGU4N2ExN2YyNDFhZmFhNTFjOTkxMTEyNGNiYWZfMy0xLTEtMS01NzMzNw_07ab3dd7-09be-427b-8737-f41d22663b19">39,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of <ix:nonFraction unitRef="number" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMjkwMg_a97c0d10-70ec-4f41-a030-d2521afbf6ac">2</ix:nonFraction>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMzAwMQ_c4ec203d-0a49-4fe2-a361-339756b43996">2</ix:nonFraction>% earnout is derived from the Company&#8217;s weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from <ix:nonFraction unitRef="number" contextRef="ida5defd37759486088c2d5f6a80ad271_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMzE3Mg_5d363061-0958-4071-8dee-4ba34e9f9f48">9.3</ix:nonFraction>% as of December&#160;31, 2021 to <ix:nonFraction unitRef="number" contextRef="icc5ad7341ef44d9e9d0eb812d5d6aef7_I20220331" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfOTg5NTYwNDY2ODEwMA_e1c90691-1d93-4bca-aa5a-90025fb1f0e3">9.0</ix:nonFraction>% as of March&#160;31, 2022. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from <ix:nonFraction unitRef="number" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMzQ4NQ_523ff1da-a94e-405f-8c08-508e1e508fbc">8.0</ix:nonFraction>% as of December&#160;31, 2021 to <ix:nonFraction unitRef="number" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNzY5NjU4MTQxMjU1Ng_7f3b4656-ab72-4c54-a895-e3fb323c7b7b">9.7</ix:nonFraction>% as of March&#160;31, 2022. The decrease in the fair value of contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMzU2MA_a9e1eb46-d0e5-4737-be53-cc5edd684605">12.9</ix:nonFraction> million for the three months ended March 31, 2022 was driven by changes in underlying assumptions used to develop the revenue projections.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaefc8d604e73460983ce9e20e592b234">In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company's proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company also learned during the meeting that the FDA is trending away from accepting single arm trials across therapeutic areas, including NMIBC, and has a strong preference for randomized controlled trials. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Incorporating the FDA feedback from the Type C meeting, plans for further discussions with the FDA prior to initiation of the additional Phase 3 clinical trial, as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company&#8217;s revenue projection models are timing of potential commercial product launch, probabilities of clinical and regulatory success, and market share. The Company anticipates further delays in the start of commercialization due to the likelihood of the requirement to conduct a randomized controlled trial which will require more patients to be enrolled, lengthen the duration of the study, and increase study costs. The company is also projecting lower estimated market share as a result of recent clinical and regulatory progress made by competitors. The Company has assessed a commercialization timeline assumption and applied a probability to each outcome based on management&#8217;s best estimate. The Company continues to assume a POS in achieving certain clinical and regulatory milestones in the range of approximately <ix:nonFraction unitRef="number" contextRef="i789b708b5a4b4f70b35c83d05b643756_I20220331" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNTc5MQ_ace41006-6dda-4cfb-8e62-478c04a1499b">45</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id5b7224c57a349dd8417b26074fdfea8_I20220331" decimals="2" name="sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNTc5Nw_541d7968-c29d-4112-b521-ec951d08eb21">55</ix:nonFraction>% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.</ix:continuation></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_97"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfMTIzNw_7dd5be35-d5bb-4dcd-ad2e-33552a5df164" continuedAt="i313f4c1a9b1945369cf74202bfd32c9e" escape="true">RECEIVABLES </ix:nonNumeric></span></div><ix:continuation id="i313f4c1a9b1945369cf74202bfd32c9e"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of March&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i37a86bcaa5c4400cb485d8e214b15877_I20220331" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfODA_68c8d31d-5b21-46d0-aee1-4a9e574fa86c">1.0</ix:nonFraction>&#160;million compared to $<ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfMjE5OTAyMzI2MzIyMw_ab9479fd-9995-464c-86ea-1ca7da948b0d">21.0</ix:nonFraction>&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $<ix:nonFraction unitRef="usd" contextRef="ie4d8a28b63694dfca536772f228dfd1f_I20211231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfMTY0OTI2NzQ0OTMwNQ_7089d413-21a7-4c93-ab7b-55bfe8325e4e">20.0</ix:nonFraction>&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of March&#160;31, 2022 is $<ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfODk5_75ce1e56-0fc0-466d-b070-6bb7b62d75a8">1.0</ix:nonFraction>&#160;million compared to $<ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfMTA5OTUxMTYyODU0NjI_3cfb703c-7f9b-44f1-a527-1ebf810d8daf">3.5</ix:nonFraction>&#160;million as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease is driven primarily by the receipt of $<ix:nonFraction unitRef="usd" contextRef="i6cc771771ec447eb817fedfab04c5064_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfNTQ5NzU1ODE0NjQ2OA_158b8d62-18bc-438b-a4f1-45c54f07dc18">1.8</ix:nonFraction>&#160;million for German VAT recovery related to drug substance sent to Baxter in 2020 and 2019.</span></div></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_103"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzY5MjA_f500c6a7-0b64-4100-86ed-21ebff50e69c" continuedAt="i35ecdfa1e0f44278919ee1355e900b95" escape="true">INTANGIBLES AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="i35ecdfa1e0f44278919ee1355e900b95" continuedAt="i181bfea407a14378a42ee76119600aa2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's condensed consolidated balance sheet are the result of the Viventia Acquisition in September 2016. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzY5MjE_5e3cceab-bc1b-4709-850e-e822b2e31cf2" continuedAt="i7e9392573d2b42a98b0a89ae82c3b78b" escape="true">The following table sets forth the composition of intangible assets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="i7e9392573d2b42a98b0a89ae82c3b78b"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i545bec4894b147faa5be77fb0ce698df_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90YWJsZTozM2MxMzhmYTdkOTQ0NjIwOWI5NjM4ODk5OGY3NGZiOC90YWJsZXJhbmdlOjMzYzEzOGZhN2Q5NDQ2MjA5Yjk2Mzg4OTk4Zjc0ZmI4XzQtMS0xLTEtNTczMzc_e92f618c-799d-48ca-9050-103ff9ea62da">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf4f0077ab4d4c7e8baa7cd8eac1afbe_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90YWJsZTozM2MxMzhmYTdkOTQ0NjIwOWI5NjM4ODk5OGY3NGZiOC90YWJsZXJhbmdlOjMzYzEzOGZhN2Q5NDQ2MjA5Yjk2Mzg4OTk4Zjc0ZmI4XzQtMy0xLTEtNTczMzc_2b8614be-504d-41f0-b1dc-69d6472781df">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e2f3183009408a88a2121d2f8320de_I20220331" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90YWJsZTozM2MxMzhmYTdkOTQ0NjIwOWI5NjM4ODk5OGY3NGZiOC90YWJsZXJhbmdlOjMzYzEzOGZhN2Q5NDQ2MjA5Yjk2Mzg4OTk4Zjc0ZmI4XzUtMS0xLTEtNTczMzc_7c74e13c-97c5-4c0c-abb9-41d3a53968c1">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9c6211a35774d058c2bc34135cd81cd_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90YWJsZTozM2MxMzhmYTdkOTQ0NjIwOWI5NjM4ODk5OGY3NGZiOC90YWJsZXJhbmdlOjMzYzEzOGZhN2Q5NDQ2MjA5Yjk2Mzg4OTk4Zjc0ZmI4XzUtMy0xLTEtNTczMzc_9cb0a48f-37a1-43bc-86aa-599bc141f361">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#8217;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there is more clarity from the FDA on next steps for Vicineum in the United States. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="if355f8cd711e40d5bb37354a4ec90cf0_D20210101-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzU0OTc1NTgxNjQ4MjY_137774e5-b591-4db9-9295-d900164ebde3">31.7</ix:nonFraction>&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i181bfea407a14378a42ee76119600aa2" continuedAt="i40d499ebbdf24dd5b838133be7c65a99"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current range of commercialization timelines and POS assumptions. This was primarily due to the fact that the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company's proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company also learned during the meeting that the FDA is trending away from accepting single arm trials across therapeutic areas, including NMIBC, and has a strong preference for randomized controlled trials. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Based on the outcome of the Type C meeting as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of the indefinite-lived intangible asset. Management updated the revenue forecast models based on further launch delays in both US and OUS regions as well as slightly lower market share. The Company anticipates further delays in the start of commercialization due to the likelihood of the requirement to conduct a randomized controlled trial which will require more patients to be enrolled, lengthen the duration of the study, and increase study costs. The company is also projecting lower estimated market share as a result of recent clinical and regulatory progress made by competitors. Accordingly, the Company identified this as a potential impairment indicator and performed an interim quantitative impairment assessment during the first quarter of 2022. The Company concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of March&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's condensed consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzQyNDQ_aa233855-905b-49b8-a8df-3109d47b8f04"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzQyNDQ_af5bb69b-48cc-40d6-99eb-e55d3b4edb62">13.1</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. Based on the outcome of the Type C meeting as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both US and OUS regions as well as slightly lower market share. Accordingly, the Company identified these changes to the revenue forecast, as well as the decline in the Company&#8217;s stock price and market capitalization during the first quarter of 2022, as potential impairment indicators and performed a quantitative impairment analysis during the first quarter of 2022, in advance of the Company's typical annual assessment date of October 1. The Company concluded that the carrying value of its goodwill of $<ix:nonFraction unitRef="usd" contextRef="ie489efabccd5453ea2dc7e35706cfaa4_I20210930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzQ3MDc_d112a134-1d03-405b-ab6b-7a5a64f23c38">13.1</ix:nonFraction>&#160;million was not impaired as of March&#160;31, 2022, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately <ix:nonFraction unitRef="number" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzc2OTY1ODE0MjYzMjY_f2a89dd6-b998-43a8-a11e-b99a215755c8">29</ix:nonFraction>%.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i40d499ebbdf24dd5b838133be7c65a99">The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in the Company's current development profile (ranging from <ix:nonFraction unitRef="number" contextRef="i789b708b5a4b4f70b35c83d05b643756_I20220331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzYzNzk_93d42297-3529-4362-8a08-a94c414b9a16">45</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id5b7224c57a349dd8417b26074fdfea8_I20220331" decimals="2" name="us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzYzODU_92ae78cb-7ed3-44c0-aace-0c14bbdaf5f6">55</ix:nonFraction>% globally) and underlying discount rates also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of NMIBC. Further reductions to probabilities of success, decrease in market share, additional development and commercial launch delays, increases in underlying discount rates, or any decision to undertake any strategic alternative as a result of the review process that the Company has initiated, have the potential to result in future goodwill impairment.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_106"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90ZXh0cmVnaW9uOmY4MGEzMGEwNDhkYzQyNTU5Yzk4MWYxNzYzMTIxZGQ2XzEzMg_0f682b2a-1629-45c4-8de6-139e08b04718" continuedAt="ic1f6bf760ac7435ca7b2799377192f3e" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="ic1f6bf760ac7435ca7b2799377192f3e"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90ZXh0cmVnaW9uOmY4MGEzMGEwNDhkYzQyNTU5Yzk4MWYxNzYzMTIxZGQ2XzEzMw_d63ef213-2596-43ea-a8c0-dced06faec72" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzItMS0xLTEtNTczMzc_8ad646a2-b867-42bd-bd25-bb5596c7d647">981</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzItMy0xLTEtNTczMzc_390e0916-4bb2-48dd-b452-1abc96e0075c">1,841</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzMtMS0xLTEtNTczMzc_446684ce-4816-4914-b951-c57473bbc3e9">2,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzMtMy0xLTEtNTczMzc_5df291fe-540f-4ea7-b1ca-fc81b553d7d6">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzQtMS0xLTEtNTczMzc_4233a927-37bc-4c71-9f4a-ada6b09d9b6c">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzQtMy0xLTEtNTczMzc_9ba7663c-7f7c-499c-bade-3adf4468a1ff">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzUtMS0xLTEtNTczMzc_abb7f3c2-5200-4f15-815d-449f659783ab">2,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzUtMy0xLTEtNTczMzc_782bdd7e-6a87-4e08-b618-2b3d67a17cd0">1,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzYtMS0xLTEtNTczMzc_7a548593-23a2-437f-8056-4912a7a66fdb">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzYtMy0xLTEtNTczMzc_9123781f-c410-464c-a8b1-7967c870cebc">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzctMS0xLTEtNTczMzc_4d850775-55a5-422d-9754-af6bf8bcb6ab">7,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzctMy0xLTEtNTczMzc_c0255bf0-9cd5-46ca-ab77-b79e8ee6d4cc">8,255</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_109"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzU0NDc_6ceb6a8b-ec6b-4bf0-bfcb-c7f8de9ff00c" continuedAt="i87e918319f6945789b6616f5154cc951" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i87e918319f6945789b6616f5154cc951" continuedAt="i0b0304240f244874b3a1446688c0e2f7"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, <ix:nonFraction unitRef="lawsuit" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzEyMTU_12535ac6-2bc6-4f83-a74e-7dbe00521909">three</ix:nonFraction> substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The <ix:nonFraction unitRef="lawsuit" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzE1OTE_3e7e1ea2-4654-4baf-94d6-abd490f3af34">three</ix:nonFraction> complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The <ix:nonFraction unitRef="lawsuit" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzE4MzA_89f86dab-9e89-4dc2-93c5-00ded1229155">three</ix:nonFraction> complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the <ix:nonFraction unitRef="lawsuit" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzE5Njk_2bc8652a-30c0-4140-b22b-f7171c2ee076">three</ix:nonFraction> cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. The court has not yet ruled on the motion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as nominal defendant. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i0b0304240f244874b3a1446688c0e2f7"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. Defendants intend to seek a similar stay of the state court derivative litigation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_112"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjU_6b336d7d-c114-4ac5-bf55-e96cfe8ede01" continuedAt="i86a6dd0972c8439a9fde7dc09a56d2a2" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i86a6dd0972c8439a9fde7dc09a56d2a2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its <ix:nonFraction unitRef="sqft" contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331" decimals="-2" name="sesn:OperatingLeasesAreaOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzE1Mw_46da70f3-a770-40fc-8828-23118c968097">31,100</ix:nonFraction> square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional <ix:nonNumeric contextRef="ie0b15da2342248bf8f341d5a7661bd17_I20220331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzM2MQ_e2e5f4f8-3b57-47c7-9be8-9a74d0e5e1ca">two years</ix:nonNumeric>, through September 2022, with a right to extend the lease for <ix:nonFraction unitRef="term" contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331" decimals="INF" name="sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzQyNg_83a8de09-258b-447e-80df-28b803172a73">one</ix:nonFraction> subsequent <ix:nonNumeric contextRef="ie0b15da2342248bf8f341d5a7661bd17_I20220331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjE_7cf3f2d9-6831-401e-abfb-f9a9a882ab29">three-year</ix:nonNumeric> term. The minimum monthly rent under this lease is CAD $<ix:nonFraction unitRef="cad" contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzUwMw_bdc73dbb-940f-4679-8417-d91922a1740b">18,100</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzUyMQ_da709d17-d202-4694-92cd-ed86be596f50">14,500</ix:nonFraction> at exchange rates in effect on March&#160;31, 2022). In addition to rent expense, the Company expects to incur CAD $<ix:nonFraction unitRef="cad" contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzYyMg_7d0f0f37-40af-450b-97c7-b95419948bf4">18,200</ix:nonFraction> per month related to operating expenses (approximately $<ix:nonFraction unitRef="usd" contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzY4MA_3d6cce09-cdf3-4d7d-9696-16d3ad767797">14,500</ix:nonFraction> at exchange rates in effect on March&#160;31, 2022). Operating lease cost under this lease, including the related operating costs, were $<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzgwOQ_20167ad8-1c04-4c70-9c12-daee0a484353"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-5" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzgwOQ_4240b0b8-0c6f-4abd-a810-a9282d3dcacb">0.1</ix:nonFraction></ix:nonFraction>&#160;million for the three months ended March&#160;31, 2022 and March&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_70e2c78d-7000-4550-b39c-7708486d9514"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_a608af25-a8c3-43f1-bc13-bde655007b13">other assets</span></span> on the Company's condensed consolidated balance sheets. The right of use asset total was $<ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzMyOTg1MzQ4ODYyOTQ_95e73548-4eed-4250-b9f2-6b46af1ed698"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="0" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzMyOTg1MzQ4ODYyOTQ_ca2c6cd1-9b0e-4a77-9044-0ce2913d0044">0.1</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_257c3c35-2b5f-4801-99d1-da6db072ebc5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_870e15ab-96b9-4644-93c8-e07c8cee8f3a">other current liabilities</span></span> and the long-term lease liability is recorded in other liabilities on the Company&#8217;s condensed consolidated balance sheets. The short-term lease liability was $<ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzMyOTg1MzQ4ODY1MDk_1b5cff73-9acd-4e38-8496-78788fd01e2e"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzMyOTg1MzQ4ODY1MDk_c98b4303-f891-46b7-b6a6-6750d0a00738">0.1</ix:nonFraction></ix:nonFraction>&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. There was no long-term operating lease liability as of March&#160;31, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIxOTkwMjMyNTg5Mjc_107f62f1-7e63-49b3-8b18-5cce5a5aebdc">six</span> to <ix:nonNumeric contextRef="i91a2e679410d42bd9b578b3fe11ffb4a_D20220101-20220331" name="sesn:ShortTermLeaseRenewalFrequency" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIxOTkwMjMyNTg5MzI_f9b33f74-a062-4e80-a3b9-898bc1610006">twelve months</ix:nonNumeric> and currently extend through June 2023 and May 2023, respectively. The minimum monthly rent for these office spaces is $<ix:nonFraction unitRef="usd" contextRef="i145c98efedcf4ac6a1bfc225996ebb5c_D20220101-20220331" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzE2Nzc_ac81a024-8943-4a4d-bb3b-41fd98b99a6c">2,100</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ib4acdf8e88564bcaa3b39b640d7f099c_D20220101-20220331" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzE2ODQ_0f06a4ae-65ea-4d7a-9570-a40b03088a88">18,400</ix:nonFraction>, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_115"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzExMTY3_8c9e2114-a961-4e29-8691-8e446e73acf8" continuedAt="ia14b80ed52fc4adaba3926d554e3cdf7" escape="true">STOCKHOLDERS' EQUITY </ix:nonNumeric></span></div><ix:continuation id="ia14b80ed52fc4adaba3926d554e3cdf7" continuedAt="ib83d53b45238404f823712ba5117f4b1"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i4321e3e7de5f473b81eb3f2fa81fef3b_I20191129" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2NTQ0OTU_f4e93e38-2827-43f0-910c-52bc1cdc2db8">0.001</ix:nonFraction> per share, from time to time through Jefferies (the &#8220;ATM Offering&#8221;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i38aea9f975c9437f993d25b7b3b9c71b_D20210601-20210731" decimals="-6" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2NTQ1ODg_2afa4c56-2a1b-44b9-b9a9-68f3dd3a3277">200</ix:nonFraction>&#160;million of common stock pursuant to the Sale Agreement of which $<ix:nonFraction unitRef="usd" contextRef="ibb19d0c9c4ac4cbaac6c9dc28bf97c0d_I20220331" decimals="-5" name="sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2NTQ2Mjc_0187e4ec-e077-4cd1-90b2-9b71ea3d1779">97.8</ix:nonFraction>&#160;million of common stock remain available for future issuance as of March&#160;31, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to <ix:nonFraction unitRef="number" contextRef="i5bc89768d7574532a2c9411e20751c77_D20211129-20211129" decimals="INF" name="sesn:SaleOfStockCommissionFixedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2NTQ0ODk_d601e7a7-f146-4491-9543-0f1782195e8a">3.0</ix:nonFraction>% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the three months ended March 31, 2022. The Company raised $<ix:nonFraction unitRef="usd" contextRef="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2MzkwMjE_80cd3e7a-f987-49a8-87ac-7eff6273d8f7">72.6</ix:nonFraction>&#160;million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2MzkwMjk_0a09aeb5-c615-4f0f-ac53-f8f5ac50574b">30.6</ix:nonFraction>&#160;million shares </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ib83d53b45238404f823712ba5117f4b1" continuedAt="ib9c22749eddc4257bd891d9da3f60045"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2MzkwMzY_11d5fe7a-bc2d-4608-917a-ac4b90f8b652">2.44</ix:nonFraction> per share during the three months ended March 31, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2MzkwNDE_5219c350-4c26-4373-b72a-c22ed51e7655">2.2</ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM0NTU_3944a07f-e248-445f-9ffa-98acb836f61b">5.0</ix:nonFraction> million shares of "blank check" preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM0OTk_50691a6a-95ba-46e1-ab97-4197e0edf289">0.001</ix:nonFraction> par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had <ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM5NDM_3563ac6a-63ca-4833-952c-bfa127c0fadf"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM5NDM_53d531ff-1e8d-4a8d-9c37-05a04dcda56b"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM5NDM_849f35a3-f37c-4630-8ae0-5ca9d420f74f"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM5NDM_af309297-051d-4704-8615-88d2f23b0763">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred stock issued and outstanding as of March&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="iad87f2a2e4064dc8babf6447190779eb_I20210502" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyMTQ_9daa4122-16f8-4ec9-b2cb-9d00fa3db834">200</ix:nonFraction>&#160;million to <ix:nonFraction unitRef="shares" contextRef="ib6a9e7c16bd84278a88fc26407cd68a3_I20210503" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyMjA_d1be7f97-15d2-480d-9f01-3fd51db8c013">400</ix:nonFraction>&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyNDA_36d4efd8-14d9-4c24-9ecf-39d2b75f7282"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyNDA_5547cbde-5175-49de-b6c9-cc6ffa44638b"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyNDA_9d611f14-2402-427c-b807-ae6e42447569"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyNDA_b69ff116-2c3e-4daa-9dfa-1dd441e0e714">199</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzExMTY0_e17dbf95-7cbf-4f7f-beb3-b111ff833a77" continuedAt="i2116b750d2444fefa3cc14fe9eea7eb7" escape="true">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><ix:continuation id="i2116b750d2444fefa3cc14fe9eea7eb7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:67.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzItMS0xLTEtNTczMzc_caaf6bfa-a05f-41ac-909a-32989ca8edc4">199,464</ix:nonFraction></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzItMy0xLTEtNTczMzc_8aeeb8ee-c65f-4571-8b97-4d6bfcb0048f">199,464</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i21ceb143543841428ec32f3c9ad4b0be_I20220331" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzQtMS0xLTEtNTczMzc_a8ebc42b-2e30-4e64-b98c-1ccddf638d0d">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0fe2c623a9d74a7389296573a31bbb22_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzQtMy0xLTEtNTczMzc_2ddd350c-7a37-44a1-bdd7-5228c8f27765">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3baa1439c0ea43b08add2b44f358ac2d_I20220331" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzUtMS0xLTEtNTczMzc_49e20a66-ad01-48ad-871d-1143a94225f9">16,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i221c8962daf4444ebdf4d3c88988461b_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzUtMy0xLTEtNTczMzc_932191bf-9992-4e2b-8893-d41c7fdd98c4">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2d1253ec7414a4b84ffbe87119b85ff_I20220331" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzYtMS0xLTEtNTczMzc_e6125035-a6b0-49cc-92a7-1f79a491f9d6">4,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id98165c78fa5475887c60e7c8804b011_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzYtMy0xLTEtNTczMzc_8ccb00ad-a142-45e5-b0c7-ebbef8a1111e">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3c6c33e3cf54dd39de56d11701d0b0d_I20220331" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzctMS0xLTEtNTczMzc_54c75f37-9d92-45f5-b8c1-bddf5456726c">3,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iefba41b22eac4b17ad9b01a9511c163f_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzctMy0xLTEtNTczMzc_c9692134-7014-4797-bd17-dd22aed6572c">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b8342820bc14fc18dcb66343e2d8dbb_I20220331" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzgtMS0xLTEtNTczMzc_4b316c63-7649-4e39-ba31-29a847f80396">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i60a06969725e4e0ab841501477d0ab94_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzgtMy0xLTEtNTczMzc_e3c3018b-d2ad-4b26-af1b-f27f987216c7">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzktMS0xLTEtNTczMzc_925539c6-2263-4bf2-af7d-8e46b1365cd9">227,275</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzktMy0xLTEtNTczMzc_d8066f23-def4-4c90-bd27-0c1dc7417f3f">229,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="i46b9def9cc834e2e9e98a5e65496e75a_D20220101-20220331" decimals="INF" name="sesn:NumberofVotesEntitledForEachShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQ3MTg_6aa423b1-fb29-4d46-8cf4-9f8936163437">one</ix:nonFraction> vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (&#8220;ASC 815-40&#8221;). <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzExMTY2_34fcb045-cd53-44a8-9596-79107ca0e11b" continuedAt="i384712f3736d4659a88e9eea320a4b70" escape="true">The following table sets forth the Company's warrant activity for the three months ended March 31, 2022 (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ib9c22749eddc4257bd891d9da3f60045"><ix:continuation id="i384712f3736d4659a88e9eea320a4b70"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i874e45992d94489c9ad7c98356670dc7_I20220331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItMi0xLTEtNTczMzc_c1bad728-b381-416c-b33a-1f63b2abca63">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i900115e3ca494438812c53a74b2e941e_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItNi0xLTEtNTczMzc_8ccb58b6-1a39-4dc8-ac26-c3b30af1e860">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie30fcbf9c3814ac980e2533dce4fe035_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItOC0xLTEtNTczMzc_29dd1334-ebfb-4f34-88a6-b9ac8a65ceea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie30fcbf9c3814ac980e2533dce4fe035_D20220101-20220331" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItMTAtMS0xLTU3MzM3_314f4f48-4cbc-40c7-93ef-911b5d816978">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie30fcbf9c3814ac980e2533dce4fe035_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItMTItMS0xLTU3MzM3_0c158ad9-b0d6-43bb-a312-b1564072b344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i874e45992d94489c9ad7c98356670dc7_I20220331" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItMTQtMS0xLTU3MzM3_94b03bef-e6b1-4422-bc4b-e7f83cf26f28">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3779abea087b4610ba82ce1d85f2bf38_I20220331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtMi0xLTEtNTczMzc_168187a6-1bd6-4c73-b541-65c7833d2b74">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic2a61ca27ef84e2aa470147840bc3c1a_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtNi0xLTEtNTczMzc_a31fd6a0-d256-4810-bab3-ef815f1e2ed1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87c1ad53e5a84769a79cc00b7c419f7f_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtOC0xLTEtNTczMzc_13aa74dd-0b49-478e-8786-a1ad1260f7da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87c1ad53e5a84769a79cc00b7c419f7f_D20220101-20220331" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtMTAtMS0xLTU3MzM3_866a88e8-5a28-4020-a20d-f5d7a1145293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87c1ad53e5a84769a79cc00b7c419f7f_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtMTItMS0xLTU3MzM3_41636cec-5c02-46d2-943d-cbe1c0bd7c43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3779abea087b4610ba82ce1d85f2bf38_I20220331" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtMTQtMS0xLTU3MzM3_537ce7cd-b071-49e0-aa60-55c3c6caca69">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1240079e3b784011876aef3004337651_I20220331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtMi0xLTEtNTczMzc_1723de1a-c893-4e65-b07a-72a13c8555ee">11.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id2db8bf0bb154bf988c5f0cbf4b1fa14_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtNi0xLTEtNTczMzc_86fc3fd8-7982-4c61-acdc-76f9fa240a68">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8543e2bf0407481b92ce314c98882350_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtOC0xLTEtNTczMzc_b2399c89-c612-470b-b657-f395247ecdf1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8543e2bf0407481b92ce314c98882350_D20220101-20220331" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtMTAtMS0xLTU3MzM3_f345c056-2bde-45f4-921f-67eb806bb90c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8543e2bf0407481b92ce314c98882350_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtMTItMS0xLTU3MzM3_90d14c67-b7ef-4074-a78c-f83e209b4dee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1240079e3b784011876aef3004337651_I20220331" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtMTQtMS0xLTU3MzM3_e3ca020e-7c8a-4976-989d-00e1f73a27db">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7b139b5a19b94648b6cd590da2967190_I20220331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtMi0xLTEtNTczMzc_dec0630b-cc05-4266-a786-f45aaad74f13">11.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0474ce6e41f94994aa5166f4cef01656_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtNi0xLTEtNTczMzc_c456632e-b563-460d-8f92-65f8633b84ac">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i491f8467f7ff45e0b2e6a6bc33dabb45_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtOC0xLTEtNTczMzc_675c216c-33bf-455a-86dd-45ebd9180e8e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i491f8467f7ff45e0b2e6a6bc33dabb45_D20220101-20220331" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtMTAtMS0xLTU3MzM3_d8b7b2eb-4627-40ef-a813-14f4bc9218fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i491f8467f7ff45e0b2e6a6bc33dabb45_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtMTItMS0xLTU3MzM3_21316b5c-7347-4edf-bf1a-8b65717a75a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7b139b5a19b94648b6cd590da2967190_I20220331" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtMTQtMS0xLTU3MzM3_2929b52c-d484-42d3-9221-00720a47f535">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtNi0xLTEtNTczMzc_ee8857fc-576b-41b1-8014-37698a2241f9">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtOC0xLTEtNTczMzc_e6827987-8b19-4b22-b83d-b31bbab58896">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtMTAtMS0xLTU3MzM3_d07dd146-11a0-4a85-b209-f0abeae02aba">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtMTItMS0xLTU3MzM3_c12bba18-c974-4971-b905-e43aadd769d7">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtMTQtMS0xLTU3MzM3_b5e4811e-23a0-4927-ba6e-d1f4c6bf7139">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note. 12 Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div></ix:continuation></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_118"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90ZXh0cmVnaW9uOjNjNDcxOTZjMmZlYzQwOGI5ZmUyNzlmY2I4NjMzOWZlXzI4MDA_544314c0-c5ca-4606-8812-f4a35c1635de" continuedAt="if5722b85d5144f29965da36e33bf09fc" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="if5722b85d5144f29965da36e33bf09fc"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90ZXh0cmVnaW9uOjNjNDcxOTZjMmZlYzQwOGI5ZmUyNzlmY2I4NjMzOWZlXzU0OTc1NTgxNDMwNzU_056946f6-6cf8-462d-b1cb-7592f5dc6981" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of March&#160;31, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"></td><td style="width:61.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ad7b614817843a2a51daa8dac6c033e_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzItMS0xLTEtNjY5NTY_63449a8c-08a3-4a05-8877-d2a2735f3c2c">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id1d7e92567284313b0215206d23cf138_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzItMy0xLTEtNjY5NTY_baa1835a-d7a6-4199-80ef-68583d9c196b">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01f86ee5c7454a6daf1539b8ff9154fd_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzMtMS0xLTEtNjY5NTY_e22058c4-12e4-4fdb-96d6-494378aa01a6">16,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1d1313b2a80c4a2b83d39bef2b31ff64_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzMtMy0xLTEtNjY5NTY_37c161d9-7a42-4391-a9fe-3bbdf9bdf1e3">14,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6df6b49ba9af4253b2980614997544b3_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzQtMS0xLTEtNjY5NTY_4a2170b6-e5f0-4c37-8731-7173cbad3987"><ix:nonFraction unitRef="shares" contextRef="i442503d958e94d1cbb92a12c86bfd18d_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzQtMS0xLTEtNjY5NTY_8c0ac15e-7400-4d56-a40d-74f33ebfdc86">6,555</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i638a4bc304a64fefb58743f705706eb0_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzQtMy0xLTEtNjY5NTY_15befb67-bc52-436c-8e75-e1e89c7e9f05"><ix:nonFraction unitRef="shares" contextRef="ifb83446dcd9e42a599260539ad1c0a9e_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzQtMy0xLTEtNjY5NTY_95b1cd95-50f9-449b-ad14-94576d0fd348">&#8212;</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzUtMS0xLTEtNjczNzA_8e6b32e1-d9b6-45d8-bc54-af9eb70ddc6a">23,537</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzUtMy0xLTEtNjczNjg_30f70133-10fd-428e-8645-75150316a0e8">15,774</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_121"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyNDc_9c8814ac-b73a-4fd5-b005-8f93fe184e8b" continuedAt="i997977ee568042b3b244665be03cd2fb" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i997977ee568042b3b244665be03cd2fb" continuedAt="i91322bb86055488da6cd71c332c68ee5"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyNDA_5f476810-fdb8-4f19-8e18-5b27199cee39" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations and Comprehensive Loss for three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:433.50pt"><tr><td style="width:1.0pt"></td><td style="width:277.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:73.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08791a0aa370455b99495a2b83190943_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzItMS0xLTEtNTczMzc_c366e0eb-8ef2-4f24-8444-2a9db365dc52">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b72109f9aee425d9d32f4948d46c658_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzItMy0xLTEtNTczMzc_9d47beb0-1a39-4f95-9d55-6903ecf37bcb">178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i548c92c454ec4c8eb027f6787d1601b5_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzMtMS0xLTEtNTczMzc_f803c2e4-8720-47e1-ad40-d97ca6505ba3">1,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064bfd4b1d304882b1628ad085b4d6c2_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzMtMy0xLTEtNTczMzc_8dc1701a-bd59-4f0b-a8aa-27505d9f4e1a">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzQtMS0xLTEtNTczMzc_cbd5c0bb-3e2a-40d6-8f44-d09b6916febb">1,894</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzQtMy0xLTEtNTczMzc_c6ff2285-9c3c-425b-b3fb-aadaa1e4013e">958</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i91322bb86055488da6cd71c332c68ee5" continuedAt="i35b414f64b3941fb860bdea565432929"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by <ix:nonFraction unitRef="shares" contextRef="icf9f504438bf430eb66685abf363cbbe_D20190601-20190630" decimals="-5" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzExMDA_17ae0bbd-1f56-4efd-849f-9a42072ad7dc">7.9</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by <ix:nonFraction unitRef="shares" contextRef="id04c1f00c3054d6b86cd44222571b020_D20210501-20210531" decimals="-6" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzE1Njk_186d25f9-f402-4448-8e74-b3e72793a8d4">12</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately <ix:nonFraction unitRef="shares" contextRef="i0ed5641b729d40d8b652fe7425a4c97c_I20220331" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzE2Nzc_197130e7-7bb4-456c-a0e3-5af4ff7039bc">3.6</ix:nonFraction>&#160;million shares of common stock available for issuance under the 2014 Plan as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a <ix:nonNumeric contextRef="i3414053ba29c49659486e8317c638717_D20220101-20220331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyMzk_e0976c9a-9e45-4a96-a6f1-e3cb2bf28409">four-year</ix:nonNumeric> period at the rate of <ix:nonFraction unitRef="number" contextRef="i3644a46ac29a4cd088a111e400276c65_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzE4NTQ_0b012fed-e7fb-4087-acd0-51536232d69d">25</ix:nonFraction>% of the grant vesting on the first anniversary of the date of grant and <ix:nonFraction unitRef="number" contextRef="i843c8c42b555485e8edc0700629c070d_D20220101-20220331" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzE5Mjg_9df13bc1-fcfd-4d62-9a4a-7ff6a8a2dd22">6.25</ix:nonFraction>% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of <ix:nonNumeric contextRef="i3414053ba29c49659486e8317c638717_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIwODc_bc8ff8d8-de03-48e8-bd21-55e1d810ff54">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i0ed5641b729d40d8b652fe7425a4c97c_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU0OTc1NTgxNTA4OTM_d76d9811-6fab-416c-ae83-0886a78463d3">13.2</ix:nonFraction>&#160;million stock options outstanding under the 2014 Plan as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="i7b5fbafca91d4ed69dc2dd77e2c3d271_I20211001" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzEwOTk1MTE2MzY4NDk_94854535-d587-469d-be57-a7e06c334e29">one</ix:nonFraction> share of the Company&#8217;s common stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately <ix:nonFraction unitRef="number" contextRef="i070828932cb7457b89a6d3428bf1884e_I20211001" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMzNjA_02eb1e05-b6e3-4dd7-ae03-9e5573b8c2ec">fifty</ix:nonFraction> percent of current base salary. Each PSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="i070828932cb7457b89a6d3428bf1884e_I20211001" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzM0NDU_b20e7da0-495c-4bb4-8a6e-9a656cd8eb39">one</ix:nonFraction> share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of March&#160;31, 2022 achievement was deemed probable for only the cash management milestone, representing  <ix:nonFraction unitRef="number" contextRef="ibe0c595a8b504aa7a9ef9bed9511cc7c_I20220331" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIxOTkwMjMyODAwNzQ_5db50417-6b15-46ea-88a5-da0ce5faf6ae">20</ix:nonFraction>% of the PSU awards.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of <ix:nonNumeric contextRef="i20b6c5aa1a3c4bd7a85f15364a9f7f10_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzUzMzc_d33f41fb-dac6-4f14-af08-3dd0a5e7daa3">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i20b6c5aa1a3c4bd7a85f15364a9f7f10_D20220101-20220331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzUzODk_474771d6-dedf-46aa-8a75-4c4a582b3d96">0.1</ix:nonFraction> million fully vested stock options outstanding under the 2009 Plan as of March&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately <ix:nonFraction unitRef="shares" contextRef="i8efee58bbcb34cfeb4ebe4d44af7870e_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU4OTc_3ec9a96c-e542-4d4f-a3f0-352c09cc8ff0">3.5</ix:nonFraction> million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyMzQ_f3afa9e2-daea-46a6-b03c-3b3c2967769b" continuedAt="i8710763cc2764dbfa872f8768e3ede5e" escape="true">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the three months ended March 31, 2022:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i35b414f64b3941fb860bdea565432929" continuedAt="ic068028c06254b73a0d303081601a440"><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="i8710763cc2764dbfa872f8768e3ede5e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:41.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzktMS0xLTEtNTczMzc_63335b3e-8641-4b4d-8a00-7ac88de1d42d">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzktMy0xLTEtNTczMzc_6650d19e-5169-40df-ab19-7ff5e417bc09">1.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4a6dde7845004b009c604f58eaaf54f2_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzktNS0xLTEtNTczMzc_4223d77c-4c23-4d95-b7fb-8a6d84ae39ef">8.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzktNy0xLTEtNTczMzc_b2aba3a2-e76a-4086-88ee-9795a009fa41">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEwLTEtMS0xLTU3MzM3_3a9345aa-e7fa-41d8-b303-16b4c4b9b340">1,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEwLTMtMS0xLTU3MzM3_d0121aee-2d31-4c4f-9eb4-e1b51df5a599">0.71</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzExLTEtMS0xLTU3MzM3_80b0b06d-2913-49a0-a324-0defa81163b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzExLTMtMS0xLTU3MzM3_8051bf34-28a7-4abe-aeb0-48d4abb28ab8">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEyLTEtMS0xLTU3MzM3_c6519f6d-253b-459a-9fb1-bf0a0a3202bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEyLTMtMS0xLTU3MzM3_4e1955ac-6fcd-4b5d-be6c-5c6105e22e08">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEzLTEtMS0xLTU3MzM3_ee2122e7-d313-42d3-b65c-c715a8290c15">16,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEzLTMtMS0xLTU3MzM3_4a5a99d3-dbec-4930-9d00-69be0c229be0">1.85</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEzLTUtMS0xLTU3MzM3_063913eb-e7cb-484e-baf8-fe35354503a5">7.92</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEzLTctMS0xLTU3MzM3_cb196aa0-883d-410b-a13f-da5a5e53d7d4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzE0LTEtMS0xLTU3MzM3_1db4361e-f806-46ca-bcbc-42184dcd75b7">8,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzE0LTMtMS0xLTU3MzM3_2fb7045d-08d7-408e-9817-bdf085952b6c">1.68</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzE0LTUtMS0xLTU3MzM3_01b6ee48-08d1-4cb9-88ab-832bd3c4df9e">7.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzE0LTctMS0xLTU3MzM3_1a79a733-732d-4f2d-8489-3231b92121f5">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ4OTMyNjY_cae28894-94e6-4d16-953a-757dc3903f19">1.9</ix:nonFraction>&#160;million for the three months ended March 31, 2022. The stock option related expenses were</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY0MDE_7532ad19-0217-4d97-b6fa-208a9a3e129a">1.3</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzEwOTk1MTE2MzUyMjA_e6b2eb88-d781-43cd-ac67-cd05b2b13668">1.0</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March 31, 2022 and 2021, respectively. As of March&#160;31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY2MzI_8609337d-9175-4e57-b4cb-bd16702abe65">9.6</ix:nonFraction> million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY3ODQ_3fcbcc96-dec0-4269-97a7-c4582eb96c59">2.56</ix:nonNumeric> years. The weighted-average grant-date fair value of stock options granted during the three months ended March 31, 2022 and 2021 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY5MDM_122fe888-456f-4f93-8bf1-337063f851be">0.45</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY5MDc_4c4c8da1-ffb2-4cfa-ac45-8b4dd0ab3584">2.05</ix:nonFraction>, respectively. <ix:nonFraction unitRef="shares" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIxOTkwMjMyODAwODI_ed694df5-cf62-40c9-a674-3c84335b8c26">No</ix:nonFraction> stock options were exercised during the three months ended March 31, 2022. The total intrinsic value of stock options exercised for the three months ended March 31, 2021 was de minimis.</span></div><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyNDQ_724a3b75-4ffd-44ab-b517-c90344a46e1c" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:64.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzItMS0xLTEtNTczMzc_77f1fe5e-890c-4ef7-8c93-a3062913fd78">0.71</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzItMy0xLTEtNTczMzc_82bf6ac4-e22d-487a-b91e-71f1464e0afa">3.15</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i3baa1439c0ea43b08add2b44f358ac2d_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzMtMS0xLTEtNTczMzc_2a52a63c-ad9d-4759-a00b-7c626e87b78f">0.71</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i721f2630aa8b4812af090675ea7c48d8_I20210331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzMtMy0xLTEtNTczMzc_7c28631a-9700-4110-8c4f-57cdf1f765ff">3.15</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzQtMS0xLTEtNTczMzc_39f784a9-8324-4057-914a-8c871d8a8edd">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzQtMy0xLTEtNTczMzc_74ac8209-a2b5-4752-8fb3-201f9f66db13">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzUtMS0xLTEtNTczMzc_a656431e-6011-46d6-998b-65d08637118e">1.7</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzUtMy0xLTEtNTczMzc_f3ed09a1-99bf-44a3-8944-087235931770">0.8</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzYtMS0xLTEtNTczMzc_48d679b9-cbe5-41af-921e-bd459a84d05e">71.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzYtMy0xLTEtNTczMzc_8eb8da68-96ff-4a0a-a0e9-d3d416c3e318">75.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzctMS0xLTEtNTczMzc_48efc603-3898-4f12-83ae-638f6342b90e">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzctMy0xLTEtNTczMzc_9f4524e1-fe94-48eb-83a4-16c480564ad2">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units </span></div><ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU0OTc1NTgxNjE4NTE_55c13a8f-a6ea-490a-a25e-9913c47ec891" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the three months ended March 31, 2022:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:60.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzEtMS0xLTEtNjc2MjY_ec02523e-7c75-4581-833c-fa157751a5e4">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzEtMy0xLTEtNjk5Mzg_fea032d5-3632-423f-8f17-820d42cbbff1">0.80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6795b392d224fd1958f431310a8ae42_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzItMS0xLTEtNjc2MjY_2a7045a0-8012-4fe9-bbce-ce05e05530e1">3,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="if6795b392d224fd1958f431310a8ae42_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzItMy0xLTEtNjk3MTI_c61d5e2a-6c0c-4fe1-af83-3666ca7cb22f">0.67</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c321cdcae954377903223a91776e0b9_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzMtMS0xLTEtNjc2MjY_83ab7b9f-31d4-4a0b-bde8-ff88eeb8c91c">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1c321cdcae954377903223a91776e0b9_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzMtMy0xLTEtNjk3MTI_b03ad00c-53f9-4524-8b7a-335f7cce455d">0.67</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzQtMS0xLTEtNjc2Mjg_da85325a-441b-41bd-a525-9e04434a13c9">8,005</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzQtMy0xLTEtNjk5NDA_ad4ef1da-38bb-4a98-8233-ccaaf8dc3c8d">0.72</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="shares" contextRef="i41cd54bf6e0e43108d5f54b38cbcef44_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU0OTc1NTgxNjA5NjA_e1735b19-3abc-487d-9e12-3cb5c11121a6"><ix:nonFraction unitRef="shares" contextRef="ie9646b6fad074c349a38b736d334913f_D20210101-20210331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU0OTc1NTgxNjA5NjA_e466559e-ea25-44b3-a3fa-4ec4c67d94bc">no</ix:nonFraction></ix:nonFraction>t grant any RSUs or PSUs during the three months ended March 31, 2021. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic068028c06254b73a0d303081601a440">The share-based compensation expense related to RSUs and PSUs for the three months ended March 31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="if6795b392d224fd1958f431310a8ae42_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzEwOTk1MTE2NDkxMjk_3f0273bc-47c8-4354-aad7-67040b08208c"><ix:nonFraction unitRef="usd" contextRef="i1c321cdcae954377903223a91776e0b9_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzEwOTk1MTE2NDkxMjk_dce094e3-67ab-4d42-bb12-6585fcca4d34">0.6</ix:nonFraction></ix:nonFraction>&#160;million. There was <ix:nonFraction unitRef="usd" contextRef="ie9646b6fad074c349a38b736d334913f_D20210101-20210331" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIxOTkwMjMyODAwOTE_b0d4bb97-5770-4850-a23b-bd8ba2838178"><ix:nonFraction unitRef="usd" contextRef="i41cd54bf6e0e43108d5f54b38cbcef44_D20210101-20210331" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIxOTkwMjMyODAwOTE_b79e8573-f5dd-4e60-a8e3-81a3c1977c83">no</ix:nonFraction></ix:nonFraction> shared-based compensation expense related to RSUs and PSUs for the three months ended March 31, 2021. As of March 31, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="if180a9498a6049c5a369d46136508c69_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ5MDU5NDc_79653a1b-85db-4ff8-9a75-e3887254f7bd"><ix:nonFraction unitRef="usd" contextRef="id2d1253ec7414a4b84ffbe87119b85ff_I20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ5MDU5NDc_f42828f8-0de9-4786-a7ce-ee14a503453e">5.0</ix:nonFraction></ix:nonFraction>&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="i1c321cdcae954377903223a91776e0b9_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ5MDU5NjI_04854ce1-c577-4b1a-9e80-a2293f953ecc"><ix:nonNumeric contextRef="if6795b392d224fd1958f431310a8ae42_D20220101-20220331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ5MDU5NjI_bbd488fc-43e3-41a9-bf84-a786aaccdd2c">2.94</ix:nonNumeric></ix:nonNumeric> years.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzI2NTQ_8f06958c-42a4-4f21-818f-27f09fb76260" continuedAt="i2d3892836d4d4c5fb0e4cf2a3c018f7e" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i2d3892836d4d4c5fb0e4cf2a3c018f7e" continuedAt="i9ff3da1753234d72b4398a29e790a7e0"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of <ix:nonFraction unitRef="shares" contextRef="i249eb5f45f4a43748f1453177c588a6e_I20140228" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzM4Ng_1a9d040e-dd8f-4512-967d-3b61035440ca">0.2</ix:nonFraction>&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by <ix:nonFraction unitRef="shares" contextRef="ia471201fe4bb48848f6167bcc65d599c_D20210501-20210531" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzYxNg_b57cb2fb-6e95-4ca2-8a7a-4cd7e2328ca2">2.3</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="i015e286376344c4c9c156e22c95fc9c6_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzk2Mw_4adea22b-8b77-4f36-adf1-10b07d56e208">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of March&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i703ddc2f34bf4c4fa0e273c40ad0142a_I20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzEzNzY_9dafa3e7-d853-4142-863d-0d6051cdc026">2.3</ix:nonFraction>&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP for the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to <ix:nonFraction unitRef="number" contextRef="i1448067179f94f71ac95826b8ee7a5be_D20220101-20220331" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzE4NzE_3e04efaa-d7af-45ab-a709-8a75b71e3fca">100</ix:nonFraction>% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i1448067179f94f71ac95826b8ee7a5be_D20220101-20220331" decimals="INF" name="sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzIwNzA_0d36f63f-8dfb-45e9-a005-4902d3cbc674">4,000</ix:nonFraction> per year. The expenses incurred for the periods presented were de minimis amount for each of the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9ff3da1753234d72b4398a29e790a7e0">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first <ix:nonFraction unitRef="number" contextRef="i719e07b970f244aaa770a65739f6261a_D20220101-20220331" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzI0NjI_427aefee-2255-4b4a-90d4-26e32c09a7a7">4</ix:nonFraction>% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the three months ended March 31, 2022 and 2021, respectively.</ix:continuation> </span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_130"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="sesn:LicenseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzIwOTQw_ea782f0d-4d26-4520-b0ee-3a6ac524fc90" continuedAt="ib5770a486484422fbc37ab6f38a9ee58" escape="true">LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="ib5770a486484422fbc37ab6f38a9ee58" continuedAt="iceb86784cb5b44458fc5d0f3b08d192b"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $<ix:nonFraction unitRef="usd" contextRef="i75fda142f1274858950bc952a648690a_D20220101-20220331" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY4Mw_81d82ca6-896c-4405-8a26-b1b3b86da105">0.5</ix:nonFraction>&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a <ix:nonFraction unitRef="number" contextRef="id114c77b04144d64bd3d93db2ab92506_D20220101-20220331" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc2NQ_e641166e-0104-4a20-b274-2b63f02f523f">4</ix:nonFraction>% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is <ix:nonFraction unitRef="number" contextRef="id114c77b04144d64bd3d93db2ab92506_D20220101-20220331" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzEwMzY_8d6ba2f9-7006-44de-8e24-cd8d7f82a0af">10</ix:nonFraction>% or greater, provided that the royalty rate to Zurich may not be less than <ix:nonFraction unitRef="number" contextRef="id114c77b04144d64bd3d93db2ab92506_D20220101-20220331" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzExMTM_f902e8dc-8c02-41f0-aebf-2e31520cd5b5">2</ix:nonFraction>% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="i2e725e6c9c5548a683b0b8cd8414f46c_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MDU_15f85c13-a135-4e9b-ae5b-494064d2c143">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6f0b7b32437649f0aebbff5cb5bced22_D20210701-20210930" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MTI_25c8bc14-be96-4120-ad3b-8c92eadd970c">0.5</ix:nonFraction>&#160;million related to meeting a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of March&#160;31, 2022, the Company may be obligated to pay up to &#8364;<ix:nonFraction unitRef="eur" contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzIyODc_b89ffe97-7016-44e3-9000-8c8cc7eb4ce7">2.4</ix:nonFraction>&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $<ix:nonFraction unitRef="usd" contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzI0MzQ_375b0df0-2f8d-4a10-8f79-eafa994d894e">2.7</ix:nonFraction>&#160;million at exchange rates in effect on March&#160;31, 2022). The Company is also required to pay up to a <ix:nonFraction unitRef="number" contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzI1MTc_774c3aeb-d5a7-4c87-a3c4-f50cc0efc4b8">3.5</ix:nonFraction>% </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="iceb86784cb5b44458fc5d0f3b08d192b" continuedAt="i1fff6c78070a444ebf40b66e149a47d5"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to <ix:nonFraction unitRef="number" contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331" decimals="INF" name="sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzI2ODY_d465cdb7-3898-4b40-857d-d97c039cfb55">1.5</ix:nonFraction>% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;<ix:nonFraction unitRef="eur" contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331" decimals="-3" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzMwNzk_a9e9c2a6-38e1-42e7-a51e-2e4b0534897f">50,000</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331" decimals="0" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzMwOTc_837ad622-9049-4f61-88e0-93ad0947a899">55,559</ix:nonFraction> at exchange rates in effect as of March&#160;31, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i3170a4ca7c3743c2af7e5c8f5d4ce2eb_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzMyNTQ_b92e2053-3ba8-4dd0-b1f1-7a1de18ddb67">0.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i3170a4ca7c3743c2af7e5c8f5d4ce2eb_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzMyNTg_c870a08d-8ee4-4943-8d07-150b02d6d7c1">0.9</ix:nonFraction>&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i6b8e64e250af4d2790f73c3b79426507_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzM0Nzk_3031afd6-91eb-4c33-b674-e88624977713">0.5</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i6b8e64e250af4d2790f73c3b79426507_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzM0ODM_aa2338d9-a273-42ab-9a59-ebf885b7b70e">0.6</ix:nonFraction>&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $<ix:nonFraction unitRef="usd" contextRef="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331" decimals="-4" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzQxOTI_5454d925-2e6a-4fc8-bfc7-937a0607e112">0.25</ix:nonFraction>&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#8217;s clinical development pathway. The Company is also required to pay a <ix:nonFraction unitRef="number" contextRef="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzQ1MjI_537affa1-c5e4-43ac-ac12-ddb298955d39">2.5</ix:nonFraction>% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than <ix:nonFraction unitRef="number" contextRef="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzQ4NDA_9b1b9739-d757-442a-aaec-6d37bd1ed32b">1.75</ix:nonFraction>% of net sales. In addition, the foregoing royalty rates are reduced by <ix:nonFraction unitRef="number" contextRef="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzQ5MTM_82897b9a-fc12-465a-9103-f55f507398d2">50</ix:nonFraction>% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i5115ded926c24cf0bfdc639b4a65bd23_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzYxMzM_03152e80-540a-4fa0-91ec-1c6f444e6864">7.5</ix:nonFraction>&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="i5115ded926c24cf0bfdc639b4a65bd23_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAdditionalUpFrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzYyOTk_47c46f7c-212e-4bd7-b142-9a10ba97266a">262.5</ix:nonFraction>&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="i35b7f963b9974be1ae64730ce05532ff_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY0ODU_6a1e3af4-b4a8-4fde-ab0e-ebca38b4f54e">197.5</ix:nonFraction>&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="i0f201162abfc475998aec36e2f378832_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY2MTQ_8dd2bb7b-1cff-4169-81bc-f34b915b7328">72.5</ix:nonFraction>&#160;million in development milestones, the next of which is $<ix:nonFraction unitRef="usd" contextRef="i860ae1f5203e49a08aa91ee83b20d7e5_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY2NjU_61ec173d-6451-4893-b5ff-964b15d590e1">30</ix:nonFraction>&#160;million for initiation of the first Phase III clinical trial, (ii) $<ix:nonFraction unitRef="usd" contextRef="i8aab7a1843994c3488d3876ab37fc007_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY3Mjc_173861ef-85ed-4e63-a4ce-804e73fff412">50</ix:nonFraction>&#160;million in regulatory milestones and (iii) $<ix:nonFraction unitRef="usd" contextRef="i425a0d3a4bfe493e99909f42b47fd556_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY3NjU_3294b4c5-acf1-42a7-b18e-8dc81148f91e">75</ix:nonFraction>&#160;million in commercialization milestones. Additional amounts of up to $<ix:nonFraction unitRef="usd" contextRef="ide74b46daaba4a75ad68f84d5d0e6d0f_D20220101-20220331" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY4Mjk_38b9bbde-bafd-4166-af12-d8e92ae9b84f">65</ix:nonFraction>&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $<ix:nonFraction unitRef="usd" contextRef="i607e98a9eea546b983ca1b261b279229_D20160901-20160930" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzcwMTg_9b1090b0-7791-4bfa-8862-50ba0714d2f1">22.5</ix:nonFraction>&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $<ix:nonFraction unitRef="usd" contextRef="i4aafe20143b64883857f4e9a3c846e12_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzcxNjE_64afd44b-f816-40a9-b442-0d94325ba6ce">20</ix:nonFraction>&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the provisions of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification 606, Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606&#8221;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company invoiced Roche $<ix:nonFraction unitRef="usd" contextRef="i05e3cb0224f54a1186393da585df2efb_I20220331" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc0NzU_b2d22bf8-9cff-41d1-887a-46647efd5ac8">20</ix:nonFraction>&#160;million with payment terms of <ix:nonNumeric contextRef="i2fba7eecc61a49598234f514785e0ed0_D20220101-20220331" name="sesn:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc1MDA_c8428466-54d8-4b05-88ac-b85d78703947">30</ix:nonNumeric> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $<ix:nonFraction unitRef="usd" contextRef="ic5ec8b79f17f43bbb84e97e2a5566d46_D20211001-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc2MTY_ff9bb9d8-8573-4e93-b00e-16a988fd6236">20</ix:nonFraction>&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $<ix:nonFraction unitRef="usd" contextRef="i4b8e98722c2b4cdcb4f305e34994b6e7_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc3Mzk_d770ac7b-04f4-4ae9-817c-543fe882b489">20</ix:nonFraction>&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from <ix:nonFraction unitRef="number" contextRef="id273db7a5ed6402bb34a4872220bae45_I20220331" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc4OTQ_9e24854a-9139-4524-b186-a4f818c21c10">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i17d89aea5f0f47dd8400fd0b5a4720c9_I20220331" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc5MDA_b95baaaf-087c-4ec8-bfb7-2401d116ab99">15</ix:nonFraction>% of net sales of potential future products containing EBI-031 and up to <ix:nonFraction unitRef="number" contextRef="icf94f20a694b4bee91f6f6da52f38a93_I20220331" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc5NzQ_cd421653-ced8-473e-b2e0-cc451b3a9d23">50</ix:nonFraction>% of these rates for net </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i1fff6c78070a444ebf40b66e149a47d5" continuedAt="ib440e15621c94157aa94b3b3d4289c65"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for <ix:nonFraction unitRef="period" contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630" decimals="INF" name="sesn:LicenseAgreementOptionPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzgyMzg_ad0613e8-f9b8-4cf2-86f9-c9db51864cca">two</ix:nonFraction> &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $<ix:nonFraction unitRef="usd" contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzg3Mzc_713e8b9d-ad31-4a3f-afc2-ed73d12ce395">135</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzg3NDc_9c52cc27-0685-4353-947c-60ee43b617b9">30</ix:nonNumeric> days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within <ix:nonNumeric contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzkyNTM_276f41cc-ef8a-494b-9a37-642bada9921a">30</ix:nonNumeric> days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $<ix:nonFraction unitRef="usd" contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzkzNTE_f3326ac6-ea4c-48bf-8139-c55c17ebe54f">265</ix:nonFraction>&#160;million, which amount would be reduced to $<ix:nonFraction unitRef="usd" contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzkzODg_f6612019-4469-4633-ad7e-e80b7f0296c1">220</ix:nonFraction>&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#8220;Qilu License Agreement&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="iea001a4f9d934dd893e45269b2383c74_D20200730-20200730" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzExNjQx_8471dda9-1e81-43bd-95af-1d1c1d15531f">12</ix:nonFraction>&#160;million, and milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="iea001a4f9d934dd893e45269b2383c74_D20200730-20200730" decimals="-6" name="sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzExNjgz_c8066d0b-9e1f-44ca-a400-e9fed33766b5">23</ix:nonFraction>&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a <ix:nonFraction unitRef="number" contextRef="iea001a4f9d934dd893e45269b2383c74_D20200730-20200730" decimals="2" name="sesn:BusinessCombinationRoyaltyPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzExOTg1_488227b5-6495-4fb1-b7ae-7307702dc93e">12</ix:nonFraction>% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) <ix:nonNumeric contextRef="i6f42a6de33704f62b0e682799149f0e6_D20200730-20200730" name="sesn:CollaborativeArrangementRoyaltyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzIxOTkwMjMyNzk0MTc_0bfd6ed5-ca7b-46e7-902c-1302df974960">twelve years</ix:nonNumeric> after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ib440e15621c94157aa94b3b3d4289c65" continuedAt="id57e5b7d810f4dff9a71850e53e40104"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $<ix:nonFraction unitRef="usd" contextRef="i40d094d92f884dde854fd3394639b343_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MDI1_a81e9226-9a90-43ad-ab79-767f52ec7cb0">11.2</ix:nonFraction>&#160;million and was based on the up-front fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="id8142289592f45f3ac1543eeb3a12d8f_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MDgx_2b8ec1d3-85a0-44ee-9907-e288e3bbd603">12</ix:nonFraction>&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $<ix:nonFraction unitRef="usd" contextRef="ibd649cc1b18c474ab1dd1aab76c6641c_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1Mjk2_a7d5641b-e33d-47ba-8c6a-24a12a3bee3d">11.2</ix:nonFraction>&#160;million of the total $<ix:nonFraction unitRef="usd" contextRef="ibd649cc1b18c474ab1dd1aab76c6641c_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MzEy_3d9ecb38-4660-4ff6-a893-54312be5c64e">11.2</ix:nonFraction>&#160;million transaction price was considered earned and the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i7ad5cac1a07b45d6ba8c79753fc4a02f_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1Mzgw_21f65d5d-2d5f-4531-b89c-bec1404bac39">11.2</ix:nonFraction>&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $<ix:nonFraction unitRef="usd" contextRef="ibcc08ea5943f404b9c1b2ff1c2b62d78_D20210101-20210331" decimals="-6" name="sesn:BusinessCombinationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1NjUy_5d6a3473-c59c-487b-a43b-ce347afd551b">3</ix:nonFraction>&#160;million milestone payment from Qilu, the first milestone payment out of the $<ix:nonFraction unitRef="usd" contextRef="ibcc08ea5943f404b9c1b2ff1c2b62d78_D20210101-20210331" decimals="-6" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1NzIz_f4d073bf-43fb-4cf2-90a0-46c27df5dc63">23</ix:nonFraction>&#160;million in potential milestone payments. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="ibcc08ea5943f404b9c1b2ff1c2b62d78_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1Nzgw_97fe8cca-802f-4500-b226-28fc979e7bcb">2.8</ix:nonFraction>&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i6380f74d6af34e0fb121780679e0dbd2_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE2MTg5_84b5e03c-81ec-4153-a13f-a047f0573dc8">0.9</ix:nonFraction>&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i7ab08b81f1a8468bb8602311426ac4a5_D20201130-20201130" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE3MDkz_1d9637bc-fc1d-4e0a-9251-8657c7b72c0f">3</ix:nonFraction>&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $<ix:nonFraction unitRef="usd" contextRef="i0473c8cf700e465d8a8670d029d1a17e_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE3NTI0_0163c53c-654a-4484-8b41-6297fe9d99ab">1.5</ix:nonFraction>&#160;million as of December 31, 2020 and was based on <ix:nonFraction unitRef="number" contextRef="i0473c8cf700e465d8a8670d029d1a17e_I20201231" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE3NTY4_1af5f7b3-a0ee-490f-a400-5a3f6f17cd19">50</ix:nonFraction>% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($<ix:nonFraction unitRef="usd" contextRef="i0473c8cf700e465d8a8670d029d1a17e_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE3NzIy_5623fa36-727b-4f56-9a70-90bbeb6eb936">1.5</ix:nonFraction>&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained and recorded as deferred revenue. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $<ix:nonFraction unitRef="usd" contextRef="i4d312124644e44a09f50ee532d536d0c_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE4NDA5_9cc882bb-9dd3-4b20-89f8-5678108b50fb">1.5</ix:nonFraction>&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of March&#160;31, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ia2dcc52dfed04067b81a5e2472d5ab8d_I20210805" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE5NDI3_c827158d-d170-472f-8a5a-df2881fcc170">1.5</ix:nonFraction>&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $<ix:nonFraction unitRef="usd" contextRef="ib2f514ca47c14bcc81a567e7c8ee3089_D20210805-20210805" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE5Njg2_c5c6f48e-9e0e-4822-a7c7-a8227fe5a311">2.0</ix:nonFraction>&#160;million and is also entitled to receive a <ix:nonFraction unitRef="number" contextRef="ib0ea7fa933c347ecacaa65b87757c77a_I20210805" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE5NzIz_a19f5ab3-3e5d-4013-9fd7-ede32c57b1b8">30</ix:nonFraction>% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of March&#160;31, 2022, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="id57e5b7d810f4dff9a71850e53e40104" continuedAt="i712f23ecdcf640528050171c037e2b3e"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was estimated by management</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, therefore no revenue was recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of March&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i712f23ecdcf640528050171c037e2b3e"> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</ix:continuation> </span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_136"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90ZXh0cmVnaW9uOjIxZjU2MWEzN2IwNzQ0YTM4NmY5YzM5MDNhOTcyMjQ2XzEwNzI_dc82289c-8c41-4dc2-b70d-eac6947f8759" continuedAt="i58d3c50912aa4ade9f7528122e3f3f20" escape="true">RESTRUCTURING AND RELATED ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i58d3c50912aa4ade9f7528122e3f3f20"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restructuring Plan included a reduction in the Company&#8217;s workforce by <ix:nonFraction unitRef="position" contextRef="i35e5be36237a414280b903dade9eff3e_D20210830-20210830" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90ZXh0cmVnaW9uOjIxZjU2MWEzN2IwNzQ0YTM4NmY5YzM5MDNhOTcyMjQ2XzQxOQ_ab405c40-213e-45f0-9ed2-6369463a08d6">18</ix:nonFraction> positions (or approximately <ix:nonFraction unitRef="number" contextRef="i35e5be36237a414280b903dade9eff3e_D20210830-20210830" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90ZXh0cmVnaW9uOjIxZjU2MWEzN2IwNzQ0YTM4NmY5YzM5MDNhOTcyMjQ2XzQ1MA_5825f03f-d6ae-4e42-89ca-46966747c586">35</ix:nonFraction>% of the Company&#8217;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90ZXh0cmVnaW9uOjIxZjU2MWEzN2IwNzQ0YTM4NmY5YzM5MDNhOTcyMjQ2XzEwNzM_fbee2a37-e44e-47f4-aada-e204f64ce580" continuedAt="i6ab332ef72664bf49a89fdfafaab0ead" escape="true">The following is a summary of accrued restructuring costs related to the Restructuring Plan, (in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="i6ab332ef72664bf49a89fdfafaab0ead"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90YWJsZTo4YTJjMDExYzRiYzA0MzJkYWUxZTAwODkwYzcwMGEwMy90YWJsZXJhbmdlOjhhMmMwMTFjNGJjMDQzMmRhZTFlMDA4OTBjNzAwYTAzXzItMS0xLTEtNTczMzc_e6b40f96-3e8f-4ddc-a284-ffa9df914d7f">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRestructuring" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90YWJsZTo4YTJjMDExYzRiYzA0MzJkYWUxZTAwODkwYzcwMGEwMy90YWJsZXJhbmdlOjhhMmMwMTFjNGJjMDQzMmRhZTFlMDA4OTBjNzAwYTAzXzMtMS0xLTEtNTczMzc_1141b181-dd15-4103-9e70-3b5fc1a67349">507</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90YWJsZTo4YTJjMDExYzRiYzA0MzJkYWUxZTAwODkwYzcwMGEwMy90YWJsZXJhbmdlOjhhMmMwMTFjNGJjMDQzMmRhZTFlMDA4OTBjNzAwYTAzXzctMS0xLTEtNTczMzc_c112f171-9ccd-42b4-a008-c266228d7376">990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that substantially all of the accrued restructuring costs as of March&#160;31, 2022 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div></ix:continuation><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1522"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xNTIyL2ZyYWc6NzU3ZGJkMzYwMTI3NDQ1NDk3YWRmN2U2NjRhNTA1ZWEvdGV4dHJlZ2lvbjo3NTdkYmQzNjAxMjc0NDU0OTdhZGY3ZTY2NGE1MDVlYV8xMzc0Mzg5NTM1NDcyMA_3d6b2162-d1c0-4c15-84dd-42d181b097e0" continuedAt="icad205f9b4ed4a6c8035e9e1d1806f03" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icad205f9b4ed4a6c8035e9e1d1806f03">On May 3, 2022, Sesen Bio, Inc., (the &#8220;Company&#8221;) announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of the Company&#8217;s proprietary technologies. The Company is actively working with an investment bank in this process. Pending any decision to undertake any strategic alternative, the Company is continuing its development activities in accordance with its existing business strategy.</ix:continuation></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1230"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form 10-Q, should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes thereto appearing elsewhere herein and our audited annual consolidated financial statements and related notes thereto and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2022. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, the impact of the COVID-19 pandemic, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resolve the issues identified in the complete response letter (&#8220;CRL&#8221;) we received from the US Food and Drug Administration (&#8220;FDA&#8221;) regarding our Biologics License Application (&#8220;BLA&#8221;) for Vicineum&#8482; for the treatment of bacillus Calmette-Gu&#233;rin (&#8220;BCG&#8221;)-unresponsive non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;); </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resolve the concerns identified in the European Medicines Agency&#8217;s (&#8220;EMA&#8221;) Withdrawal Assessment Report related to our marketing authorization application ("MAA") for Vysyneum&#8482; (the &#8220;EMA Withdrawal Report&#8221;);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that we have a clear understanding of what additional information regarding chemistry, manufacturing and controls ("CMC") is required for potential resubmission of a BLA for Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, including an additional Phase 3 clinical trial, and that any such future clinical trials can proceed while addressing CMC issues raised in the CRL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to conduct an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC to address questions related to clinical matters raised in the CRL;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to review strategic alternatives with the goal of maximizing shareholder value</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to continue our development activities in accordance with our existing business strategy pending any decision to undertake any strategic alternative;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resubmit a BLA for Vicineum for the treatment of NMIBC to the FDA following the issuance of the CRL by the FDA, and if approved by the FDA, our ability to commercialize Vicineum for the treatment of NMIBC;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans and ability to resume pursuing regulatory approval of Vysyneum</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8482;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union) of NMIBC in the European Union when there is more clarity from the FDA on next steps for Vicineum in the US;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to work closely with the FDA to understand next steps for Vicineum for the treatment of NMIBC in the US;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to work closely with the EMA to understand next steps for Vysyneum</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of NMIBC in the European Union;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the completion of the independent internal review completed in February 2022, including any related investigations, reviews or proceedings, shareholder lawsuits or reputational harm;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expected future loss and accumulated deficit levels;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the difficulties and expenses associated with obtaining and maintaining regulatory approval of Vicineum for the treatment of NMIBC in the United States, the European Union and other non-US jurisdictions, and the labeling under any approval we may obtain;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected financial position and estimated cash burn rate;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that we will have sufficient future cash flows from additional geographic regions outside the US to support the value of our goodwill and EU indefinite-lived, acquired in-process research and development ("IPR&amp;D");</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of NMIBC;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimations regarding any remeasurement of contingent consideration liability in the future;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimations regarding any potential impairment to our goodwill and indefinite-lived intangible asset in the future;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for, and ability to obtain, additional</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financing;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our need to raise substantial additional capital to fund our operations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success, cost and timing of our pre-clinical studies and clinical trials in the United States and other non-US</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and costs associated with our manufacturing process and technology transfer to Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) for the production of Vicineum drug substance and drug product, and our reliance on Qilu to perform under our agreement with Qilu;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size and growth of the potential markets for our product candidates, and our ability to serve those markets;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates and our proprietary technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategic operating plan to sublicense Vicineum for the treatment of NMIBC to business development partners in all regions outside the US, including the European Union, to earn a potential combination of upfront, milestone, and royalty payments, and the business development partner to bear the majority of regulatory and commercialization costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding key advantages of our targeted fusion protein therapeutics (&#8220;TFPT&#8221;) platform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that Vicineum may work via a dual mechanism of action to directly kill cancer cells and activate a local inflammatory process that stimulates T-cells, which then proliferate and destroy the cancer cells;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectation that there may be potential for a synergistic effect when Vicineum is given in combination with checkpoint inhibitors; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the amount and timing of milestone and royalty payments pursuant to our out-license agreements and OUS business development partnership agreements, including our license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;), (the &#8220;Roche License Agreement&#8221;) and our exclusive license agreement with Qilu for the development, manufacture and commercialization of Vicineum in China, Hong Kong, Macau and Taiwan ("Greater China").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, among others, the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may need to raise substantial additional capital to fund our operations;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to resolve the issues raised in the CRL we received from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to resolve the concerns identified in the EMA Withdrawal Assessment Report;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not determine a viable path forward for continued clinical development of Vicineum, which would prevent us from resubmitting a BLA for Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits or enhances shareholder value;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our exploration and evaluation of strategic alternatives or the public announcement thereof may be disruptive to our business operations or cause our stock price to fluctuate significantly;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not achieve profitable operations or access needed capital;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays or difficulties related to the continued clinical development of Vicineum for the treatment of NMIBC, including delays in clinical trial sites receiving the supplies and materials needed to conduct clinical trials, difficulty in establishing or managing relationships with contract research organizations ("CROs"), difficulties in recruiting clinical site investigators and clinical site staff and difficulties in enrolling patients or treating patients in active trials due to COVID-19 or otherwise;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of Vicineum for the treatment of NMIBC, including an additional Phase 3 clinical trial for Vicineum, or any of our other product candidates, may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other non-US regulatory authorities or otherwise produce favorable results;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not obtain marketing approval of Vicineum for the treatment of NMIBC in the United States, the European Union or other non-US jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Vicineum may not gain market acceptance for the treatment of NMIBC in the United States, the European Union or other non-US jurisdictions;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market opportunity for Vicineum may be limited to those patients who are ineligible for established therapies or for</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whom prior therapies have failed;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience issues or delays with third-party disposition, labelling and packaging of clinical supply of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors may discover, develop or commercialize products before, or more successfully than, we do;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to obtain, maintain, defend and enforce patent claims and other intellectual property rights; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to defend against pending or threatened litigation, which may be costly and time-consuming;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may fail to comply with all regulatory requirements or experience unanticipated problems with our products;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may recognize impairment of our goodwill and indefinite-lived intangible asset; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not meet the Nasdaq minimum bid price requirement during any compliance period or in the future;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be granted relief from delisting from Nasdaq if necessary; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such other factors described throughout Part I, Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q and throughout Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates are investigational biologics undergoing clinical development and have not been approved by the FDA, EMA or other comparable non-US regulatory authorities. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. In October and December 2021, we participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. In March 2022, we participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. We plan to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. On May 3, 2022, we announced that we have initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this process. Pending any decision to undertake any strategic alternative, we are continuing our development activities in accordance with our existing business strategy.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;Sesen,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Sesen Bio, Inc. and its subsidiaries.</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_31"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. We genetically fuse the targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary one-step, microbial manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates ("ADCs") where a payload is chemically attached to a targeting antibody. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of NMIBC. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Update</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. On August 20, 2021, we withdrew our MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the European Union until there is more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union. In October 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. Due to the high concordance between FDA and European Commission approvals, we believe that the probability of success of future approval in the European Union for Vysyneum increases if FDA approval for Vicineum has already been obtained. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we participated in a Type A Meeting with the FDA to discuss questions related to CMC raised in the CRL (the &#8220;CMC Type A Meeting&#8221;). During the CMC Type A Meeting, we and the FDA reviewed issues related to CMC to be further discussed during the review of a BLA for Vicineum upon potential resubmission. We believe we have a clear understanding of what additional information regarding CMC is required for a potential resubmission of a BLA. Additionally, although not discussed in the CRL, the FDA confirmed at the CMC Type A Meeting that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials. The FDA also confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL, and that these potential trials can proceed while addressing CMC issues.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 8, 2021, we participated in a Type A Meeting with the FDA to discuss design elements of an additional Phase 3 clinical trial for Vicineum (the &#8220;Clinical Type A Meeting&#8221;), which the FDA confirmed will be required for a potential resubmission of a BLA. The trial design may include these elements:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A randomized clinical trial assessing the safety and efficacy of Vicineum compared to investigators&#8217; choice of intravesical chemotherapy;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Trial may include both patients who have received adequate BCG</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and patients who have received less than adequate BCG;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA encouraged us to submit the final results from the Phase 3 Vista Trial for Vicineum with a BLA resubmission.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As per the 2018 FDA guidance on NMIBC, adequate BCG is defined as at least one of the following: (i) at least five of six doses of an initial induction course plus at least two of three doses of maintenance therapy or (ii) at least five of six doses of an initial induction course plus at least two of six doses of a second induction course.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 28, 2022, we participated in a Type C meeting with the FDA. During the meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. We plan to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prior Phase 3 Clinical Trial &#8211; VISTA Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2015 in the United States and Canada, through our subsidiary Viventia, we commenced our single-arm, multi-center, open-label Phase 3 clinical trial (&#8220;VISTA Trial&#8221;) in patients with BCG-unresponsive NMIBC who have received adequate BCG and whose disease is now BCG-unresponsive, and for whom the then-current standard of care was a radical cystectomy. Based on safety and efficacy data observed with the longer 12-week induction in our Phase 2 clinical trial, the FDA agreed to our plan to employ more frequent dosing in the VISTA Trial, in which the primary endpoints were complete response (&#8220;CR&#8221;) and duration of response (&#8220;DoR&#8221;) in patients with CIS whose disease is BCG-unresponsive. In November 2016, the FDA issued draft guidance regarding appropriate clinical trial design for new drugs and biologics for BCG-unresponsive NMIBC, including the use of single-arm trials. The FDA finalized this guidance in February 2018 and retained many of the recommendations from the 2016 draft guidance regarding clinical trial design, including the use of single-arm trials. We believe that our VISTA Trial design was consistent with these aspects of the FDA&#8217;s guidance.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of the VISTA Trial were CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive and DoR for BCG-unresponsive CIS patients who experience a CR.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate&#8224;:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8224;Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="margin-bottom:12pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) is 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) shows that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis shows that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy is a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) is 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. On August 13, 2021, the FDA issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety Results</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%) - all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a Master Bioprocessing Services Agreement with Fujifilm (the "Fujifilm MSA") for the manufacturing process and technology transfer of Vicineum drug substance production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter for the manufacturing process and technology transfer of Vicineum drug product production.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we completed manufacturing of the drug substance process performance qualification (&#8220;PPQ&#8221;) batches at Fujifilm and in September 2020, we successfully completed the drug product PPQ batches at Baxter. All of the completed drug substance PPQ batches and drug product PPQ batches met all quality acceptance criteria.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we received and analyzed all of the analytical comparability test results from the drug substance and drug product PPQ batches. For analytical comparability, we conducted testing across four categories: release testing, biophysical characterization, forced degradation studies, and stability studies. This approach is in alignment with requirements of the FDA, the EMA and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. The test results for Vicineum produced by Fujifilm and Baxter were found to be comparable to supply of Vicineum manufactured at our Winnipeg facility for the VISTA trial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, at the CMC Type A Meeting, the FDA confirmed that Vicineum manufactured using the proposed commercial process is comparable to Vicineum used in prior clinical trials and confirmed that we can utilize Vicineum manufactured during process validation for any future clinical trials needed to address issues raised in the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, and that any of these future trials can proceed while addressing CMC issues raised in the CRL.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, we signed a Scope of Work ("SOW #11") with Fujifilm under the Fujifilm MSA for the manufacturing of GMP batches of Vicineum in 2022 and 2023. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use Vicineum produced by Fujifilm and Baxter for any future clinical trials of Vicineum and, if approved, for commercial supply.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Outside of United States ("OUS") Business Development Partnering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu Pharmaceutical, Co., Ltd. ("Qilu") pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan ("Greater China"). We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retain (i) development and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received a total of $10 million in net proceeds associated with the Qilu License Agreement. We are also entitled to receive up to an additional $23 million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i) twelve years after the first commercial sale of Vicineum in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii) the expiration of regulatory or data exclusivity for Vicineum in such region. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty rate is subject to reduction under certain circumstances, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application ("IND") for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. We recorded $2.8 million (net of VAT) as license revenue during the three-month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of value-added tax ("VAT") recovery. As such, we recorded $0.9 million of revenue during the three months ended June 30, 2021, for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. We will not be subject to VAT on future potential milestone payments to Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the Qilu License Agreement, the trial is being run at the sole cost of Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">MENA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, we and our wholly owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Hikma Pharmaceuticals LLC, to develop and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in MENA region (20 countries in Middle East and North Africa) (the &#8220;MENA License Agreement&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consideration for the rights granted by us, Hikma agreed to pay to us an upfront payment, sales related milestones payments, and royalties on net sales in the MENA region for the term of the Hikma License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Turkey</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, we entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which we granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus. Under the terms of the licensing agreement, we are entitled to receive an upfront payment of $1.5 million. We and EIP have amended the license agreement to defer EIP&#8217;s payment of the upfront payment to coincide with the potential FDA approval of Vicineum. We are also eligible to receive additional regulatory and commercial milestone payments of $2.0 million and are entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Internal Review</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2022, we announced the completion of an independent internal review initiated by our board of directors (the &#8220;Board&#8221;) and conducted by outside counsel with the assistance of subject matter experts focusing on the conduct of, and data generated from, the clinical trials of Vicineum for the treatment of BCG-unresponsive NMIBC, and the overall safety of Vicineum (the &#8220;Review&#8221;). The Review took place over the course of five months, involved full cooperation from our management team, a review of more than 600,000 documents, and 39 interviews of current and former employees and consultants. As a result of the Review, the Board continues to fully support our current management team and believes no changes or amendments relating to our prior disclosures to the SEC or the FDA relating to Vicineum, the Phase 3 VISTA trial for Vicineum for the treatment of BCG-unresponsive NMIBC, or the BLA for Vicineum are warranted. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review of Strategic Alternatives</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2022, we announced that we have initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this process. Pending any decision to undertake any strategic alternative, we are continuing its development activities in accordance with our existing business strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1248"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Related Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue consists of revenue recognized pursuant to our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the Qilu License Agreement, which is assessed under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606"). In the future, we may generate revenue from a combination of up-front payments, milestone payments and royalties in connection with our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of Vicineum for the treatment of NMIBC, which include: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and share-based compensation expense;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with CROs and investigative sites that conduct our clinical trials, including the additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with transferring manufacturing capabilities to contract manufacturing organizations ("CMOs") for commercial-scale production;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with regulatory activities; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with license milestone fees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful development and commercialization of Vicineum for the treatment of NMIBC is highly uncertain. This is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, outcome and costs of our clinical trials, including the additional Phase 3 clinical trial, and other research and development activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages of Vicineum for the treatment of NMIBC compared to alternative treatments, including any standard of care;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the market acceptance of Vicineum for the treatment of NMIBC;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of the implementation of commercial-scale manufacturing of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant and changing government regulation;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and terms of any marketing approvals.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of Vicineum for the treatment of NMIBC could mean a significant change in the costs and timing associated with the development of Vicineum for the treatment of NMIBC. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials or other testing beyond those that we currently contemplate will be required for the completion of clinical development of Vicineum for the treatment of NMIBC, we could be required to expend significant additional financial resources and time on the completion of clinical development of Vicineum for the treatment of NMIBC.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, costs related to manufacturing or purchasing clinical trial materials and technology transfer and license milestone fees, to specific product programs. We do not allocate employee and contractor-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product programs because these costs may be deployed across multiple product programs under research and development and, as such, are separately classified. The table below provides research and development expenses incurred for Vicineum for the treatment of NMIBC and other expenses by category. We have deferred further development of Vicineum for the treatment of SCCHN and VB6-845d in order to focus our efforts and our resources on our ongoing development and, if approved, commercialization of Vicineum for the treatment of NMIBC. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not allocate research and development expenses to any other specific product program during the periods presented (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Programs:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum for the treatment of NMIBC</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct program expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,566&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel and other expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and contractor-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform-related lab expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total personnel and other expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Research and Development</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,760</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,078</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation and benefits, in executive, operational, finance, legal, business development and human resource functions. Other general and administrative expenses include facility-related costs, professional fees for legal, insurance, investment banking fees, patent, consulting and accounting services, and pre-commercial United States market research.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Viventia Acquisition in September 2016, we recorded contingent consideration pertaining to the amounts potentially payable to Viventia's shareholders pursuant to the terms of the Share Purchase Agreement among us, Viventia and the other signatories thereto and are based on regulatory approval in certain markets and future revenue levels. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized in earnings (or loss) for the period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income earned on cash and cash equivalents and, to a lesser extent, any gains or losses on foreign exchange.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit for income taxes is driven by the intangible impairment charge, changing the value of deferred tax liabilities. Provision for income taxes consists of income taxes incurred to non-US jurisdictions pursuant to our OUS business development partnership agreements, including the Qilu License Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1272"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended March 31, 2022 and 2021 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,310)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,310)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,318)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,900)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,060)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,531&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,696)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(835)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,221)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,033)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(807)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55,224)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss and Comprehensive Loss After Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(807)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55,512)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any revenue for the three months ended March 31, 2022. Revenue for the three months ended March 31, 2021 was $4.3 million, which was due to the recognition of revenue resulting from the delivery of the performance obligations under our agreement with our partner in MENA, and achieving the IND milestone in China pursuant to the Qilu License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $4.8 million for the three months ended March 31, 2022, compared to $6.1 million for the three months ended March 31, 2021. The decrease of $1.3 million was primarily due to lower costs associated with technology transfer and manufacturing ($1.4 million), regulatory and clinical consulting fees ($0.6 million) and license milestone fees ($0.6 million), which were partially offset by increases in employee-related compensation, primarily driven by increased headcount and the retention program implemented in the fourth quarter of 2021, ($1.2 million) and other R&amp;D expenses ($0.1 million). We anticipate that R&amp;D expenses may increase in 2022 due to costs related to the additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $9.0 million for the three months ended March 31, 2022, compared to $5.3 million for the three months ended March 31, 2021. The increase of $3.7 million was primarily due to increases in legal expenses related, in part, to the independent internal review completed in February 2022 ($3.0 million), employee-related compensation ($1.1 million), primarily driven by increased headcount and the retention program implemented in the fourth quarter of 2021, insurance expense ($0.1 million) and other general expenses ($0.2 million). This was partially offset by a decrease in consultant fees incurred in preparation for commercial launch as a result of the subsequent CRL received in August 2021 ($0.7 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash change in fair value of contingent consideration was income of $12.9 million for the three months ended March 31, 2022, compared to a loss of $48.2 million for the three months ended March 31, 2021. The decrease in the fair value of contingent consideration of $12.9 million for the three months ended March 31, 2022 was driven by changes in underlying assumptions used to develop the revenue projections. In March 2022, we participated in a Type C meeting with the FDA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. We also learned during the meeting that the FDA is trending away from accepting single arm trials across therapeutic areas, including NMIBC, and has a strong preference for randomized controlled trials. We plan to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Incorporating the FDA feedback from the Type C meeting, plans for further discussions with the FDA prior to initiation of the additional Phase 3 clinical trial, as well as updates to the competitive landscape, we reassessed the underlying assumptions used to develop our revenue projections upon which the fair value of our contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of potential commercial product launch, probabilities of clinical and regulatory success, and market share. We anticipate further delays in the start of commercialization due to the likelihood of the requirement to conduct a randomized controlled trial which will require more patients to be enrolled, lengthen the duration of the study, and increase study costs. We are also projecting lower estimated market share as a result of recent clinical and regulatory progress made by competitors. We have assessed a commercialization timeline assumption and applied a probability to each outcome based on management&#8217;s best estimate. In addition, we continue to assume a POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was a loss of $48.2 million for the three months ended March 31, 2021. This was primarily attributable to changes in the competitive landscape, higher probability of regulatory success, expanded patient population, and to a lesser extent by refinement of timelines in certain markets outside the United States, which was prior to the receipt of a CRL from the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No provision for income taxes was recorded for the three months ended March 31, 2022. For the three months ended March 31, 2021, we recorded a provision for income taxes of $0.3 million. This provision consisted of income taxes paid to non-US jurisdictions pursuant to our commercialization partnership agreements.</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1297"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had cash and cash equivalents of $169.8 million, net working capital of $172.2 million and an accumulated deficit of $317.1 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We generated cash flows from operating activitie</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of $7.2 million fo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r the three months ended March 31, 2022 compared to negative cash flows of $18.5 million for the three months ended March 31, 2021. We believe that our cash and cash equivalents of $169.8 million as of March&#160;31, 2022, are sufficient to fund our operating plan into the fourth quarter of 2024. Our forecasted cash runway is based upon our current business plan, however if an alternative plan is enacted, this runway could vary materially.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have received no revenue from sales of our products, and we anticipate that operating losses will continue for the foreseeable future as we seek to address the issues raised in the CRL we received for our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, complete an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC, and seek marketing approval from the FDA and the European Commission and, if approved, commercialize Vicineum, or in connection with any strategic alternatives that we may pursue. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our IPO, follow-on public offerings, sales effected in ATM offerings, our OUS business development partnerships and license agreements and, to a lesser extent, from a collaboration.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an Open Market Sale Agreement with Jefferies LLC ("Jefferies") dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"),, under which we may issue and sell shares of our common stock, par value $0.001 per share from time to time through Jefferies (the "ATM Offering"). In June and July 2021, we filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of our common stock pursuant to the Sale Agreement of which $97.8 million of common shares remain available for future issuance as of March&#160;31, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for our common stock. We may sell shares of our common stock efficiently from time to time but have no obligation to sell any of our common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon our instructions, which </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">include a prohibition on sales below a minimum price set by us from time to time. We have provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. We did not sell any shares of common stock pursuant to the Sale Agreement during the three months ended March 31, 2022. We raised $72.6 million of net proceeds from the sale of 30.6 million shares of common stock at a weighted-average price of $2.44 per share during the three months ended March 31, 2021. Share issue costs, including sales agent commissions, related to the ATM Offering totaled $2.2&#160;million for the three months ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor the effect of the outbreak of COVID-19. We are proactively executing risk mitigation strategies to attenuate the impact of COVID-19 on us, and at this time, we have not yet experienced any business disruptions as a result of the pandemic. We are continually assessing the effect of the COVID-19 pandemic on our operations, and we are monitoring the spread of COVID-19 and the actions implemented to combat the virus throughout the world.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on our ability to develop and, if approved, commercialize our product candidates, including Vicineum for the treatment of NMIBC, and ultimately upon our ability to attain profitable operations. In order to commercialize our product candidates, including Vicineum, we need to complete clinical development and comply with comprehensive regulatory requirements. Additionally, we have announced </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we have initiated a process to review strategic alternatives with the goal of maximizing shareholder value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this process. Pending any decision to undertake any strategic alternative, we are continuing our development activities in accordance with our existing business strategy. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this process. Pending any decision to undertake any strategic alternative, we are continuing our development activities in accordance with our existing business strategy.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of risks similar to other late-stage clinical companies, including, but not limited to, successful discovery and development of our product candidates, raising additional capital, development and commercialization by our competitors of new technological innovations, protection of proprietary technology and market acceptance of our products. The successful discovery, development and, if approved, commercialization of product candidates, including Vicineum for the treatment of NMIBC, requires substantial working capital, and we expect to seek additional funds through equity or debt financings or through additional OUS business development partnerships, collaborations, licensing transactions or other sources. We may be unable to obtain equity or debt financings or enter into additional </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnerships, collaborations,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or licensing transactions at favorable terms, or at all, and, if necessary, we may be required to implement cost reduction strategies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incur substantial expenses if and as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">address the issues identified in the CRL we received from the FDA for our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC and the concerns identified in the EMA Withdrawal Assessment Report, including the completion of an additional Phase 3 clinical trial;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for Vicineum for the treatment of NMIBC;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish and implement sales, marketing and distribution capabilities and scale up and validate external manufacturing capabilities (including completing the manufacturing process and technology transfer to any third-party manufacturers) to commercialize Vicineum for the treatment of NMIBC, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">add equipment and physical infrastructure to support our research and development;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical, regulatory, quality control, scientific and management personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operational, financial and management systems and personnel;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conduct research and pre-clinical and clinical development of Vicineum for the treatment of NMIBC and our other product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explore, evaluate and pursue any strategic alternatives in connection with the review process we have initiated;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek to discover and develop additional product candidates; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">in-license or acquire the rights to other products, product candidates or technologies.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the scope, initiation, progress, timing, costs and results of pre-clinical development and laboratory testing and clinical trials for Vicineum for the treatment of NMIBC and our other product candidates, including an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of any pending or future litigation involving us or our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome of the process we have initiated to review strategic alternatives, which may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ongoing COVID-19 pandemic and its impact on our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional OUS business development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships, collaborations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or licensing arrangements on favorable terms, if at all, particularly manufacturing, marketing and distribution arrangements for our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of the implementation of commercial-scale manufacturing activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of establishing and implementing sales, marketing and distribution capabilities for Vicineum for the treatment of NMIBC, if approved;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty and other payments to third-party licensors under our licensing agreements;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we in-license or acquire rights to other products, product candidates or technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory review by the FDA, EMA, and comparable non-US regulatory authorities for Vicineum for the treatment of NMIBC, including the potential for the FDA or comparable non-US regulatory authorities to require that we perform more studies than those that we currently expect to perform;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve certain future regulatory, development and commercialization milestones under our out-license and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> OUS business development partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effect of competing technological and market developments; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of Vicineum for the treatment of NMIBC, if approved.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial product revenues from commercial sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, government or other third-party funding, strategic OUS business development </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">partnerships,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> alliances, and licensing arrangements. We do not have any committed external source of funds other than the amounts payable under our out-license and OUS business development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, strategic </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OUS business development partnerships, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">alliances or licensing arrangements, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has negatively impacted the global economy, disrupted business operations and created significant volatility and disruption to financial markets. Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on our operations, and on the global economy as a whole. The extent and duration of the pandemic could continue to disrupt global markets and may affect our ability to raise additional capital in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual and Other Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to our cash requirements from known contractual and other obligations, see the description of Contingent Consideration in Note 5 &#8220;Fair Value Measurement and Financial Instruments,&#8221; as well as the description of our leases in Note 10 &#8220;Leases&#8221;, and the description of our license agreement and collaborations in Note 15, &#8220;License Agreements&#8221; of Part I - Item 1. Financial Statements - Notes to Condensed Consolidated Financial Statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.304%"><tr><td style="width:1.0%"></td><td style="width:67.277%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided By (Used in) Operating Activities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,475)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,051&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,154</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,576</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided By (Used in) Operating Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was $7.2 million for the three months ended March 31, 2022 and consisted primarily of the $20.0 million</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> milestone payment received from Roche for initiating a Phase II clinical trial in the fourth quarter of 2021 and the receipt of $2.4 million related to German VAT recovery, related to drug substance sent to Baxter. This was partially offset by adjustments for non-cash items including, share-based compensation of $1.9 million, a decrease in the fair value of contingent consideration of $12.9 million and a net decrease in operating assets and liabilities of $19.0&#160;million. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n operating activities was $18.5 million for the three months ended March 31, 2021 and consisted primarily of a net loss of $55.5 million, which includes $4.3 million of revenue recognized pursuant to the Qilu Agreement, adjusted for non-cash items, including share-based compensation of $1.0 million, an increase in the fair value of contingent consideration of $48.2 million and a net decrease in operating assets and liabilities of $12.1 million</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities consisted of de minimis purchases and sales or property and equipment during the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was de minimis for the three months ended March 31, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $73.1 million for the three months ended March 31, 2021 and consisted of $72.6 million net proceeds from the sale of common stock under the ATM Offering and $0.5 million in proceeds from the exercise of common stock warrants.</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1321"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in accordance with GAAP and the rules and regulations of the SEC require the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Our critical accounting policies are those policies which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Management has determined that our most critical accounting policies are those relating to the fair value of indefinite-lived intangible assets, goodwill; contingent consideration; revenue recognition; development and regulatory milestone payments and other costs; and research and development costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired in-process research and development ("IPR&amp;D") worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts. Amortization over the estimated useful life will commence at the time of Vicineum's commercial launch in the respective markets, if approved. If regulatory approval to market Vicineum for the treatment of NMIBC is not obtained, we will immediately expense the related capitalized cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. We plan to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Based on the outcome of the Type C meeting as well as updates to the competitive landscape, we reassessed the underlying assumptions used to develop our revenue projections, which were then used as significant inputs to determine the fair value of the indefinite-lived intangible asset. Management updated the revenue forecast models based on further launch delays in both US and OUS regions as well as slightly lower market share. Accordingly, we identified this as a potential impairment indicator and performed an interim quantitative impairment assessment. We concluded that the carrying value of our intangible asset of Vicineum EU rights was not impaired as of March&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on our condensed consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. We recognize a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. We have only one reporting unit. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. In March 2022, we participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. We plan to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Based on the outcome of the Type C meeting as well as updates to the competitive landscape, we reassessed the underlying assumptions used to develop the revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated the revenue forecast models based on further launch delays in both US and OUS regions as well as slightly lower market share.  Accordingly, we identified these changes to the revenue forecast, as well as the decline in our stock price and market capitalization during the first quarter of 2022, as potential impairment indicators and performed a quantitative impairment analysis during the first quarter of 2022, in advance of our typical annual assessment date of October 1. We concluded that the carrying value of its goodwill of $13.1 million was not impaired as of March&#160;31, 2022, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately 29%. While our stock price has declined since December 31, 2021, this is consistent with the general biotech sector overall, as world economic conditions continue to be impacted by the COVID-19 pandemic and Russia's invasion of Ukraine. We believe that we have sufficient future cash flows from additional geographic regions outside the US to support the value of goodwill. We project future cash flows based on various timeline assumptions and apply a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success can also have a material effect on the estimated fair value of the equity of its reporting unit as of the impairment assessment date. We will continue to evaluate timelines for commercialization and probability of success of development of Vicineum for the treatment of NMIBC. Further reductions to probabilities of success, decrease in market share, additional development and commercial launch delays, increases in underlying discount rates, a prolonged decline in the Company&#8217;s market capitalization as compared to its carrying value, or any decision to undertake any strategic alternative as a result of the review process that we have initiated, have the potential to result in future goodwill impairment.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration on our condensed consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the discounted present value of future commercial launch milestones and net sales royalties due to the former shareholders of Viventia pursuant to the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are unpredictable and inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. In March 2022, we participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. We also learned during the meeting that the FDA is trending away from accepting single arm trials across therapeutic areas, including NMIBC, and has a strong preference for randomized controlled trials. We plan to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Incorporating the FDA feedback from the Type C meeting, plans for further discussions with the FDA prior to initiation of the additional Phase 3 clinical trial, as well as updates to the competitive landscape, we reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of our contingent consideration is based. The most significant and impactful assumptions in our revenue projection models are timing of product launch and probabilities of clinical and regulatory success, and market share. We anticipate further delays in the start of commercialization due to the likelihood of the requirement to conduct a randomized controlled trial which will require more patients to be enrolled, lengthen the duration of the study, and increase study costs. The company is also projecting lower estimated market share as a result of recent clinical and regulatory progress made by competitors. We have assessed a range of commercialization timeline assumptions and applied a probability to each outcome based on management&#8217;s best estimate. We continue to assume a POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future. The fair value of our contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from our estimated weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021 to 9.0% as of March&#160;31, 2022. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.0% as of December&#160;31, 2021 to 9.7% as of March&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. We recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. We recognize accrued interest and penalties related to uncertain tax positions as income tax expense in our condensed consolidated statements of operations. As of March&#160;31, 2022 and December&#160;31, 2021, we did not have any uncertain tax positions. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we are required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued accounting standards are discussed in &#8220;Item 1. Financial Statements - Notes to Condensed Consolidated Financial Statements - Note 4. Recent Accounting Pronouncements&#8221; of this Quarterly Report on Form 10-Q.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1358"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1353"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as defined in Exchange Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rules 13a-15(e) and 15d-15(e), that are designed to ensure information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principle financial officer, to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as the end of the period covered by this Quarterly Report on Form 10-Q. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore, the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with the policies and procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of controls, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our system of controls to enhance, where necessary, our control policies and procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, there were no changes in our internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f), which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_25"></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1371"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against us and certain of our officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. The court has not yet ruled on the motion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets and violations of federal securities laws, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. Defendants intend to seek a similar stay of the state court derivative litigation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages, and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to us.</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_19"></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2022, other than as set forth below, there were no material changes to the "Risk Factors" included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. You should carefully consider the information described therein and in this Quarterly Report on Form 10-Q, which could materially affect our business condition, results of operations and cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our exploration of strategic alternatives may not result in entering into or completing a transaction, and the process of reviewing strategic alternatives or its conclusion could adversely affect our business and our stock price.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this process. Pending any decision to undertake any strategic alternative, we are continuing our development activities in accordance with our existing business strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any potential transaction would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction with us and the availability of financing to us or third parties in a potential transaction with us on reasonable terms. The process of reviewing strategic alternatives may be time consuming and disruptive to our business operations and may involve the dedication of significant resources and may require us to incur significant costs and expenses. It could divert the attention of management and our board of directors from our business, negatively impact our ability to attract, retain and motivate key employees, and expose us to potential litigation in connection with this process or any resulting transaction. If we are unable to effectively manage the process, our business, financial condition and results of operations could be adversely affected. In addition, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to the future of our company could cause our stock price to fluctuate significantly. Further, any strategic alternative that may be pursued and completed ultimately may not deliver the anticipated benefits or enhance shareholder value. There can be no guarantee that the process of evaluating strategic alternatives will result in our company entering into or completing a potential transaction, and we have not set a timetable for the completion of this review process.</span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_1445"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any unregistered equity securities during the three months ended March 31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_49"></div><div style="-sec-extract:summary;margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312516715368/d261598dex21.htm">Share Purchase Agreement, effective as of September 20, 2016, by and between Eleven Biotherapeutics, Inc., Viventia Bio Inc. and Clairmark Investments Ltd., as representative of the selling shareholders (we hereby agree to furnish supplementally a copy of any omitted schedules to the SEC upon request). Incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed on September 21, 2016 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514056904/d679756dex31.htm">Restated Certificate of Incorporation of Eleven Biotherapeutics, Inc. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 18, 2014 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit31-ebioxcertificate.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000103/ex33-certificateofamendm.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q filed on May 10, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit32-elevenbiotherape.htm">Amended and Restated By-Laws. Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex41.htm">Specimen Stock Certificate evidencing the shares of common stock. Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A filed on January 23, 2014 (Reg. No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514448885/d704357dex1023.htm">Form of Warrant issued to Silicon Valley Bank and Life Science Loans, LLC dated November 25, 2014. Incorporated by reference to Exhibit 10.23 to our Registration Statement on Form S-1 filed on December 19, 2014 (Reg. No. 333-201176).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500317000132/ex41ebiopre-fundedwarrant1.htm">Form of Common Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on November 3, 2017 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit41.htm">Form of Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2017warrantamendmenta.htm">Form of 2017 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2018warrantamendmenta.htm">Form of 2018 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*&#8224;<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="sesn-ex101xzurichlicenseag.htm">License Agreement, effective January 13, 2003, as amended and restated on October 14, 2015, by and between The University of Zurich and Viventia Bio Inc. </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-03312022x10qex3111.htm">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-03312022x10qex3111.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-03312022x10qex3121.htm">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-03312022x10qex3211.htm">Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-03312022x10qex3221.htm">Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted in compliance with Item 601 of Regulation S-K.</span></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i5c128332a7fc4e0a80e34b1a19796bcf_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:142.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:285.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SESEN BIO, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="margin-bottom:1pt;text-align:right"><span><br/></span></div><div style="margin-bottom:1pt;text-align:right"><span><br/></span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Monica Forbes&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sesn-ex101xzurichlicenseag.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ifcc42d45de2a46fc884b0c161f0c89eb_1"></div><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 10.1 </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information has been omitted from this exhibit because it is both (i) not material and (ii) is the type that Sesen Bio, Inc. treats as private or confidential. Information that has been omitted is denoted as &#8220;&#91;**&#93;&#8221;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSE AGREEMENT </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This agreement (&#8220;Agreement&#8221;) is made by and between</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">The University of Z&#252;rich </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">R&#228;mistrasse 71, CH-8006 Z&#252;rich (SWITZERLAND) </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(hereinafter referred to as UNIVERSITY) </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Viventia BioInc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">147 Hamelin Street </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Winnipeg MB, R3T 3Z1 (CANADA) </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(&#8220;LICENSEE&#8221;) </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement is effective January 9, 2003 (&#8220;Effective Date&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RECITALS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, UNIVERSITY is owner of Patent Rights as defined below on a stabilized anti-EGP-2 scFv fragment termed 4D5MOC-B (&#8220;Invention&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, LICENSEE entered into an Option Agreement with UNIVERSITY, effective March 19, 2002, (&#8220;Option Agreement&#8221;), for the purpose of negotiating this Agreement&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, UNIVERSITY is desirous that the Invention be developed and utilized to the fullest possible extent so that its benefits can be enjoyed by the general public&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">WHEREAS, LICENSEE wishes to obtain, and UNIVERSITY is willing to grant, an exclusive license to the Patent Rights on the terms and conditions set out below. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOW, THEREFORE, the parties agree&#58; </font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE I</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>DEFINITIONS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The terms, as defined herein, shall have the same meanings in both their singular and plural forms. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Affiliate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any corporation or other business entity in which LICENSEE owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors, or in which  LICENSEE is owned or controlled directly or indirectly by at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Sublicensee&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">means a third party to whom LICENSEE grants a sublicense of certain rights granted to LICENSEE under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Field&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the treatment, stasis, and palliation of disease in humans by anti-EGP-2 antibodies or antibody fragments, whether by themselves or in combination with other materials or methods. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Territory&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means world-wide. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Term&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the period of time beginning on the Effective Date and ending on the expiration date of the longest-lived Patent Rights. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Patent Rights&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any of the patent applications set forth in Attachment A to this Agreement and any other patents or patent applications now or in the future owned or controlled by UNIVERSITY, including those jointly-owned or jointly-controlled by UNIVERSITY and LICENSEE, describing or claiming the Invention (including methods of making or using same) and continuing applications thereof including divisions, substitutions, and continuations-in-part&#59; any patents issuing on said applications including reissues, reexaminations and extensions. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Licensed Method&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any method that is covered by Patent Rights the use of which would constitute, but for the license granted to LICENSEE under this Agreement, an infringement of any pending or issued and unexpired Valid Claim within Patent Rights. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Licensed Product&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means any composition or product that is covered by the claims of Patent Rights, or that is produced by the Licensed Method, the manufacture, use, sale, offer for sale, or importation of which would constitute, but for the license granted to LICENSEE by UNIVERSITY herein, an infringement of any pending or issued and unexpired Valid Claim within the Patent Rights. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">&#8220;Net Sales&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means the total of the gross invoice prices of Licensed Products sold by LICENSEE, its Sublicensee, an Affiliate, a distributor or any combination thereof, to end-user customers of Licensed Products less the sum of the following actual and customary deductions where applicable and separately itemized on the invoice and actually paid or allowed&#58; cash, trade, or quantity discounts&#59; value added, sales or use taxes, and custom duties&#59; transportation charges&#59; or credits to customers because of rejections or returns. Net Sales shall be calculated on the price from Licensee, a sublicensee, a distributor or their Affiliates to the first purchaser who is an end-user and not on sales between or among Licensee, sublicensees, distributors or their Affiliates for the purpose of resale. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">&#8220;Patent Costs&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means all out-of-pocket expenses for the preparation, filing, prosecution, and maintenance of all patents included in Patent Rights in at least the following countries&#58; US, Canada, Japan, Europe (i. e. the following EPC-countries&#59; AT, BE, CH, DE, DK, FR, GB, IT, NL, SE). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">&#8220;Valid Claim&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> means a claim of the Patent Rights which has not been withdrawn, canceled, or disclaimed, nor held invalid by a court of competent jurisdiction in any unappealed or unappealable decision in the country where the product or process was made, use or sold by LICENSEE, its Affiliate or sublicensee. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE II</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>GRANTS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">License.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Subject to the limitations set forth in this Agreement, UNIVERSITY hereby grants to LICENSEE, and LICENSEE hereby accepts, a royalty bearing, exclusive license (with the right to sublicense) under Patent Rights to make, have made, use, sell, offer for sale, and import Licensed Products and to practice Licensed Methods, in the Field within the Territory and during the Term. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The license granted herein is exclusive for Patent Rights and UNIVERSITY shall not grant to third parties a further license under Patent Rights in the Field, within the Territory and during the Term. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon expiration of each patent within the Patent Rights, Viventia shall have a fully paid-up, royalty-free license under such patent in the respective country to make, have made, use, sell, offer for sale, and import Licensed Products and to practice the Licensed Methods, in the Field. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Sublicense.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The license granted in Paragraph 2.1 includes the right of LICENSEE to grant sublicense to third parties during the Term. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">With respect to sublicense granted pursuant to Paragraph 2.2(a), LICENSEE shall&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">to the extent applicable, include all of the rights of and obligations due to UNIVERSITY and contained in this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">promptly provide UNIVERSITY with a copy of each sublicense issued&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">collect and guarantee payment of all payments due, directly or indirectly, to UNIVERSITY from Sublicensees and summarize and deliver all reports due, directly or indirectly, to UNIVERSITY from Sublicensees. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Upon termination of this Agreement for any reason, UNIVERSITY, at its sole discretion, shall determine whether LICENSEE shall cancel or assign to UNIVERSITY any and all sublicenses. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Reservation of Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> UNIVERSITY reserves the right to&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">use the Invention, and Patent Rights for educational and research purposes&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">notwithstanding the provisions of Paragraph 5.1.b publish or otherwise disseminate any information about the Invention at any time&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">allow other academic, nonprofit institutions to use Invention, and Patent Rights for educational and non-commercial research purposes in their facilities, subject to a written agreement from such institution acknowledging such restriction and agreeing that no Licensed Products will be transferred to any other person or institution. LICENSEE shall have the right to consult UNIVERSITY in setting up such written agreements and UNIVERSITY shall consider LICENSEE&#8217;s comments in good faith. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE III</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>CONSIDERATIONS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Fees and Royalties.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The parties hereto understand that the fees and royalties payable by LICENSEE to UNIVERSITY under this Agreement are partial considerations for the license granted herein to LICENSEE under Patent Rights. LICENSEE shall pay UNIVERSITY&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">license issue fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of fifty thousand United States Dollars (US$ 50,000) upon execution of the this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">milestone payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> in the amounts payable according to the following schedule or events by LICENSEE, its Affiliates or sublicensees with respect to the first Licensed Product&#58; </font></div><div style="padding-left:2.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:20.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.965%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amount</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Event</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1) US$ 250,000-</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Completion of first Phase II clinical studies</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2) US$ 250,000-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">First Filing of a New Drug Application (NDA) or equivalent</font></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3) US$ 500,000-</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:10pt;text-indent:-10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Within 30 days of completion of regulatory agency review of New Drug Application (NDA) or equivalent, regardless whether the NDA or equivalent is approved or not</font></div></td></tr></table></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">an </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">earned royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of four percent (4%) on Net Sales of Licensed Products by LICENSEE, its Affiliates, or sublicensees&#59; If LICENSEE is required to pay royalties to third parties on sales of Licensed Products under patents claiming the composition and&#47;or method of making or using such Licensed Products and the resulting aggregate royalty rate is 10% or greater, then the royalty rate will be adjusted as follows&#58; The royalty rate payable to UNIVERSITY will be reduced to a rate determined by multiplying the royalty rate by a fraction, the numerator of which is 10% and the denominator of which is the aggregate royalty rate, provided that University shall not receive less than 2% royalties. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All fees and royalty payments specified in Paragraphs 3.1(a) through 3.1(c) above shall be paid by LICENSEE pursuant to Paragraph 4.3 and shall be delivered by LICENSEE to UNIVERSITY as noted in Paragraph 10.1. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Patent Costs.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> LICENSEE shall reimburse UNIVERSITY all Patent Costs within thirty (30) days following receipt by LICENSEE of an itemized invoice from UNIVERSITY. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Due Diligence.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">LICENSEE shall&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">diligently proceed with the development, manufacture and sale of Licensed Products&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">upon market entry on a country-by-country basis, use its reasonable efforts to promote the sale of the Licensed Products in the Territory as widely as its resources reasonably permit and reasonably fill the market demand for Licensed Products at any time during the term of this Agreement&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">obtain all necessary governmental approvals for the manufacture, use and sale of Licensed Products. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">If LICENSEE fails to perform any of its obligations specified in Paragraphs 3.3(a)(1)-(3), then UNIVERSITY shall have the right to demand a development and, if applicable, marketing plan, detailing key activities and expected timetables. If UNIVERSITY rejects such a plan, the Parties shall meet to discuss in good faith possible amendments to the development and&#47;or marketing plan. In the absence of agreement to such amendments the UNIVERSITY shall have the right and option to terminate this Agreement. If LICENSEE disagrees with such termination it shall have the right within 60 days of the notification of termination to seek arbitration as foreseen in clause 10.6. The arbitrators shall decide whether the termination is justified or not and if the conclude that the termination is not justified decide which amendments to the development and&#47;or marketing plan shall be done. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE IV</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>REPORTS, RECORDS AND PAYMENTS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Reports.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Progress Reports. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Beginning January 1, 2004 and ending on the date of first commercial sale of a Licensed Product, LICENSEE shall submit to UNIVERSITY annual progress reports covering LICENSEE&#8217;s (and Affiliate&#8217;s and Sublicensee&#8217;s) activities to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such reports shall include a summary of work completed&#59; summary of work in progress&#59; current schedule of anticipated events or milestones&#59; market plans for introduction of Licensed Products&#59; and summary of resources spent in the reporting period. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">LICENSEE shall also report to UNIVERSITY, in its immediately subsequent progress report, the date of first commercial sale of a Licensed Product in each country. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Royalty Reports.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> After the first commercial sale of a Licensed Product anywhere in the world, LICENSEE shall submit to UNIVERSITY quarterly royalty reports on a schedule to be determined by LICENSEE based on its fiscal year or other related license agreements. Each royalty report shall cover LICENSEE&#8217;s (and each Affiliate&#8217;s and Sublicensee&#8217;s) most recently completed quarter and shall show&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the gross sales, deductions as provided in Paragraph 1.9, and Net Sales during the most recently completed quarter and the royalties payable with respect thereto&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the number of each type of Licensed Product sold&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">sublicense fees and royalties received during the most recently completed quarter, payable with respect thereto&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the method used to calculate the royalties&#59; and </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">the exchange rates used. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If no sales of Licensed Products has been made and no sublicense revenues has been received by LICENSEE during any reporting period, LICENSEE shall so report. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Records &#38; Audits.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">LICENSEE shall keep, and shall require its Affiliates and Sublicensees to keep, accurate and correct records of all Licensed Products manufactured, used, and sold, and sublicense fees received under this Agreement. Such records shall be retained by LICENSEE for at least three (3) years following a given reporting period. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">All records shall be available during normal business hours for inspection at the expense of UNIVERSITY by an independent public accountant selected by UNIVERSITY and reasonably acceptable to LICENSEE and in compliance with the other terms of this Agreement for the sole purpose of verifying reports and payments&#59; such accountant shall not be retained on a contingency-fee basis or on any other terms by which the accountant&#8217;s compensation depends on the results of the audit. Such accountant shall not disclose to UNIVERSITY any information other than information relating to the accuracy of reports and payments made under this Agreement or other compliance issues. In the event that any such inspection shows an under reporting and underpayment in excess of five percent (5%) for any twelve (12) month period, then LICENSEE shall pay the reasonable cost of the audit as well as any additional sum that would have been payable to UNIVERSITY had the LICENSEE reported correctly, plus an interest charge at a rate of ten percent (10%) per year. Such interest shall be calculated from the date the correct payment was due to UNIVERSITY up to the date when such payment is actually made by LICENSEE. For underpayment not in excess of five percent (5%) for any twelve (12) month period, LICENSEE shall pay the difference within thirty (30) days without interest charge or inspection cost. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Payments. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">All fees due UNIVERSITY shall be paid in accordance with Attachment B&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.02pt">Royalty Payments. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">LICENSEE shall pay earned royalties quarterly on a schedule to be determined by LICENSEE based on its fiscal year or other related license agreements. Each such payment shall be for earned royalties accrued within LICENSEE&#8217;s most recently completed calendar quarter. </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Royalties earned on sales occurring or under sublicense granted pursuant to this Agreement shall not be reduced by LICENSEE for any taxes, fees, or other charges imposed by the government of such country on the payment of royalty income, except that all payments made by LICENSEE in fulfillment of UNIVERSITY&#8217; tax liability in any particular country may be credited against earned royalties or fees due UNIVERSITY for that country. LICENSEE shall pay all bank charges resulting from the transfer of such royalty payments. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">In the event that any patent or patent claim within Patent Rights is held invalid in a final decision by a patent office from which no appeal or additional patent prosecution has been or can be taken, or by a court of competent jurisdiction and last resort and from which no appeal has or can be taken, all obligation to pay royalties based solely on that patent or claim or any claim patentably indistinct therefrom shall cease as of the date of such final decision. LICENSEE shall not, however, be relieved from paying any royalties that accrued before the date of such final decision, that are based on another patent or claim not involved in such final decision. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt">Late Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In the event royalty, reimbursement and&#47;or fee payments are not received by UNIVERSITY when due, LICENSEE shall pay to UNIVERSITY interest charges at a rate of ten percent (10%) per year. Such interest shall be calculated from the date payment was due until actually received by UNIVERSITY. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE V</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>PATENT MATTERS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Patent Prosecution and Maintenance. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">LICENSEE, at its own expense, shall be responsible for and have control over the filing, prosecution and maintenance of patents and patent applications in Patent Rights, including the appointment of local patent counsel as agents of record. All patents and patent applications in Patent Rights shall be assigned solely to UNIVERSITY and LICENSEE shall be acting in the best interest of UNIVERSITY in filing, prosecuting and maintaining Patent Rights. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">UNIVERSITY shall provide LICENSEE with all necessary information including patent application drafts in order to enable LICENSEE to file, prosecute and maintain patents and patent applications in Patent Rights. LICENSEE shall consult in good faith with UNIVERSITY as to the content of all applications and papers to be filed, and shall act in good faith upon comments received from UNIVERSITY. UNIVERSITY shall ensure that no public disclosures are made prior to filing of patent applications. LICENSEE shall provide UNIVERSITY with copies of all documentation relating to the filing, prosecution and maintenance of Patent Rights and UNIVERSITY shall keep this documentation confidential. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">LICENSEE shall apply for an extension of the term of any patent in Patent Rights if appropriate under the US Drug Price Competition and Patent Term Restoration Act and&#47;or European, Japanese and other counterparts thereof. LICENSEE shall prepare all documents for such application, and UNIVERSITY shall execute such documents and take any other additional action as LICENSEE reasonably requests in connection therewith. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Patent Infringement.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If LICENSEE learns of any substantial infringement of Patent Rights, LICENSEE shall so inform UNIVERSITY and provide UNIVERSITY with reasonable evidence of the infringement. Neither party shall notify a third party of the infringement of Patent Rights without the consent of the other party. Both parties shall use reasonable efforts and cooperation to terminate infringement without litigation. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">LICENSEE may request UNIVERSITY to take legal action against such third party for the infringement of Patent Rights. Such request shall be made in writing </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">and shall include reasonable evidence of such infringement and damages to LICENSEE. If the infringing activity has not abated ninety (90) days following LICENSEE&#8217;s request, UNIVERSITY shall elect to or not to commence suit on its own account. UNIVERSITY shall give notice of its election in writing to LICENSEE by the end of the one-hundredth (100th) day after receiving notice of such request from LICENSEE. LICENSEE may thereafter bring suit for patent infringement in its own name (and in the name of UNIVERSITY if necessary) and at its own expense, if and only if UNIVERSITY elects not to commence suit and the infringement occurred in a jurisdiction where LICENSEE has an exclusive license under this Agreement. If LICENSEE elects to bring suit, UNIVERSITY may join that suit at its own expense. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Recoveries from actions brought pursuant to Paragraph 5.2(b) shall belong to the party bringing suit except that in the event that LICENSEE brings suit for infringement of Patent Rights and an acceptable settlement is entered into or monetary damages are awarded in a final non-appealable judgment, UNIVERSITY shall be reimbursed for any amount which would have been due to UNIVERSITY under this Agreement if the products sold by the infringer actually had been sold by LICENSEE. Legal actions brought jointly by UNIVERSITY and LICENSEE and fully participated in by both shall be at the joint expense of the parties and all recoveries shall be shared jointly by them in proportion to the share of expense paid by each party. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Each party shall cooperate with the other in litigation proceedings at the expense of the party bringing suit. Litigation shall be controlled by the party bringing the suit, except that UNIVERSITY may choose to be represented by counsel of its choice (at its expense) in any suit brought by LICENSEE. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Patent Marking.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> LICENSEE shall mark all Licensed Products made, used or sold under the terms of this Agreement, or their containers, in accordance with the applicable patent marking laws. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE VI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>GOVERNMENTAL MATTERS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Governmental Approval or Registration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> If this Agreement or any associated transaction is required by the law of any nation to be either approved or registered with any governmental agency, LICENSEE shall assume all legal obligations to do so. LICENSEE shall notify UNIVERSITY if it becomes aware that this Agreement is subject to any government reporting or approval requirement. LICENSEE shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE VII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>TERMINATION OF THE AGREEMENT </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Termination by UNIVERSITY.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If LICENSEE fails to perform or violates any term of this Agreement, then UNIVERSITY may give written notice of default (&#8220;Notice of Default&#8221;) to LICENSEE. If LICENSEE fails to cure the default within sixty (60) days of the Notice of Default with respect to the failure to make payments required under this Agreement or within one hundred twenty (120) days for any other breach, UNIVERSITY may terminate this Agreement and the license granted herein by a second written notice (&#8220;Notice of Termination&#8221;) to LICENSEE. If a Notice of Termination is sent to LICENSEE, this Agreement shall automatically terminate on the effective date of that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">notice. Termination shall not relieve LICENSEE of its obligation to pay any fees owed at the time of termination and shall not impair any accrued right of UNIVERSITY. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">UNIVERSITY shall have the right to terminate this Agreement by giving written notice, in the event of filing by LICENSEE of a petition of bankruptcy or insolvency or both, or in the event of an adjudication that LICENSEE is bankrupt or insolvent or both, or after filing by LICENSEE of any petition or pleading asking reorganization, readjustment or rearrangement of its business under any law relating to bankruptcy or insolvency, or upon or after appointment of a receiver for all or substantially all of the property of LICENSEE or upon or after the making of any assignment for the benefit of creditors or upon or after the institution of any proceedings for the liquidation or winding-up of LICENSEE&#8217;s business or for the termination of its corporate charter, and this Agreement shall terminate upon the date specified in such written notice. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Termination by Licensee.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">LICENSEE shall have the right at any time and for any reason to terminate this Agreement upon a ninety (90) day written notice to UNIVERSITY. Said notice shall state LICENSEE&#8217;s reason for terminating this Agreement. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Any termination under Paragraph 7.2(a) shall not relieve LICENSEE of any obligation or liability accrued under this Agreement prior to termination or rescind any payment made to UNIVERSITY or action by LICENSEE prior to the time termination becomes effective. Termination shall not affect in any manner any rights of UNIVERSITY arising under this Agreement prior to termination. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Survival on Termination.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The following Paragraphs and Articles shall survive the termination of this Agreement&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Article 4 (REPORTS, RECORDS AND PAYMENTS)&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Paragraph 7.4 (Disposition of Licensed Products on Hand)&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Paragraph 8.2 (Indemnification)&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Article 9 (USE OF NAMES AND TRADEMARKS)&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Paragraph 10.2 hereof (Secrecy)&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt">Paragraph 10.5 (Failure to Perform). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Disposition of Licensed Products on Hand.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Upon termination of this Agreement, LICENSEE may dispose of all previously made or partially made Licensed Product within a period of one hundred and twenty (120) days of the effective date of such termination provided that the sale of such Licensed Product by LICENSEE, its Sublicensees, or Affiliates shall be subject to the terms of this Agreement, including but not limited to the rendering of reports and payment of royalties required under this Agreement. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE VIII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br> LIMITED WARRANTY AND INDEMNIFICATION </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Limited Warranty.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">UNIVERSITY warrants that it has the lawful right to grant this license, that Attachment A to this Agreement is a complete list of all patents and applications owned or controlled by UNIVERSITY pertaining to the Invention, and that it has good and sufficient title to the Licensed Patents to grant the licenses herein free and clear of the rightful claim of any third party. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The license granted herein is provided &#8220;AS IS&#8221; and without WARRANTY OF MERCHANTABILITY or WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE or any other warranty, express or implied. UNIVERSITY makes no representation or warranty that the Licensed Product, Licensed Method or the use of Patent Rights will not infringe any other patent or other proprietary rights. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">In no event shall UNIVERSITY be liable for any incidental, special or consequential damages resulting from exercise of the license granted herein or the use of the Invention, Licensed Product, or Licensed Method. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Nothing in this Agreement shall be construed as&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a warranty or representation by UNIVERSITY as to the validity or scope of any Patent Rights&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">a warranty or representation that anything made, used, sold or otherwise disposed of under any license granted in this Agreement is or shall be free from infringement of patents of third parties&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">an obligation to bring or prosecute actions or suits against third parties for patent infringement except as provided in Paragraph 5.2 hereof&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">conferring by implication, estoppel or otherwise any license or rights under any patents of UNIVERSITY other than Patent Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Patent Rights&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">an obligation to furnish any know-how not provided in Patent Rights. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Indemnification.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">LICENSEE shall indemnify, hold harmless and defend UNIVERSITY, its officers, employees, and agents&#59; the sponsors of the research that led to the Invention&#59; and the inventors of the patents and patent applications in Patent Rights and their employers against any and all claims, suits, losses, damage, costs, fees, and expenses resulting from or arising out of exercise of this license or any sublicense. This indemnification shall include, but not be limited to, any product liability. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">LICENSEE, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain insurance or an equivalent program of self-insurance. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">UNIVERSITY shall notify LICENSEE in writing of any claim or suit brought against UNIVERSITY in respect of which UNIVERSITY intends to invoke the provisions of this Article. LICENSEE shall keep UNIVERSITY informed on a current basis of its defense of any claims under this Article. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE IX</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>USE OF NAMES AND TRADEMARKS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including contraction, abbreviation or simulation of any of the foregoing). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt">UNIVERSITY may acknowledge the existence of this Agreement and the extent of the grant in Article 2 to third parties, but UNIVERSITY shall not disclose the financial terms of this Agreement to third parties, except where UNIVERSITY is required by law to do so. </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-weight:400;line-height:100%">ARTICLE X</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><br>MISCELLANEOUS PROVISIONS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Correspondence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> Any notice or payment required to be given to either party under this Agreement shall be deemed to have been properly given and effective&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">on the date of delivery if delivered in person, or </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">five (5) days after mailing if mailed by registered mail, postage paid, to the respective addresses given below, or to such other address as is designated by written notice given to the other party. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If sent to LICENSEE&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Viventia Bio, Inc. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">147 Hamelin Street </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Winnipeg MD, R3T 3Z1 (CANADA) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Attention&#58; Mr. Stephen A. Hurly </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If sent to UNIVERSITY&#58; </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">University of Zurich </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c&#47;o Unitectra&#59; Ref. UZ-03&#47;064 </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Scheuchzerstrasse 21&#59; CH-8006 Zurich (SWITZERLAND) </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Secrecy.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.7pt"> &#8220;Confidential Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> shall mean information relating to the Invention or activities hereunder disclosed by one party to the other during the term of this Agreement, which if disclosed in writing shall be marked &#8220;Confidential.&#8221; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">The Receiving party of any such Confidential Information shall&#58; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">use the Confidential Information for the sole purpose of performing under the terms of this Agreement&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">safeguard Confidential Information against disclosure to others with the same degree of care as it exercises with its own data of a similar nature&#59; </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">not disclose Confidential Information to others (except to its employees, agents or consultants who are bound to it by a like obligation of confidentiality) without the express written permission of the Disclosing party, , except that the Receiving party shall not be prevented from using or disclosing any of the Confidential Information that&#58; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">it can demonstrate by written records was previously known to it&#59; </font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">is now, or becomes in the future, public knowledge other than through acts or omissions of it&#59; or </font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">is lawfully obtained by it from sources independent of Disclosing party. </font></div><div style="margin-bottom:12pt;padding-left:180pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">is required to be disclosed by government authority&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that Receiving party has provided reasonable advance notice of the impending disclosure to Disclosing party and will disclose the Confidential Information to the extent necessary and to such authority only. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">The obligations of the Receiving party with respect to Confidential Information shall continue for a period ending five (5) years from the termination date of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Assignability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> UNIVERSITY and LICENSEE each agree that their rights and obligations under this Agreement may not be transferred or assigned to a third party without the prior written consent of the other party thereto, such consent not to be unreasonably withheld. Notwithstanding the foregoing, in the event of a merger, consolidation or similar reorganization of either Party with or into another party, or in the event of a sale of all or substantially all of the assets of a Party or the business unit or product to which this Agreement pertains, this Agreement shall be assigned to or become the obligation and liability of the acquiring entity, subject to written notification of such acquisition or merger to the other Party. The terms and conditions of this Agreement shall be binding upon and inure to the benefit of the permitted successors and assigns of the Parties. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">No Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> No waiver by either party of any breach or default of any covenant or agreement set forth in this Agreement shall be deemed a waiver as to any subsequent and&#47;or similar breach or default. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Failure to Perform. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of a failure of performance due under this Agreement and if it becomes necessary for either party to undertake legal action against the other on account thereof, then the prevailing party shall be entitled to reasonable attorney&#8217;s fees in addition to costs and necessary disbursements. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Governing Laws&#59; Arbitration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> THIS AGREEMENT SHALL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF SWITZERLAND, except that matters concerning the validity or infringement of any patent shall be governed by the national laws of the jurisdiction issuing such patent. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">All disputes, differences or controversies arising out of or in connection with this Agreement, its interpretation, performance, or termination, which may arise between the Parties arising out of, or related to, this Agreement shall be amicably settled between the Parties. In case of failure of amicable settlement between the Parties, it shall be finally settled by binding arbitration conducted in accordance with the Rules of Concilliation and Arbitration of the International Chamber of Commerce (Paris, France) (the &#8220;ICC&#8221;). The arbitration panel shall be composed of three arbitrators, one of whom shall be selected by UNIVERSITY, one of whom shall be selected by LICENSEE and the third of whom shall be selected by the two so selected. If both or either of UNIVERSITY OR LICENSEE fails to select an arbitrator or arbitrators within </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">fourteen (14) days after receiving notice of commencement of arbitration or if the two arbitrators fail to select a third arbitrator within fourteen (14) days after their appointment, the ICC shall, in accordance with said rules, upon the request of both or either of the Parties to the arbitration, appoint the arbitrator or arbitrators required to complete the panel. The venue of arbitration shall be Zurich. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Parties shall share the costs of the arbitration, including administrative and arbitrators&#8217; fees equally. Each Party shall bear its own costs and attorneys&#8217; and witnesses&#8217; fees&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the prevailing Party, as determined by the arbitration panel, shall be entitled to an award against the other Party in the amount of the prevailing Party&#8217;s costs and reasonable attorneys&#8217; fees. The arbitration award shall be final and each Party shall comply in good faith and submit itself to the jurisdiction of the appropriate courts in Zurich for the sole purpose of the entry of such arbitrator&#8217;s award to render effective such arbitration decision. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Force Majeure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> A party to this Agreement may be excused from any performance required herein if such performance is rendered impossible or unfeasible due to any catastrophe or other major event beyond its reasonable control, including, without limitation, war, riot, and insurrection&#59; laws, proclamations, edicts, ordinances, or regulations&#59; strikes, lockouts, or other serious labor disputes&#59; and floods, fires, explosions, or other natural disasters. When such events have abated, the non-performing party&#8217;s obligations herein shall resume. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Headings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.9</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:21pt">Entire Agreement. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter hereof. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Amendments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> No amendment or modification of this Agreement shall be valid or binding on the parties unless made in writing and signed on behalf of each party. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.11</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:15pt">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> In the event that any of the provisions contained in this Agreement is held to be invalid, illegal, or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, both UNIVERSITY and LICENSEE have executed this amended and restated Agreement, in duplicate originals, by their respective and duly authorized officers on 14 October, 2015. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.641%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.470%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.530%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">UNIVERSITY</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 14, 2015</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prof. Dr. Andreas Pl&#252;ckthun</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Dr. Andreas Pl&#252;ckthun</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">(Signature)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 14, 2015</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Prof. Dr. Christoph Hock</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Dr. Christoph Hock</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">(Signature)</font></td></tr><tr style="height:12pt"><td colspan="9" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LICENSEE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VIVENTIA BIO, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 14, 2015</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Stephen A. Hurly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Stephen A. Hurly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and CEO</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">(Signature)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">October 14, 2015</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Erick J. Lucera</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Erick J. Lucera</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">(Signature)</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Attachment A </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;**&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div><hr style="page-break-after:always"><div style="background-color:#ffffff"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Attachment B </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Payments </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;**&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> </font></div></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sesn-03312022x10qex3111.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="ib4705d899a614abcb2f3e79be6fbd26d_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Thomas R. Cannell, D.V.M., certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.777%"><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sesn-03312022x10qex3121.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="if60761a4fa9d429bafcc48092fce0fe1_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Monica Forbes, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:0.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>sesn-03312022x10qex3211.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i56f3a1b2218f4e8096061c8f2ec4395f_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Quarterly Report on Form 10-Q of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:0.37pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>sesn-03312022x10qex3221.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i68c62297229a44adb7e220f88f94facd_1"></div><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Quarterly Report on Form 10-Q of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:0.37pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sesn-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:543d6d7e-07fa-4fa5-80cd-d905631091cd,g:997a4fa6-361a-4df1-8bb3-52045b6d76b9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sesn="http://www.sesenbio.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sesenbio.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sesenbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION">
        <link:definition>2103102 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS">
        <link:definition>2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables">
        <link:definition>2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
        <link:definition>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLES" roleURI="http://www.sesenbio.com/role/RECEIVABLES">
        <link:definition>2112106 - Disclosure - RECEIVABLES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLESDetails" roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails">
        <link:definition>2413405 - Disclosure - RECEIVABLES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILL" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL">
        <link:definition>2114107 - Disclosure - INTANGIBLES AND GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLTables" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables">
        <link:definition>2315302 - Disclosure - INTANGIBLES AND GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails">
        <link:definition>2416406 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLESANDGOODWILLNarrativeDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails">
        <link:definition>2417407 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES">
        <link:definition>2118108 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2319303 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails">
        <link:definition>2420408 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2121109 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2422409 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.sesenbio.com/role/LEASES">
        <link:definition>2123110 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails">
        <link:definition>2424410 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2125111 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2326304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYEquityFinancingDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails">
        <link:definition>2427411 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYPreferredStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails">
        <link:definition>2428412 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYCommonStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails">
        <link:definition>2429413 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails">
        <link:definition>2430414 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYWarrantsDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails">
        <link:definition>2431415 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2132112 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2333305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>2434416 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2135113 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2336306 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
        <link:definition>2437417 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2438418 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>2439419 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
        <link:definition>2440420 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
        <link:definition>2441421 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2142114 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>2443422 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTS" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS">
        <link:definition>2144115 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails">
        <link:definition>2445423 - Disclosure - LICENSE AGREEMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIES" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES">
        <link:definition>2146116 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESTables" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables">
        <link:definition>2347307 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails">
        <link:definition>2448424 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails">
        <link:definition>2449425 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS">
        <link:definition>2150117 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sesn_SharesOfCommonStockReservedForIssuanceAbstract" abstract="true" name="SharesOfCommonStockReservedForIssuanceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" abstract="false" name="LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_LicenseAgreementTextBlock" abstract="false" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" abstract="true" name="CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SecondIndicationMember" abstract="true" name="SecondIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberOfLawsuits" abstract="false" name="NumberOfLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchievementExpense" abstract="false" name="LicenseAgreementMilestoneAchievementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationLineItems" abstract="true" name="OrganizationAndBasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_GermanVATRecoveryMember" abstract="true" name="GermanVATRecoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_MENALicenseAgreementMember" abstract="true" name="MENALicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" abstract="false" name="SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyRate" abstract="false" name="LicenseAgreementRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_AccruedRestructuringChargesRelatedCurrent" abstract="false" name="AccruedRestructuringChargesRelatedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OperatingLeaseOtherMonthlyOperatingExpenses" abstract="false" name="OperatingLeaseOtherMonthlyOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseRevenueMember" abstract="true" name="LicenseRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_IL6Member" abstract="true" name="IL6Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRoyaltyPeriod" abstract="false" name="CollaborativeArrangementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_UniversityOfZurichMember" abstract="true" name="UniversityOfZurichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" abstract="false" name="SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_OperatingLeasesAreaOfOfficeSpace" abstract="false" name="OperatingLeasesAreaOfOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2022Member" abstract="true" name="WarrantsExpiringNovember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_WarrantsExpiringMarch2023Member" abstract="true" name="WarrantsExpiringMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_XOMAIrelandLimitedMember" abstract="true" name="XOMAIrelandLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_StockIncentivePlan2009Member" abstract="true" name="StockIncentivePlan2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_BusinessCombinationRoyaltyPaymentPercent" abstract="false" name="BusinessCombinationRoyaltyPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" abstract="false" name="LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" abstract="false" name="SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightIssuedDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_A2014EmployeeStockPurchasePlanMember" abstract="true" name="A2014EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_QiluPharmaceuticalCoLtdMember" abstract="true" name="QiluPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementAdditionalUpFrontFee" abstract="false" name="LicenseAgreementAdditionalUpFrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" abstract="false" name="SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_EBI031Member" abstract="true" name="EBI031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementOptionPeriods" abstract="false" name="LicenseAgreementOptionPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" abstract="false" name="SaleOfStockMaximumAggregateSalesPriceInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" abstract="false" name="StockIssuedDuringPeriodNewIssuesIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" abstract="true" name="EczacibasiPharmaceuticalsMarketingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberOfPatients" abstract="false" name="NumberOfPatients" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_LicenseAgreementUpfrontFee" abstract="false" name="LicenseAgreementUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_WarrantOrRightOutstandingRollForward" abstract="true" name="WarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_SaleOfStockCommissionFixedRate" abstract="false" name="SaleOfStockCommissionFixedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_CommonStockSharesIssuedAndReservedForFuture" abstract="false" name="CommonStockSharesIssuedAndReservedForFuture" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ViventiaBioInc.Member" abstract="true" name="ViventiaBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementProceedsFromMilestoneAchieved" abstract="false" name="LicenseAgreementProceedsFromMilestoneAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationTable" abstract="true" name="OrganizationAndBasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberofVotesEntitledForEachShare" abstract="false" name="NumberofVotesEntitledForEachShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" abstract="false" name="LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" abstract="true" name="WarrantsExpiringNovember2024IssuedNovember2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" abstract="false" name="DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" abstract="false" name="LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedMay2015Member" abstract="true" name="WarrantsExpiringNovember2024IssuedMay2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_MicrometAGMember" abstract="true" name="MicrometAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ShortTermLeaseRenewalFrequency" abstract="false" name="ShortTermLeaseRenewalFrequency" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" abstract="false" name="BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OperatingLeaseMonthlyRent" abstract="false" name="OperatingLeaseMonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_FirstIndicationMember" abstract="true" name="FirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_StockIncentivePlanTwoThousandFourteenMember" abstract="true" name="StockIncentivePlanTwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchieved" abstract="false" name="LicenseAgreementMilestoneAchieved" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" abstract="false" name="LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_RetentionProgramMember" abstract="true" name="RetentionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_AccountsReceivablePaymentTerms" abstract="false" name="AccountsReceivablePaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" abstract="false" name="ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseMaintenanceFees" abstract="false" name="LicenseMaintenanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" abstract="false" name="SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ViciniumMember" abstract="true" name="ViciniumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ATMFacilityMember" abstract="true" name="ATMFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_BusinessCombinationMilestonePayments" abstract="false" name="BusinessCombinationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WeightedAverageCostOfCapital" abstract="false" name="WeightedAverageCostOfCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" abstract="false" name="StockIssuedDuringPeriodExerciseOfWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" abstract="false" name="RightOfUseAssetRelatedToAdoptionOfAccountingStandard" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RoyaltyRevenuePercentage" abstract="false" name="RoyaltyRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>sesn-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:543d6d7e-07fa-4fa5-80cd-d905631091cd,g:997a4fa6-361a-4df1-8bb3-52045b6d76b9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_0feaa5ad-007c-4635-9ff1-9126ad3c44a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_040c92b4-93c8-4ed4-a1a8-00e5b47ad97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_0feaa5ad-007c-4635-9ff1-9126ad3c44a4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_040c92b4-93c8-4ed4-a1a8-00e5b47ad97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_75acedf4-b24d-449a-ab41-e7e66789b7e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_0feaa5ad-007c-4635-9ff1-9126ad3c44a4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_75acedf4-b24d-449a-ab41-e7e66789b7e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e88f645f-e689-4b16-8e15-0b5fcd9f85d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_0feaa5ad-007c-4635-9ff1-9126ad3c44a4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_e88f645f-e689-4b16-8e15-0b5fcd9f85d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b14788fe-ca02-4b38-b0ea-067bed0d2617" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_594cdc10-8610-446d-996e-aa978880b5d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b14788fe-ca02-4b38-b0ea-067bed0d2617" xlink:to="loc_us-gaap_StockholdersEquity_594cdc10-8610-446d-996e-aa978880b5d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8159b838-9311-4f87-8e59-9c2806bb9168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b14788fe-ca02-4b38-b0ea-067bed0d2617" xlink:to="loc_us-gaap_Liabilities_8159b838-9311-4f87-8e59-9c2806bb9168" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_b2952888-ae7a-49a0-9b14-c0cbdb85555d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_98102a6b-b366-41d2-9426-ddc01cd3a8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b2952888-ae7a-49a0-9b14-c0cbdb85555d" xlink:to="loc_us-gaap_Goodwill_98102a6b-b366-41d2-9426-ddc01cd3a8fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_912dcd9a-3be9-49a9-b956-7f477fde1812" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b2952888-ae7a-49a0-9b14-c0cbdb85555d" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_912dcd9a-3be9-49a9-b956-7f477fde1812" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bed8a167-09e8-413e-9f5c-ce8ae525ac04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b2952888-ae7a-49a0-9b14-c0cbdb85555d" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bed8a167-09e8-413e-9f5c-ce8ae525ac04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4750b8d0-cacf-4903-9f09-35e6a10f28cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b2952888-ae7a-49a0-9b14-c0cbdb85555d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4750b8d0-cacf-4903-9f09-35e6a10f28cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_20afe8f9-0fae-41c8-ab19-80b00944dc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b2952888-ae7a-49a0-9b14-c0cbdb85555d" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_20afe8f9-0fae-41c8-ab19-80b00944dc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3ca92518-d32e-43a9-9ef1-3783a81c15e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_b2952888-ae7a-49a0-9b14-c0cbdb85555d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_3ca92518-d32e-43a9-9ef1-3783a81c15e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b47d4c4e-862c-464e-b8aa-ca634350e5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_7871e2bd-6c63-45f9-8984-ad7139d2fd43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b47d4c4e-862c-464e-b8aa-ca634350e5da" xlink:to="loc_us-gaap_CommonStockValue_7871e2bd-6c63-45f9-8984-ad7139d2fd43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2dee23cf-f55d-42bd-9dc6-0efbf90ee55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b47d4c4e-862c-464e-b8aa-ca634350e5da" xlink:to="loc_us-gaap_PreferredStockValue_2dee23cf-f55d-42bd-9dc6-0efbf90ee55b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b406e195-4a8c-492d-9b03-c993d3b56c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b47d4c4e-862c-464e-b8aa-ca634350e5da" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b406e195-4a8c-492d-9b03-c993d3b56c94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bb7b9e16-1174-4e1b-a052-ed0247b11ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_b47d4c4e-862c-464e-b8aa-ca634350e5da" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bb7b9e16-1174-4e1b-a052-ed0247b11ff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_490fa64f-529b-477c-b62e-503f400e48bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_2e9e2257-8920-4389-a010-166ebc78403e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_490fa64f-529b-477c-b62e-503f400e48bc" xlink:to="loc_us-gaap_AccountsPayableCurrent_2e9e2257-8920-4389-a010-166ebc78403e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f4d34403-f054-4b11-997d-dab3797a5ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_490fa64f-529b-477c-b62e-503f400e48bc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f4d34403-f054-4b11-997d-dab3797a5ec9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_77eaedda-4812-4c1a-b8d8-fcffd22f8ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_490fa64f-529b-477c-b62e-503f400e48bc" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_77eaedda-4812-4c1a-b8d8-fcffd22f8ff8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7eceb701-2bf1-47d0-98e0-e1cc811b92c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_633deb4e-e22c-4406-a25e-e2d2c891e769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eceb701-2bf1-47d0-98e0-e1cc811b92c3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_633deb4e-e22c-4406-a25e-e2d2c891e769" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1d8a786c-4dbc-4c46-a79c-bf07ec0a94b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eceb701-2bf1-47d0-98e0-e1cc811b92c3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1d8a786c-4dbc-4c46-a79c-bf07ec0a94b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_36ad9177-bd11-41db-9a14-5a991ed8dc49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eceb701-2bf1-47d0-98e0-e1cc811b92c3" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_36ad9177-bd11-41db-9a14-5a991ed8dc49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c2cca48f-178d-42ab-a35b-d03097cf1914" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7eceb701-2bf1-47d0-98e0-e1cc811b92c3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c2cca48f-178d-42ab-a35b-d03097cf1914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_84c3ad3e-aebe-4439-9a89-81a7f1ac4de6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_a618853d-01c8-460f-8801-826e030ab45e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84c3ad3e-aebe-4439-9a89-81a7f1ac4de6" xlink:to="loc_us-gaap_AssetsNoncurrent_a618853d-01c8-460f-8801-826e030ab45e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6894344f-2050-434e-99ed-d4c30232614e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_84c3ad3e-aebe-4439-9a89-81a7f1ac4de6" xlink:to="loc_us-gaap_AssetsCurrent_6894344f-2050-434e-99ed-d4c30232614e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e7d5b0c8-d6e6-431a-ab74-29d264024bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b905fe19-59f9-4771-b6cb-a91c0e67e8ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7d5b0c8-d6e6-431a-ab74-29d264024bbd" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b905fe19-59f9-4771-b6cb-a91c0e67e8ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_abf7514b-64ef-4f83-9215-ba1dbaf45564" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e7d5b0c8-d6e6-431a-ab74-29d264024bbd" xlink:to="loc_us-gaap_LiabilitiesCurrent_abf7514b-64ef-4f83-9215-ba1dbaf45564" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_8c86e88b-0f61-4949-a60e-fd8ee097cd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_fe4a4ac3-ff84-4056-bb3b-e01f04cc4269" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_8c86e88b-0f61-4949-a60e-fd8ee097cd1e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_fe4a4ac3-ff84-4056-bb3b-e01f04cc4269" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_5d9807f4-9101-4c71-b1a4-6b71df9029cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_8c86e88b-0f61-4949-a60e-fd8ee097cd1e" xlink:to="loc_us-gaap_OperatingIncomeLoss_5d9807f4-9101-4c71-b1a4-6b71df9029cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_41c75041-997d-4c03-a42c-83b73a768ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9b246dad-1372-46c7-ad17-004d14d7bbc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41c75041-997d-4c03-a42c-83b73a768ef7" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9b246dad-1372-46c7-ad17-004d14d7bbc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_37dc8624-c7d5-4ec1-b69e-3e40c0747067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41c75041-997d-4c03-a42c-83b73a768ef7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_37dc8624-c7d5-4ec1-b69e-3e40c0747067" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_618e8008-4170-4d11-8d38-5109216bbc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_41c75041-997d-4c03-a42c-83b73a768ef7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_618e8008-4170-4d11-8d38-5109216bbc05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_56743358-8438-4627-9454-7cece918e098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a4e3013f-4dce-46e5-9108-48bd35dc3650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_56743358-8438-4627-9454-7cece918e098" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_a4e3013f-4dce-46e5-9108-48bd35dc3650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e4f9d8b3-52f1-4417-9823-7dcb1faa4052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_56743358-8438-4627-9454-7cece918e098" xlink:to="loc_us-gaap_OperatingExpenses_e4f9d8b3-52f1-4417-9823-7dcb1faa4052" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c20bf6af-f74b-4438-833b-0e9f295a438e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_9cdabe36-7c47-4776-baab-22654d06604f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c20bf6af-f74b-4438-833b-0e9f295a438e" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_9cdabe36-7c47-4776-baab-22654d06604f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d93986c8-c4aa-415f-a3e5-b3dd14977e33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c20bf6af-f74b-4438-833b-0e9f295a438e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d93986c8-c4aa-415f-a3e5-b3dd14977e33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_4b03d5ab-d1b6-4455-899a-562845363ede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f760f312-c165-4a80-b1c4-85096a3e878d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_4b03d5ab-d1b6-4455-899a-562845363ede" xlink:to="loc_us-gaap_NetIncomeLoss_f760f312-c165-4a80-b1c4-85096a3e878d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e20c3241-a2f4-4621-b7ac-d67b2816f6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0abfbadb-78b4-4aa4-917f-6fb8428e4944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e20c3241-a2f4-4621-b7ac-d67b2816f6e5" xlink:to="loc_us-gaap_NetIncomeLoss_0abfbadb-78b4-4aa4-917f-6fb8428e4944" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a2092a2-6b56-4f85-ac17-f7b0d181da66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8d13744d-1e5d-4389-ab64-ca8a7315d148" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a2092a2-6b56-4f85-ac17-f7b0d181da66" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8d13744d-1e5d-4389-ab64-ca8a7315d148" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f4f94fcb-0df0-440d-a375-1f47dc9e4431" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a2092a2-6b56-4f85-ac17-f7b0d181da66" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f4f94fcb-0df0-440d-a375-1f47dc9e4431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_74b25aa0-b89e-4fe5-9abe-0648ffd08322" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a2092a2-6b56-4f85-ac17-f7b0d181da66" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_74b25aa0-b89e-4fe5-9abe-0648ffd08322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c78da2e5-feff-4adf-a612-c94fc74eae25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0ccb808-3993-481b-8a0b-c85376402150" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c78da2e5-feff-4adf-a612-c94fc74eae25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0ccb808-3993-481b-8a0b-c85376402150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60523b6d-9621-4757-b3bf-223e860d79bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c78da2e5-feff-4adf-a612-c94fc74eae25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_60523b6d-9621-4757-b3bf-223e860d79bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e0fe5b2-8e19-4153-9dda-0b8b2379e8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c78da2e5-feff-4adf-a612-c94fc74eae25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_9e0fe5b2-8e19-4153-9dda-0b8b2379e8c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78ecebb6-8a4d-4653-98b4-0e34066c0e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78ecebb6-8a4d-4653-98b4-0e34066c0e56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_eb09e3be-dda0-43d7-b911-6e0303fe57e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_eb09e3be-dda0-43d7-b911-6e0303fe57e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8a878468-2897-4145-b6c5-99b95d442c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_8a878468-2897-4145-b6c5-99b95d442c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_f0259f56-e0e3-42d9-bcdf-7d23bd1b1747" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_f0259f56-e0e3-42d9-bcdf-7d23bd1b1747" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3e82661b-4056-4ae5-993b-c60b165d03a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_NetIncomeLoss_3e82661b-4056-4ae5-993b-c60b165d03a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7f0e60a8-da1b-4e17-9344-0d68aa0f8b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7f0e60a8-da1b-4e17-9344-0d68aa0f8b83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_72100657-e59b-4706-b3db-d533ab27d1ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_72100657-e59b-4706-b3db-d533ab27d1ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_a2faa8ea-bd00-4b9f-9a07-e0e2bb140eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_DepreciationAndAmortization_a2faa8ea-bd00-4b9f-9a07-e0e2bb140eb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6ade40e8-e906-43a7-9642-1a774eec7c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_ShareBasedCompensation_6ade40e8-e906-43a7-9642-1a774eec7c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_3e923774-c68e-43d6-b5cc-b328413ab7cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_3e923774-c68e-43d6-b5cc-b328413ab7cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_bb77de07-78fa-4af3-b5b7-35f1ef89fc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_bb77de07-78fa-4af3-b5b7-35f1ef89fc7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_82803b52-550c-4253-9113-79cc04a00f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6174775b-9e43-4285-b11e-47e40777da32" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_82803b52-550c-4253-9113-79cc04a00f51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_27704958-c632-4711-9ff8-d265d45fea57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7c80d3d6-9944-4891-a4ef-766cc4dce696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_27704958-c632-4711-9ff8-d265d45fea57" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7c80d3d6-9944-4891-a4ef-766cc4dce696" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e1990361-0a44-4a9a-ae8a-4254980a9800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_27704958-c632-4711-9ff8-d265d45fea57" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e1990361-0a44-4a9a-ae8a-4254980a9800" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_49a384bb-0cbe-4a83-9973-4dec4bef9f64" xlink:href="sesn-20220331.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_27704958-c632-4711-9ff8-d265d45fea57" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_49a384bb-0cbe-4a83-9973-4dec4bef9f64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_4b2517be-4713-461a-bc86-b9dd73019362" xlink:href="sesn-20220331.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_27704958-c632-4711-9ff8-d265d45fea57" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_4b2517be-4713-461a-bc86-b9dd73019362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_36b336d3-4e73-40ab-80f9-ec993a460a76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_27704958-c632-4711-9ff8-d265d45fea57" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_36b336d3-4e73-40ab-80f9-ec993a460a76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_771aac83-84c8-4f5b-8171-029f9bb9e1c3" xlink:href="sesn-20220331.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_75de9325-302f-45da-bc70-5094ea97def6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_771aac83-84c8-4f5b-8171-029f9bb9e1c3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_75de9325-302f-45da-bc70-5094ea97def6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_34edf104-e627-4a7e-b434-c2c74ede1994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_771aac83-84c8-4f5b-8171-029f9bb9e1c3" xlink:to="loc_us-gaap_CommonStockSharesIssued_34edf104-e627-4a7e-b434-c2c74ede1994" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>sesn-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:543d6d7e-07fa-4fa5-80cd-d905631091cd,g:997a4fa6-361a-4df1-8bb3-52045b6d76b9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i74a83e5f636c45f9a057f6fcd85ecbde_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f16d5677-7ee0-4156-b841-f75a72f110f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f16d5677-7ee0-4156-b841-f75a72f110f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49b788b8-8d61-4ae9-919b-c7822f5b27df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49b788b8-8d61-4ae9-919b-c7822f5b27df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ca4465bf-4dac-4390-99d4-065441e7d8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ca4465bf-4dac-4390-99d4-065441e7d8fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bf6a47aa-9aaf-4277-9c52-64b29e0a9189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bf6a47aa-9aaf-4277-9c52-64b29e0a9189" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_80c2fe28-b027-4cb6-b6a2-ae54d2bbb510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:to="loc_us-gaap_OperatingExpenses_80c2fe28-b027-4cb6-b6a2-ae54d2bbb510" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1aa50e38-531f-474d-a74e-35bc2ece0298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_OperatingIncomeLoss_1aa50e38-531f-474d-a74e-35bc2ece0298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_43082a00-d125-48f0-9292-5432fc09537f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_43082a00-d125-48f0-9292-5432fc09537f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_2e4335c9-ba2f-453d-85ca-17c8640ad54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_2e4335c9-ba2f-453d-85ca-17c8640ad54e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72b7799a-0a87-4459-a892-55c178b5ea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72b7799a-0a87-4459-a892-55c178b5ea5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4914257-60fe-4a47-9248-6fd36d0dbf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_NetIncomeLoss_f4914257-60fe-4a47-9248-6fd36d0dbf1a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_21c92714-da43-4e3d-83c7-4928c10e23f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_21c92714-da43-4e3d-83c7-4928c10e23f3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e767b11f-581d-48a7-84f2-fe36720634bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e767b11f-581d-48a7-84f2-fe36720634bc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90a51a37-30f9-4cb0-8687-04b6b593ffd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90a51a37-30f9-4cb0-8687-04b6b593ffd0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_56b4a41f-cd9a-480b-90f0-562828e80343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_EarningsPerShareBasic_56b4a41f-cd9a-480b-90f0-562828e80343" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_17693c19-1a85-4b74-9b10-d9cea7009f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_17693c19-1a85-4b74-9b10-d9cea7009f9b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3a9cd15-1a21-476a-94b6-14a3c8e0eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3a9cd15-1a21-476a-94b6-14a3c8e0eac4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b092773-2da5-4752-aac1-8d752a36e2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b092773-2da5-4752-aac1-8d752a36e2ce" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3d1ca72-03b6-4cc9-bbbb-a5b76d81dd26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_StatementTable_a3d1ca72-03b6-4cc9-bbbb-a5b76d81dd26" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9711c225-d22c-4564-80b7-0a9907a8781f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a3d1ca72-03b6-4cc9-bbbb-a5b76d81dd26" xlink:to="loc_srt_ProductOrServiceAxis_9711c225-d22c-4564-80b7-0a9907a8781f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9711c225-d22c-4564-80b7-0a9907a8781f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9711c225-d22c-4564-80b7-0a9907a8781f" xlink:to="loc_srt_ProductsAndServicesDomain_9711c225-d22c-4564-80b7-0a9907a8781f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d1dfbba-42b3-4fbc-8fd4-f1a97b326f02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9711c225-d22c-4564-80b7-0a9907a8781f" xlink:to="loc_srt_ProductsAndServicesDomain_6d1dfbba-42b3-4fbc-8fd4-f1a97b326f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseRevenueMember_59e1ec6c-7fdc-469e-8486-44b41bf1f5c3" xlink:href="sesn-20220331.xsd#sesn_LicenseRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6d1dfbba-42b3-4fbc-8fd4-f1a97b326f02" xlink:to="loc_sesn_LicenseRevenueMember_59e1ec6c-7fdc-469e-8486-44b41bf1f5c3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i756ef8814cb04701b97e9479d80a3b3b_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0d42a915-7af7-4e33-a93f-930294c13719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0d42a915-7af7-4e33-a93f-930294c13719" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_16774898-53c7-4e2b-943a-b15cd18e68e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_SharesOutstanding_16774898-53c7-4e2b-943a-b15cd18e68e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4091ccf-08ab-4782-bc28-4b268c0b8ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockholdersEquity_d4091ccf-08ab-4782-bc28-4b268c0b8ca5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_877af71e-392b-4d21-82fb-cb5a861b4223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_NetIncomeLoss_877af71e-392b-4d21-82fb-cb5a861b4223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9dba0d20-0ee7-4865-853c-8f7beb0d0d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9dba0d20-0ee7-4865-853c-8f7beb0d0d52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_625c9e66-e372-422c-af82-e528893bc68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_625c9e66-e372-422c-af82-e528893bc68a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ee02c0e-b85f-4c12-a307-c442cf3ffaff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ee02c0e-b85f-4c12-a307-c442cf3ffaff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1e3529b9-97dc-43a0-bb5c-951016dac93f" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1e3529b9-97dc-43a0-bb5c-951016dac93f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_04bc35b7-f281-4c0c-8938-0c0f64784a75" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_04bc35b7-f281-4c0c-8938-0c0f64784a75" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f81c14e8-5424-4c1c-8717-2607720d5afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f81c14e8-5424-4c1c-8717-2607720d5afd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0e09e068-3fa1-47b2-9762-1bd3d85d3830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0e09e068-3fa1-47b2-9762-1bd3d85d3830" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_96a75709-f50a-47fe-acfc-a9120ce3b8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b5c1dc97-2db7-47d0-a1aa-f43f34f742d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0d42a915-7af7-4e33-a93f-930294c13719" xlink:to="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_733447fb-c378-4cc5-906b-88c059efad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_733447fb-c378-4cc5-906b-88c059efad6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_733447fb-c378-4cc5-906b-88c059efad6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_733447fb-c378-4cc5-906b-88c059efad6d" xlink:to="loc_us-gaap_EquityComponentDomain_733447fb-c378-4cc5-906b-88c059efad6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_733447fb-c378-4cc5-906b-88c059efad6d" xlink:to="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2df09310-5b82-4874-b1f8-b7c477940d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:to="loc_us-gaap_CommonStockMember_2df09310-5b82-4874-b1f8-b7c477940d61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8a63ed69-9300-475d-8b60-df74f9bb1dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8a63ed69-9300-475d-8b60-df74f9bb1dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9d2ec6b3-3ff2-43ed-96f9-8cf6c5f43724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:to="loc_us-gaap_RetainedEarningsMember_9d2ec6b3-3ff2-43ed-96f9-8cf6c5f43724" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_38e21561-4c93-47fb-a090-ccc6eb3ff209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_38e21561-4c93-47fb-a090-ccc6eb3ff209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38e21561-4c93-47fb-a090-ccc6eb3ff209_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_38e21561-4c93-47fb-a090-ccc6eb3ff209" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_38e21561-4c93-47fb-a090-ccc6eb3ff209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb545517-47ed-4fdf-9435-bcde1671811b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_38e21561-4c93-47fb-a090-ccc6eb3ff209" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb545517-47ed-4fdf-9435-bcde1671811b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_dad8f38c-aa38-4b7f-a3a4-af51ac680599" xlink:href="sesn-20220331.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb545517-47ed-4fdf-9435-bcde1671811b" xlink:to="loc_sesn_ATMFacilityMember_dad8f38c-aa38-4b7f-a3a4-af51ac680599" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="i2557e570e8874cfa89423aff7cf270a9_DESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfPatients_46195840-9b77-4bf5-9fb2-210d428ba6d5" xlink:href="sesn-20220331.xsd#sesn_NumberOfPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_NumberOfPatients_46195840-9b77-4bf5-9fb2-210d428ba6d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_f12859d8-54b9-4f08-8d64-fdbe5c37cfd3" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_f12859d8-54b9-4f08-8d64-fdbe5c37cfd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6c09b668-c70b-44db-98f0-2fe3df46203a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6c09b668-c70b-44db-98f0-2fe3df46203a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_1fa8b3a6-fccf-4a8f-a7d9-8b598fdf0383" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_1fa8b3a6-fccf-4a8f-a7d9-8b598fdf0383" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_3441b41b-9e8f-4e8b-897e-4559e5f156f9" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_3441b41b-9e8f-4e8b-897e-4559e5f156f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_59f6b227-4fcc-46fa-b951-ff4d7735c5eb" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_59f6b227-4fcc-46fa-b951-ff4d7735c5eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_202512b0-d2f5-464b-a961-302400915110" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_202512b0-d2f5-464b-a961-302400915110" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bfa82486-6163-4ace-8b09-01641ca913f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bfa82486-6163-4ace-8b09-01641ca913f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bfa82486-6163-4ace-8b09-01641ca913f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bfa82486-6163-4ace-8b09-01641ca913f2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bfa82486-6163-4ace-8b09-01641ca913f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_196df476-b91f-4906-8229-a5dd7651970d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bfa82486-6163-4ace-8b09-01641ca913f2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_196df476-b91f-4906-8229-a5dd7651970d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_45c9d0cb-ebf6-4b15-bc20-edfdaf3d9081" xlink:href="sesn-20220331.xsd#sesn_ViventiaBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_196df476-b91f-4906-8229-a5dd7651970d" xlink:to="loc_sesn_ViventiaBioInc.Member_45c9d0cb-ebf6-4b15-bc20-edfdaf3d9081" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9f183229-65ec-4f2b-b231-bcf357435727" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_srt_ProductOrServiceAxis_9f183229-65ec-4f2b-b231-bcf357435727" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9f183229-65ec-4f2b-b231-bcf357435727_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9f183229-65ec-4f2b-b231-bcf357435727" xlink:to="loc_srt_ProductsAndServicesDomain_9f183229-65ec-4f2b-b231-bcf357435727_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_450a6e70-3343-4371-9e03-2a79d9036bbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9f183229-65ec-4f2b-b231-bcf357435727" xlink:to="loc_srt_ProductsAndServicesDomain_450a6e70-3343-4371-9e03-2a79d9036bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_59c00ee4-de52-434c-b598-0f42672f8933" xlink:href="sesn-20220331.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_450a6e70-3343-4371-9e03-2a79d9036bbd" xlink:to="loc_sesn_ViciniumMember_59c00ee4-de52-434c-b598-0f42672f8933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_038146de-c3b8-47ad-ac8c-cbf29651b1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_038146de-c3b8-47ad-ac8c-cbf29651b1b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_038146de-c3b8-47ad-ac8c-cbf29651b1b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_038146de-c3b8-47ad-ac8c-cbf29651b1b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_038146de-c3b8-47ad-ac8c-cbf29651b1b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59a35401-a619-46d9-8ff0-e18c61e79009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_038146de-c3b8-47ad-ac8c-cbf29651b1b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59a35401-a619-46d9-8ff0-e18c61e79009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_982a5146-4477-4d0a-9fad-435c51b8ae4d" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59a35401-a619-46d9-8ff0-e18c61e79009" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_982a5146-4477-4d0a-9fad-435c51b8ae4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_298cf1c7-2607-4fd5-ac3b-84878fd69957" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_srt_StatementGeographicalAxis_298cf1c7-2607-4fd5-ac3b-84878fd69957" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_298cf1c7-2607-4fd5-ac3b-84878fd69957_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_298cf1c7-2607-4fd5-ac3b-84878fd69957" xlink:to="loc_srt_SegmentGeographicalDomain_298cf1c7-2607-4fd5-ac3b-84878fd69957_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_298cf1c7-2607-4fd5-ac3b-84878fd69957" xlink:to="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3e286d7d-8bd7-438d-a8c5-11c3c2d5f9ba" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:to="loc_country_US_3e286d7d-8bd7-438d-a8c5-11c3c2d5f9ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_e86638c7-e621-4ac6-9c34-eb7a1b38d9bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:to="loc_srt_EuropeMember_e86638c7-e621-4ac6-9c34-eb7a1b38d9bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_f978b206-d58f-4727-8916-864e6377401e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:to="loc_country_JP_f978b206-d58f-4727-8916-864e6377401e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i1c039436fe104759acbe95999b3d95f9_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da8c5708-3b09-4e6b-ba7f-ff5b5c14e5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bfcc7b4-92ab-457a-adeb-cbd1e34c0212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da8c5708-3b09-4e6b-ba7f-ff5b5c14e5b4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bfcc7b4-92ab-457a-adeb-cbd1e34c0212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62f968dc-5929-4e65-9834-35051b5d6375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bfcc7b4-92ab-457a-adeb-cbd1e34c0212" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62f968dc-5929-4e65-9834-35051b5d6375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e359c08b-59c8-4b9e-b002-4eb94949c61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da8c5708-3b09-4e6b-ba7f-ff5b5c14e5b4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e359c08b-59c8-4b9e-b002-4eb94949c61c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9cfc4413-fd3b-4908-a54b-1261472ea6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e359c08b-59c8-4b9e-b002-4eb94949c61c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9cfc4413-fd3b-4908-a54b-1261472ea6fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da8c5708-3b09-4e6b-ba7f-ff5b5c14e5b4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a54e4df1-2582-4edc-9322-6883eab5b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a54e4df1-2582-4edc-9322-6883eab5b1e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a54e4df1-2582-4edc-9322-6883eab5b1e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a54e4df1-2582-4edc-9322-6883eab5b1e7" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_a54e4df1-2582-4edc-9322-6883eab5b1e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f2926c2a-78a3-45bb-9eaf-62056a40f694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a54e4df1-2582-4edc-9322-6883eab5b1e7" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f2926c2a-78a3-45bb-9eaf-62056a40f694" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_dbcdc245-3e14-48d9-a93e-c1da6c074b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f2926c2a-78a3-45bb-9eaf-62056a40f694" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_dbcdc245-3e14-48d9-a93e-c1da6c074b2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3ebc2abf-9641-403f-b89e-ed36efcce6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_dbcdc245-3e14-48d9-a93e-c1da6c074b2f" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3ebc2abf-9641-403f-b89e-ed36efcce6a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c33f07e4-3594-42c4-b322-98c3066416d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_dbcdc245-3e14-48d9-a93e-c1da6c074b2f" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c33f07e4-3594-42c4-b322-98c3066416d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_70f0a19d-605c-46ee-8c89-bdae0e81b589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_70f0a19d-605c-46ee-8c89-bdae0e81b589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_70f0a19d-605c-46ee-8c89-bdae0e81b589_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_70f0a19d-605c-46ee-8c89-bdae0e81b589" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_70f0a19d-605c-46ee-8c89-bdae0e81b589_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_10c6a4c3-23b3-4d15-b17f-afce671de20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_70f0a19d-605c-46ee-8c89-bdae0e81b589" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_10c6a4c3-23b3-4d15-b17f-afce671de20f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f769f9e6-98ad-4958-ada6-b3c470e8c083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_10c6a4c3-23b3-4d15-b17f-afce671de20f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f769f9e6-98ad-4958-ada6-b3c470e8c083" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f204be18-8b68-49b6-994c-d295f7b9a5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f204be18-8b68-49b6-994c-d295f7b9a5ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f204be18-8b68-49b6-994c-d295f7b9a5ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f204be18-8b68-49b6-994c-d295f7b9a5ef" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f204be18-8b68-49b6-994c-d295f7b9a5ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f204be18-8b68-49b6-994c-d295f7b9a5ef" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_741ae2d7-3d45-4a0a-b110-c79bf43d95f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_741ae2d7-3d45-4a0a-b110-c79bf43d95f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_546b2046-1de0-4729-94af-ae9332727b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_546b2046-1de0-4729-94af-ae9332727b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e569b8f8-e00d-4d80-8cee-962f2951b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e569b8f8-e00d-4d80-8cee-962f2951b8e5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="ieb0e835af64e4df0b927acf0d569bb68_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8e1fbcb4-da17-4463-ae4f-621d0ba56e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8e1fbcb4-da17-4463-ae4f-621d0ba56e82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_6609c00f-4951-4421-9191-5c975fc7771b" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_6609c00f-4951-4421-9191-5c975fc7771b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_1c3be62a-1e34-41fc-b0ee-ac0c39bb33f8" xlink:href="sesn-20220331.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_sesn_WeightedAverageCostOfCapital_1c3be62a-1e34-41fc-b0ee-ac0c39bb33f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_277e0517-5f37-4db2-acc4-ebf55a9f21b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_277e0517-5f37-4db2-acc4-ebf55a9f21b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_97ce01c2-847d-4fc1-bad4-71552eb4f584" xlink:href="sesn-20220331.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_97ce01c2-847d-4fc1-bad4-71552eb4f584" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_10c96d2e-01bf-4792-840d-923f893bb446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_10c96d2e-01bf-4792-840d-923f893bb446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_10c96d2e-01bf-4792-840d-923f893bb446_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_10c96d2e-01bf-4792-840d-923f893bb446" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_10c96d2e-01bf-4792-840d-923f893bb446_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d05a8087-fbb9-426a-8f41-547cc9b33c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_10c96d2e-01bf-4792-840d-923f893bb446" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d05a8087-fbb9-426a-8f41-547cc9b33c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_15d319df-14c8-4eba-bde0-8ad9d6fce609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d05a8087-fbb9-426a-8f41-547cc9b33c7d" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_15d319df-14c8-4eba-bde0-8ad9d6fce609" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d512f20e-6469-47a7-b315-0234b9234bd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:to="loc_srt_RangeAxis_d512f20e-6469-47a7-b315-0234b9234bd3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d512f20e-6469-47a7-b315-0234b9234bd3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d512f20e-6469-47a7-b315-0234b9234bd3" xlink:to="loc_srt_RangeMember_d512f20e-6469-47a7-b315-0234b9234bd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3221551b-7624-4d67-8ea3-a5fd918df58f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d512f20e-6469-47a7-b315-0234b9234bd3" xlink:to="loc_srt_RangeMember_3221551b-7624-4d67-8ea3-a5fd918df58f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_083f6639-af63-444e-baa1-fa8211ae649c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3221551b-7624-4d67-8ea3-a5fd918df58f" xlink:to="loc_srt_MinimumMember_083f6639-af63-444e-baa1-fa8211ae649c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_755c164f-93e5-4acc-9981-464e788392fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3221551b-7624-4d67-8ea3-a5fd918df58f" xlink:to="loc_srt_MaximumMember_755c164f-93e5-4acc-9981-464e788392fb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended" id="iebcee075c17b4e2cbf4fd87dcf6569c5_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_00fd956a-a22d-4ac0-90b8-8c20d776c6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_00fd956a-a22d-4ac0-90b8-8c20d776c6ba" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c9ef8f1a-9c03-42ad-9047-036f277ce4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c9ef8f1a-9c03-42ad-9047-036f277ce4d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_3038322c-3e69-4582-99d9-19ea3aeae6bf" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_3038322c-3e69-4582-99d9-19ea3aeae6bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4f97f197-5eaf-4012-99a8-58b8fcdd4fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e161fd5c-723f-42d5-897b-f6c1e357ad71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_00fd956a-a22d-4ac0-90b8-8c20d776c6ba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e161fd5c-723f-42d5-897b-f6c1e357ad71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f634c483-a82f-4a8d-a958-565194e7f900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e161fd5c-723f-42d5-897b-f6c1e357ad71" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f634c483-a82f-4a8d-a958-565194e7f900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f634c483-a82f-4a8d-a958-565194e7f900_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f634c483-a82f-4a8d-a958-565194e7f900" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f634c483-a82f-4a8d-a958-565194e7f900_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecf78b98-49e8-4ba8-a9cb-c83747846791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f634c483-a82f-4a8d-a958-565194e7f900" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecf78b98-49e8-4ba8-a9cb-c83747846791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ff31af0c-bbb8-46e0-860d-b822abe9ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecf78b98-49e8-4ba8-a9cb-c83747846791" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ff31af0c-bbb8-46e0-860d-b822abe9ef7b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#RECEIVABLESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended" id="i68543d5cac9341f0b8cd2fcb4d59bdc3_RECEIVABLESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c36c51ad-c4d6-41df-844b-806471b9f7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c36c51ad-c4d6-41df-844b-806471b9f7f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_812a988c-bc4f-44af-b655-180ef6060529" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_812a988c-bc4f-44af-b655-180ef6060529" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_bf6253d4-ee04-4610-8261-cd99079e9757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_bf6253d4-ee04-4610-8261-cd99079e9757" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_418af630-f91c-486c-9fd4-7cf5ca025e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_418af630-f91c-486c-9fd4-7cf5ca025e43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_99b6f272-fff9-415f-a10c-737b2230afe8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:to="loc_srt_CounterpartyNameAxis_99b6f272-fff9-415f-a10c-737b2230afe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b6f272-fff9-415f-a10c-737b2230afe8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_99b6f272-fff9-415f-a10c-737b2230afe8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99b6f272-fff9-415f-a10c-737b2230afe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_158f4950-2d4a-40dc-bdfa-215437f5443d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_99b6f272-fff9-415f-a10c-737b2230afe8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_158f4950-2d4a-40dc-bdfa-215437f5443d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_bf474f61-d7b3-4039-9827-c94291905045" xlink:href="sesn-20220331.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_158f4950-2d4a-40dc-bdfa-215437f5443d" xlink:to="loc_sesn_RocheMember_bf474f61-d7b3-4039-9827-c94291905045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d95d2b8f-4fbd-4048-b817-871d1d6367f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d95d2b8f-4fbd-4048-b817-871d1d6367f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_d95d2b8f-4fbd-4048-b817-871d1d6367f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d95d2b8f-4fbd-4048-b817-871d1d6367f3" xlink:to="loc_us-gaap_ReceivableTypeDomain_d95d2b8f-4fbd-4048-b817-871d1d6367f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_2c9c7b89-1d8a-4dd2-a667-7f4a64174e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d95d2b8f-4fbd-4048-b817-871d1d6367f3" xlink:to="loc_us-gaap_ReceivableTypeDomain_2c9c7b89-1d8a-4dd2-a667-7f4a64174e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember_b3e927f2-d61a-4d0c-b512-3580fdf0ec69" xlink:href="sesn-20220331.xsd#sesn_GermanVATRecoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_2c9c7b89-1d8a-4dd2-a667-7f4a64174e79" xlink:to="loc_sesn_GermanVATRecoveryMember_b3e927f2-d61a-4d0c-b512-3580fdf0ec69" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="extended" id="i2e81f0edee0e424d931dfa4c2652340c_INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5998f3b7-c72d-4c4a-bd47-965c28c78f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_9de8e7d8-a747-4ddc-a1b1-49a6ca4c424e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5998f3b7-c72d-4c4a-bd47-965c28c78f7b" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_9de8e7d8-a747-4ddc-a1b1-49a6ca4c424e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5998f3b7-c72d-4c4a-bd47-965c28c78f7b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_35d7965c-c91a-4c9f-8875-597c1830022c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:to="loc_srt_StatementGeographicalAxis_35d7965c-c91a-4c9f-8875-597c1830022c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_35d7965c-c91a-4c9f-8875-597c1830022c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_35d7965c-c91a-4c9f-8875-597c1830022c" xlink:to="loc_srt_SegmentGeographicalDomain_35d7965c-c91a-4c9f-8875-597c1830022c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6076ae07-dc35-4c37-a1b4-fffd625a8ea1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_35d7965c-c91a-4c9f-8875-597c1830022c" xlink:to="loc_srt_SegmentGeographicalDomain_6076ae07-dc35-4c37-a1b4-fffd625a8ea1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2d7f2277-ad4d-481d-9494-afe7fb3ed0a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_6076ae07-dc35-4c37-a1b4-fffd625a8ea1" xlink:to="loc_srt_EuropeMember_2d7f2277-ad4d-481d-9494-afe7fb3ed0a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0208f899-ddc8-47dc-85c0-db1a6529d896" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:to="loc_srt_ProductOrServiceAxis_0208f899-ddc8-47dc-85c0-db1a6529d896" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0208f899-ddc8-47dc-85c0-db1a6529d896_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0208f899-ddc8-47dc-85c0-db1a6529d896" xlink:to="loc_srt_ProductsAndServicesDomain_0208f899-ddc8-47dc-85c0-db1a6529d896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a27ac849-e373-42eb-8f7f-b080cf3b5624" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0208f899-ddc8-47dc-85c0-db1a6529d896" xlink:to="loc_srt_ProductsAndServicesDomain_a27ac849-e373-42eb-8f7f-b080cf3b5624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_926bd72f-275d-45ca-ae19-185abeec9808" xlink:href="sesn-20220331.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a27ac849-e373-42eb-8f7f-b080cf3b5624" xlink:to="loc_sesn_ViciniumMember_926bd72f-275d-45ca-ae19-185abeec9808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cedbd2be-6e1f-497d-b432-1041c5712a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cedbd2be-6e1f-497d-b432-1041c5712a9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cedbd2be-6e1f-497d-b432-1041c5712a9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cedbd2be-6e1f-497d-b432-1041c5712a9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cedbd2be-6e1f-497d-b432-1041c5712a9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7c44fd3c-2987-45e7-85bb-865234ef2fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cedbd2be-6e1f-497d-b432-1041c5712a9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7c44fd3c-2987-45e7-85bb-865234ef2fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_65436c00-7de1-408f-a738-f61ff0fee9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7c44fd3c-2987-45e7-85bb-865234ef2fd2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_65436c00-7de1-408f-a738-f61ff0fee9fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#INTANGIBLESANDGOODWILLNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="extended" id="id933e0c9d20e4e8eaafc7486c98608d3_INTANGIBLESANDGOODWILLNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_83172e64-9bb4-4a39-98ea-ab0fab0e7a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_83172e64-9bb4-4a39-98ea-ab0fab0e7a4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7edd2ad7-6656-411b-b7bd-84df6153ec80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:to="loc_us-gaap_Goodwill_7edd2ad7-6656-411b-b7bd-84df6153ec80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9736b61f-c585-44f6-a0b6-ceac798f23a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9736b61f-c585-44f6-a0b6-ceac798f23a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7937a047-0073-4467-95e4-888fe4bd3866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7937a047-0073-4467-95e4-888fe4bd3866" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a4b59038-4360-4883-9137-bf1c69ca933c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7937a047-0073-4467-95e4-888fe4bd3866" xlink:to="loc_srt_RangeAxis_a4b59038-4360-4883-9137-bf1c69ca933c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a4b59038-4360-4883-9137-bf1c69ca933c_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a4b59038-4360-4883-9137-bf1c69ca933c" xlink:to="loc_srt_RangeMember_a4b59038-4360-4883-9137-bf1c69ca933c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0822d3c1-a10a-49f9-9c2d-6ee9e7d44437" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a4b59038-4360-4883-9137-bf1c69ca933c" xlink:to="loc_srt_RangeMember_0822d3c1-a10a-49f9-9c2d-6ee9e7d44437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1feaa857-c5f0-410b-8ace-5f28cd6924e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0822d3c1-a10a-49f9-9c2d-6ee9e7d44437" xlink:to="loc_srt_MinimumMember_1feaa857-c5f0-410b-8ace-5f28cd6924e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73ca7241-a966-41a1-af05-69a64d0f399b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0822d3c1-a10a-49f9-9c2d-6ee9e7d44437" xlink:to="loc_srt_MaximumMember_73ca7241-a966-41a1-af05-69a64d0f399b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#LEASESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="extended" id="i97c35da3a8b849afbdf170b8139da7bb_LEASESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_4b947061-7ef1-4e50-b175-1936b7cecfdc" xlink:href="sesn-20220331.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_4b947061-7ef1-4e50-b175-1936b7cecfdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_222e4baf-35a9-4076-aa98-5d4cc7f3405a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_222e4baf-35a9-4076-aa98-5d4cc7f3405a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_a90cbe58-f1ab-4204-adca-917de6cf608d" xlink:href="sesn-20220331.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_a90cbe58-f1ab-4204-adca-917de6cf608d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9ba6b353-a6d0-4f8f-a6b9-d50c46a62b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9ba6b353-a6d0-4f8f-a6b9-d50c46a62b21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_c31ba912-b5ba-49bf-960b-5124f3016b0e" xlink:href="sesn-20220331.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_c31ba912-b5ba-49bf-960b-5124f3016b0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_81fe740f-18e6-4c22-95e5-9717b8f5ffa7" xlink:href="sesn-20220331.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_81fe740f-18e6-4c22-95e5-9717b8f5ffa7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cf9a9db7-dd4d-4cb9-8a41-17338b9e4c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseCost_cf9a9db7-dd4d-4cb9-8a41-17338b9e4c49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_5f423357-d5b9-435b-8523-bb214fcc09fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_5f423357-d5b9-435b-8523-bb214fcc09fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9d0eeb37-6fdc-4dab-8386-7c24734e92a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9d0eeb37-6fdc-4dab-8386-7c24734e92a1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c4c3887b-8d9a-40a4-95f9-869c7232f094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c4c3887b-8d9a-40a4-95f9-869c7232f094" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2cef3739-7cb1-4754-abfd-622b5052656a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2cef3739-7cb1-4754-abfd-622b5052656a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShortTermLeaseRenewalFrequency_1ecebb7f-c8a3-4397-9873-930fddbc2de3" xlink:href="sesn-20220331.xsd#sesn_ShortTermLeaseRenewalFrequency"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_ShortTermLeaseRenewalFrequency_1ecebb7f-c8a3-4397-9873-930fddbc2de3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_35ee8136-0b04-4608-a507-bd21c22b6561" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:to="loc_srt_StatementGeographicalAxis_35ee8136-0b04-4608-a507-bd21c22b6561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_35ee8136-0b04-4608-a507-bd21c22b6561_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_35ee8136-0b04-4608-a507-bd21c22b6561" xlink:to="loc_srt_SegmentGeographicalDomain_35ee8136-0b04-4608-a507-bd21c22b6561_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_35ee8136-0b04-4608-a507-bd21c22b6561" xlink:to="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_4ecb87db-73bf-4dee-a51f-4cc83e38fe54" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:to="loc_country_CA_4ecb87db-73bf-4dee-a51f-4cc83e38fe54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_8a242b89-e763-4ab9-951c-bf7d191a6984" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:to="loc_stpr_MA_8a242b89-e763-4ab9-951c-bf7d191a6984" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_5d4eede6-f591-448f-8f18-366b7b97822b" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:to="loc_stpr_PA_5d4eede6-f591-448f-8f18-366b7b97822b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:to="loc_srt_RangeAxis_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d" xlink:to="loc_srt_RangeMember_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be20d1dc-dbfb-45dc-8cf5-864cf20900d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d" xlink:to="loc_srt_RangeMember_be20d1dc-dbfb-45dc-8cf5-864cf20900d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_508341f3-38d1-4205-bc4b-9f21a81b34c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_be20d1dc-dbfb-45dc-8cf5-864cf20900d2" xlink:to="loc_srt_MinimumMember_508341f3-38d1-4205-bc4b-9f21a81b34c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b6c59d7c-e7dd-4000-aebe-eea90ab8da82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_be20d1dc-dbfb-45dc-8cf5-864cf20900d2" xlink:to="loc_srt_MaximumMember_b6c59d7c-e7dd-4000-aebe-eea90ab8da82" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYEquityFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="extended" id="i66ef2c47edf147aa93c4ec2fea0aa89b_STOCKHOLDERSEQUITYEquityFinancingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c8d8fb95-930b-4336-98f5-b3246e1ef05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c8d8fb95-930b-4336-98f5-b3246e1ef05f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_578a01ed-04c2-482b-9b68-78ebf0a4c7f8" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_578a01ed-04c2-482b-9b68-78ebf0a4c7f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_c70b332d-0b05-4998-a5c9-c6a6d99bfed6" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_c70b332d-0b05-4998-a5c9-c6a6d99bfed6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_3081542c-996e-433e-b801-c8ab1d02f488" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_3081542c-996e-433e-b801-c8ab1d02f488" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cc961e47-877c-4c90-ac7b-8ff28513e115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cc961e47-877c-4c90-ac7b-8ff28513e115" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b4f88d0-c10f-42e3-85c9-d61209bc565d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b4f88d0-c10f-42e3-85c9-d61209bc565d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_045defd8-3912-4a42-9914-da203c1740d5" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_045defd8-3912-4a42-9914-da203c1740d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_fc2011da-fbfb-4ccf-a9e7-3b9820e659af" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_fc2011da-fbfb-4ccf-a9e7-3b9820e659af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ca710ed3-bb8a-474f-9e4c-b0d5e9ad0571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ca710ed3-bb8a-474f-9e4c-b0d5e9ad0571" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_36e2aa14-740f-4fba-8808-c877bc5dd30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ca710ed3-bb8a-474f-9e4c-b0d5e9ad0571" xlink:to="loc_us-gaap_CreditFacilityAxis_36e2aa14-740f-4fba-8808-c877bc5dd30d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_36e2aa14-740f-4fba-8808-c877bc5dd30d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_36e2aa14-740f-4fba-8808-c877bc5dd30d" xlink:to="loc_us-gaap_CreditFacilityDomain_36e2aa14-740f-4fba-8808-c877bc5dd30d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8d4b863f-69d7-4d48-b451-7ad59837b1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_36e2aa14-740f-4fba-8808-c877bc5dd30d" xlink:to="loc_us-gaap_CreditFacilityDomain_8d4b863f-69d7-4d48-b451-7ad59837b1d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_39fe14e9-9563-43a3-b34e-14277f36e209" xlink:href="sesn-20220331.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_8d4b863f-69d7-4d48-b451-7ad59837b1d4" xlink:to="loc_sesn_ATMFacilityMember_39fe14e9-9563-43a3-b34e-14277f36e209" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="extended" id="i5be0629579724cf7b629b374fe5f3246_STOCKHOLDERSEQUITYCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f47f7c6f-f1db-4913-a0d2-8015d8ecc28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f47f7c6f-f1db-4913-a0d2-8015d8ecc28b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b862013a-ddef-4a9b-8caf-4f6678aef98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_us-gaap_CommonStockSharesIssued_b862013a-ddef-4a9b-8caf-4f6678aef98d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eddf6fdb-9507-4468-b4b9-78a3398339b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_eddf6fdb-9507-4468-b4b9-78a3398339b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_43f306d4-bb0b-4e4e-abc7-c7dd0a56945c" xlink:href="sesn-20220331.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_43f306d4-bb0b-4e4e-abc7-c7dd0a56945c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7fe5b101-d05e-4471-bbe0-ec6b708fc5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7fe5b101-d05e-4471-bbe0-ec6b708fc5f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af848240-ae96-4d2f-9aa8-18a7e5bacc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7fe5b101-d05e-4471-bbe0-ec6b708fc5f3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af848240-ae96-4d2f-9aa8-18a7e5bacc09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_af848240-ae96-4d2f-9aa8-18a7e5bacc09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af848240-ae96-4d2f-9aa8-18a7e5bacc09" xlink:to="loc_us-gaap_EquityComponentDomain_af848240-ae96-4d2f-9aa8-18a7e5bacc09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45cb06b4-6e6f-4b67-9f63-40e73d99ba61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af848240-ae96-4d2f-9aa8-18a7e5bacc09" xlink:to="loc_us-gaap_EquityComponentDomain_45cb06b4-6e6f-4b67-9f63-40e73d99ba61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f55b7c8d-210c-4bb7-8cb6-f24bb7357d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_45cb06b4-6e6f-4b67-9f63-40e73d99ba61" xlink:to="loc_us-gaap_CommonStockMember_f55b7c8d-210c-4bb7-8cb6-f24bb7357d2f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended" id="ib615100f63244c2a9392da883bbecc76_STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9f8eaac1-577a-46c8-9b46-d21285803334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7a1cb9fb-b00b-4ef9-b230-35afdb9d9e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9f8eaac1-577a-46c8-9b46-d21285803334" xlink:to="loc_us-gaap_CommonStockSharesIssued_7a1cb9fb-b00b-4ef9-b230-35afdb9d9e91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_89d2affc-e6d2-41d7-86f9-11175ba08d85" xlink:href="sesn-20220331.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9f8eaac1-577a-46c8-9b46-d21285803334" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_89d2affc-e6d2-41d7-86f9-11175ba08d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6e2d46f5-2c74-480e-9233-cd3b188218ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_89d2affc-e6d2-41d7-86f9-11175ba08d85" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6e2d46f5-2c74-480e-9233-cd3b188218ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_3d9db850-586c-4a4b-8dca-b0cee1c8f6ee" xlink:href="sesn-20220331.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_89d2affc-e6d2-41d7-86f9-11175ba08d85" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_3d9db850-586c-4a4b-8dca-b0cee1c8f6ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_004b662f-6a52-43e2-91ca-254badb8652f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9f8eaac1-577a-46c8-9b46-d21285803334" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_004b662f-6a52-43e2-91ca-254badb8652f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42b21c6b-ed83-43de-9c1b-979949490579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_004b662f-6a52-43e2-91ca-254badb8652f" xlink:to="loc_us-gaap_AwardTypeAxis_42b21c6b-ed83-43de-9c1b-979949490579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42b21c6b-ed83-43de-9c1b-979949490579_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_42b21c6b-ed83-43de-9c1b-979949490579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42b21c6b-ed83-43de-9c1b-979949490579_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_42b21c6b-ed83-43de-9c1b-979949490579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ab54516a-b980-4b5a-825d-8b0ebc950798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_WarrantMember_ab54516a-b980-4b5a-825d-8b0ebc950798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5edda917-b3b4-4e98-b17a-4fdef455b5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5edda917-b3b4-4e98-b17a-4fdef455b5c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2ab442c6-b5dc-4856-b705-a22538dce034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2ab442c6-b5dc-4856-b705-a22538dce034" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_94cd8a41-92e9-4e1a-adf0-937b4470b49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_StockCompensationPlanMember_94cd8a41-92e9-4e1a-adf0-937b4470b49a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2eacd275-11ae-4814-8024-49dce9206b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_EmployeeStockMember_2eacd275-11ae-4814-8024-49dce9206b26" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="extended" id="iafd23a2bb6d543b8b2e5a1b2f9805e8f_STOCKHOLDERSEQUITYWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_fa0d872f-69d5-4d74-ac7c-d9bc8ac16552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33877f1c-56f3-4635-a395-f4d520501437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_fa0d872f-69d5-4d74-ac7c-d9bc8ac16552" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33877f1c-56f3-4635-a395-f4d520501437" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:href="sesn-20220331.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_fa0d872f-69d5-4d74-ac7c-d9bc8ac16552" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ab5241d2-c6f7-472e-9c60-f8a69a3934fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ab5241d2-c6f7-472e-9c60-f8a69a3934fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_9877770b-9828-45af-bf69-e8b150c06ac5" xlink:href="sesn-20220331.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_9877770b-9828-45af-bf69-e8b150c06ac5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_eb018e48-23a7-4e29-87a9-9fba8da08aff" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_eb018e48-23a7-4e29-87a9-9fba8da08aff" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_e4f371c2-dec9-4e03-a42f-d62750d93511" xlink:href="sesn-20220331.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_e4f371c2-dec9-4e03-a42f-d62750d93511" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_839aee84-5580-4be8-92bd-1f3deb821df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d6142bea-a6ae-4879-a9aa-bcf2648657fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_fa0d872f-69d5-4d74-ac7c-d9bc8ac16552" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d6142bea-a6ae-4879-a9aa-bcf2648657fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b72b2dc8-f6d4-4b0e-a167-eabef615980a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d6142bea-a6ae-4879-a9aa-bcf2648657fa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b72b2dc8-f6d4-4b0e-a167-eabef615980a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b72b2dc8-f6d4-4b0e-a167-eabef615980a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b72b2dc8-f6d4-4b0e-a167-eabef615980a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b72b2dc8-f6d4-4b0e-a167-eabef615980a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b72b2dc8-f6d4-4b0e-a167-eabef615980a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_af473235-97e4-4c52-8ce9-f067d774dcff" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_af473235-97e4-4c52-8ce9-f067d774dcff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_0a7634ee-67f0-4ccb-9ea5-e3884d7104c1" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_0a7634ee-67f0-4ccb-9ea5-e3884d7104c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_d4dcd44b-044f-444d-939b-66b7c1e673b2" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_d4dcd44b-044f-444d-939b-66b7c1e673b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_462797f2-bd2c-4a58-93ca-42c894ba4837" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_462797f2-bd2c-4a58-93ca-42c894ba4837" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="i935d5653604c4f7bb906b06f275aa26b_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b972c99-cb75-482b-b8e1-a0521f931077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_132525bf-94cf-41c6-8a4e-4b547a99b6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b972c99-cb75-482b-b8e1-a0521f931077" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_132525bf-94cf-41c6-8a4e-4b547a99b6f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0bb8bbb6-3b0f-4665-a61d-d322219f47c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b972c99-cb75-482b-b8e1-a0521f931077" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0bb8bbb6-3b0f-4665-a61d-d322219f47c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0bb8bbb6-3b0f-4665-a61d-d322219f47c6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8b96ddd5-7e12-4bf1-a82a-4aee97984c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:to="loc_us-gaap_WarrantMember_8b96ddd5-7e12-4bf1-a82a-4aee97984c04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b1061216-427b-472e-834b-8d5dfafac391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b1061216-427b-472e-834b-8d5dfafac391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_63dad547-c676-420d-a1d6-014b05d4985c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_63dad547-c676-420d-a1d6-014b05d4985c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4e664c53-0809-45b1-9172-2c6e6c224946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:to="loc_us-gaap_PerformanceSharesMember_4e664c53-0809-45b1-9172-2c6e6c224946" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended" id="i2c635c999a8743c4aa859ac295cdaea9_SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f93c549-02b5-41ca-9f02-3b31bcf4d875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ee636a82-5852-46a5-a359-727ec00358d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f93c549-02b5-41ca-9f02-3b31bcf4d875" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ee636a82-5852-46a5-a359-727ec00358d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0af5478-5f89-4cf2-a289-2ea16f08a833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f93c549-02b5-41ca-9f02-3b31bcf4d875" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0af5478-5f89-4cf2-a289-2ea16f08a833" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0af5478-5f89-4cf2-a289-2ea16f08a833" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b624378-61d3-4d20-a18f-99e7cb60ee20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b624378-61d3-4d20-a18f-99e7cb60ee20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_74f48e89-d520-4fee-a99d-0617d508e51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b624378-61d3-4d20-a18f-99e7cb60ee20" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_74f48e89-d520-4fee-a99d-0617d508e51d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4f297929-8267-4fc0-a1e1-ae274ca475e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b624378-61d3-4d20-a18f-99e7cb60ee20" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4f297929-8267-4fc0-a1e1-ae274ca475e5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="i8f044ff1874741b3a8d5862e51f3cd1a_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_70cad0d5-7e7a-4fba-9b78-57f73c1129de" xlink:href="sesn-20220331.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_70cad0d5-7e7a-4fba-9b78-57f73c1129de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_676ea9b7-bea7-471e-bcb4-1d139f41f063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_676ea9b7-bea7-471e-bcb4-1d139f41f063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c5820dde-ddfd-4f9d-82ea-8991f0b51244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c5820dde-ddfd-4f9d-82ea-8991f0b51244" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0620cfbe-b733-4325-9b30-41cf756a2fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0620cfbe-b733-4325-9b30-41cf756a2fb9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c5554ca5-7d84-4799-91f7-213fee1f5411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c5554ca5-7d84-4799-91f7-213fee1f5411" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b0ce8ae6-85c5-4bbe-bf62-7237823edc96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b0ce8ae6-85c5-4bbe-bf62-7237823edc96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_09ec93a9-4658-41c9-a80a-5686f59764cf" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_09ec93a9-4658-41c9-a80a-5686f59764cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_5f4bbcff-a6c1-4740-b5f8-e4aa5c874a3e" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_5f4bbcff-a6c1-4740-b5f8-e4aa5c874a3e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_14d1c0a5-7daf-414a-a4e2-a61b4d715d79" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_14d1c0a5-7daf-414a-a4e2-a61b4d715d79" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26d2cf2c-22f5-4e6f-af7f-a9044a7d6bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26d2cf2c-22f5-4e6f-af7f-a9044a7d6bf6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b75ad3f4-a3ee-401c-ace4-0cccad1e9aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b75ad3f4-a3ee-401c-ace4-0cccad1e9aca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2650a146-f2e3-4b67-b721-fe3a821160ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2650a146-f2e3-4b67-b721-fe3a821160ad" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3ce9d634-e87f-4df0-8d35-f0732298c557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3ce9d634-e87f-4df0-8d35-f0732298c557" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0678d20a-8f6f-4d2c-9318-0a2722fbc3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0678d20a-8f6f-4d2c-9318-0a2722fbc3f2" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd89656c-1fb4-4980-9570-4b72ee5cf57d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd89656c-1fb4-4980-9570-4b72ee5cf57d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_457b1d79-248b-4fdb-a315-a3429b247e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_457b1d79-248b-4fdb-a315-a3429b247e53" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d0ffa043-2cc7-45e8-8990-38a5d16e0bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d0ffa043-2cc7-45e8-8990-38a5d16e0bd7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_990690e8-f3f4-4475-8909-20398b43122a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_AwardTypeAxis_990690e8-f3f4-4475-8909-20398b43122a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_990690e8-f3f4-4475-8909-20398b43122a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_990690e8-f3f4-4475-8909-20398b43122a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_990690e8-f3f4-4475-8909-20398b43122a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_990690e8-f3f4-4475-8909-20398b43122a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fbaf9868-f9b3-40f4-8675-68f9a8f62d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fbaf9868-f9b3-40f4-8675-68f9a8f62d86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_076f8947-162b-4d30-a4d4-0f6c8f055e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_076f8947-162b-4d30-a4d4-0f6c8f055e69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ff74e9d3-787a-4f71-95a3-e6cdd4f77e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:to="loc_us-gaap_PerformanceSharesMember_ff74e9d3-787a-4f71-95a3-e6cdd4f77e0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4e60e93e-021f-4f05-a92b-534b949a4a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_PlanNameAxis_4e60e93e-021f-4f05-a92b-534b949a4a33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4e60e93e-021f-4f05-a92b-534b949a4a33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4e60e93e-021f-4f05-a92b-534b949a4a33" xlink:to="loc_us-gaap_PlanNameDomain_4e60e93e-021f-4f05-a92b-534b949a4a33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4e60e93e-021f-4f05-a92b-534b949a4a33" xlink:to="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_222b7508-da5e-4ddb-9eae-62d213925cf8" xlink:href="sesn-20220331.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_222b7508-da5e-4ddb-9eae-62d213925cf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_297b0b11-7485-4338-a921-ddeb4c86b3b6" xlink:href="sesn-20220331.xsd#sesn_RetentionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:to="loc_sesn_RetentionProgramMember_297b0b11-7485-4338-a921-ddeb4c86b3b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_e4cde93d-1c4d-4067-9737-9b5036f957ed" xlink:href="sesn-20220331.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:to="loc_sesn_StockIncentivePlan2009Member_e4cde93d-1c4d-4067-9737-9b5036f957ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_a326d8d8-b252-4982-8091-dc9ed9d3e32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_VestingAxis_a326d8d8-b252-4982-8091-dc9ed9d3e32d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_a326d8d8-b252-4982-8091-dc9ed9d3e32d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_a326d8d8-b252-4982-8091-dc9ed9d3e32d" xlink:to="loc_us-gaap_VestingDomain_a326d8d8-b252-4982-8091-dc9ed9d3e32d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_96228ac3-8855-4110-ab6b-672ffdee3881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_a326d8d8-b252-4982-8091-dc9ed9d3e32d" xlink:to="loc_us-gaap_VestingDomain_96228ac3-8855-4110-ab6b-672ffdee3881" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fcafd0a6-55c0-4e12-86c6-f7264cbfa1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_96228ac3-8855-4110-ab6b-672ffdee3881" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fcafd0a6-55c0-4e12-86c6-f7264cbfa1b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a70d18e3-8745-42ea-ac04-6ca2f310c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_96228ac3-8855-4110-ab6b-672ffdee3881" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a70d18e3-8745-42ea-ac04-6ca2f310c8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_GranteeStatusAxis_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12" xlink:to="loc_us-gaap_GranteeStatusDomain_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_5b27b556-d923-40f3-a514-1a63e4a32f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12" xlink:to="loc_us-gaap_GranteeStatusDomain_5b27b556-d923-40f3-a514-1a63e4a32f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_292c3702-177a-41c4-a772-6e88d0af7df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_5b27b556-d923-40f3-a514-1a63e4a32f5e" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_292c3702-177a-41c4-a772-6e88d0af7df0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended" id="i752fa11c0cd048d1b719b1d4665507b2_SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_30ebb301-3c31-496c-a4d2-45b8c85e5972" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_30ebb301-3c31-496c-a4d2-45b8c85e5972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_43ae25fc-b15d-4c83-8878-4dbd9432aa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_43ae25fc-b15d-4c83-8878-4dbd9432aa20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b633960e-9a6e-4738-a4fb-884ac9650d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b633960e-9a6e-4738-a4fb-884ac9650d7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6cdf896b-756e-442c-aa81-48ebe6a1f14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6cdf896b-756e-442c-aa81-48ebe6a1f14a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d03e5b2-2b70-4226-9783-2a03ebfb3cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d03e5b2-2b70-4226-9783-2a03ebfb3cf3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f9691c0-dce6-43d0-a92c-26f4cc8c005c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f9691c0-dce6-43d0-a92c-26f4cc8c005c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6120ba60-444c-4689-ae62-00ceca5bad41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6120ba60-444c-4689-ae62-00ceca5bad41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75b2fb8b-4010-484b-8a2a-0f8263ada9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6120ba60-444c-4689-ae62-00ceca5bad41" xlink:to="loc_us-gaap_AwardTypeAxis_75b2fb8b-4010-484b-8a2a-0f8263ada9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75b2fb8b-4010-484b-8a2a-0f8263ada9c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_75b2fb8b-4010-484b-8a2a-0f8263ada9c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75b2fb8b-4010-484b-8a2a-0f8263ada9c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00f76505-81b7-4eb5-95ab-67eed22cac13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_75b2fb8b-4010-484b-8a2a-0f8263ada9c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00f76505-81b7-4eb5-95ab-67eed22cac13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ee247f95-7875-45fe-a0d2-0d85bd72e962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00f76505-81b7-4eb5-95ab-67eed22cac13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ee247f95-7875-45fe-a0d2-0d85bd72e962" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended" id="i4d4e4555297647daa1e387d68fd89e17_SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_396d506a-8349-4ed4-ab19-336452dd9e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_396d506a-8349-4ed4-ab19-336452dd9e07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2e4cadf-e66f-4c1e-89cd-18cea767b980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2e4cadf-e66f-4c1e-89cd-18cea767b980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_475fecc3-41b7-4b98-aac6-0856d044d771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_475fecc3-41b7-4b98-aac6-0856d044d771" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f45080fe-602c-453a-a54a-3cbeec5c5c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_396d506a-8349-4ed4-ab19-336452dd9e07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6249c90-e4d5-4ff0-9851-ed2049810761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6249c90-e4d5-4ff0-9851-ed2049810761" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f11186f7-be38-4e9c-b302-ee3ba20a461a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f11186f7-be38-4e9c-b302-ee3ba20a461a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7d41757-eca8-4317-8259-7be76c43752e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_690b3b7b-aec7-47fd-8de2-431ee97fcb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_396d506a-8349-4ed4-ab19-336452dd9e07" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_690b3b7b-aec7-47fd-8de2-431ee97fcb44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5f3475b-628a-42e9-b0c1-ba9c7a565c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_690b3b7b-aec7-47fd-8de2-431ee97fcb44" xlink:to="loc_us-gaap_AwardTypeAxis_f5f3475b-628a-42e9-b0c1-ba9c7a565c10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f3475b-628a-42e9-b0c1-ba9c7a565c10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f5f3475b-628a-42e9-b0c1-ba9c7a565c10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f5f3475b-628a-42e9-b0c1-ba9c7a565c10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239f150c-2e9c-40dc-a767-86cee2377a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f5f3475b-628a-42e9-b0c1-ba9c7a565c10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239f150c-2e9c-40dc-a767-86cee2377a63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6a456949-906a-4180-8abc-370bbe62aa15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239f150c-2e9c-40dc-a767-86cee2377a63" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6a456949-906a-4180-8abc-370bbe62aa15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_44d86810-447a-403e-9816-f22d4d0b4bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239f150c-2e9c-40dc-a767-86cee2377a63" xlink:to="loc_us-gaap_PerformanceSharesMember_44d86810-447a-403e-9816-f22d4d0b4bea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="i0c0c62a16104459a9af1aee1e51a6b9b_EMPLOYEEBENEFITPLANSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1924a868-c87f-42ce-aedf-ae1834ab701b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1924a868-c87f-42ce-aedf-ae1834ab701b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d075f232-151d-4113-9dcc-4e2c721dc7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d075f232-151d-4113-9dcc-4e2c721dc7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f50a4c5f-b73d-43e7-9e35-d546889fa95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f50a4c5f-b73d-43e7-9e35-d546889fa95b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f091a491-23ea-49d7-b8d4-d097309d9ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f091a491-23ea-49d7-b8d4-d097309d9ab4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2d77e587-3849-4109-bd92-86caff119667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2d77e587-3849-4109-bd92-86caff119667" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_bae820a2-647b-43c2-b653-1328858891b0" xlink:href="sesn-20220331.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_bae820a2-647b-43c2-b653-1328858891b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6cd51157-b0f0-4c50-81b7-4a79c9ac206f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6cd51157-b0f0-4c50-81b7-4a79c9ac206f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0f3e305f-05a0-483e-8608-8f3c72434222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:to="loc_us-gaap_PlanNameAxis_0f3e305f-05a0-483e-8608-8f3c72434222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0f3e305f-05a0-483e-8608-8f3c72434222_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0f3e305f-05a0-483e-8608-8f3c72434222" xlink:to="loc_us-gaap_PlanNameDomain_0f3e305f-05a0-483e-8608-8f3c72434222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4702a002-872f-40f8-b026-ddc62632ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0f3e305f-05a0-483e-8608-8f3c72434222" xlink:to="loc_us-gaap_PlanNameDomain_4702a002-872f-40f8-b026-ddc62632ee3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_1bbe1782-73b7-4a6d-9416-a1258702335b" xlink:href="sesn-20220331.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_4702a002-872f-40f8-b026-ddc62632ee3f" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_1bbe1782-73b7-4a6d-9416-a1258702335b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_30cd8114-d8a7-498e-8166-960c061f6ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_30cd8114-d8a7-498e-8166-960c061f6ec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_30cd8114-d8a7-498e-8166-960c061f6ec9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_30cd8114-d8a7-498e-8166-960c061f6ec9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_30cd8114-d8a7-498e-8166-960c061f6ec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_da4e90dd-bcde-46fc-a048-0db8baa7bacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_30cd8114-d8a7-498e-8166-960c061f6ec9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_da4e90dd-bcde-46fc-a048-0db8baa7bacc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_36c06911-b836-4928-b724-4c2504c7815a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_da4e90dd-bcde-46fc-a048-0db8baa7bacc" xlink:to="loc_us-gaap_DomesticPlanMember_36c06911-b836-4928-b724-4c2504c7815a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2966b1bb-2d44-4762-9560-6aa2e6770e92" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_36c06911-b836-4928-b724-4c2504c7815a" xlink:to="loc_country_US_2966b1bb-2d44-4762-9560-6aa2e6770e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f06cb8f6-6b1c-48dc-a98c-32ad83fc5339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_da4e90dd-bcde-46fc-a048-0db8baa7bacc" xlink:to="loc_us-gaap_ForeignPlanMember_f06cb8f6-6b1c-48dc-a98c-32ad83fc5339" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#LICENSEAGREEMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails" xlink:type="extended" id="i1241ceb4e82e447b994b407699a671fa_LICENSEAGREEMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:href="sesn-20220331.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_63959694-82f2-4b36-9fcc-08311a0e048f" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_63959694-82f2-4b36-9fcc-08311a0e048f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_fe6515de-68c3-491c-a948-0e03e2c90dc7" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_fe6515de-68c3-491c-a948-0e03e2c90dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_5f0c6c7c-ddc7-4911-ae72-5bc0b060dcf0" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_5f0c6c7c-ddc7-4911-ae72-5bc0b060dcf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_ec894599-d858-4ce3-8511-2fd1dd648310" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_ec894599-d858-4ce3-8511-2fd1dd648310" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_a73cb02a-9a36-4266-aaed-3ae555758996" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_a73cb02a-9a36-4266-aaed-3ae555758996" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_c58f25a3-5ea8-41c3-9dcc-a1a28706bd0e" xlink:href="sesn-20220331.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_c58f25a3-5ea8-41c3-9dcc-a1a28706bd0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_ec0ef979-4d81-4fdf-9d49-e58f14ffd00f" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_ec0ef979-4d81-4fdf-9d49-e58f14ffd00f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_3d0cb94c-8b12-4a5b-9cfd-e2594a2f64f1" xlink:href="sesn-20220331.xsd#sesn_LicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseMaintenanceFees_3d0cb94c-8b12-4a5b-9cfd-e2594a2f64f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_783e9f79-d172-4ebd-b029-6e41b88e41f1" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_783e9f79-d172-4ebd-b029-6e41b88e41f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_1abd896e-83cd-418f-a48c-b0b20f7a7291" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_1abd896e-83cd-418f-a48c-b0b20f7a7291" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_9172a759-efd8-4275-b05f-59bcabcaa674" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_9172a759-efd8-4275-b05f-59bcabcaa674" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_223a0685-e348-428b-b1d9-8bf9da82ab42" xlink:href="sesn-20220331.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_223a0685-e348-428b-b1d9-8bf9da82ab42" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_38577353-6bde-424b-9a4c-de96825cedb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_38577353-6bde-424b-9a4c-de96825cedb6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_9842ebe4-d61a-4332-9834-8e90519e80e8" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_9842ebe4-d61a-4332-9834-8e90519e80e8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_850bf4a5-5ffe-4076-bc81-dd240c89841c" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_850bf4a5-5ffe-4076-bc81-dd240c89841c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_be5a8815-15e3-4770-968d-7a2cd25d3495" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_be5a8815-15e3-4770-968d-7a2cd25d3495" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_6c816726-cb89-43ad-ac8a-d3f1945d4b1d" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_6c816726-cb89-43ad-ac8a-d3f1945d4b1d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_a59ed5d2-87c5-49d7-aa68-a876bd5d3e60" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_a59ed5d2-87c5-49d7-aa68-a876bd5d3e60" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_16b3e6f2-6dd5-458e-b73f-aaa18a0cedea" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_16b3e6f2-6dd5-458e-b73f-aaa18a0cedea" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_144cba25-36f7-4fb5-a1d7-246f9b1e3870" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_144cba25-36f7-4fb5-a1d7-246f9b1e3870" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9d79d091-90b2-4d1f-91dc-543e0c0b770b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9d79d091-90b2-4d1f-91dc-543e0c0b770b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_4383ffff-2859-49dd-b0e7-b8f689a9e646" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_4383ffff-2859-49dd-b0e7-b8f689a9e646" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_8bf03a54-d72f-4d4d-b582-38d943e84ee0" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_8bf03a54-d72f-4d4d-b582-38d943e84ee0" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod_f17c03cc-45bf-46c3-87c9-742ea8df3d33" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_CollaborativeArrangementRoyaltyPeriod_f17c03cc-45bf-46c3-87c9-742ea8df3d33" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a9ea9273-51c1-48c8-8409-2b6cee3665b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a9ea9273-51c1-48c8-8409-2b6cee3665b1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_0390f167-b7b8-45c4-a02b-0729c495b69c" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_0390f167-b7b8-45c4-a02b-0729c495b69c" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_66c03ce8-b179-48c2-a65c-503868bc1743" xlink:href="sesn-20220331.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_RoyaltyRevenuePercentage_66c03ce8-b179-48c2-a65c-503868bc1743" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:href="sesn-20220331.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_srt_CounterpartyNameAxis_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_a6fab9b4-7817-40f2-b6cd-ac9e7d54716a" xlink:href="sesn-20220331.xsd#sesn_UniversityOfZurichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_UniversityOfZurichMember_a6fab9b4-7817-40f2-b6cd-ac9e7d54716a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_4c4b68e5-67a8-4dd6-a160-a98a630435de" xlink:href="sesn-20220331.xsd#sesn_MicrometAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_MicrometAGMember_4c4b68e5-67a8-4dd6-a160-a98a630435de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_cce5f9f3-59a5-4682-b423-1e2afc36c9d2" xlink:href="sesn-20220331.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_XOMAIrelandLimitedMember_cce5f9f3-59a5-4682-b423-1e2afc36c9d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_e3e9d082-1931-45a5-a2e1-a1ee23afb3c8" xlink:href="sesn-20220331.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_RocheMember_e3e9d082-1931-45a5-a2e1-a1ee23afb3c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_2eb9c153-743f-4ea4-9315-a7f30a667023" xlink:href="sesn-20220331.xsd#sesn_MENALicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_MENALicenseAgreementMember_2eb9c153-743f-4ea4-9315-a7f30a667023" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_ef378123-de61-45fd-b59e-ec3c1e7d1787" xlink:href="sesn-20220331.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_ef378123-de61-45fd-b59e-ec3c1e7d1787" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_5ceb482e-3281-4118-81f8-985c45be43b7" xlink:href="sesn-20220331.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_5ceb482e-3281-4118-81f8-985c45be43b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_5beac7e9-c093-45a1-a7ac-3cdc0dd119d0" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_5beac7e9-c093-45a1-a7ac-3cdc0dd119d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_54c98741-755b-4acc-bd2f-6df11ca59033" xlink:href="sesn-20220331.xsd#sesn_FirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_FirstIndicationMember_54c98741-755b-4acc-bd2f-6df11ca59033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_a892c673-a44b-436b-a8a7-ae4636a129ed" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_a892c673-a44b-436b-a8a7-ae4636a129ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_d0911f21-ebe1-4ec7-8eb5-998498ddb102" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_d0911f21-ebe1-4ec7-8eb5-998498ddb102" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_f2194803-a6a6-4109-80b0-c048d6e807ef" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_f2194803-a6a6-4109-80b0-c048d6e807ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_db635ceb-4c14-4869-aafa-dac65d457d0a" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_db635ceb-4c14-4869-aafa-dac65d457d0a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_27836362-dd7d-4255-a189-8ead34927879" xlink:href="sesn-20220331.xsd#sesn_SecondIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_SecondIndicationMember_27836362-dd7d-4255-a189-8ead34927879" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7674e4e7-e7e4-482e-8686-933034c6877b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_srt_ProductOrServiceAxis_7674e4e7-e7e4-482e-8686-933034c6877b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7674e4e7-e7e4-482e-8686-933034c6877b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7674e4e7-e7e4-482e-8686-933034c6877b" xlink:to="loc_srt_ProductsAndServicesDomain_7674e4e7-e7e4-482e-8686-933034c6877b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b79a63c7-41eb-4dd2-84b2-e8aca33d9fa2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7674e4e7-e7e4-482e-8686-933034c6877b" xlink:to="loc_srt_ProductsAndServicesDomain_b79a63c7-41eb-4dd2-84b2-e8aca33d9fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_56a58c2a-a2e9-425e-a4c2-c07246d8a35c" xlink:href="sesn-20220331.xsd#sesn_EBI031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b79a63c7-41eb-4dd2-84b2-e8aca33d9fa2" xlink:to="loc_sesn_EBI031Member_56a58c2a-a2e9-425e-a4c2-c07246d8a35c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member_01c94959-6c75-4875-a11b-100b7859d205" xlink:href="sesn-20220331.xsd#sesn_IL6Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b79a63c7-41eb-4dd2-84b2-e8aca33d9fa2" xlink:to="loc_sesn_IL6Member_01c94959-6c75-4875-a11b-100b7859d205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3fad1941-47bb-4127-8c98-e8e8922ae931" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_srt_RangeAxis_3fad1941-47bb-4127-8c98-e8e8922ae931" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3fad1941-47bb-4127-8c98-e8e8922ae931_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_3fad1941-47bb-4127-8c98-e8e8922ae931" xlink:to="loc_srt_RangeMember_3fad1941-47bb-4127-8c98-e8e8922ae931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2326b3ff-1747-4a2b-a2ed-cd4eeb7e7bf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_3fad1941-47bb-4127-8c98-e8e8922ae931" xlink:to="loc_srt_RangeMember_2326b3ff-1747-4a2b-a2ed-cd4eeb7e7bf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d87c5148-4e3c-4504-b305-66d22da0f9bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2326b3ff-1747-4a2b-a2ed-cd4eeb7e7bf9" xlink:to="loc_srt_MinimumMember_d87c5148-4e3c-4504-b305-66d22da0f9bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_18988a81-d80a-4ba7-94b6-919770db21df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2326b3ff-1747-4a2b-a2ed-cd4eeb7e7bf9" xlink:to="loc_srt_MaximumMember_18988a81-d80a-4ba7-94b6-919770db21df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f7d4e831-827a-4ae7-b573-e187851e5a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f7d4e831-827a-4ae7-b573-e187851e5a7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f7d4e831-827a-4ae7-b573-e187851e5a7f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f7d4e831-827a-4ae7-b573-e187851e5a7f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f7d4e831-827a-4ae7-b573-e187851e5a7f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_183ed7fc-39a4-4635-a4a0-239645121f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f7d4e831-827a-4ae7-b573-e187851e5a7f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_183ed7fc-39a4-4635-a4a0-239645121f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_1f41c0ef-35d0-46f5-831a-95b225955282" xlink:href="sesn-20220331.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_183ed7fc-39a4-4635-a4a0-239645121f33" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_1f41c0ef-35d0-46f5-831a-95b225955282" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_97cc54b8-3604-4e78-8a13-1237f0e588ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_97cc54b8-3604-4e78-8a13-1237f0e588ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_97cc54b8-3604-4e78-8a13-1237f0e588ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_97cc54b8-3604-4e78-8a13-1237f0e588ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_97cc54b8-3604-4e78-8a13-1237f0e588ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9b245af-4c58-49a8-b0fd-189e456163e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_97cc54b8-3604-4e78-8a13-1237f0e588ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9b245af-4c58-49a8-b0fd-189e456163e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_77388e8c-739f-479e-b2ab-271a5faaa49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9b245af-4c58-49a8-b0fd-189e456163e3" xlink:to="loc_us-gaap_LicensingAgreementsMember_77388e8c-739f-479e-b2ab-271a5faaa49a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_654552c2-5556-4009-b0a7-caa424660c64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_srt_StatementGeographicalAxis_654552c2-5556-4009-b0a7-caa424660c64" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_654552c2-5556-4009-b0a7-caa424660c64_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_654552c2-5556-4009-b0a7-caa424660c64" xlink:to="loc_srt_SegmentGeographicalDomain_654552c2-5556-4009-b0a7-caa424660c64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32b9046c-03fc-47ba-95c0-4af69efe4ba5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_654552c2-5556-4009-b0a7-caa424660c64" xlink:to="loc_srt_SegmentGeographicalDomain_32b9046c-03fc-47ba-95c0-4af69efe4ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_77948bc5-0cff-40b4-bfd9-238def75e5a2" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_32b9046c-03fc-47ba-95c0-4af69efe4ba5" xlink:to="loc_country_TR_77948bc5-0cff-40b4-bfd9-238def75e5a2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>sesn-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:543d6d7e-07fa-4fa5-80cd-d905631091cd,g:997a4fa6-361a-4df1-8bb3-52045b6d76b9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_4c66da41-4852-4030-b74b-1d13051b1cc4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_5609e810-6999-45d2-8f13-6d53da455bd1_terseLabel_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_label_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_documentation_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember" xlink:href="sesn-20220331.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_XOMAIrelandLimitedMember" xlink:to="lab_sesn_XOMAIrelandLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5ebe782-9562-4650-b0ec-6010364d54aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b740b8c3-993a-49e0-8461-b83a000c0b9e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss After Taxes</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_840608f6-2be8-4f28-8ff1-b9ee030c1516_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_00fa30d5-1c95-4a35-b626-d014877ff4da_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_52ce1ee5-617e-4274-b78b-8582e4030467_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_4ec75756-25d5-4e99-a732-a396e0c4e91a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b7949fa6-5c33-4c7a-a381-0a278f1700e2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_ed5e8ca9-3880-464f-b125-397810ef2760_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_dd468ff7-6822-4be7-bb0b-ebb5b5b264c9_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_18d651b6-0d45-4363-ba91-1be2764e17d4_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0078b554-6aaf-479c-b7d7-6f3f724453c9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_d32c688a-60ad-49f5-926f-9060a930b032_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price, discount rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_5bd1f45e-1d0a-432f-9d42-1dab31b4fc1a_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_f5d811d5-8c3f-438c-b628-1374c62f23cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_dfde4236-2837-4ad3-9d13-91dc5a6ec331_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_83cbae52-8e75-488c-8aab-739871c62665_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_f32a78a8-e930-4989-a0a1-3ecf34054734_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received per award (in shares)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f2a9f907-74dc-4a68-8017-49ebb4dff179_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6a658414-8dab-425e-869d-be54650d8e69_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for sale (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_ca59bc4e-ed7a-4add-b538-b71d39942d3d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_9badc611-6e71-4283-9d2f-29ba4474bbbe_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_f1f079e9-b512-4fb4-b9ab-d7effb501098_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D intangible assets:</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_557949f9-7ec4-4f33-bb07-f7c7a3b128cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_47e25cde-9ca6-4497-aa36-f33e69eb2a83_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_781ab1cf-6e62-4bdc-97d5-63b6f4691ea8_terseLabel_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue, percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_label_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_documentation_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage" xlink:href="sesn-20220331.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RoyaltyRevenuePercentage" xlink:to="lab_sesn_RoyaltyRevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c694633b-b7ae-4ad6-8924-74fa6b74f428_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4db11024-6d91-4512-b156-3130afe2be33_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2240c41b-fec6-4b08-ab5c-b6abf61dd6e8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_3736e2d0-fc75-41f9-89a4-023313fdedd4_terseLabel_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal option</link:label>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_label_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</link:label>
    <link:label id="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_documentation_en-US" xlink:label="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:href="sesn-20220331.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:to="lab_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_92e2e8d8-4ff3-4ca1-9d43-ac6f82f097aa_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementUpfrontFee" xlink:to="lab_sesn_LicenseAgreementUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_11b4f594-3c43-4356-977e-aef6cafb4f43_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bbbe1294-0b97-4888-9140-b1abb6fe205f_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_ca7b5af1-d5ad-49ff-9e45-47c7c72610f2_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party minimum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_7a576109-4c31-4e4f-95a1-5c7f34c5f9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d4b23e67-04f5-4a7b-8457-712fae002208_netLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_f62c7165-615f-4bbe-80c5-387245bd3048_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_f338f70b-eebb-49a6-b97f-cce0d607d82e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_63953bfd-69af-4cd0-99d1-7f1a3c551cf1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7bfd5a92-9709-414b-b220-111957f0dc90_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_08a09fca-fe60-4829-9d6e-77b63399342c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_a0685b24-ef26-4dcc-b056-a25bedd81661_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space (in square feet)</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_label_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_documentation_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:href="sesn-20220331.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:to="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a8d532b-eaaa-4d5f-8c71-753f256b7f69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_94416a75-91a8-4a2c-8a37-ae4cce2410d3_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_dfd390ba-54a5-45d9-9a80-a1d18138d440_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_a5bd8529-16c5-4814-9846-1bfc8c320678_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_6611b908-8dec-4210-bf4c-483b1a345427_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on regulatory milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_bd1bc32f-f85a-47b1-8b71-f52f37a19e50_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4581be3c-6694-4fc1-aec5-a76cafbbee82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c96e04c7-5fa8-4ef5-9a78-7301fc9610e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested grant restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ef7b738c-2efb-4687-a777-381019b3b713_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_43a089f5-5d18-416c-a512-12c9d95290eb_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLES AND GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_7a9aa52c-ac5f-44a8-88ab-6a22a49055cc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at March&#160;31, 2022 and December&#160;31, 2021; no shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_26b5e079-67d3-435c-8823-4397a0a033dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0badc945-6b8e-4120-a11c-1ed433f3e530_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8e06bfc8-c981-4aef-ad53-dff467646112_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_GermanVATRecoveryMember_8c5d158b-2476-4192-8205-6087bd585a1b_terseLabel_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery</link:label>
    <link:label id="lab_sesn_GermanVATRecoveryMember_label_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery [Member]</link:label>
    <link:label id="lab_sesn_GermanVATRecoveryMember_documentation_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember" xlink:href="sesn-20220331.xsd#sesn_GermanVATRecoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_GermanVATRecoveryMember" xlink:to="lab_sesn_GermanVATRecoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_21e8044b-4c03-4011-b66e-b56a84bd3e60_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ed84b515-5cbb-4dbc-b1a4-ab381de22a53_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_f305b92a-0d80-40bb-bf02-1cda5ee9cc02_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fc4618ed-f4c0-42f9-89ff-b57a9af534da_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0e2c6cf-8dbd-4e64-a9b5-b891c2fb6e2a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_083e2526-7c82-46f0-baa7-a6dde1856e56_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party maximum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:to="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_92f9995d-e124-4c3f-8068-016532ce2b3e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_890854b5-e320-4bef-bc69-563d964b2bb5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_eb243914-045b-40f9-99db-66cc7e761aac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original number of shares subject to the option vesting</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_64d04cd6-03b9-45bc-8855-dced4780882b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_fdf8aa68-4b9d-41c5-b334-dbd164178086_terseLabel_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of achieving clinical and regulatory milestones</link:label>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_label_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Achieving Clinical and Regulatory Milestones, Percentage</link:label>
    <link:label id="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_documentation_en-US" xlink:label="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Achieving Clinical and Regulatory Milestones, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:href="sesn-20220331.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:to="lab_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_ff741a87-0c4c-4481-97a2-ec39a0054382_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3781f16a-ebb4-4d50-8218-03f30848f3f0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_c5bb1807-50f9-45cc-b56f-8567e3f6a0d0_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment, percentage</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_label_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:to="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5853bec8-19ee-4244-8158-dc5614518209_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d83f196-ed00-4bac-a76b-b1a832ca860e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_959553e4-1a62-4e0d-a890-104c54350c83_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_31235bae-6d00-4c5c-8438-2f16abbf5639_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4f0c6e20-6682-4e8a-889b-4774bd0d12f5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_45e09d60-fbdb-4ee2-9952-fb142ab9f867_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_FirstIndicationMember_6a8a5a82-8e91-42a3-bab8-5a690618f19a_terseLabel_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_label_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_documentation_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember" xlink:href="sesn-20220331.xsd#sesn_FirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_FirstIndicationMember" xlink:to="lab_sesn_FirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a4b9f7e8-8e62-44a1-a09a-48bbf5391833_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_9402601f-7b15-48d3-b008-e392c197e4c5_terseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_label_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009 [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member" xlink:href="sesn-20220331.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlan2009Member" xlink:to="lab_sesn_StockIncentivePlan2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_e7ca01b1-0e56-40ed-a4ad-d5b127d38db3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_63f62de6-03ee-494e-b967-8719357be596_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_1a040ee6-1a0c-4835-976c-923da9c219e3_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfLawsuits_a6ba8a73-162e-4fbc-a3c8-37c49139c8fd_terseLabel_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_label_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_documentation_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits" xlink:href="sesn-20220331.xsd#sesn_NumberOfLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfLawsuits" xlink:to="lab_sesn_NumberOfLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_cef0ba8d-2b19-4e4f-bfc7-d913fdbfcc4d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_3d5e4a45-5776-47a1-9379-c18ae26b0fb9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_f8286e93-c005-43ad-b82a-4b83ea4eaabd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_88506ed5-0cfb-489f-9d00-9c86238a694b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_0432c06c-ca46-4886-8aa1-7a5c2cd4c9b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0160c71b-2df8-4335-9248-01449bb7c212_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting on the First Anniversary of Date of Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_4274eea7-34ee-40fb-88b9-1d9402506039_terseLabel_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary match per participating employee, maximum</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_label_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_documentation_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:href="sesn-20220331.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:to="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bf509ae8-0686-48e1-a475-d64318b39e59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ab80cc67-ed3f-4332-90e0-de276f771330_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_51ee1788-6f7d-40d1-b171-17692ad107ed_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8bec37df-766a-4ac9-8120-97df105f945a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_567ca270-b8fb-4405-b9b5-040062bb1c71_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_4927afd3-1b4a-41fb-be0f-55ffc84c14c8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_bb09dcf7-3c27-4338-9a2a-f940b12ef582_terseLabel_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:href="sesn-20220331.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:to="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8810a8df-69e8-4196-b0b5-9a7a1c575b77_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e6ad1e90-5c3b-4e9d-86aa-bdc256f8f7c6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_fbc93086-67ba-4833-85a9-73b04af345c1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4e02e051-67e8-4b6c-8419-2cfff27d3665_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_08d3098d-64e6-4d84-94b8-f50a1c97bc3b_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_ddb1ec1d-32d1-465c-9ce3-1b86d48db6a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_d2fb181c-c3f0-4432-b8d6-4432eba5f776_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5072894a-c6f0-4062-9b31-05b1c5b0ff2d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bc2768e9-6ddb-449a-abda-f6246e7fd757_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in the fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_2d6bcbd1-7874-4b24-9c55-bda139175bb3_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sales price</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_label_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_documentation_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:to="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_c085db68-1b24-4131-81d1-5572a92e93e0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_01dc926c-d836-4595-b62f-d940233fe791_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0d44aa8c-8f40-4d48-9926-fef7b5fee374_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_f635a3ff-de6a-4d24-8f18-afeaca002bee_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_608553c0-ea81-4e4a-8cbb-e224ebdfee45_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7fc54078-d9f3-45ad-8b17-f0b89494553b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_27735fa4-cfa2-4bd4-b5a0-f31c9ab87ed3_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_3da004ac-9824-4d1e-88de-26240f9e3614_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, option periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_label_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementOptionPeriods" xlink:to="lab_sesn_LicenseAgreementOptionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_39ba2ca0-0d2e-4de5-b533-d9720110336b_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_46eb3cfc-74c0-425d-9297-44145f2b86e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IL6Member_c07aee28-bb49-471f-a7d2-7cd526580c7b_terseLabel_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6</link:label>
    <link:label id="lab_sesn_IL6Member_label_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6 [Member]</link:label>
    <link:label id="lab_sesn_IL6Member_documentation_en-US" xlink:label="lab_sesn_IL6Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IL-6 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member" xlink:href="sesn-20220331.xsd#sesn_IL6Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IL6Member" xlink:to="lab_sesn_IL6Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_87cc721a-9d51-4c62-8a4f-e5ecd8cdad46_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7669b974-4334-409e-9824-823a6b454d0b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_37c21c3a-fd62-424c-b750-154c7f6290db_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_c9058828-7e3c-48d5-9e9b-0fce297f7564_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_2ab9d76f-7cee-4837-b738-8e9c2d0c876b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under ATM Offering, net of issuance costs of $2.2 million</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_d83c35b9-6167-47e8-8b80-4e08de50a07f_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_9fdd4f8e-3330-4ddd-8511-5985beb77c83_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:href="sesn-20220331.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8c255ad6-83a9-4742-8e4d-1a362e49588b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_d8297dd1-db61-4634-8a82-56dcd6326039_terseLabel_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_label_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_documentation_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms" xlink:href="sesn-20220331.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccountsReceivablePaymentTerms" xlink:to="lab_sesn_AccountsReceivablePaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShortTermLeaseRenewalFrequency_9e62e2cb-135f-4a06-810c-0448e64f896d_terseLabel_en-US" xlink:label="lab_sesn_ShortTermLeaseRenewalFrequency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease, renewal frequency</link:label>
    <link:label id="lab_sesn_ShortTermLeaseRenewalFrequency_label_en-US" xlink:label="lab_sesn_ShortTermLeaseRenewalFrequency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Renewal Frequency</link:label>
    <link:label id="lab_sesn_ShortTermLeaseRenewalFrequency_documentation_en-US" xlink:label="lab_sesn_ShortTermLeaseRenewalFrequency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Renewal Frequency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShortTermLeaseRenewalFrequency" xlink:href="sesn-20220331.xsd#sesn_ShortTermLeaseRenewalFrequency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShortTermLeaseRenewalFrequency" xlink:to="lab_sesn_ShortTermLeaseRenewalFrequency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_1d3c2fcf-501b-4a6f-89cf-0a5f88d3c55d_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_bfe338fd-7283-4da0-a8e9-68ade34dcbcd_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3b7eede0-4798-4641-b4d6-2ff84729e9a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_57dea06a-8bcb-4c48-a2d8-cae1152186f7_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_915d240d-fefe-4346-a9ea-2b1bacfd9202_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_cb7976e1-6444-481a-ae4e-9da8961d459a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_576abc6b-0ffa-4ab7-b512-3eb6ea57abec_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e77e97b5-d6e5-4eb6-9bc8-f211d26e1d2b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under ATM Offering, net of issuance costs of $2.2 million (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_e6793aae-ba92-4105-903d-519298ea2759_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:to="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_fc8de2ec-f5d8-4fb0-89c8-ec557e4190b4_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_5351bb4b-3d39-464c-9fae-345a1b9ee793_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8fbf19fd-d57d-4c37-a919-c9750c7e43b1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_f81549c2-3fac-4c2d-bae1-0cd8187f469d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 400,000,000 shares authorized at March&#160;31, 2022 and December&#160;31, 2021; 199,463,645 shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_661e213a-cf73-4247-a14b-384a42e6919d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period unvested stock to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_74705aec-0177-4c25-8835-f2733de9cfe9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6a31ba45-ee95-4499-8f89-9d0fbfce86af_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_3583b429-7853-437f-ac80-1f4e91c67bbb_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_add89057-2c0f-4362-8961-5c5ab16451bd_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_ba123e90-d4cd-4ebe-a093-5d0a4b0e3542_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4c95894c-77d8-47d7-aaf0-579d7202b362_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_e611b2ea-3446-42e6-bc1b-cc375a37336c_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fixed rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_label_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_documentation_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockCommissionFixedRate" xlink:to="lab_sesn_SaleOfStockCommissionFixedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_49fc2f5e-5733-4328-9d0f-c06754cdcd0d_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ace8daf9-2036-4470-8d77-28665c374b16_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_c42e24f5-c0d5-4b0f-b19d-ae7a01e978bb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_0c5c5078-9fe9-487c-a2d1-541db94ecad9_terseLabel_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_label_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_documentation_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:href="sesn-20220331.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:to="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_babd153f-71bc-4ed8-995e-56f5aacdce84_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7c9e106b-648c-4012-9bf4-4828716d0c5d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_25d95499-6d7f-42aa-ad75-e3b1583e7233_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_f29ca3ef-711c-4d6d-83c0-46304d89c039_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2bd439f1-3582-404e-b7c2-c5c1687f399e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b4cd3a28-089b-4432-b2a1-97784840aa57_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_c135150f-938e-4b8a-8f1d-e3e2f8492b3c_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_09f557e6-c270-42e2-afa1-b4047b717ee4_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, period to pay buyout option once exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_label_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:to="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_bc7853b7-3c9f-441b-a63d-a0346bb57d19_totalLabel_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock issued and reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_label_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_documentation_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:href="sesn-20220331.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:to="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_b14614a8-f9c9-4624-859b-91278f6b35f2_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECEIVABLES</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9b508794-ee1d-4a7a-b196-69d5195d3739_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1517c9ba-71a1-453d-bbe9-55a2a30fd892_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_53c43290-1f7d-4be6-9f56-68bc909968e6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_b287d69a-c431-4e98-9728-fc80ff938b44_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_743a1655-e8a3-41ae-a75f-91d93c8b092a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_74fb1669-7905-4a6d-9177-a48d7fdffb2f_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_75e1e434-8a7d-4634-aa44-ce0924099483_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_48d209fc-9e46-45fc-b889-28470f35919e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_e9b18498-eb74-4961-8ca3-96c914974abb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_edb28a17-9ad9-4e22-8723-4f4fcd7918c8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_121e7d91-2d69-4079-b3ae-47252ddded0a_verboseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_label_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent" xlink:href="sesn-20220331.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseMonthlyRent" xlink:to="lab_sesn_OperatingLeaseMonthlyRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3ab50866-79d4-4dab-8b93-310bd2d12f86_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f8796e1d-f2d7-400a-a678-1324ee426345_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_6bd609cd-ab66-4312-b3a5-095bf2b94df8_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued to the selling shareholders (in shares)</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_label_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:to="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c863f994-b0f1-445e-814b-d1ec77bc5063_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_9c3cc512-cae1-48e7-ac35-b521efada5f2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_b935ba6a-23cc-4a38-80c0-0fd152d5b273_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_460f0ee7-62ac-42af-9e67-5086f04ebfac_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING AND RELATED ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1b2db830-6fa4-43b6-a1bf-4e24b8f6016c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7380b5bf-57c0-40c5-a2d8-8e447c6d2e50_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_43a2b5be-bd2a-4586-aa54-6a8d8812aacc_terseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:href="sesn-20220331.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_ab4fb0e7-321d-4ec4-bbbe-a5e9fd1ce860_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_2f7e9c6b-0944-4fd0-97dd-115fee6b597e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2284c602-d475-44db-b9cd-b8a69a6be67f_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_1c44775f-b224-4a11-9435-d757ac4dbc4b_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyRate" xlink:to="lab_sesn_LicenseAgreementRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_be2b9014-214d-4dd5-9780-692b29959c0d_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c0e47526-f99e-4ddb-9ecb-d8d208b662eb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_881ab897-9a43-4273-a332-e168e5af3f05_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance amount</link:label>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_label_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Shares Amount Available For Future Issuance</link:label>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Shares Amount Available For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:to="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4f7d109e-c06e-4fd7-9b2f-37a23840c6ee_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_c71f0de0-894a-4db2-9654-fbd7372afed6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_0a6b10ae-bc7f-4bd3-aed1-7acdf9cd1733_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time milestone payment upon first sale of product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:to="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_8e0cb332-fd8b-4764-b11a-17a308e4af49_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of base salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_89f8b355-45c6-4f7c-95e3-eda00e355a35_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringMarch2023Member" xlink:to="lab_sesn_WarrantsExpiringMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_ca96139f-7d7d-4f85-a309-7cf16baf4747_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_abca0f5a-6f82-41cd-949a-62c1ba7f5d3e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_ea9d8520-31a2-42aa-8413-d0ec76b67405_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5d6b8a23-7815-4218-8b5e-f2cf71e17401_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_29dc7421-e671-46dd-bf42-50138eff5531_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_cc084df2-2c9e-4474-ae4d-1cef28cac6c0_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfPatients_5e6bc434-b7d5-4c10-a46b-a85ca38ad4a0_terseLabel_en-US" xlink:label="lab_sesn_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_sesn_NumberOfPatients_label_en-US" xlink:label="lab_sesn_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:label id="lab_sesn_NumberOfPatients_documentation_en-US" xlink:label="lab_sesn_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfPatients" xlink:href="sesn-20220331.xsd#sesn_NumberOfPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfPatients" xlink:to="lab_sesn_NumberOfPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b5d02a25-443c-416d-ada9-ed0a81b72d3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ATMFacilityMember_bc9e3258-ee10-43f3-9eb6-80c396a4eb2f_terseLabel_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_label_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_documentation_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember" xlink:href="sesn-20220331.xsd#sesn_ATMFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ATMFacilityMember" xlink:to="lab_sesn_ATMFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_ca1b216a-a26e-4dc6-996d-768b60eda32f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_3fd7598a-7c25-469d-bac3-c937417567cf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_11f908e0-e168-4303-9d53-183cf01a5122_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a4e8dad6-4da0-47a0-a316-1239759ea677_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b37b9201-f67f-4450-a977-af8e5742c61e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RetentionProgramMember_21bfbdaf-c09b-4333-9265-cacf4f7dfc6a_terseLabel_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_label_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_documentation_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember" xlink:href="sesn-20220331.xsd#sesn_RetentionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RetentionProgramMember" xlink:to="lab_sesn_RetentionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3df49121-fb1d-4fe7-97b4-9163f4f202fc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8a33513c-0def-405a-9d9f-29ada208ab9d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_7ab9246e-355f-421c-8d26-0e7532fb2c3c_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Period</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:to="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c679ba50-2ae1-4084-a033-b4b6f70bc858_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9950ccaa-1028-4d03-87ef-25a0adf6e7e0_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_a0d487c9-9471-4574-a6da-2e51582b2615_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4962abac-4128-4c66-acf8-43eb9137142e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_302d023f-82a0-439c-8232-f197d4f15bd3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_487ed060-de3d-4f61-8682-155bde3d29c5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_2f6c445d-2eb2-4ea9-bbd5-370516e3b897_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_09edae14-8340-40bd-a61f-4710916344cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_f95c8769-1057-4c2a-b07b-254f0a779da4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_575bb576-ba66-4db2-b9e5-e9e00ab0d453_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_a6b48e0f-fee6-460b-bc0a-264e41644465_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6791b457-1f35-40fe-9d16-d0923464c759_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4703af18-a6e8-427d-90f7-cbd16e7cb0ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_687941e5-3780-4bcb-8431-c79b974c3dc0_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant under 2014 Stock Incentive Plan</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_41fef9f6-685b-406b-b40f-e12dfd0b8346_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_026629c2-a2f7-46ce-b1a5-8137500e4f22_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, additional up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:to="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a9d5490b-a66a-4b43-9284-2c85b2dde1bc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_795c76c6-2fbc-4441-8663-012b1ac790a4_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0320fb18-5419-43c2-a654-d4d7b4d49ae6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_112759f7-81e7-42de-8047-f6509fdb2a1e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c3cb7922-6e29-412d-a442-4cc000cb34aa_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_7c547c94-5471-4ed8-8c28-3b974a8234a7_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value (in dollars per share)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_08bafcb3-0f82-4d4b-b4e2-f38813798fa9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_ef98cab1-ea70-4a97-86ab-298c8a5cb0a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting at End of Each Successive Three-Month Period Thereafter</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a61d688c-df7c-4413-98af-05f26ac3a4d4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_b872b1e4-9ada-4fe0-a756-2fc7bc094963_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement deemed probable, percent</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4d1daf39-6635-4b20-8bb9-7eb12f3141b3_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_56926b16-cbfe-4fb6-9117-723f340723a3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_1598116d-a421-4336-b4ee-0c2cbeb152db_terseLabel_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_label_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_documentation_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare" xlink:href="sesn-20220331.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberofVotesEntitledForEachShare" xlink:to="lab_sesn_NumberofVotesEntitledForEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_8a82a66d-972d-4fe1-a52e-ecc8da9fc71b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d75a3460-6873-428d-a838-cbcf29a0a232_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_448e130e-6a5b-4700-9054-6cb7b9819cc6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4776b61e-ff13-427a-ae2e-c12a5822f77a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d3d8a073-a4fc-4782-bced-d24d04e092db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_ba45ba4b-4b02-4736-959f-88cd0af0391f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c91b627b-2891-46d2-8cec-a4fbfd5573df_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2053c375-31e6-4d54-8d0f-ded09c330f87_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8be0f39e-34c9-4cd5-afec-fa28e5e02217_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e463a488-0f1f-4499-9f18-63d0acb1a91d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_83c7aa0e-4b03-4556-bdfb-aaaed122fe71_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_24dae444-5d1f-4798-901e-9d2d97bd8070_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_09098c6b-fbc3-439a-990a-eed952539b38_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_579ee814-92b1-49f2-ad1f-704ee19a42bc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ed9c0c92-f0ed-4f27-8b1c-627d435e8c8d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_1d31e076-02b8-46e7-a9f1-327eaf03246b_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:href="sesn-20220331.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4458cb1c-d581-41df-ac15-a534092d434d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_b6c8548c-b093-4817-9c4f-21490aeb5bfc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_35e700a8-c890-46b4-bc1c-213137800c9d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_5848ec84-d08c-48f0-bf91-d600326fcb66_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_09e93611-6e8d-44d4-ac13-df5d9d6757b0_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_44b9d50a-3533-493a-852a-c0f98cb4d5e9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_580dd193-d655-4906-b5e6-535cc27661cb_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c7b01e8f-3704-48ce-b607-21bc6365dc5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrants Outstanding and Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_cc4fc0ef-88d4-4829-8ab4-59a9131ff702_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_597f71cc-33ca-41ba-9207-57d7cdfa1f1d_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_925eecc4-2763-4bc7-b19a-4f93e5c84548_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_407ed777-5bd4-43de-aa01-77baf412b455_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e80aae00-bf4d-413d-9e55-5945dbb06bb0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_816c4bd6-c59f-4793-87d9-20bbdd586042_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_b37a586a-c328-4bc8-be1a-54d05d7b71fb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_4e61f5ea-a424-4cc5-a9a3-45850bf879ac_negatedTerseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Cancelled (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:href="sesn-20220331.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5f6ba33f-a3c4-4c17-a7d5-268cb4fb8d6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_75434c08-83bc-4912-b1f3-183a220ddefd_terseLabel_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge related</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_label_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:href="sesn-20220331.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:to="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_1fcde0b5-d778-4f3a-abd3-7dde574c458d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5d88a6a4-0364-4721-8293-83332240885c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_fe3f3d5b-f250-4b55-bdca-1bf779847fd3_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2f6ea1ff-0cb6-429f-9aec-91b4b72f1ef5_terseLabel_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance for:</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_label_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_documentation_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:href="sesn-20220331.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:to="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_5ad1b7da-4ce7-4bee-856b-23c37e67372b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_1ac8cd30-b192-4929-9666-36ba0647f654_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_bb8e0f41-bac7-4fb7-be59-1b77f47ab4af_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_fcf96c5b-0a22-4b08-b7b5-ec80fb63493e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a582f694-7c4d-4396-8a7f-03bd07b06900_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_3f007345-48ad-4b97-9e1e-34796d0d4971_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of fair value in excess of carrying amount</link:label>
    <link:label id="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_label_en-US" xlink:label="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:to="lab_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c5ca1868-b39d-4ce1-aa49-1419f640a802_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SecondIndicationMember_ef614b09-9ebe-4c58-af77-dd2246d4bdd0_terseLabel_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_label_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_documentation_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember" xlink:href="sesn-20220331.xsd#sesn_SecondIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SecondIndicationMember" xlink:to="lab_sesn_SecondIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_c5f5c818-4526-4849-8a72-898dd2f18b34_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_label_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationMilestonePayments" xlink:to="lab_sesn_BusinessCombinationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c2ac4777-8730-4227-b283-801e727316b9_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_71f681d2-0e4e-4001-8d5d-723fa4818b14_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_e4ded15a-e8ec-4aa6-b04a-0ba7f0a64cac_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EBI031Member_7ae82d2c-16c2-493a-a186-5143855bfbb9_terseLabel_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031</link:label>
    <link:label id="lab_sesn_EBI031Member_label_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:label id="lab_sesn_EBI031Member_documentation_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member" xlink:href="sesn-20220331.xsd#sesn_EBI031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EBI031Member" xlink:to="lab_sesn_EBI031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_40386ae2-1218-4838-b188-06857e2037cf_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_408e3797-ea85-47ba-8265-99c47e51526e_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_051bf873-a31c-4983-8d13-ca4fae7c125b_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_623c4c77-4932-4523-b551-045201144250_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_85259331-e673-4a76-ac92-e85533a22100_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ff18a1b3-a5ba-4904-a6b3-d9b5912e07c9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_5cbf20e1-1b79-4bdf-bf3e-a03e5e1e32f6_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_cfd785e8-de96-40eb-ae95-f5566cb26785_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_c32a1d0a-6f0e-4b7f-bca1-06b1432be8fe_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on development milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c83c4495-916b-4133-9beb-aaec346a9725_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_11300eda-632f-47d4-9654-189c4d64b3ee_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_083ee18a-6cc6-484e-9821-a8b90c972dce_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_0af424cb-4914-4a70-af5c-a5b11aa245cf_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_62ef6e0a-b7e6-4826-840e-d759b885aae6_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1fbbb534-1959-4c6b-abd0-9ba0297adce5_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_371cece3-392c-4720-8ed4-f95b31f9a982_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f1b692dd-6fb0-4cb5-9d11-d23676c45624_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_88c5b1f6-bcca-4193-a5c7-9bcf5a5f07f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Status of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ec6d6c60-1bd6-4c92-83ea-68c1c2bfff57_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_9efd1cdd-d119-4347-bec7-b66f26c6024f_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_aefe2fca-8dcb-4b7f-9453-634e0d48fd15_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_3a150882-9c05-4748-8bcb-09f4b06b4124_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_55199f51-5a76-4238-97d6-3d8962796c9f_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_df56d382-2af8-4755-8965-5305d332c7da_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_ec4ccfa1-c545-4d2f-963e-1725cf41497d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9e12b42d-cdac-46d2-af1a-2208ab08937a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_9b713ac1-4819-4061-bde4-543a6294c3a9_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_04ef24b5-4fc8-4b49-882d-a65f0f45e3c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_72e3a35e-ef15-4ce0-96cf-2722271d630d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_7fe1e05a-3f2a-431e-9b69-bb398802af9a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cb178399-2e43-4595-9fa9-6bf00bd99504_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_8c27ed41-8160-4cf3-8e6c-72b999f4ce6a_verboseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1337c746-fab9-44a4-b08f-c3762e88a33e_negatedTerseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_2d697c4b-cd5f-42f0-beb0-e153350097d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6bc3b9e2-b831-41fc-b216-c7ff2b0abf2b_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a9c7a503-aa13-46fd-9a91-3e71b34bd5f0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e961c918-4ef3-4ef5-8fb7-9e1ec2fb4ad3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_404b9a65-f28d-40d0-821e-2e16b811be5f_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales of quarterly earn-out payments during earn-out periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:to="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_66901b4e-de98-4c9e-8bac-eee66009fb31_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_1c0112d1-40b4-44c8-9227-832100c997c6_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_64834b69-0acd-490c-9bb1-5d30003cef34_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_d7812369-34c4-43de-89e5-9e09939e2e99_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance cost</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:to="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4c3d5588-ef9f-42dc-8a6a-2000a6b78f63_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss After Taxes</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_dc42111c-688f-44f8-83a4-838e95f0e9bd_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_39f70d26-9d58-4c59-9785-7426e4d41566_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_460e1ea6-67f6-4de5-8be0-84454c99935b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_489e399e-23cc-4be9-9276-b34abe866083_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:to="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_cd8e943b-4e0e-4e1d-b35c-42ce5bcdff0f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated, period percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_31570c06-da0b-44fe-bb9d-499f913521ba_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19869e1c-59be-4b35-bb4e-e1d8fa294a54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_ddd572dc-ff0a-4493-9bc2-c009cf1886a2_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_44750892-c9a3-4554-8476-cb719b9faeeb_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_07ca3efb-0ebb-4194-aba5-a7ed9c53f3a5_terseLabel_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_label_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement [Member]</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_documentation_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:href="sesn-20220331.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:to="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b82c65ae-f197-4d05-83d3-6e79e1c56377_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_e00416b5-460b-4eab-a697-044fda592c2a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_ee0317a1-1099-4ca5-adad-3932197a8888_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3e99ba4c-942f-4386-af87-c4172979317f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e3e6bc64-ba23-4b9b-aadc-507f7fb04f6a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_961ba873-0720-4670-bdba-4bdacfd6a30e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsCurrent" xlink:to="lab_us-gaap_IntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_90628837-bf22-495c-8332-4ad22be731a5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a56505f9-9d85-4efa-b9a6-f8653e77af21_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_b3c10760-b281-4502-9153-3476bb7a620f_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to achievement of development milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:to="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5175f13d-a348-419c-bea9-4c78dfa33acc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_acd161f4-c291-45c8-9a94-8e87c087a6a1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_UniversityOfZurichMember_62509eb0-91ad-4539-8054-3cb7c769a3ca_terseLabel_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_label_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich [Member]</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_documentation_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember" xlink:href="sesn-20220331.xsd#sesn_UniversityOfZurichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_UniversityOfZurichMember" xlink:to="lab_sesn_UniversityOfZurichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fff1998b-a1fe-4bb2-91cc-e7b1ff50af8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares under Option (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_d97ef84d-fea6-4422-a6c2-34173da0b86a_verboseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Stock Incentive Plan</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_label_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:href="sesn-20220331.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:to="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dd75c43c-4fa3-4a12-b23e-587d935f748a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_9e5fdbee-f95d-4b22-a6e9-139700827bec_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_86e886a6-f8c1-41d6-ae16-6ce138eba053_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_16b0f2c7-e012-4334-8c24-2e48044632d2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_cc81857d-15c1-45be-908a-ef74088d541d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7f2aec40-5c99-42e1-934e-a1866b36cdb6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RocheMember_688cbc09-7948-43e0-8597-18647704e287_terseLabel_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_sesn_RocheMember_label_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_sesn_RocheMember_documentation_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember" xlink:href="sesn-20220331.xsd#sesn_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RocheMember" xlink:to="lab_sesn_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_c12c6186-6433-4693-924c-fc6db5977ca3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_a91fc571-cfcf-408b-af9f-7677a0f13cb6_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of common stock warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:to="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_31863e71-a6f3-4c92-a7e2-9baca0deafb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_1da81b32-90af-4b28-aadb-9d2156f96298_terseLabel_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:href="sesn-20220331.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:to="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4590749d-d900-4903-a1c0-951166fcc32b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_d3fdc56d-7bb2-4d73-9fb0-d8c84e89a7d3_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_17d470c8-9b59-4506-a515-de87a9a77416_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_5b63cfbe-893a-4c59-92f7-c795d46164b1_terseLabel_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average cost of capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_label_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital" xlink:href="sesn-20220331.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WeightedAverageCostOfCapital" xlink:to="lab_sesn_WeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a5389c46-08e8-4f24-b97b-b20ef7c2e159_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_120c371e-2fda-4535-906e-4372f3832c2c_terseLabel_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:href="sesn-20220331.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:to="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViventiaBioInc.Member_47dee606-a5ca-47cd-8450-64a260fa6e85_terseLabel_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio Inc.</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_label_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc. [Member]</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_documentation_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member" xlink:href="sesn-20220331.xsd#sesn_ViventiaBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViventiaBioInc.Member" xlink:to="lab_sesn_ViventiaBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseRevenueMember_9f670597-777b-466f-a1bc-d5a78652d4d5_terseLabel_en-US" xlink:label="lab_sesn_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related revenue</link:label>
    <link:label id="lab_sesn_LicenseRevenueMember_label_en-US" xlink:label="lab_sesn_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue [Member]</link:label>
    <link:label id="lab_sesn_LicenseRevenueMember_documentation_en-US" xlink:label="lab_sesn_LicenseRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseRevenueMember" xlink:href="sesn-20220331.xsd#sesn_LicenseRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseRevenueMember" xlink:to="lab_sesn_LicenseRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7627c989-b932-45fa-b4e1-23b81b2a6eb6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f22fd46b-9c46-4499-bdda-c2f4cf2c40f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_71406a53-8ff6-4b52-947a-d69350f49bbf_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_6d53e360-7176-4666-99fe-c513ae7959a7_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment obligation, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_bba96dcc-7368-4817-b51f-75a4bdb5f44a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_18346fc3-9b0d-4006-aadd-ef3c8eb2c037_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_e197296a-a4ad-4523-87e3-22f7d3f02981_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Share Based Compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6594987f-4215-4fbc-a67e-ce7b979745b4_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_d7ec02db-6625-47f1-923a-c94dacd010d4_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_3a3600d5-2015-4604-b4d5-fa0e58d2e9bf_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_55e7e579-9a2f-478d-9ad1-4812515731ac_verboseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_6d366977-3cff-45a0-a540-6dcb93ff72f1_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseMaintenanceFees_1475aafb-09e7-4d0b-9f0e-81bfe4664658_terseLabel_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License maintenance fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_label_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_documentation_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees" xlink:href="sesn-20220331.xsd#sesn_LicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseMaintenanceFees" xlink:to="lab_sesn_LicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_42134773-4de5-46e5-a53b-f1ae989e7779_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_237c00dd-314c-49f1-8f7f-28ae67509d5d_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_3aa722b0-adf2-4636-a343-dd5faa396483_terseLabel_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="sesn-20220331.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_fa5a2799-14c3-4058-9093-8dd7c01f74ec_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_bb29e69a-1c8e-44c8-b406-f3ab41e2bf83_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_bb5fb252-baf1-4ad8-85b4-332ddea5f622_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e6a5877b-6248-499c-a90d-13584463bd31_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_053002c6-7ee8-4835-9f78-f1d170bf743c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_4c4b826a-5e79-419a-80bd-5cf257d5c5cf_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of units issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_28aac612-d80f-42fa-bb01-195f0943e2e5_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6f059d0d-1f4b-463c-ae8a-982954842226_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_f0350988-544f-41e8-be99-fceb59562f13_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_3e9cf944-5599-40da-9c5c-65aced1bbe49_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_a17d9d25-8203-40d7-9410-5284081c9ca1_terseLabel_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_label_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_documentation_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:href="sesn-20220331.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:to="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_1988fc34-2a48-4d4d-9f1c-af9daaa89c30_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_ebaa4abe-d63c-4694-974d-4f55f8349773_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9e788313-e7d3-46d8-b04a-190083e2efa9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1ddacb64-27ca-4c6f-8583-b1c6cb282adb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_d2593dee-b63e-412b-baba-d5afcbc5798c_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2022Member" xlink:to="lab_sesn_WarrantsExpiringNovember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bff24bb8-537d-43b8-9c0c-cdc3ba27901f_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds (cash equivalents)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_baaf01d1-268d-4896-a61c-bf8a65a00ff9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_eaf7bd22-d3f1-47b8-9909-b98a79b6dd12_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_f48af23e-10c0-4bb7-b1c5-6ebde67cadb6_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_8febcdfe-1fbe-44cf-96f9-0a2bbcd69acd_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under first option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1dd92775-b63d-4387-9162-16249ca1bc3b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_74b259e6-5e82-4407-bb02-92a30b67ccde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_1e36db42-7bfc-4c4d-b64c-966194bf889e_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_label_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementTextBlock" xlink:to="lab_sesn_LicenseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fde3d7f7-babb-4c2f-8eda-ddc8deece4c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_84aad0e6-8b81-45ae-8628-f132e70137d7_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_5d570524-2324-4f3c-8c63-8eb722b0cb9c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d33e85da-2393-4895-876c-63c89bfda378_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_94c408fc-92c0-48c3-b78e-62b09197695f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_d93a1c7d-0516-4e3a-aa95-3efaa8df5d71_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9792b42f-c73e-4515-96bc-42f4cbf7f8cc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d7389a08-a869-4a25-8b09-c7828f227f0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bbe4a38-6c6f-4137-b852-ad6b7c6fa027_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_872c247d-fabd-48dc-946b-d0904ce4a8dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_3e8e8517-2be0-41ed-b13b-df5d58bb5d83_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c31091e4-c254-4476-bdb0-42c24845670c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_1c3263f9-9479-448b-b23d-1273b5b276dc_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_3c5f90fb-29eb-4069-95f5-8c5494553b2c_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average stock price per share (in dollars per share)</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_90132838-9f5d-4260-8933-4b91eac5dcd0_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_13e7fb13-3605-4bff-a6da-f895812a1fa2_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_7d60202f-6e0c-4107-ba2e-4d64171c081a_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_336cf772-b3d2-46ef-b403-4b3745d2086d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b1a4cf39-8d8a-4246-b825-5a98231ed281_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_a20a584c-6a96-49dc-8a0f-103e7913dfeb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for sale under 2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_1b511543-a032-463b-8d20-542fa2d6ec60_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MicrometAGMember_85eab41c-e74b-47b7-a709-7fcf3b38a945_terseLabel_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG</link:label>
    <link:label id="lab_sesn_MicrometAGMember_label_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG [Member]</link:label>
    <link:label id="lab_sesn_MicrometAGMember_documentation_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember" xlink:href="sesn-20220331.xsd#sesn_MicrometAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MicrometAGMember" xlink:to="lab_sesn_MicrometAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_bd7ca419-88f0-420e-8b5d-1976256d4c92_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_8bb58514-1221-4f0d-8fb4-970deceb43d3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7c31b639-37fa-4c88-9733-c9bfe1ca1b32_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' eligible compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_9a5d9ac2-7ee1-424f-b755-f333e080bcb2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_6a2482c9-bd07-43ab-a4b9-271752a950c3_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which quarterly earn-outs are payable after date of net sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:to="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9ea721c9-ce5b-4516-a2e5-491fa16c2d02_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_1120e6bc-436e-41c3-ae31-82cf38948052_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, amount payable upon achievement of specified milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_label_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:to="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_77ed48ad-9185-4bdf-9096-2cf68304383e_terseLabel_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_label_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_documentation_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:href="sesn-20220331.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:to="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViciniumMember_6008353c-8561-4f64-9857-8bcd35bf387a_terseLabel_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium</link:label>
    <link:label id="lab_sesn_ViciniumMember_label_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:label id="lab_sesn_ViciniumMember_documentation_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember" xlink:href="sesn-20220331.xsd#sesn_ViciniumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViciniumMember" xlink:to="lab_sesn_ViciniumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f85808b9-cd01-40c3-a808-3711d6bbe995_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_65081db9-3912-4e4b-9667-a95fb8e93034_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_f3f25b40-8164-49b5-8a4f-56c10ef44ede_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty payment, reduction, conditions not met</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:to="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_22fb13c1-f616-46b6-ae79-262117edd580_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b3bf4b4f-1903-4894-bb16-6a7e37875b49_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_a44616a8-f49e-49dc-b3be-9ad9eae43ce7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_65355338-167f-4b6f-b9e6-2460e1232558_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_7808cfe8-f734-4c4c-9d0f-81d427435064_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_454a0f89-6900-447b-94ba-59912a4c9d10_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3b5dfe39-1960-4b08-83ab-86f21deeb4b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MENALicenseAgreementMember_b923ac54-ee99-4b09-99df-d5ca192fc2bf_terseLabel_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_label_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement [Member]</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_documentation_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember" xlink:href="sesn-20220331.xsd#sesn_MENALicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MENALicenseAgreementMember" xlink:to="lab_sesn_MENALicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_08f45204-a81c-414f-9acb-f5f133d4b841_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_27c5c184-22dd-4171-8138-a30e0e2a6c87_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_77f0574f-e751-4a74-912a-bcae0b996a1c_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_label_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:to="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_2a666a54-b10c-439a-a573-7ed5dfd654a2_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost, including related operating cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_571558dc-1d5b-4177-adf3-000b7f55ec16_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on commercialization milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_24a02706-77cb-49aa-af50-66dbc06a6de8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_91fd9d87-d3c9-4bbf-b319-ae5025624bb2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution retirement plan, maximum employee contribution deferred</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_224811dc-7ee8-4453-9bac-3f0e212dc05b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_dc7d3634-c8e8-442a-82ce-918c2caab9ef_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related operating expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_label_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:href="sesn-20220331.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:to="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>sesn-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:543d6d7e-07fa-4fa5-80cd-d905631091cd,g:997a4fa6-361a-4df1-8bb3-52045b6d76b9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/Cover" xlink:type="simple" xlink:href="sesn-20220331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_38a897b4-8e38-4c0e-82fe-f8f7315dfee6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_DocumentType_38a897b4-8e38-4c0e-82fe-f8f7315dfee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_085a418e-2ae5-4e42-a82e-5490868af243" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_DocumentQuarterlyReport_085a418e-2ae5-4e42-a82e-5490868af243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_164a1188-2e7b-49d8-b179-dd6c576f7dba" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_DocumentPeriodEndDate_164a1188-2e7b-49d8-b179-dd6c576f7dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e267ae49-790c-4fb2-b7a4-6d7aa354bd22" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_DocumentTransitionReport_e267ae49-790c-4fb2-b7a4-6d7aa354bd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_7cc91bd9-df5e-406e-80ba-abee48a787ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityFileNumber_7cc91bd9-df5e-406e-80ba-abee48a787ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_2c30d513-b082-4f6e-a6bc-52c80f5287ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityRegistrantName_2c30d513-b082-4f6e-a6bc-52c80f5287ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_179ed986-7d32-43e4-a64d-1aaeb704a2b4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_179ed986-7d32-43e4-a64d-1aaeb704a2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_737b4d7e-4343-4eed-96a2-cfceed5cd591" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityTaxIdentificationNumber_737b4d7e-4343-4eed-96a2-cfceed5cd591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f2291860-f657-4df7-8c16-a4ad29c4ae67" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityAddressAddressLine1_f2291860-f657-4df7-8c16-a4ad29c4ae67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a46e6744-86a9-40dd-b511-076b7356baf7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityAddressAddressLine2_a46e6744-86a9-40dd-b511-076b7356baf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_bea83249-7f60-4309-8b92-e1a0c7d52d30" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityAddressCityOrTown_bea83249-7f60-4309-8b92-e1a0c7d52d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_946fe3ef-ec57-4ab2-ac39-c9314641b0c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityAddressStateOrProvince_946fe3ef-ec57-4ab2-ac39-c9314641b0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_453ff89b-28e9-46fa-88e4-8598487ffbf2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityAddressPostalZipCode_453ff89b-28e9-46fa-88e4-8598487ffbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_c4553efc-4fe1-48a1-934e-84696b87b69d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_CityAreaCode_c4553efc-4fe1-48a1-934e-84696b87b69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_9a79edf1-ad05-49b9-9b9c-6f2e2af40fa4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_LocalPhoneNumber_9a79edf1-ad05-49b9-9b9c-6f2e2af40fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cf2576cc-3f15-48f8-92d8-8871ab30cb37" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_Security12bTitle_cf2576cc-3f15-48f8-92d8-8871ab30cb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_66e712b6-41fa-435f-ab29-a31fd152a437" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_TradingSymbol_66e712b6-41fa-435f-ab29-a31fd152a437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_32fce47d-1d12-49ed-88ef-cc6a594d2629" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_SecurityExchangeName_32fce47d-1d12-49ed-88ef-cc6a594d2629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3df999fd-fb44-405a-a932-bd399cabf46e" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityCurrentReportingStatus_3df999fd-fb44-405a-a932-bd399cabf46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_59510d7f-8b82-4774-9fe8-b62a638c6332" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityInteractiveDataCurrent_59510d7f-8b82-4774-9fe8-b62a638c6332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cc7a9943-3259-4272-b4c2-7b1b4eb3e875" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityFilerCategory_cc7a9943-3259-4272-b4c2-7b1b4eb3e875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e6dcd406-9464-471d-b975-63235c4415eb" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntitySmallBusiness_e6dcd406-9464-471d-b975-63235c4415eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_a3af7e03-5eb3-405f-b498-046baa222eb0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityEmergingGrowthCompany_a3af7e03-5eb3-405f-b498-046baa222eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d9258f1e-dc0c-479e-8fec-0f1ae20b75fa" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityShellCompany_d9258f1e-dc0c-479e-8fec-0f1ae20b75fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_da1caf3c-476a-4342-948d-ab1069a67cb4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_da1caf3c-476a-4342-948d-ab1069a67cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7f294cf4-0d3d-4aa8-80e2-a85d00a710e5" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_EntityCentralIndexKey_7f294cf4-0d3d-4aa8-80e2-a85d00a710e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0827d849-e5df-4202-a8a0-4003d1f9c51a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_CurrentFiscalYearEndDate_0827d849-e5df-4202-a8a0-4003d1f9c51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_1ec26941-f98b-493b-a8a0-a6ccb16ab1e2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_DocumentFiscalYearFocus_1ec26941-f98b-493b-a8a0-a6ccb16ab1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_5b5b028d-55b9-484f-be0f-28a95b1d07c2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_5b5b028d-55b9-484f-be0f-28a95b1d07c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1652ca13-4624-4e1e-9f3c-8dd6a7b63d97" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_7bf2a328-727e-41b8-bf88-3868b682455f" xlink:to="loc_dei_AmendmentFlag_1652ca13-4624-4e1e-9f3c-8dd6a7b63d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a597c5db-ef9c-4039-8fd9-5074b08c88dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_d08de216-1570-46ec-bedc-9ed569a8cec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a597c5db-ef9c-4039-8fd9-5074b08c88dd" xlink:to="loc_us-gaap_AssetsAbstract_d08de216-1570-46ec-bedc-9ed569a8cec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e6f4a565-67b6-493a-9c1e-4fdea0f25c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d08de216-1570-46ec-bedc-9ed569a8cec8" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e6f4a565-67b6-493a-9c1e-4fdea0f25c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_acd3b96c-aacb-46e1-96a8-3915d26a1a69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6f4a565-67b6-493a-9c1e-4fdea0f25c2f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_acd3b96c-aacb-46e1-96a8-3915d26a1a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8ea3568c-c251-48de-8c5b-204852acdbb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6f4a565-67b6-493a-9c1e-4fdea0f25c2f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8ea3568c-c251-48de-8c5b-204852acdbb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_ea92aa4f-5623-40a4-a6a9-e45812a19bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6f4a565-67b6-493a-9c1e-4fdea0f25c2f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_ea92aa4f-5623-40a4-a6a9-e45812a19bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a683023c-089b-4723-8d24-9bb68a6b7ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6f4a565-67b6-493a-9c1e-4fdea0f25c2f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a683023c-089b-4723-8d24-9bb68a6b7ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e6981886-8b30-43c7-81c4-6ba6b9db32aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e6f4a565-67b6-493a-9c1e-4fdea0f25c2f" xlink:to="loc_us-gaap_AssetsCurrent_e6981886-8b30-43c7-81c4-6ba6b9db32aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d08de216-1570-46ec-bedc-9ed569a8cec8" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fab184a1-cbf1-48c7-9b94-c022c7f65614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_fab184a1-cbf1-48c7-9b94-c022c7f65614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_977de1ed-7343-4c24-a53b-1afe38ea69d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_977de1ed-7343-4c24-a53b-1afe38ea69d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f775b517-c765-4974-985b-41231f73bc00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_f775b517-c765-4974-985b-41231f73bc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f15d51b1-4230-4202-8a69-01358d6b8f59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:to="loc_us-gaap_Goodwill_f15d51b1-4230-4202-8a69-01358d6b8f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_60c240cf-78b5-4017-a044-6d34a68b84ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_60c240cf-78b5-4017-a044-6d34a68b84ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_31f16228-74de-4bea-8a8d-16544f668a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_31f16228-74de-4bea-8a8d-16544f668a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_114b7620-b7dd-4ead-b8b7-8bd820d9357a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_1cb532ba-be39-49fa-9c08-e119f29076be" xlink:to="loc_us-gaap_AssetsNoncurrent_114b7620-b7dd-4ead-b8b7-8bd820d9357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a304bf31-51ce-46a3-ac39-f1f69d538439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_d08de216-1570-46ec-bedc-9ed569a8cec8" xlink:to="loc_us-gaap_Assets_a304bf31-51ce-46a3-ac39-f1f69d538439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4aa601f2-6bc4-49ad-a9f0-2c106a922d57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a597c5db-ef9c-4039-8fd9-5074b08c88dd" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4aa601f2-6bc4-49ad-a9f0-2c106a922d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8fdcf073-89a8-4463-9758-0cdebfd28828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4aa601f2-6bc4-49ad-a9f0-2c106a922d57" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8fdcf073-89a8-4463-9758-0cdebfd28828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ccc86727-77f4-4894-8235-d4d1d8ff3f50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fdcf073-89a8-4463-9758-0cdebfd28828" xlink:to="loc_us-gaap_AccountsPayableCurrent_ccc86727-77f4-4894-8235-d4d1d8ff3f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f2dbd9c0-8738-4a2f-8253-772a62118824" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fdcf073-89a8-4463-9758-0cdebfd28828" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f2dbd9c0-8738-4a2f-8253-772a62118824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_6b845ca2-0fe9-4e03-b8f4-7d3fea544643" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fdcf073-89a8-4463-9758-0cdebfd28828" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_6b845ca2-0fe9-4e03-b8f4-7d3fea544643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_73fffb1c-d324-4333-a379-bfaeca033aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fdcf073-89a8-4463-9758-0cdebfd28828" xlink:to="loc_us-gaap_LiabilitiesCurrent_73fffb1c-d324-4333-a379-bfaeca033aec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_61fd2a4f-9d2e-486d-a146-1b3674e930b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4aa601f2-6bc4-49ad-a9f0-2c106a922d57" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_61fd2a4f-9d2e-486d-a146-1b3674e930b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a05fb96a-12a2-4c96-98d2-2ffe64e21d96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_61fd2a4f-9d2e-486d-a146-1b3674e930b0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_a05fb96a-12a2-4c96-98d2-2ffe64e21d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_36aafc7c-4fb4-41cf-b3f4-ac5007ff8edd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_61fd2a4f-9d2e-486d-a146-1b3674e930b0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_36aafc7c-4fb4-41cf-b3f4-ac5007ff8edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8d4d7b85-4a76-40fe-85dc-addbfb1d47a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_61fd2a4f-9d2e-486d-a146-1b3674e930b0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_8d4d7b85-4a76-40fe-85dc-addbfb1d47a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_b12a6ef9-d45e-44a5-995d-679209312da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_61fd2a4f-9d2e-486d-a146-1b3674e930b0" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_b12a6ef9-d45e-44a5-995d-679209312da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_82ec917d-ac52-47e9-b06f-64bb5ef9c38e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4aa601f2-6bc4-49ad-a9f0-2c106a922d57" xlink:to="loc_us-gaap_Liabilities_82ec917d-ac52-47e9-b06f-64bb5ef9c38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_06594135-1405-4d88-8859-567b8946ce1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4aa601f2-6bc4-49ad-a9f0-2c106a922d57" xlink:to="loc_us-gaap_StockholdersEquityAbstract_06594135-1405-4d88-8859-567b8946ce1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4ae1c85b-a448-4b09-bc34-88ddb7454baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06594135-1405-4d88-8859-567b8946ce1b" xlink:to="loc_us-gaap_PreferredStockValue_4ae1c85b-a448-4b09-bc34-88ddb7454baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dee70c1f-40d0-4d5b-8cf7-c315f661fe98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06594135-1405-4d88-8859-567b8946ce1b" xlink:to="loc_us-gaap_CommonStockValue_dee70c1f-40d0-4d5b-8cf7-c315f661fe98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_55aa360f-237c-4b83-af05-ed429fd41171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06594135-1405-4d88-8859-567b8946ce1b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_55aa360f-237c-4b83-af05-ed429fd41171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_265270a3-78e1-4a6a-a27f-a43959e46fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06594135-1405-4d88-8859-567b8946ce1b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_265270a3-78e1-4a6a-a27f-a43959e46fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1a02d0be-271a-45e9-8198-968e7653a69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_06594135-1405-4d88-8859-567b8946ce1b" xlink:to="loc_us-gaap_StockholdersEquity_1a02d0be-271a-45e9-8198-968e7653a69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad1783d-85da-47b5-861b-b35a7e6f3389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4aa601f2-6bc4-49ad-a9f0-2c106a922d57" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_cad1783d-85da-47b5-861b-b35a7e6f3389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a51f3422-3d72-4230-8413-547213e83cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a51f3422-3d72-4230-8413-547213e83cf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_aee75d5c-61fa-4b00-8137-0c1912d5aa10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_aee75d5c-61fa-4b00-8137-0c1912d5aa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_dfef548f-17af-4243-8864-e5534f136991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:to="loc_us-gaap_PreferredStockSharesIssued_dfef548f-17af-4243-8864-e5534f136991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_9f07a0d6-98a3-4959-a6ef-19feebf148d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_9f07a0d6-98a3-4959-a6ef-19feebf148d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_84c05995-97b7-4356-a7d2-5f970253440e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_84c05995-97b7-4356-a7d2-5f970253440e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3263afb1-317c-471c-aa88-3a5b8581d8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3263afb1-317c-471c-aa88-3a5b8581d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_54c4b935-897d-4f0e-b98b-625ea73bcf70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:to="loc_us-gaap_CommonStockSharesIssued_54c4b935-897d-4f0e-b98b-625ea73bcf70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c72f074-1328-4d2d-996c-25dba9c0006a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_51cfedcc-20f3-45de-ac1e-d346dd18d452" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8c72f074-1328-4d2d-996c-25dba9c0006a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ef1c1218-6368-4436-9397-1abf9c2f4560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a3d1ca72-03b6-4cc9-bbbb-a5b76d81dd26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ef1c1218-6368-4436-9397-1abf9c2f4560" xlink:to="loc_us-gaap_StatementTable_a3d1ca72-03b6-4cc9-bbbb-a5b76d81dd26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9711c225-d22c-4564-80b7-0a9907a8781f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3d1ca72-03b6-4cc9-bbbb-a5b76d81dd26" xlink:to="loc_srt_ProductOrServiceAxis_9711c225-d22c-4564-80b7-0a9907a8781f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6d1dfbba-42b3-4fbc-8fd4-f1a97b326f02" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9711c225-d22c-4564-80b7-0a9907a8781f" xlink:to="loc_srt_ProductsAndServicesDomain_6d1dfbba-42b3-4fbc-8fd4-f1a97b326f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseRevenueMember_59e1ec6c-7fdc-469e-8486-44b41bf1f5c3" xlink:href="sesn-20220331.xsd#sesn_LicenseRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6d1dfbba-42b3-4fbc-8fd4-f1a97b326f02" xlink:to="loc_sesn_LicenseRevenueMember_59e1ec6c-7fdc-469e-8486-44b41bf1f5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a3d1ca72-03b6-4cc9-bbbb-a5b76d81dd26" xlink:to="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f16d5677-7ee0-4156-b841-f75a72f110f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_f16d5677-7ee0-4156-b841-f75a72f110f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49b788b8-8d61-4ae9-919b-c7822f5b27df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49b788b8-8d61-4ae9-919b-c7822f5b27df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_ca4465bf-4dac-4390-99d4-065441e7d8fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_ca4465bf-4dac-4390-99d4-065441e7d8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bf6a47aa-9aaf-4277-9c52-64b29e0a9189" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_bf6a47aa-9aaf-4277-9c52-64b29e0a9189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_80c2fe28-b027-4cb6-b6a2-ae54d2bbb510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_719e482b-8828-4aa9-be2d-e3a4be358493" xlink:to="loc_us-gaap_OperatingExpenses_80c2fe28-b027-4cb6-b6a2-ae54d2bbb510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1aa50e38-531f-474d-a74e-35bc2ece0298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_OperatingIncomeLoss_1aa50e38-531f-474d-a74e-35bc2ece0298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_43082a00-d125-48f0-9292-5432fc09537f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_43082a00-d125-48f0-9292-5432fc09537f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_2e4335c9-ba2f-453d-85ca-17c8640ad54e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_2e4335c9-ba2f-453d-85ca-17c8640ad54e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_72b7799a-0a87-4459-a892-55c178b5ea5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_72b7799a-0a87-4459-a892-55c178b5ea5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4914257-60fe-4a47-9248-6fd36d0dbf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_NetIncomeLoss_f4914257-60fe-4a47-9248-6fd36d0dbf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_21c92714-da43-4e3d-83c7-4928c10e23f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_21c92714-da43-4e3d-83c7-4928c10e23f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e767b11f-581d-48a7-84f2-fe36720634bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_e767b11f-581d-48a7-84f2-fe36720634bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90a51a37-30f9-4cb0-8687-04b6b593ffd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90a51a37-30f9-4cb0-8687-04b6b593ffd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_56b4a41f-cd9a-480b-90f0-562828e80343" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_EarningsPerShareBasic_56b4a41f-cd9a-480b-90f0-562828e80343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_17693c19-1a85-4b74-9b10-d9cea7009f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_17693c19-1a85-4b74-9b10-d9cea7009f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3a9cd15-1a21-476a-94b6-14a3c8e0eac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c3a9cd15-1a21-476a-94b6-14a3c8e0eac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b092773-2da5-4752-aac1-8d752a36e2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3998c0ae-2769-4c30-bbe2-c2da349ef00e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3b092773-2da5-4752-aac1-8d752a36e2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ddb27f18-96c3-4230-bed5-62b57408bd14" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ddb27f18-96c3-4230-bed5-62b57408bd14" xlink:to="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_733447fb-c378-4cc5-906b-88c059efad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_733447fb-c378-4cc5-906b-88c059efad6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_733447fb-c378-4cc5-906b-88c059efad6d" xlink:to="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2df09310-5b82-4874-b1f8-b7c477940d61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:to="loc_us-gaap_CommonStockMember_2df09310-5b82-4874-b1f8-b7c477940d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_8a63ed69-9300-475d-8b60-df74f9bb1dff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_8a63ed69-9300-475d-8b60-df74f9bb1dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_9d2ec6b3-3ff2-43ed-96f9-8cf6c5f43724" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_04f59c08-e0bd-4f1b-9526-9c0bef3a7a3d" xlink:to="loc_us-gaap_RetainedEarningsMember_9d2ec6b3-3ff2-43ed-96f9-8cf6c5f43724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_38e21561-4c93-47fb-a090-ccc6eb3ff209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_38e21561-4c93-47fb-a090-ccc6eb3ff209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb545517-47ed-4fdf-9435-bcde1671811b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_38e21561-4c93-47fb-a090-ccc6eb3ff209" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb545517-47ed-4fdf-9435-bcde1671811b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_dad8f38c-aa38-4b7f-a3a4-af51ac680599" xlink:href="sesn-20220331.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cb545517-47ed-4fdf-9435-bcde1671811b" xlink:to="loc_sesn_ATMFacilityMember_dad8f38c-aa38-4b7f-a3a4-af51ac680599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0d42a915-7af7-4e33-a93f-930294c13719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f694d83f-6efb-48bb-a4b6-77de7bba9931" xlink:to="loc_us-gaap_StatementLineItems_0d42a915-7af7-4e33-a93f-930294c13719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0d42a915-7af7-4e33-a93f-930294c13719" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_16774898-53c7-4e2b-943a-b15cd18e68e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_SharesOutstanding_16774898-53c7-4e2b-943a-b15cd18e68e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d4091ccf-08ab-4782-bc28-4b268c0b8ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockholdersEquity_d4091ccf-08ab-4782-bc28-4b268c0b8ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_877af71e-392b-4d21-82fb-cb5a861b4223" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_NetIncomeLoss_877af71e-392b-4d21-82fb-cb5a861b4223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9dba0d20-0ee7-4865-853c-8f7beb0d0d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_9dba0d20-0ee7-4865-853c-8f7beb0d0d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_625c9e66-e372-422c-af82-e528893bc68a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_625c9e66-e372-422c-af82-e528893bc68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ee02c0e-b85f-4c12-a307-c442cf3ffaff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5ee02c0e-b85f-4c12-a307-c442cf3ffaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1e3529b9-97dc-43a0-bb5c-951016dac93f" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_1e3529b9-97dc-43a0-bb5c-951016dac93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_04bc35b7-f281-4c0c-8938-0c0f64784a75" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_04bc35b7-f281-4c0c-8938-0c0f64784a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f81c14e8-5424-4c1c-8717-2607720d5afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f81c14e8-5424-4c1c-8717-2607720d5afd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0e09e068-3fa1-47b2-9762-1bd3d85d3830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0e09e068-3fa1-47b2-9762-1bd3d85d3830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_96a75709-f50a-47fe-acfc-a9120ce3b8c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_SharesOutstanding_96a75709-f50a-47fe-acfc-a9120ce3b8c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b5c1dc97-2db7-47d0-a1aa-f43f34f742d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_528d8621-8ad5-4e37-b91a-3f72a6ea13cc" xlink:to="loc_us-gaap_StockholdersEquity_b5c1dc97-2db7-47d0-a1aa-f43f34f742d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_2d11930d-4a0d-4740-9f77-bfe277d26525" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_32399836-b6f4-4b66-8ad1-71fbeadc656d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_2d11930d-4a0d-4740-9f77-bfe277d26525" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_32399836-b6f4-4b66-8ad1-71fbeadc656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20220331.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fbddd855-df29-4595-be47-ea0993a95c39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8c2e9ba3-de9c-4cdc-acad-30ef02e0a131" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fbddd855-df29-4595-be47-ea0993a95c39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8c2e9ba3-de9c-4cdc-acad-30ef02e0a131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4a355901-165d-4267-bddb-e59b65561198" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8c2e9ba3-de9c-4cdc-acad-30ef02e0a131" xlink:to="loc_us-gaap_NetIncomeLoss_4a355901-165d-4267-bddb-e59b65561198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f0b47886-b1d0-4ef7-ae0c-f5c4cf492a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8c2e9ba3-de9c-4cdc-acad-30ef02e0a131" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f0b47886-b1d0-4ef7-ae0c-f5c4cf492a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5f1960e4-c398-4b1c-90c1-b326ccfc6205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f0b47886-b1d0-4ef7-ae0c-f5c4cf492a2c" xlink:to="loc_us-gaap_DepreciationAndAmortization_5f1960e4-c398-4b1c-90c1-b326ccfc6205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6e8187c8-bd1e-45da-be5c-6a8bb4bc6c20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f0b47886-b1d0-4ef7-ae0c-f5c4cf492a2c" xlink:to="loc_us-gaap_ShareBasedCompensation_6e8187c8-bd1e-45da-be5c-6a8bb4bc6c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1f730a4c-85c9-432b-a5fe-528534243f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f0b47886-b1d0-4ef7-ae0c-f5c4cf492a2c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1f730a4c-85c9-432b-a5fe-528534243f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f0b47886-b1d0-4ef7-ae0c-f5c4cf492a2c" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b2e06d40-65d0-4bdb-b794-327299804f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b2e06d40-65d0-4bdb-b794-327299804f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7e1ad698-6ec4-4822-a5b6-d18f25e59bab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_7e1ad698-6ec4-4822-a5b6-d18f25e59bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b2a48850-232d-4b7c-880d-16a1ba832a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b2a48850-232d-4b7c-880d-16a1ba832a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_3e5144ef-9e0f-42f7-9dc9-17f99a0b6494" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_3e5144ef-9e0f-42f7-9dc9-17f99a0b6494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c293c264-f7bb-49d1-9d3a-79e28fcf8db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_c293c264-f7bb-49d1-9d3a-79e28fcf8db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ed9ab0a-edae-43b4-aa10-686096405ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6ed9ab0a-edae-43b4-aa10-686096405ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d0e16c47-c7c7-451c-a898-e9fe9892dc03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_d0e16c47-c7c7-451c-a898-e9fe9892dc03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_da253db8-2c82-4482-b7a5-eb470358694f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cebbe272-3a3b-451d-9ad4-6be5c6182491" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_da253db8-2c82-4482-b7a5-eb470358694f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_241c0642-1c83-48c9-bd4c-e7ddbe8b6dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_8c2e9ba3-de9c-4cdc-acad-30ef02e0a131" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_241c0642-1c83-48c9-bd4c-e7ddbe8b6dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_45810ee0-9962-4193-b62a-ffbc7138a850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fbddd855-df29-4595-be47-ea0993a95c39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_45810ee0-9962-4193-b62a-ffbc7138a850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ab9bf21-4c33-401c-823a-c26ce54f00a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_45810ee0-9962-4193-b62a-ffbc7138a850" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ab9bf21-4c33-401c-823a-c26ce54f00a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c35b1f3d-3c17-4a98-8e13-b1aa4bf658ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fbddd855-df29-4595-be47-ea0993a95c39" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c35b1f3d-3c17-4a98-8e13-b1aa4bf658ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4c94b980-22e4-4055-8c19-10f0e42658c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c35b1f3d-3c17-4a98-8e13-b1aa4bf658ad" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4c94b980-22e4-4055-8c19-10f0e42658c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df7e5180-41d8-4c26-bcb7-e765cbe7932e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c35b1f3d-3c17-4a98-8e13-b1aa4bf658ad" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_df7e5180-41d8-4c26-bcb7-e765cbe7932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1e52ef11-4043-4893-a371-b970987eb7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c35b1f3d-3c17-4a98-8e13-b1aa4bf658ad" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1e52ef11-4043-4893-a371-b970987eb7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a98c3a1-8e59-4a2e-a774-944cd70c8dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_c35b1f3d-3c17-4a98-8e13-b1aa4bf658ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a98c3a1-8e59-4a2e-a774-944cd70c8dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1e5a0a46-7035-416a-9425-56e116533d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fbddd855-df29-4595-be47-ea0993a95c39" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1e5a0a46-7035-416a-9425-56e116533d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51e6e5ca-91d2-4381-8fe3-ca4c4d218414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fbddd855-df29-4595-be47-ea0993a95c39" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51e6e5ca-91d2-4381-8fe3-ca4c4d218414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e70f8b29-2380-4b24-8dde-34e2c93a7791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fbddd855-df29-4595-be47-ea0993a95c39" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e70f8b29-2380-4b24-8dde-34e2c93a7791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1512d279-0ae8-48c1-8b15-6efaba4ab722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fbddd855-df29-4595-be47-ea0993a95c39" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1512d279-0ae8-48c1-8b15-6efaba4ab722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_14ae2375-d7bb-4721-9cb2-f6474688d6a7" xlink:href="sesn-20220331.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1512d279-0ae8-48c1-8b15-6efaba4ab722" xlink:to="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_14ae2375-d7bb-4721-9cb2-f6474688d6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="sesn-20220331.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64678272-dd4c-4730-89fd-15e82ee0b378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_602b2a14-b07d-4b53-953a-4677d07583be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_64678272-dd4c-4730-89fd-15e82ee0b378" xlink:to="loc_us-gaap_NatureOfOperations_602b2a14-b07d-4b53-953a-4677d07583be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e62d8aba-e7fa-41b0-a7e8-0e9fa95a92f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e62d8aba-e7fa-41b0-a7e8-0e9fa95a92f3" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_bfa82486-6163-4ace-8b09-01641ca913f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_bfa82486-6163-4ace-8b09-01641ca913f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_196df476-b91f-4906-8229-a5dd7651970d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_bfa82486-6163-4ace-8b09-01641ca913f2" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_196df476-b91f-4906-8229-a5dd7651970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_45c9d0cb-ebf6-4b15-bc20-edfdaf3d9081" xlink:href="sesn-20220331.xsd#sesn_ViventiaBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_196df476-b91f-4906-8229-a5dd7651970d" xlink:to="loc_sesn_ViventiaBioInc.Member_45c9d0cb-ebf6-4b15-bc20-edfdaf3d9081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9f183229-65ec-4f2b-b231-bcf357435727" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_srt_ProductOrServiceAxis_9f183229-65ec-4f2b-b231-bcf357435727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_450a6e70-3343-4371-9e03-2a79d9036bbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9f183229-65ec-4f2b-b231-bcf357435727" xlink:to="loc_srt_ProductsAndServicesDomain_450a6e70-3343-4371-9e03-2a79d9036bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_59c00ee4-de52-434c-b598-0f42672f8933" xlink:href="sesn-20220331.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_450a6e70-3343-4371-9e03-2a79d9036bbd" xlink:to="loc_sesn_ViciniumMember_59c00ee4-de52-434c-b598-0f42672f8933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_038146de-c3b8-47ad-ac8c-cbf29651b1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_038146de-c3b8-47ad-ac8c-cbf29651b1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59a35401-a619-46d9-8ff0-e18c61e79009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_038146de-c3b8-47ad-ac8c-cbf29651b1b9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59a35401-a619-46d9-8ff0-e18c61e79009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_982a5146-4477-4d0a-9fad-435c51b8ae4d" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_59a35401-a619-46d9-8ff0-e18c61e79009" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_982a5146-4477-4d0a-9fad-435c51b8ae4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_298cf1c7-2607-4fd5-ac3b-84878fd69957" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_srt_StatementGeographicalAxis_298cf1c7-2607-4fd5-ac3b-84878fd69957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_298cf1c7-2607-4fd5-ac3b-84878fd69957" xlink:to="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_3e286d7d-8bd7-438d-a8c5-11c3c2d5f9ba" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:to="loc_country_US_3e286d7d-8bd7-438d-a8c5-11c3c2d5f9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_e86638c7-e621-4ac6-9c34-eb7a1b38d9bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:to="loc_srt_EuropeMember_e86638c7-e621-4ac6-9c34-eb7a1b38d9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_f978b206-d58f-4727-8916-864e6377401e" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1f392068-a588-4486-8f65-44ace3056ee9" xlink:to="loc_country_JP_f978b206-d58f-4727-8916-864e6377401e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_6a53a72b-5a5f-4a33-9388-6cc11ce919a1" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfPatients_46195840-9b77-4bf5-9fb2-210d428ba6d5" xlink:href="sesn-20220331.xsd#sesn_NumberOfPatients"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_NumberOfPatients_46195840-9b77-4bf5-9fb2-210d428ba6d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_f12859d8-54b9-4f08-8d64-fdbe5c37cfd3" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_f12859d8-54b9-4f08-8d64-fdbe5c37cfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6c09b668-c70b-44db-98f0-2fe3df46203a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_6c09b668-c70b-44db-98f0-2fe3df46203a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_1fa8b3a6-fccf-4a8f-a7d9-8b598fdf0383" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_1fa8b3a6-fccf-4a8f-a7d9-8b598fdf0383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_3441b41b-9e8f-4e8b-897e-4559e5f156f9" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_3441b41b-9e8f-4e8b-897e-4559e5f156f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_59f6b227-4fcc-46fa-b951-ff4d7735c5eb" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_59f6b227-4fcc-46fa-b951-ff4d7735c5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_202512b0-d2f5-464b-a961-302400915110" xlink:href="sesn-20220331.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_2ae1d323-f034-46ef-9537-e6018e8c1ea1" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_202512b0-d2f5-464b-a961-302400915110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="sesn-20220331.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_920d36f3-a0e1-4cbc-b1fe-f722e28a3409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_9d6b22ca-7b62-460d-9bd4-3977e22576c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_920d36f3-a0e1-4cbc-b1fe-f722e28a3409" xlink:to="loc_us-gaap_BasisOfAccounting_9d6b22ca-7b62-460d-9bd4-3977e22576c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sesn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_27baaaec-6c50-453e-b448-da11f788b0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6f51b35a-cc25-4af5-a13f-ed54e990e893" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_27baaaec-6c50-453e-b448-da11f788b0ac" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_6f51b35a-cc25-4af5-a13f-ed54e990e893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sesn-20220331.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_746f5922-64d6-4ea6-844e-2d32d6b8fdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_60b2abe5-5914-41ab-a687-74a31b510919" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_746f5922-64d6-4ea6-844e-2d32d6b8fdf4" xlink:to="loc_us-gaap_UseOfEstimates_60b2abe5-5914-41ab-a687-74a31b510919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d35bbc1b-3393-4e56-959f-113aa6bbc8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_746f5922-64d6-4ea6-844e-2d32d6b8fdf4" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d35bbc1b-3393-4e56-959f-113aa6bbc8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5795bef0-7a47-48c1-82ca-0d218c28e699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_746f5922-64d6-4ea6-844e-2d32d6b8fdf4" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_5795bef0-7a47-48c1-82ca-0d218c28e699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9530e79b-011f-4391-8ae3-23bfddf8c8df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_746f5922-64d6-4ea6-844e-2d32d6b8fdf4" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9530e79b-011f-4391-8ae3-23bfddf8c8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_63eb0b28-d683-4711-9d42-3443bd1f815a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_746f5922-64d6-4ea6-844e-2d32d6b8fdf4" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_63eb0b28-d683-4711-9d42-3443bd1f815a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="sesn-20220331.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_44ac9273-5b02-423d-966e-e067e40257a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0a6090f1-d449-44da-96c8-00660f632590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_44ac9273-5b02-423d-966e-e067e40257a4" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_0a6090f1-d449-44da-96c8-00660f632590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="sesn-20220331.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_92575cb3-3838-4880-a38f-9c69c7014f02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_f1291fd6-84a7-4792-9bcf-1ab50c5d4785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_92575cb3-3838-4880-a38f-9c69c7014f02" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_f1291fd6-84a7-4792-9bcf-1ab50c5d4785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="sesn-20220331.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_f081af6c-8f27-4266-b4de-9cf5fde2fd93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_41f42a14-ff6d-4256-a468-661c2353866a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f081af6c-8f27-4266-b4de-9cf5fde2fd93" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_41f42a14-ff6d-4256-a468-661c2353866a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_5e23dc3c-e639-4286-9b4d-2eda862f371c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_f081af6c-8f27-4266-b4de-9cf5fde2fd93" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_5e23dc3c-e639-4286-9b4d-2eda862f371c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4dc73863-0ae0-4058-bef3-63d67d344d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4dc73863-0ae0-4058-bef3-63d67d344d4e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_a54e4df1-2582-4edc-9322-6883eab5b1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_a54e4df1-2582-4edc-9322-6883eab5b1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f2926c2a-78a3-45bb-9eaf-62056a40f694" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_a54e4df1-2582-4edc-9322-6883eab5b1e7" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f2926c2a-78a3-45bb-9eaf-62056a40f694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_dbcdc245-3e14-48d9-a93e-c1da6c074b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_f2926c2a-78a3-45bb-9eaf-62056a40f694" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_dbcdc245-3e14-48d9-a93e-c1da6c074b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3ebc2abf-9641-403f-b89e-ed36efcce6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_dbcdc245-3e14-48d9-a93e-c1da6c074b2f" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_3ebc2abf-9641-403f-b89e-ed36efcce6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c33f07e4-3594-42c4-b322-98c3066416d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_dbcdc245-3e14-48d9-a93e-c1da6c074b2f" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c33f07e4-3594-42c4-b322-98c3066416d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_70f0a19d-605c-46ee-8c89-bdae0e81b589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_70f0a19d-605c-46ee-8c89-bdae0e81b589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_10c6a4c3-23b3-4d15-b17f-afce671de20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_70f0a19d-605c-46ee-8c89-bdae0e81b589" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_10c6a4c3-23b3-4d15-b17f-afce671de20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f769f9e6-98ad-4958-ada6-b3c470e8c083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_10c6a4c3-23b3-4d15-b17f-afce671de20f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f769f9e6-98ad-4958-ada6-b3c470e8c083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f204be18-8b68-49b6-994c-d295f7b9a5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f204be18-8b68-49b6-994c-d295f7b9a5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f204be18-8b68-49b6-994c-d295f7b9a5ef" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_741ae2d7-3d45-4a0a-b110-c79bf43d95f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_741ae2d7-3d45-4a0a-b110-c79bf43d95f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_546b2046-1de0-4729-94af-ae9332727b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_546b2046-1de0-4729-94af-ae9332727b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_e569b8f8-e00d-4d80-8cee-962f2951b8e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_85a32089-7fcc-4111-aa6f-6aac91847b90" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_e569b8f8-e00d-4d80-8cee-962f2951b8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da8c5708-3b09-4e6b-ba7f-ff5b5c14e5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e955ecb-3333-47aa-a528-e7effed3e7fa" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da8c5708-3b09-4e6b-ba7f-ff5b5c14e5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bfcc7b4-92ab-457a-adeb-cbd1e34c0212" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da8c5708-3b09-4e6b-ba7f-ff5b5c14e5b4" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bfcc7b4-92ab-457a-adeb-cbd1e34c0212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62f968dc-5929-4e65-9834-35051b5d6375" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0bfcc7b4-92ab-457a-adeb-cbd1e34c0212" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_62f968dc-5929-4e65-9834-35051b5d6375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e359c08b-59c8-4b9e-b002-4eb94949c61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_da8c5708-3b09-4e6b-ba7f-ff5b5c14e5b4" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e359c08b-59c8-4b9e-b002-4eb94949c61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9cfc4413-fd3b-4908-a54b-1261472ea6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_e359c08b-59c8-4b9e-b002-4eb94949c61c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_9cfc4413-fd3b-4908-a54b-1261472ea6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_087b3128-7dae-41fd-be8f-2f3bc42825f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_087b3128-7dae-41fd-be8f-2f3bc42825f4" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_10c96d2e-01bf-4792-840d-923f893bb446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_10c96d2e-01bf-4792-840d-923f893bb446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d05a8087-fbb9-426a-8f41-547cc9b33c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_10c96d2e-01bf-4792-840d-923f893bb446" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d05a8087-fbb9-426a-8f41-547cc9b33c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_15d319df-14c8-4eba-bde0-8ad9d6fce609" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_d05a8087-fbb9-426a-8f41-547cc9b33c7d" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_15d319df-14c8-4eba-bde0-8ad9d6fce609" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d512f20e-6469-47a7-b315-0234b9234bd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:to="loc_srt_RangeAxis_d512f20e-6469-47a7-b315-0234b9234bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3221551b-7624-4d67-8ea3-a5fd918df58f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d512f20e-6469-47a7-b315-0234b9234bd3" xlink:to="loc_srt_RangeMember_3221551b-7624-4d67-8ea3-a5fd918df58f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_083f6639-af63-444e-baa1-fa8211ae649c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3221551b-7624-4d67-8ea3-a5fd918df58f" xlink:to="loc_srt_MinimumMember_083f6639-af63-444e-baa1-fa8211ae649c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_755c164f-93e5-4acc-9981-464e788392fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3221551b-7624-4d67-8ea3-a5fd918df58f" xlink:to="loc_srt_MaximumMember_755c164f-93e5-4acc-9981-464e788392fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_497e1ddf-aa11-4a86-afaf-a4b2cc574152" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8e1fbcb4-da17-4463-ae4f-621d0ba56e82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_8e1fbcb4-da17-4463-ae4f-621d0ba56e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_6609c00f-4951-4421-9191-5c975fc7771b" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_6609c00f-4951-4421-9191-5c975fc7771b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_1c3be62a-1e34-41fc-b0ee-ac0c39bb33f8" xlink:href="sesn-20220331.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_sesn_WeightedAverageCostOfCapital_1c3be62a-1e34-41fc-b0ee-ac0c39bb33f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_277e0517-5f37-4db2-acc4-ebf55a9f21b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_277e0517-5f37-4db2-acc4-ebf55a9f21b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_97ce01c2-847d-4fc1-bad4-71552eb4f584" xlink:href="sesn-20220331.xsd#sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_6c6c7234-15df-4f22-bbef-2b8187fca18b" xlink:to="loc_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage_97ce01c2-847d-4fc1-bad4-71552eb4f584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e63d9df6-70a2-47e4-af97-0ad387a74743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e161fd5c-723f-42d5-897b-f6c1e357ad71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e63d9df6-70a2-47e4-af97-0ad387a74743" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e161fd5c-723f-42d5-897b-f6c1e357ad71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f634c483-a82f-4a8d-a958-565194e7f900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e161fd5c-723f-42d5-897b-f6c1e357ad71" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f634c483-a82f-4a8d-a958-565194e7f900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecf78b98-49e8-4ba8-a9cb-c83747846791" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f634c483-a82f-4a8d-a958-565194e7f900" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecf78b98-49e8-4ba8-a9cb-c83747846791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ff31af0c-bbb8-46e0-860d-b822abe9ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ecf78b98-49e8-4ba8-a9cb-c83747846791" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ff31af0c-bbb8-46e0-860d-b822abe9ef7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_00fd956a-a22d-4ac0-90b8-8c20d776c6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e161fd5c-723f-42d5-897b-f6c1e357ad71" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_00fd956a-a22d-4ac0-90b8-8c20d776c6ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_00fd956a-a22d-4ac0-90b8-8c20d776c6ba" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c9ef8f1a-9c03-42ad-9047-036f277ce4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_c9ef8f1a-9c03-42ad-9047-036f277ce4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_3038322c-3e69-4582-99d9-19ea3aeae6bf" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_3038322c-3e69-4582-99d9-19ea3aeae6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4f97f197-5eaf-4012-99a8-58b8fcdd4fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_96af050f-9969-4b1a-94f9-1b220cac2944" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_4f97f197-5eaf-4012-99a8-58b8fcdd4fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="simple" xlink:href="sesn-20220331.xsd#RECEIVABLES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_4613b0e7-ef33-49f3-aa69-558e3d6de9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_e011b724-cfde-49f0-a3f1-524ff6d73a72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_4613b0e7-ef33-49f3-aa69-558e3d6de9f7" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_e011b724-cfde-49f0-a3f1-524ff6d73a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#RECEIVABLESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_f3aa4365-5941-426a-9972-431f9d7c94cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_f3aa4365-5941-426a-9972-431f9d7c94cc" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_99b6f272-fff9-415f-a10c-737b2230afe8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:to="loc_srt_CounterpartyNameAxis_99b6f272-fff9-415f-a10c-737b2230afe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_158f4950-2d4a-40dc-bdfa-215437f5443d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_99b6f272-fff9-415f-a10c-737b2230afe8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_158f4950-2d4a-40dc-bdfa-215437f5443d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_bf474f61-d7b3-4039-9827-c94291905045" xlink:href="sesn-20220331.xsd#sesn_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_158f4950-2d4a-40dc-bdfa-215437f5443d" xlink:to="loc_sesn_RocheMember_bf474f61-d7b3-4039-9827-c94291905045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d95d2b8f-4fbd-4048-b817-871d1d6367f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d95d2b8f-4fbd-4048-b817-871d1d6367f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_2c9c7b89-1d8a-4dd2-a667-7f4a64174e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_d95d2b8f-4fbd-4048-b817-871d1d6367f3" xlink:to="loc_us-gaap_ReceivableTypeDomain_2c9c7b89-1d8a-4dd2-a667-7f4a64174e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember_b3e927f2-d61a-4d0c-b512-3580fdf0ec69" xlink:href="sesn-20220331.xsd#sesn_GermanVATRecoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_2c9c7b89-1d8a-4dd2-a667-7f4a64174e79" xlink:to="loc_sesn_GermanVATRecoveryMember_b3e927f2-d61a-4d0c-b512-3580fdf0ec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a865fda2-c811-4532-bd1c-fbb8070e71e4" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c36c51ad-c4d6-41df-844b-806471b9f7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c36c51ad-c4d6-41df-844b-806471b9f7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_812a988c-bc4f-44af-b655-180ef6060529" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_812a988c-bc4f-44af-b655-180ef6060529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_bf6253d4-ee04-4610-8261-cd99079e9757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_bf6253d4-ee04-4610-8261-cd99079e9757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_418af630-f91c-486c-9fd4-7cf5ca025e43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_4bf06c46-64b9-492f-90fe-bd71f7a245b9" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_418af630-f91c-486c-9fd4-7cf5ca025e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL" xlink:type="simple" xlink:href="sesn-20220331.xsd#INTANGIBLESANDGOODWILL"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9388113b-d6cb-4558-9687-d26931745f95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d85027d7-f157-4e07-b2bb-a67ba0695dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9388113b-d6cb-4558-9687-d26931745f95" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_d85027d7-f157-4e07-b2bb-a67ba0695dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables" xlink:type="simple" xlink:href="sesn-20220331.xsd#INTANGIBLESANDGOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9f718e4-0af5-447a-aafd-02e4dcf78596" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_504047ce-551a-4082-94bd-68b30a86b95c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e9f718e4-0af5-447a-aafd-02e4dcf78596" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_504047ce-551a-4082-94bd-68b30a86b95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc9c03d6-4d08-40cc-965b-b324d8967879" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cc9c03d6-4d08-40cc-965b-b324d8967879" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_35d7965c-c91a-4c9f-8875-597c1830022c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:to="loc_srt_StatementGeographicalAxis_35d7965c-c91a-4c9f-8875-597c1830022c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6076ae07-dc35-4c37-a1b4-fffd625a8ea1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_35d7965c-c91a-4c9f-8875-597c1830022c" xlink:to="loc_srt_SegmentGeographicalDomain_6076ae07-dc35-4c37-a1b4-fffd625a8ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_2d7f2277-ad4d-481d-9494-afe7fb3ed0a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_6076ae07-dc35-4c37-a1b4-fffd625a8ea1" xlink:to="loc_srt_EuropeMember_2d7f2277-ad4d-481d-9494-afe7fb3ed0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0208f899-ddc8-47dc-85c0-db1a6529d896" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:to="loc_srt_ProductOrServiceAxis_0208f899-ddc8-47dc-85c0-db1a6529d896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a27ac849-e373-42eb-8f7f-b080cf3b5624" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0208f899-ddc8-47dc-85c0-db1a6529d896" xlink:to="loc_srt_ProductsAndServicesDomain_a27ac849-e373-42eb-8f7f-b080cf3b5624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_926bd72f-275d-45ca-ae19-185abeec9808" xlink:href="sesn-20220331.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a27ac849-e373-42eb-8f7f-b080cf3b5624" xlink:to="loc_sesn_ViciniumMember_926bd72f-275d-45ca-ae19-185abeec9808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cedbd2be-6e1f-497d-b432-1041c5712a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cedbd2be-6e1f-497d-b432-1041c5712a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7c44fd3c-2987-45e7-85bb-865234ef2fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_cedbd2be-6e1f-497d-b432-1041c5712a9e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7c44fd3c-2987-45e7-85bb-865234ef2fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_65436c00-7de1-408f-a738-f61ff0fee9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7c44fd3c-2987-45e7-85bb-865234ef2fd2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_65436c00-7de1-408f-a738-f61ff0fee9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5998f3b7-c72d-4c4a-bd47-965c28c78f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_68af0f49-9e4b-44ed-9503-bdd92a572743" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5998f3b7-c72d-4c4a-bd47-965c28c78f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_9de8e7d8-a747-4ddc-a1b1-49a6ca4c424e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_5998f3b7-c72d-4c4a-bd47-965c28c78f7b" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_9de8e7d8-a747-4ddc-a1b1-49a6ca4c424e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#INTANGIBLESANDGOODWILLNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be16b0a2-4197-4e14-a083-467b4633fb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7937a047-0073-4467-95e4-888fe4bd3866" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be16b0a2-4197-4e14-a083-467b4633fb0a" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7937a047-0073-4467-95e4-888fe4bd3866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a4b59038-4360-4883-9137-bf1c69ca933c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7937a047-0073-4467-95e4-888fe4bd3866" xlink:to="loc_srt_RangeAxis_a4b59038-4360-4883-9137-bf1c69ca933c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0822d3c1-a10a-49f9-9c2d-6ee9e7d44437" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a4b59038-4360-4883-9137-bf1c69ca933c" xlink:to="loc_srt_RangeMember_0822d3c1-a10a-49f9-9c2d-6ee9e7d44437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1feaa857-c5f0-410b-8ace-5f28cd6924e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0822d3c1-a10a-49f9-9c2d-6ee9e7d44437" xlink:to="loc_srt_MinimumMember_1feaa857-c5f0-410b-8ace-5f28cd6924e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73ca7241-a966-41a1-af05-69a64d0f399b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0822d3c1-a10a-49f9-9c2d-6ee9e7d44437" xlink:to="loc_srt_MaximumMember_73ca7241-a966-41a1-af05-69a64d0f399b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_7937a047-0073-4467-95e4-888fe4bd3866" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_83172e64-9bb4-4a39-98ea-ab0fab0e7a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_83172e64-9bb4-4a39-98ea-ab0fab0e7a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7edd2ad7-6656-411b-b7bd-84df6153ec80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:to="loc_us-gaap_Goodwill_7edd2ad7-6656-411b-b7bd-84df6153ec80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9736b61f-c585-44f6-a0b6-ceac798f23a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_eaf70f9c-1f65-4ecf-a04b-40defe370663" xlink:to="loc_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount_9736b61f-c585-44f6-a0b6-ceac798f23a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="sesn-20220331.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3e7bd2ad-e6fc-45fb-93c8-04910957998e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_fb39447a-efc6-4740-b8fa-30b1a4c17d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3e7bd2ad-e6fc-45fb-93c8-04910957998e" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_fb39447a-efc6-4740-b8fa-30b1a4c17d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="sesn-20220331.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e6d4f5b5-40bc-4c3a-9514-1b4775b5e5f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b1336523-8656-429f-806d-1fa0565d3768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e6d4f5b5-40bc-4c3a-9514-1b4775b5e5f5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b1336523-8656-429f-806d-1fa0565d3768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ad677abd-6332-4564-99ab-20b51d9b9bca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_22965ae3-db8d-45ae-97c8-c87b407cf99b" xlink:href="sesn-20220331.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ad677abd-6332-4564-99ab-20b51d9b9bca" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_22965ae3-db8d-45ae-97c8-c87b407cf99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ec14bc34-5089-4583-ab1c-392475c9b955" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ad677abd-6332-4564-99ab-20b51d9b9bca" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ec14bc34-5089-4583-ab1c-392475c9b955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_e785a978-415a-47c9-9f39-be03bccabe10" xlink:href="sesn-20220331.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ad677abd-6332-4564-99ab-20b51d9b9bca" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_e785a978-415a-47c9-9f39-be03bccabe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_95790303-dc51-4013-b1ec-7e80e74dff36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ad677abd-6332-4564-99ab-20b51d9b9bca" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_95790303-dc51-4013-b1ec-7e80e74dff36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_95adcc8c-9102-4c3f-959a-b3d132e35d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ad677abd-6332-4564-99ab-20b51d9b9bca" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_95adcc8c-9102-4c3f-959a-b3d132e35d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3e1fac02-b893-45db-95fb-3d77ea840be7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ad677abd-6332-4564-99ab-20b51d9b9bca" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3e1fac02-b893-45db-95fb-3d77ea840be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sesn-20220331.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd39f0a2-a018-4c9c-b808-39d32d671414" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6673d577-ee38-417e-9978-e06e99d0b0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd39f0a2-a018-4c9c-b808-39d32d671414" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6673d577-ee38-417e-9978-e06e99d0b0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_83abdc7d-e431-49a6-944e-89285c80c956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits_ff82f552-0fc4-4657-843a-9745ce57040b" xlink:href="sesn-20220331.xsd#sesn_NumberOfLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_83abdc7d-e431-49a6-944e-89285c80c956" xlink:to="loc_sesn_NumberOfLawsuits_ff82f552-0fc4-4657-843a-9745ce57040b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASES" xlink:type="simple" xlink:href="sesn-20220331.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_68bc4e54-c089-441b-97c7-91d8754d5535" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ee9a21a4-0c19-4b06-8a78-f9a3fc23e422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68bc4e54-c089-441b-97c7-91d8754d5535" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ee9a21a4-0c19-4b06-8a78-f9a3fc23e422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_94b44cf6-9c6e-4706-be46-554423f095f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_94b44cf6-9c6e-4706-be46-554423f095f9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_35ee8136-0b04-4608-a507-bd21c22b6561" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:to="loc_srt_StatementGeographicalAxis_35ee8136-0b04-4608-a507-bd21c22b6561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_35ee8136-0b04-4608-a507-bd21c22b6561" xlink:to="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_4ecb87db-73bf-4dee-a51f-4cc83e38fe54" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:to="loc_country_CA_4ecb87db-73bf-4dee-a51f-4cc83e38fe54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_8a242b89-e763-4ab9-951c-bf7d191a6984" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_MA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:to="loc_stpr_MA_8a242b89-e763-4ab9-951c-bf7d191a6984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_5d4eede6-f591-448f-8f18-366b7b97822b" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_PA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_f5ac1d50-ae31-484a-b1a0-fccd811d80fd" xlink:to="loc_stpr_PA_5d4eede6-f591-448f-8f18-366b7b97822b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:to="loc_srt_RangeAxis_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be20d1dc-dbfb-45dc-8cf5-864cf20900d2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5a61b8df-ba04-4c4a-b07a-ae1b7b8a856d" xlink:to="loc_srt_RangeMember_be20d1dc-dbfb-45dc-8cf5-864cf20900d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_508341f3-38d1-4205-bc4b-9f21a81b34c9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_be20d1dc-dbfb-45dc-8cf5-864cf20900d2" xlink:to="loc_srt_MinimumMember_508341f3-38d1-4205-bc4b-9f21a81b34c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_b6c59d7c-e7dd-4000-aebe-eea90ab8da82" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_be20d1dc-dbfb-45dc-8cf5-864cf20900d2" xlink:to="loc_srt_MaximumMember_b6c59d7c-e7dd-4000-aebe-eea90ab8da82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6a1e3a2f-0c82-4dcc-802a-8f96d58080a5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_4b947061-7ef1-4e50-b175-1936b7cecfdc" xlink:href="sesn-20220331.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_4b947061-7ef1-4e50-b175-1936b7cecfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_222e4baf-35a9-4076-aa98-5d4cc7f3405a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_222e4baf-35a9-4076-aa98-5d4cc7f3405a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_a90cbe58-f1ab-4204-adca-917de6cf608d" xlink:href="sesn-20220331.xsd#sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption_a90cbe58-f1ab-4204-adca-917de6cf608d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9ba6b353-a6d0-4f8f-a6b9-d50c46a62b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_9ba6b353-a6d0-4f8f-a6b9-d50c46a62b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_c31ba912-b5ba-49bf-960b-5124f3016b0e" xlink:href="sesn-20220331.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_c31ba912-b5ba-49bf-960b-5124f3016b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_81fe740f-18e6-4c22-95e5-9717b8f5ffa7" xlink:href="sesn-20220331.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_81fe740f-18e6-4c22-95e5-9717b8f5ffa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_cf9a9db7-dd4d-4cb9-8a41-17338b9e4c49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseCost_cf9a9db7-dd4d-4cb9-8a41-17338b9e4c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_5f423357-d5b9-435b-8523-bb214fcc09fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_5f423357-d5b9-435b-8523-bb214fcc09fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9d0eeb37-6fdc-4dab-8386-7c24734e92a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9d0eeb37-6fdc-4dab-8386-7c24734e92a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c4c3887b-8d9a-40a4-95f9-869c7232f094" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_c4c3887b-8d9a-40a4-95f9-869c7232f094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2cef3739-7cb1-4754-abfd-622b5052656a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2cef3739-7cb1-4754-abfd-622b5052656a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShortTermLeaseRenewalFrequency_1ecebb7f-c8a3-4397-9873-930fddbc2de3" xlink:href="sesn-20220331.xsd#sesn_ShortTermLeaseRenewalFrequency"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_8f57ebdd-6ba2-4078-b3e5-9627353d1b38" xlink:to="loc_sesn_ShortTermLeaseRenewalFrequency_1ecebb7f-c8a3-4397-9873-930fddbc2de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9c3f97ec-86d9-43dc-be89-c45f6cd85cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_77c321c8-a2e0-4ffc-969d-4f0f6d13087d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9c3f97ec-86d9-43dc-be89-c45f6cd85cf9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_77c321c8-a2e0-4ffc-969d-4f0f6d13087d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e7b56a56-94b1-4deb-86b4-483e05a962a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_30e597a4-24ed-40d9-9e71-a1dc2c5bc1de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e7b56a56-94b1-4deb-86b4-483e05a962a3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_30e597a4-24ed-40d9-9e71-a1dc2c5bc1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_59d93725-14d2-4b5a-970b-31655f1aa9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e7b56a56-94b1-4deb-86b4-483e05a962a3" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_59d93725-14d2-4b5a-970b-31655f1aa9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYEquityFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d1f455e6-79d9-40c0-96fe-c7e0cfe3ce18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_ca710ed3-bb8a-474f-9e4c-b0d5e9ad0571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d1f455e6-79d9-40c0-96fe-c7e0cfe3ce18" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_ca710ed3-bb8a-474f-9e4c-b0d5e9ad0571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_36e2aa14-740f-4fba-8808-c877bc5dd30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ca710ed3-bb8a-474f-9e4c-b0d5e9ad0571" xlink:to="loc_us-gaap_CreditFacilityAxis_36e2aa14-740f-4fba-8808-c877bc5dd30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_8d4b863f-69d7-4d48-b451-7ad59837b1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_36e2aa14-740f-4fba-8808-c877bc5dd30d" xlink:to="loc_us-gaap_CreditFacilityDomain_8d4b863f-69d7-4d48-b451-7ad59837b1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_39fe14e9-9563-43a3-b34e-14277f36e209" xlink:href="sesn-20220331.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_8d4b863f-69d7-4d48-b451-7ad59837b1d4" xlink:to="loc_sesn_ATMFacilityMember_39fe14e9-9563-43a3-b34e-14277f36e209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_ca710ed3-bb8a-474f-9e4c-b0d5e9ad0571" xlink:to="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c8d8fb95-930b-4336-98f5-b3246e1ef05f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c8d8fb95-930b-4336-98f5-b3246e1ef05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_578a01ed-04c2-482b-9b68-78ebf0a4c7f8" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_578a01ed-04c2-482b-9b68-78ebf0a4c7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_c70b332d-0b05-4998-a5c9-c6a6d99bfed6" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_c70b332d-0b05-4998-a5c9-c6a6d99bfed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_3081542c-996e-433e-b801-c8ab1d02f488" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_3081542c-996e-433e-b801-c8ab1d02f488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cc961e47-877c-4c90-ac7b-8ff28513e115" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_cc961e47-877c-4c90-ac7b-8ff28513e115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b4f88d0-c10f-42e3-85c9-d61209bc565d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8b4f88d0-c10f-42e3-85c9-d61209bc565d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_045defd8-3912-4a42-9914-da203c1740d5" xlink:href="sesn-20220331.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_045defd8-3912-4a42-9914-da203c1740d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_fc2011da-fbfb-4ccf-a9e7-3b9820e659af" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_449512fc-0e1e-4792-b8a9-13dd9eb0c8a6" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_fc2011da-fbfb-4ccf-a9e7-3b9820e659af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8c408d10-c10a-4319-80b8-f6c041974bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_186e7c0e-a600-4a03-97dd-972bb210233c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c408d10-c10a-4319-80b8-f6c041974bd2" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_186e7c0e-a600-4a03-97dd-972bb210233c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c4d2cc7c-b8eb-41de-9994-3e0e41294b18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c408d10-c10a-4319-80b8-f6c041974bd2" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c4d2cc7c-b8eb-41de-9994-3e0e41294b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_41563b39-ab7c-47c8-b386-e21a140c528d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c408d10-c10a-4319-80b8-f6c041974bd2" xlink:to="loc_us-gaap_PreferredStockSharesIssued_41563b39-ab7c-47c8-b386-e21a140c528d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_2eac9239-c3a5-43f8-8e6b-9b3e2a58ed9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8c408d10-c10a-4319-80b8-f6c041974bd2" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_2eac9239-c3a5-43f8-8e6b-9b3e2a58ed9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_245c4084-d7ac-4f27-b3ee-3be1d02dec4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_7fe5b101-d05e-4471-bbe0-ec6b708fc5f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_245c4084-d7ac-4f27-b3ee-3be1d02dec4e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_7fe5b101-d05e-4471-bbe0-ec6b708fc5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_af848240-ae96-4d2f-9aa8-18a7e5bacc09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7fe5b101-d05e-4471-bbe0-ec6b708fc5f3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_af848240-ae96-4d2f-9aa8-18a7e5bacc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_45cb06b4-6e6f-4b67-9f63-40e73d99ba61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_af848240-ae96-4d2f-9aa8-18a7e5bacc09" xlink:to="loc_us-gaap_EquityComponentDomain_45cb06b4-6e6f-4b67-9f63-40e73d99ba61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f55b7c8d-210c-4bb7-8cb6-f24bb7357d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_45cb06b4-6e6f-4b67-9f63-40e73d99ba61" xlink:to="loc_us-gaap_CommonStockMember_f55b7c8d-210c-4bb7-8cb6-f24bb7357d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_7fe5b101-d05e-4471-bbe0-ec6b708fc5f3" xlink:to="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f47f7c6f-f1db-4913-a0d2-8015d8ecc28b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f47f7c6f-f1db-4913-a0d2-8015d8ecc28b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b862013a-ddef-4a9b-8caf-4f6678aef98d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_us-gaap_CommonStockSharesIssued_b862013a-ddef-4a9b-8caf-4f6678aef98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_eddf6fdb-9507-4468-b4b9-78a3398339b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_eddf6fdb-9507-4468-b4b9-78a3398339b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_43f306d4-bb0b-4e4e-abc7-c7dd0a56945c" xlink:href="sesn-20220331.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7b321892-410b-4433-a8df-57e45fe988e8" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_43f306d4-bb0b-4e4e-abc7-c7dd0a56945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b07cb488-abdf-44ea-b524-5b3aa63f4171" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_004b662f-6a52-43e2-91ca-254badb8652f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b07cb488-abdf-44ea-b524-5b3aa63f4171" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_004b662f-6a52-43e2-91ca-254badb8652f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42b21c6b-ed83-43de-9c1b-979949490579" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_004b662f-6a52-43e2-91ca-254badb8652f" xlink:to="loc_us-gaap_AwardTypeAxis_42b21c6b-ed83-43de-9c1b-979949490579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_42b21c6b-ed83-43de-9c1b-979949490579" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ab54516a-b980-4b5a-825d-8b0ebc950798" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_WarrantMember_ab54516a-b980-4b5a-825d-8b0ebc950798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5edda917-b3b4-4e98-b17a-4fdef455b5c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5edda917-b3b4-4e98-b17a-4fdef455b5c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2ab442c6-b5dc-4856-b705-a22538dce034" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2ab442c6-b5dc-4856-b705-a22538dce034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_94cd8a41-92e9-4e1a-adf0-937b4470b49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_StockCompensationPlanMember_94cd8a41-92e9-4e1a-adf0-937b4470b49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_2eacd275-11ae-4814-8024-49dce9206b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee3509db-3824-40c1-b07b-ced350bd8eeb" xlink:to="loc_us-gaap_EmployeeStockMember_2eacd275-11ae-4814-8024-49dce9206b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_9f8eaac1-577a-46c8-9b46-d21285803334" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_004b662f-6a52-43e2-91ca-254badb8652f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_9f8eaac1-577a-46c8-9b46-d21285803334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7a1cb9fb-b00b-4ef9-b230-35afdb9d9e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9f8eaac1-577a-46c8-9b46-d21285803334" xlink:to="loc_us-gaap_CommonStockSharesIssued_7a1cb9fb-b00b-4ef9-b230-35afdb9d9e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_89d2affc-e6d2-41d7-86f9-11175ba08d85" xlink:href="sesn-20220331.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_9f8eaac1-577a-46c8-9b46-d21285803334" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_89d2affc-e6d2-41d7-86f9-11175ba08d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6e2d46f5-2c74-480e-9233-cd3b188218ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_89d2affc-e6d2-41d7-86f9-11175ba08d85" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6e2d46f5-2c74-480e-9233-cd3b188218ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_3d9db850-586c-4a4b-8dca-b0cee1c8f6ee" xlink:href="sesn-20220331.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_89d2affc-e6d2-41d7-86f9-11175ba08d85" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_3d9db850-586c-4a4b-8dca-b0cee1c8f6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#STOCKHOLDERSEQUITYWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b88020ea-4b6e-4bda-8608-0256adf64105" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_d6142bea-a6ae-4879-a9aa-bcf2648657fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b88020ea-4b6e-4bda-8608-0256adf64105" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_d6142bea-a6ae-4879-a9aa-bcf2648657fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b72b2dc8-f6d4-4b0e-a167-eabef615980a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d6142bea-a6ae-4879-a9aa-bcf2648657fa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b72b2dc8-f6d4-4b0e-a167-eabef615980a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b72b2dc8-f6d4-4b0e-a167-eabef615980a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_af473235-97e4-4c52-8ce9-f067d774dcff" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_af473235-97e4-4c52-8ce9-f067d774dcff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_0a7634ee-67f0-4ccb-9ea5-e3884d7104c1" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_0a7634ee-67f0-4ccb-9ea5-e3884d7104c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_d4dcd44b-044f-444d-939b-66b7c1e673b2" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_d4dcd44b-044f-444d-939b-66b7c1e673b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_462797f2-bd2c-4a58-93ca-42c894ba4837" xlink:href="sesn-20220331.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_ad339099-0a80-4769-9d5f-4646ba99da82" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_462797f2-bd2c-4a58-93ca-42c894ba4837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_fa0d872f-69d5-4d74-ac7c-d9bc8ac16552" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_d6142bea-a6ae-4879-a9aa-bcf2648657fa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_fa0d872f-69d5-4d74-ac7c-d9bc8ac16552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33877f1c-56f3-4635-a395-f4d520501437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_fa0d872f-69d5-4d74-ac7c-d9bc8ac16552" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_33877f1c-56f3-4635-a395-f4d520501437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:href="sesn-20220331.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_fa0d872f-69d5-4d74-ac7c-d9bc8ac16552" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ab5241d2-c6f7-472e-9c60-f8a69a3934fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_ab5241d2-c6f7-472e-9c60-f8a69a3934fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_9877770b-9828-45af-bf69-e8b150c06ac5" xlink:href="sesn-20220331.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_9877770b-9828-45af-bf69-e8b150c06ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_eb018e48-23a7-4e29-87a9-9fba8da08aff" xlink:href="sesn-20220331.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_eb018e48-23a7-4e29-87a9-9fba8da08aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_e4f371c2-dec9-4e03-a42f-d62750d93511" xlink:href="sesn-20220331.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_e4f371c2-dec9-4e03-a42f-d62750d93511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_839aee84-5580-4be8-92bd-1f3deb821df5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_1dacfc63-f69a-4dc6-8780-f2bba6000940" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_839aee84-5580-4be8-92bd-1f3deb821df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="sesn-20220331.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5182a523-0268-4cb5-a07d-6c6b9bcb6be1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_c3e666ac-869c-49d0-aecc-317b175c7d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5182a523-0268-4cb5-a07d-6c6b9bcb6be1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_c3e666ac-869c-49d0-aecc-317b175c7d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="sesn-20220331.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_acf88d8a-2d92-469f-aa8d-b25256658722" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_aa81e9a6-359e-4504-919b-4eca81d600a1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_acf88d8a-2d92-469f-aa8d-b25256658722" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_aa81e9a6-359e-4504-919b-4eca81d600a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cb2db5a4-b137-4e3b-98e2-95f2a8979d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0bb8bbb6-3b0f-4665-a61d-d322219f47c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cb2db5a4-b137-4e3b-98e2-95f2a8979d99" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0bb8bbb6-3b0f-4665-a61d-d322219f47c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0bb8bbb6-3b0f-4665-a61d-d322219f47c6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4d598bb1-08bb-4ab8-bb6e-aa0a407ba84a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8b96ddd5-7e12-4bf1-a82a-4aee97984c04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:to="loc_us-gaap_WarrantMember_8b96ddd5-7e12-4bf1-a82a-4aee97984c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b1061216-427b-472e-834b-8d5dfafac391" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b1061216-427b-472e-834b-8d5dfafac391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_63dad547-c676-420d-a1d6-014b05d4985c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_63dad547-c676-420d-a1d6-014b05d4985c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4e664c53-0809-45b1-9172-2c6e6c224946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70c4c8ce-ab0b-484d-8f2f-57ce745d48fb" xlink:to="loc_us-gaap_PerformanceSharesMember_4e664c53-0809-45b1-9172-2c6e6c224946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b972c99-cb75-482b-b8e1-a0521f931077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0bb8bbb6-3b0f-4665-a61d-d322219f47c6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b972c99-cb75-482b-b8e1-a0521f931077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_132525bf-94cf-41c6-8a4e-4b547a99b6f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_3b972c99-cb75-482b-b8e1-a0521f931077" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_132525bf-94cf-41c6-8a4e-4b547a99b6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82e851af-db7f-4a2c-9af8-74a5c4a37a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_97376b54-2fd9-4e8c-a1da-91f8604f583f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82e851af-db7f-4a2c-9af8-74a5c4a37a20" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_97376b54-2fd9-4e8c-a1da-91f8604f583f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32161484-1e62-4bd2-93c8-d28dd37260cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9ab82ad4-f6d6-4222-b824-e251663f7a29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32161484-1e62-4bd2-93c8-d28dd37260cf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_9ab82ad4-f6d6-4222-b824-e251663f7a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d08cdbbf-10eb-4b46-8e41-99e8b91109b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32161484-1e62-4bd2-93c8-d28dd37260cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d08cdbbf-10eb-4b46-8e41-99e8b91109b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c80e3852-1c17-4ffd-b8ee-f5d869e9fcf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32161484-1e62-4bd2-93c8-d28dd37260cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_c80e3852-1c17-4ffd-b8ee-f5d869e9fcf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ca59fe7e-e632-4249-8251-a6107b40f92b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32161484-1e62-4bd2-93c8-d28dd37260cf" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ca59fe7e-e632-4249-8251-a6107b40f92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bb46948-7aac-4a62-8ef1-436ca745d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0af5478-5f89-4cf2-a289-2ea16f08a833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9bb46948-7aac-4a62-8ef1-436ca745d91a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0af5478-5f89-4cf2-a289-2ea16f08a833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0af5478-5f89-4cf2-a289-2ea16f08a833" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8b624378-61d3-4d20-a18f-99e7cb60ee20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_09ff1c83-bade-44b6-85e9-a1cf56d3ba2b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8b624378-61d3-4d20-a18f-99e7cb60ee20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_74f48e89-d520-4fee-a99d-0617d508e51d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b624378-61d3-4d20-a18f-99e7cb60ee20" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_74f48e89-d520-4fee-a99d-0617d508e51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4f297929-8267-4fc0-a1e1-ae274ca475e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8b624378-61d3-4d20-a18f-99e7cb60ee20" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4f297929-8267-4fc0-a1e1-ae274ca475e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f93c549-02b5-41ca-9f02-3b31bcf4d875" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e0af5478-5f89-4cf2-a289-2ea16f08a833" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f93c549-02b5-41ca-9f02-3b31bcf4d875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ee636a82-5852-46a5-a359-727ec00358d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1f93c549-02b5-41ca-9f02-3b31bcf4d875" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ee636a82-5852-46a5-a359-727ec00358d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e4d3ea9-b83b-4c4a-89ef-3dd8a9268dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6e4d3ea9-b83b-4c4a-89ef-3dd8a9268dc2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_990690e8-f3f4-4475-8909-20398b43122a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_AwardTypeAxis_990690e8-f3f4-4475-8909-20398b43122a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_990690e8-f3f4-4475-8909-20398b43122a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_fbaf9868-f9b3-40f4-8675-68f9a8f62d86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_fbaf9868-f9b3-40f4-8675-68f9a8f62d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_076f8947-162b-4d30-a4d4-0f6c8f055e69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_076f8947-162b-4d30-a4d4-0f6c8f055e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ff74e9d3-787a-4f71-95a3-e6cdd4f77e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e793b72c-b21c-477d-baf5-c006c5f2f40b" xlink:to="loc_us-gaap_PerformanceSharesMember_ff74e9d3-787a-4f71-95a3-e6cdd4f77e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4e60e93e-021f-4f05-a92b-534b949a4a33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_PlanNameAxis_4e60e93e-021f-4f05-a92b-534b949a4a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4e60e93e-021f-4f05-a92b-534b949a4a33" xlink:to="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_222b7508-da5e-4ddb-9eae-62d213925cf8" xlink:href="sesn-20220331.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_222b7508-da5e-4ddb-9eae-62d213925cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_297b0b11-7485-4338-a921-ddeb4c86b3b6" xlink:href="sesn-20220331.xsd#sesn_RetentionProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:to="loc_sesn_RetentionProgramMember_297b0b11-7485-4338-a921-ddeb4c86b3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_e4cde93d-1c4d-4067-9737-9b5036f957ed" xlink:href="sesn-20220331.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d2c7bfda-e672-4fe4-9d7d-09f48807e8f9" xlink:to="loc_sesn_StockIncentivePlan2009Member_e4cde93d-1c4d-4067-9737-9b5036f957ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_a326d8d8-b252-4982-8091-dc9ed9d3e32d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_VestingAxis_a326d8d8-b252-4982-8091-dc9ed9d3e32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_96228ac3-8855-4110-ab6b-672ffdee3881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_a326d8d8-b252-4982-8091-dc9ed9d3e32d" xlink:to="loc_us-gaap_VestingDomain_96228ac3-8855-4110-ab6b-672ffdee3881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fcafd0a6-55c0-4e12-86c6-f7264cbfa1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_96228ac3-8855-4110-ab6b-672ffdee3881" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fcafd0a6-55c0-4e12-86c6-f7264cbfa1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a70d18e3-8745-42ea-ac04-6ca2f310c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_96228ac3-8855-4110-ab6b-672ffdee3881" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_a70d18e3-8745-42ea-ac04-6ca2f310c8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_GranteeStatusAxis_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_5b27b556-d923-40f3-a514-1a63e4a32f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_5bfe3aad-9682-44a1-9ab3-c2da8d30cc12" xlink:to="loc_us-gaap_GranteeStatusDomain_5b27b556-d923-40f3-a514-1a63e4a32f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_292c3702-177a-41c4-a772-6e88d0af7df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_5b27b556-d923-40f3-a514-1a63e4a32f5e" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_292c3702-177a-41c4-a772-6e88d0af7df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe9637c4-e756-4447-9d99-05a827696640" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_70cad0d5-7e7a-4fba-9b78-57f73c1129de" xlink:href="sesn-20220331.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_70cad0d5-7e7a-4fba-9b78-57f73c1129de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_676ea9b7-bea7-471e-bcb4-1d139f41f063" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_676ea9b7-bea7-471e-bcb4-1d139f41f063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c5820dde-ddfd-4f9d-82ea-8991f0b51244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c5820dde-ddfd-4f9d-82ea-8991f0b51244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0620cfbe-b733-4325-9b30-41cf756a2fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0620cfbe-b733-4325-9b30-41cf756a2fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c5554ca5-7d84-4799-91f7-213fee1f5411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c5554ca5-7d84-4799-91f7-213fee1f5411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b0ce8ae6-85c5-4bbe-bf62-7237823edc96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b0ce8ae6-85c5-4bbe-bf62-7237823edc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_09ec93a9-4658-41c9-a80a-5686f59764cf" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_09ec93a9-4658-41c9-a80a-5686f59764cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_5f4bbcff-a6c1-4740-b5f8-e4aa5c874a3e" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_5f4bbcff-a6c1-4740-b5f8-e4aa5c874a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_14d1c0a5-7daf-414a-a4e2-a61b4d715d79" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_14d1c0a5-7daf-414a-a4e2-a61b4d715d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26d2cf2c-22f5-4e6f-af7f-a9044a7d6bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_26d2cf2c-22f5-4e6f-af7f-a9044a7d6bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b75ad3f4-a3ee-401c-ace4-0cccad1e9aca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b75ad3f4-a3ee-401c-ace4-0cccad1e9aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2650a146-f2e3-4b67-b721-fe3a821160ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_2650a146-f2e3-4b67-b721-fe3a821160ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3ce9d634-e87f-4df0-8d35-f0732298c557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3ce9d634-e87f-4df0-8d35-f0732298c557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0678d20a-8f6f-4d2c-9318-0a2722fbc3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0678d20a-8f6f-4d2c-9318-0a2722fbc3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd89656c-1fb4-4980-9570-4b72ee5cf57d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_fd89656c-1fb4-4980-9570-4b72ee5cf57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_457b1d79-248b-4fdb-a315-a3429b247e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_457b1d79-248b-4fdb-a315-a3429b247e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d0ffa043-2cc7-45e8-8990-38a5d16e0bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7baab0c1-6b89-4f2b-9e7e-b213217a23df" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_d0ffa043-2cc7-45e8-8990-38a5d16e0bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bae631a-b8c2-4820-bb55-537e55867f42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_15016b9c-bb8b-4446-9800-928022642c24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bae631a-b8c2-4820-bb55-537e55867f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_15016b9c-bb8b-4446-9800-928022642c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_120ad617-84f0-4988-afff-34d16dc0a027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_15016b9c-bb8b-4446-9800-928022642c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_120ad617-84f0-4988-afff-34d16dc0a027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c067246d-4551-40f9-8649-32776a9db746" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_15016b9c-bb8b-4446-9800-928022642c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c067246d-4551-40f9-8649-32776a9db746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1081c19e-e940-4ec5-aeee-3c740da97f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_15016b9c-bb8b-4446-9800-928022642c24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1081c19e-e940-4ec5-aeee-3c740da97f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_103aae9e-77e6-47d3-9f74-32f8bc5b3190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_15016b9c-bb8b-4446-9800-928022642c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_103aae9e-77e6-47d3-9f74-32f8bc5b3190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1f00cdd0-7c42-4796-a421-2437a1fa66af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_15016b9c-bb8b-4446-9800-928022642c24" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1f00cdd0-7c42-4796-a421-2437a1fa66af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c0a09f4d-7e60-468e-923f-5e37d25f8ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bae631a-b8c2-4820-bb55-537e55867f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c0a09f4d-7e60-468e-923f-5e37d25f8ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ddcc01f-6e9a-45b4-8f3d-ee4ed19aa50a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bae631a-b8c2-4820-bb55-537e55867f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ddcc01f-6e9a-45b4-8f3d-ee4ed19aa50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a734e1c2-205d-4aac-813d-3bbd050d30ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ddcc01f-6e9a-45b4-8f3d-ee4ed19aa50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a734e1c2-205d-4aac-813d-3bbd050d30ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c18ad3a4-4197-4095-8107-ae014604931b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ddcc01f-6e9a-45b4-8f3d-ee4ed19aa50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c18ad3a4-4197-4095-8107-ae014604931b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e8fdab41-f353-415a-872b-c7881cdfefe6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ddcc01f-6e9a-45b4-8f3d-ee4ed19aa50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e8fdab41-f353-415a-872b-c7881cdfefe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17bb6dd9-8c71-484e-9d31-ae09e08b4122" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ddcc01f-6e9a-45b4-8f3d-ee4ed19aa50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17bb6dd9-8c71-484e-9d31-ae09e08b4122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23e75a7e-2f96-4fa3-b637-3725627dda33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6ddcc01f-6e9a-45b4-8f3d-ee4ed19aa50a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_23e75a7e-2f96-4fa3-b637-3725627dda33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dd2f18b2-dfc6-4c34-9637-b9c60ca15bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bae631a-b8c2-4820-bb55-537e55867f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_dd2f18b2-dfc6-4c34-9637-b9c60ca15bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c09d5cde-b5a8-4176-b452-6c5bc003e4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7bae631a-b8c2-4820-bb55-537e55867f42" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c09d5cde-b5a8-4176-b452-6c5bc003e4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fa5c8bbb-81e3-4eeb-a921-8a8077005d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c09d5cde-b5a8-4176-b452-6c5bc003e4de" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fa5c8bbb-81e3-4eeb-a921-8a8077005d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e4cbf4ac-270d-4c6b-9922-a69675b710f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c09d5cde-b5a8-4176-b452-6c5bc003e4de" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e4cbf4ac-270d-4c6b-9922-a69675b710f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6225384b-d9d5-41e6-9e00-6d01fa067dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c09d5cde-b5a8-4176-b452-6c5bc003e4de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6225384b-d9d5-41e6-9e00-6d01fa067dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c5a1dea8-4344-41d1-be44-65476001b0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_c09d5cde-b5a8-4176-b452-6c5bc003e4de" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c5a1dea8-4344-41d1-be44-65476001b0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_402712d5-1c23-4970-9588-36cd280e22db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6120ba60-444c-4689-ae62-00ceca5bad41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_402712d5-1c23-4970-9588-36cd280e22db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6120ba60-444c-4689-ae62-00ceca5bad41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75b2fb8b-4010-484b-8a2a-0f8263ada9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6120ba60-444c-4689-ae62-00ceca5bad41" xlink:to="loc_us-gaap_AwardTypeAxis_75b2fb8b-4010-484b-8a2a-0f8263ada9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00f76505-81b7-4eb5-95ab-67eed22cac13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_75b2fb8b-4010-484b-8a2a-0f8263ada9c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00f76505-81b7-4eb5-95ab-67eed22cac13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ee247f95-7875-45fe-a0d2-0d85bd72e962" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00f76505-81b7-4eb5-95ab-67eed22cac13" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ee247f95-7875-45fe-a0d2-0d85bd72e962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6120ba60-444c-4689-ae62-00ceca5bad41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_30ebb301-3c31-496c-a4d2-45b8c85e5972" xlink:href="sesn-20220331.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_30ebb301-3c31-496c-a4d2-45b8c85e5972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_43ae25fc-b15d-4c83-8878-4dbd9432aa20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_43ae25fc-b15d-4c83-8878-4dbd9432aa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b633960e-9a6e-4738-a4fb-884ac9650d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_b633960e-9a6e-4738-a4fb-884ac9650d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6cdf896b-756e-442c-aa81-48ebe6a1f14a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_6cdf896b-756e-442c-aa81-48ebe6a1f14a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d03e5b2-2b70-4226-9783-2a03ebfb3cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2d03e5b2-2b70-4226-9783-2a03ebfb3cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f9691c0-dce6-43d0-a92c-26f4cc8c005c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4aaef5ae-44e8-4b91-9ab9-a0b59032f2b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3f9691c0-dce6-43d0-a92c-26f4cc8c005c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1ef013d-0afa-48db-b044-6ce764651bc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_690b3b7b-aec7-47fd-8de2-431ee97fcb44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f1ef013d-0afa-48db-b044-6ce764651bc3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_690b3b7b-aec7-47fd-8de2-431ee97fcb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f5f3475b-628a-42e9-b0c1-ba9c7a565c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_690b3b7b-aec7-47fd-8de2-431ee97fcb44" xlink:to="loc_us-gaap_AwardTypeAxis_f5f3475b-628a-42e9-b0c1-ba9c7a565c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239f150c-2e9c-40dc-a767-86cee2377a63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f5f3475b-628a-42e9-b0c1-ba9c7a565c10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239f150c-2e9c-40dc-a767-86cee2377a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6a456949-906a-4180-8abc-370bbe62aa15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239f150c-2e9c-40dc-a767-86cee2377a63" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6a456949-906a-4180-8abc-370bbe62aa15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_44d86810-447a-403e-9816-f22d4d0b4bea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_239f150c-2e9c-40dc-a767-86cee2377a63" xlink:to="loc_us-gaap_PerformanceSharesMember_44d86810-447a-403e-9816-f22d4d0b4bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_396d506a-8349-4ed4-ab19-336452dd9e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_690b3b7b-aec7-47fd-8de2-431ee97fcb44" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_396d506a-8349-4ed4-ab19-336452dd9e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_396d506a-8349-4ed4-ab19-336452dd9e07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2e4cadf-e66f-4c1e-89cd-18cea767b980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b2e4cadf-e66f-4c1e-89cd-18cea767b980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_475fecc3-41b7-4b98-aac6-0856d044d771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_475fecc3-41b7-4b98-aac6-0856d044d771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f45080fe-602c-453a-a54a-3cbeec5c5c70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea06e7b1-1763-44ce-95d0-cc9832b6cbee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f45080fe-602c-453a-a54a-3cbeec5c5c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_396d506a-8349-4ed4-ab19-336452dd9e07" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6249c90-e4d5-4ff0-9851-ed2049810761" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c6249c90-e4d5-4ff0-9851-ed2049810761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f11186f7-be38-4e9c-b302-ee3ba20a461a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f11186f7-be38-4e9c-b302-ee3ba20a461a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7d41757-eca8-4317-8259-7be76c43752e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_480259a2-e985-42d7-9458-f49ab9bcc73c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b7d41757-eca8-4317-8259-7be76c43752e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="sesn-20220331.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_948b12a6-3a33-4607-9cf4-a0e386214a40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_b7ffddbc-0ce8-405a-8b36-f71290b7cd63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_948b12a6-3a33-4607-9cf4-a0e386214a40" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_b7ffddbc-0ce8-405a-8b36-f71290b7cd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_56e5c8c3-28c1-4b76-a5e4-c83136e0d082" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_56e5c8c3-28c1-4b76-a5e4-c83136e0d082" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0f3e305f-05a0-483e-8608-8f3c72434222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:to="loc_us-gaap_PlanNameAxis_0f3e305f-05a0-483e-8608-8f3c72434222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4702a002-872f-40f8-b026-ddc62632ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0f3e305f-05a0-483e-8608-8f3c72434222" xlink:to="loc_us-gaap_PlanNameDomain_4702a002-872f-40f8-b026-ddc62632ee3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_1bbe1782-73b7-4a6d-9416-a1258702335b" xlink:href="sesn-20220331.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_4702a002-872f-40f8-b026-ddc62632ee3f" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_1bbe1782-73b7-4a6d-9416-a1258702335b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_30cd8114-d8a7-498e-8166-960c061f6ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_30cd8114-d8a7-498e-8166-960c061f6ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_da4e90dd-bcde-46fc-a048-0db8baa7bacc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_30cd8114-d8a7-498e-8166-960c061f6ec9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_da4e90dd-bcde-46fc-a048-0db8baa7bacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_36c06911-b836-4928-b724-4c2504c7815a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_da4e90dd-bcde-46fc-a048-0db8baa7bacc" xlink:to="loc_us-gaap_DomesticPlanMember_36c06911-b836-4928-b724-4c2504c7815a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2966b1bb-2d44-4762-9560-6aa2e6770e92" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_36c06911-b836-4928-b724-4c2504c7815a" xlink:to="loc_country_US_2966b1bb-2d44-4762-9560-6aa2e6770e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_f06cb8f6-6b1c-48dc-a98c-32ad83fc5339" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_da4e90dd-bcde-46fc-a048-0db8baa7bacc" xlink:to="loc_us-gaap_ForeignPlanMember_f06cb8f6-6b1c-48dc-a98c-32ad83fc5339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9653a500-7e6a-4598-b1fd-cffd7c7e45ef" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1924a868-c87f-42ce-aedf-ae1834ab701b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1924a868-c87f-42ce-aedf-ae1834ab701b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d075f232-151d-4113-9dcc-4e2c721dc7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d075f232-151d-4113-9dcc-4e2c721dc7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f50a4c5f-b73d-43e7-9e35-d546889fa95b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f50a4c5f-b73d-43e7-9e35-d546889fa95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f091a491-23ea-49d7-b8d4-d097309d9ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f091a491-23ea-49d7-b8d4-d097309d9ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2d77e587-3849-4109-bd92-86caff119667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_2d77e587-3849-4109-bd92-86caff119667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_bae820a2-647b-43c2-b653-1328858891b0" xlink:href="sesn-20220331.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_bae820a2-647b-43c2-b653-1328858891b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6cd51157-b0f0-4c50-81b7-4a79c9ac206f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_e4f2470f-c02e-4809-9bb9-012d5ea26bf2" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_6cd51157-b0f0-4c50-81b7-4a79c9ac206f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="simple" xlink:href="sesn-20220331.xsd#LICENSEAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c5b427c6-59c9-4576-8027-d4fe329b7748" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock_dc7e7051-86f1-4292-9e24-0d5b4040f37f" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c5b427c6-59c9-4576-8027-d4fe329b7748" xlink:to="loc_sesn_LicenseAgreementTextBlock_dc7e7051-86f1-4292-9e24-0d5b4040f37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#LICENSEAGREEMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_529e8c32-56db-47c6-94fb-d9a6a967fb43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:href="sesn-20220331.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_529e8c32-56db-47c6-94fb-d9a6a967fb43" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_srt_CounterpartyNameAxis_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3c8d2009-4e1e-42c8-9d6c-c2539d6b5715" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_a6fab9b4-7817-40f2-b6cd-ac9e7d54716a" xlink:href="sesn-20220331.xsd#sesn_UniversityOfZurichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_UniversityOfZurichMember_a6fab9b4-7817-40f2-b6cd-ac9e7d54716a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_4c4b68e5-67a8-4dd6-a160-a98a630435de" xlink:href="sesn-20220331.xsd#sesn_MicrometAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_MicrometAGMember_4c4b68e5-67a8-4dd6-a160-a98a630435de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_cce5f9f3-59a5-4682-b423-1e2afc36c9d2" xlink:href="sesn-20220331.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_XOMAIrelandLimitedMember_cce5f9f3-59a5-4682-b423-1e2afc36c9d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_e3e9d082-1931-45a5-a2e1-a1ee23afb3c8" xlink:href="sesn-20220331.xsd#sesn_RocheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_RocheMember_e3e9d082-1931-45a5-a2e1-a1ee23afb3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_2eb9c153-743f-4ea4-9315-a7f30a667023" xlink:href="sesn-20220331.xsd#sesn_MENALicenseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_MENALicenseAgreementMember_2eb9c153-743f-4ea4-9315-a7f30a667023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_ef378123-de61-45fd-b59e-ec3c1e7d1787" xlink:href="sesn-20220331.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_ef378123-de61-45fd-b59e-ec3c1e7d1787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_5ceb482e-3281-4118-81f8-985c45be43b7" xlink:href="sesn-20220331.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dc6ec499-0450-47c0-ba61-eef9d433fde8" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_5ceb482e-3281-4118-81f8-985c45be43b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0189a6a6-f8d5-4497-90a3-a0ee0e3e6fe2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_5beac7e9-c093-45a1-a7ac-3cdc0dd119d0" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_5beac7e9-c093-45a1-a7ac-3cdc0dd119d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_54c98741-755b-4acc-bd2f-6df11ca59033" xlink:href="sesn-20220331.xsd#sesn_FirstIndicationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_FirstIndicationMember_54c98741-755b-4acc-bd2f-6df11ca59033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_a892c673-a44b-436b-a8a7-ae4636a129ed" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_a892c673-a44b-436b-a8a7-ae4636a129ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_d0911f21-ebe1-4ec7-8eb5-998498ddb102" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_d0911f21-ebe1-4ec7-8eb5-998498ddb102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_f2194803-a6a6-4109-80b0-c048d6e807ef" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_f2194803-a6a6-4109-80b0-c048d6e807ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_db635ceb-4c14-4869-aafa-dac65d457d0a" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_db635ceb-4c14-4869-aafa-dac65d457d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_27836362-dd7d-4255-a189-8ead34927879" xlink:href="sesn-20220331.xsd#sesn_SecondIndicationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b1b91452-332f-41ca-b37d-540b72c03b43" xlink:to="loc_sesn_SecondIndicationMember_27836362-dd7d-4255-a189-8ead34927879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7674e4e7-e7e4-482e-8686-933034c6877b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_srt_ProductOrServiceAxis_7674e4e7-e7e4-482e-8686-933034c6877b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b79a63c7-41eb-4dd2-84b2-e8aca33d9fa2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7674e4e7-e7e4-482e-8686-933034c6877b" xlink:to="loc_srt_ProductsAndServicesDomain_b79a63c7-41eb-4dd2-84b2-e8aca33d9fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_56a58c2a-a2e9-425e-a4c2-c07246d8a35c" xlink:href="sesn-20220331.xsd#sesn_EBI031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b79a63c7-41eb-4dd2-84b2-e8aca33d9fa2" xlink:to="loc_sesn_EBI031Member_56a58c2a-a2e9-425e-a4c2-c07246d8a35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IL6Member_01c94959-6c75-4875-a11b-100b7859d205" xlink:href="sesn-20220331.xsd#sesn_IL6Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b79a63c7-41eb-4dd2-84b2-e8aca33d9fa2" xlink:to="loc_sesn_IL6Member_01c94959-6c75-4875-a11b-100b7859d205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_3fad1941-47bb-4127-8c98-e8e8922ae931" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_srt_RangeAxis_3fad1941-47bb-4127-8c98-e8e8922ae931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2326b3ff-1747-4a2b-a2ed-cd4eeb7e7bf9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_3fad1941-47bb-4127-8c98-e8e8922ae931" xlink:to="loc_srt_RangeMember_2326b3ff-1747-4a2b-a2ed-cd4eeb7e7bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d87c5148-4e3c-4504-b305-66d22da0f9bf" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2326b3ff-1747-4a2b-a2ed-cd4eeb7e7bf9" xlink:to="loc_srt_MinimumMember_d87c5148-4e3c-4504-b305-66d22da0f9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_18988a81-d80a-4ba7-94b6-919770db21df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2326b3ff-1747-4a2b-a2ed-cd4eeb7e7bf9" xlink:to="loc_srt_MaximumMember_18988a81-d80a-4ba7-94b6-919770db21df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f7d4e831-827a-4ae7-b573-e187851e5a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f7d4e831-827a-4ae7-b573-e187851e5a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_183ed7fc-39a4-4635-a4a0-239645121f33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f7d4e831-827a-4ae7-b573-e187851e5a7f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_183ed7fc-39a4-4635-a4a0-239645121f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_1f41c0ef-35d0-46f5-831a-95b225955282" xlink:href="sesn-20220331.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_183ed7fc-39a4-4635-a4a0-239645121f33" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_1f41c0ef-35d0-46f5-831a-95b225955282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_97cc54b8-3604-4e78-8a13-1237f0e588ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_97cc54b8-3604-4e78-8a13-1237f0e588ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9b245af-4c58-49a8-b0fd-189e456163e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_97cc54b8-3604-4e78-8a13-1237f0e588ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9b245af-4c58-49a8-b0fd-189e456163e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_77388e8c-739f-479e-b2ab-271a5faaa49a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f9b245af-4c58-49a8-b0fd-189e456163e3" xlink:to="loc_us-gaap_LicensingAgreementsMember_77388e8c-739f-479e-b2ab-271a5faaa49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_654552c2-5556-4009-b0a7-caa424660c64" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_srt_StatementGeographicalAxis_654552c2-5556-4009-b0a7-caa424660c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32b9046c-03fc-47ba-95c0-4af69efe4ba5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_654552c2-5556-4009-b0a7-caa424660c64" xlink:to="loc_srt_SegmentGeographicalDomain_32b9046c-03fc-47ba-95c0-4af69efe4ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_77948bc5-0cff-40b4-bfd9-238def75e5a2" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_TR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_32b9046c-03fc-47ba-95c0-4af69efe4ba5" xlink:to="loc_country_TR_77948bc5-0cff-40b4-bfd9-238def75e5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:href="sesn-20220331.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_b538422c-801e-4d90-9c45-b029c08b1508" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_63959694-82f2-4b36-9fcc-08311a0e048f" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_63959694-82f2-4b36-9fcc-08311a0e048f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_fe6515de-68c3-491c-a948-0e03e2c90dc7" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_fe6515de-68c3-491c-a948-0e03e2c90dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_5f0c6c7c-ddc7-4911-ae72-5bc0b060dcf0" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_5f0c6c7c-ddc7-4911-ae72-5bc0b060dcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_ec894599-d858-4ce3-8511-2fd1dd648310" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_ec894599-d858-4ce3-8511-2fd1dd648310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_a73cb02a-9a36-4266-aaed-3ae555758996" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_a73cb02a-9a36-4266-aaed-3ae555758996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_c58f25a3-5ea8-41c3-9dcc-a1a28706bd0e" xlink:href="sesn-20220331.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_c58f25a3-5ea8-41c3-9dcc-a1a28706bd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_ec0ef979-4d81-4fdf-9d49-e58f14ffd00f" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_ec0ef979-4d81-4fdf-9d49-e58f14ffd00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_3d0cb94c-8b12-4a5b-9cfd-e2594a2f64f1" xlink:href="sesn-20220331.xsd#sesn_LicenseMaintenanceFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseMaintenanceFees_3d0cb94c-8b12-4a5b-9cfd-e2594a2f64f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_783e9f79-d172-4ebd-b029-6e41b88e41f1" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_783e9f79-d172-4ebd-b029-6e41b88e41f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_1abd896e-83cd-418f-a48c-b0b20f7a7291" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_1abd896e-83cd-418f-a48c-b0b20f7a7291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_9172a759-efd8-4275-b05f-59bcabcaa674" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_9172a759-efd8-4275-b05f-59bcabcaa674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_223a0685-e348-428b-b1d9-8bf9da82ab42" xlink:href="sesn-20220331.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_223a0685-e348-428b-b1d9-8bf9da82ab42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_38577353-6bde-424b-9a4c-de96825cedb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_38577353-6bde-424b-9a4c-de96825cedb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_9842ebe4-d61a-4332-9834-8e90519e80e8" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_9842ebe4-d61a-4332-9834-8e90519e80e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_850bf4a5-5ffe-4076-bc81-dd240c89841c" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_850bf4a5-5ffe-4076-bc81-dd240c89841c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_be5a8815-15e3-4770-968d-7a2cd25d3495" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_be5a8815-15e3-4770-968d-7a2cd25d3495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_6c816726-cb89-43ad-ac8a-d3f1945d4b1d" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_6c816726-cb89-43ad-ac8a-d3f1945d4b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_a59ed5d2-87c5-49d7-aa68-a876bd5d3e60" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_a59ed5d2-87c5-49d7-aa68-a876bd5d3e60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_16b3e6f2-6dd5-458e-b73f-aaa18a0cedea" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_16b3e6f2-6dd5-458e-b73f-aaa18a0cedea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_144cba25-36f7-4fb5-a1d7-246f9b1e3870" xlink:href="sesn-20220331.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_144cba25-36f7-4fb5-a1d7-246f9b1e3870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9d79d091-90b2-4d1f-91dc-543e0c0b770b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9d79d091-90b2-4d1f-91dc-543e0c0b770b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_4383ffff-2859-49dd-b0e7-b8f689a9e646" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_4383ffff-2859-49dd-b0e7-b8f689a9e646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_8bf03a54-d72f-4d4d-b582-38d943e84ee0" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_8bf03a54-d72f-4d4d-b582-38d943e84ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod_f17c03cc-45bf-46c3-87c9-742ea8df3d33" xlink:href="sesn-20220331.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_CollaborativeArrangementRoyaltyPeriod_f17c03cc-45bf-46c3-87c9-742ea8df3d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_a9ea9273-51c1-48c8-8409-2b6cee3665b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_a9ea9273-51c1-48c8-8409-2b6cee3665b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_0390f167-b7b8-45c4-a02b-0729c495b69c" xlink:href="sesn-20220331.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_0390f167-b7b8-45c4-a02b-0729c495b69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_66c03ce8-b179-48c2-a65c-503868bc1743" xlink:href="sesn-20220331.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_7686b5f3-f312-4053-b579-19a8e4112936" xlink:to="loc_sesn_RoyaltyRevenuePercentage_66c03ce8-b179-48c2-a65c-503868bc1743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="simple" xlink:href="sesn-20220331.xsd#RESTRUCTURINGANDRELATEDACTIVITIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_495252f2-2442-40f6-9e2a-31514229b432" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f7ad64e6-f2e6-4f4c-a721-21c8f3b6e299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_495252f2-2442-40f6-9e2a-31514229b432" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f7ad64e6-f2e6-4f4c-a721-21c8f3b6e299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="simple" xlink:href="sesn-20220331.xsd#RESTRUCTURINGANDRELATEDACTIVITIESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4d8fb7b8-25d1-4591-9ffd-45dbc9ca095c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_a1f557ee-b8fb-4b10-ab91-2cfe029ff28a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4d8fb7b8-25d1-4591-9ffd-45dbc9ca095c" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_a1f557ee-b8fb-4b10-ab91-2cfe029ff28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_367da828-85b9-4187-a483-ab1f29ce1018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_33198e26-61d2-4595-b8c8-e7c369dc757e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_367da828-85b9-4187-a483-ab1f29ce1018" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_33198e26-61d2-4595-b8c8-e7c369dc757e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_92acb27c-dc93-49ee-94f2-7575a48a5a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_367da828-85b9-4187-a483-ab1f29ce1018" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_92acb27c-dc93-49ee-94f2-7575a48a5a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="simple" xlink:href="sesn-20220331.xsd#RESTRUCTURINGANDRELATEDACTIVITIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c2ae6332-eed0-44f7-9458-49c5c2ca2e53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_d9997047-4535-493a-b4f1-94bad9d284f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_c2ae6332-eed0-44f7-9458-49c5c2ca2e53" xlink:to="loc_us-gaap_RestructuringReserveRollForward_d9997047-4535-493a-b4f1-94bad9d284f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_e652eb3d-5c03-4191-a6be-c89df53705c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9997047-4535-493a-b4f1-94bad9d284f9" xlink:to="loc_us-gaap_RestructuringReserve_e652eb3d-5c03-4191-a6be-c89df53705c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_364bd200-3ee5-469c-9991-ee77a7e24ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9997047-4535-493a-b4f1-94bad9d284f9" xlink:to="loc_us-gaap_PaymentsForRestructuring_364bd200-3ee5-469c-9991-ee77a7e24ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_15716bb4-580c-4cde-bf06-84e4ccff33a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_d9997047-4535-493a-b4f1-94bad9d284f9" xlink:to="loc_us-gaap_RestructuringReserve_15716bb4-580c-4cde-bf06-84e4ccff33a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sesn-20220331.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f67c7bdb-8e70-4af7-92c3-dcd2a293f036" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_330ef964-de88-4411-8366-dd621100f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f67c7bdb-8e70-4af7-92c3-dcd2a293f036" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_330ef964-de88-4411-8366-dd621100f17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232823816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sesen Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">444-8550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SESN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023233116968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 169,790<span></span>
</td>
<td class="nump">$ 162,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">1,011<span></span>
</td>
<td class="nump">21,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,795<span></span>
</td>
<td class="nump">18,476<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">180,637<span></span>
</td>
<td class="nump">205,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">14,700<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">13,064<span></span>
</td>
<td class="nump">13,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">17,301<span></span>
</td>
<td class="nump">7,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">45,203<span></span>
</td>
<td class="nump">35,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">225,840<span></span>
</td>
<td class="nump">240,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,278<span></span>
</td>
<td class="nump">8,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,474<span></span>
</td>
<td class="nump">11,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">39,100<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,969<span></span>
</td>
<td class="nump">3,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">44,569<span></span>
</td>
<td class="nump">57,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">53,043<span></span>
</td>
<td class="nump">69,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at March&#160;31, 2022 and December&#160;31, 2021; no shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 400,000,000 shares authorized at March&#160;31, 2022 and December&#160;31, 2021; 199,463,645 shares issued and outstanding at March&#160;31, 2022 and December&#160;31, 2021</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">489,662<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(317,064)<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">172,797<span></span>
</td>
<td class="nump">171,710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 225,840<span></span>
</td>
<td class="nump">$ 240,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232770760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 03, 2021</div></th>
<th class="th"><div>May 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023237831848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,760<span></span>
</td>
<td class="nump">6,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,975<span></span>
</td>
<td class="nump">5,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(12,900)<span></span>
</td>
<td class="nump">48,160<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">835<span></span>
</td>
<td class="nump">59,531<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(835)<span></span>
</td>
<td class="num">(55,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">28<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss Before Taxes</a></td>
<td class="num">(807)<span></span>
</td>
<td class="num">(55,224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss After Taxes</a></td>
<td class="num">(807)<span></span>
</td>
<td class="num">(55,512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss After Taxes</a></td>
<td class="num">(807)<span></span>
</td>
<td class="num">(55,512)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - basic</a></td>
<td class="num">(807)<span></span>
</td>
<td class="num">(55,512)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders - diluted</a></td>
<td class="num">$ (807)<span></span>
</td>
<td class="num">$ (55,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="nump">$ (0.00)<span></span>
</td>
<td class="num">$ (0.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">157,033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">157,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_LicenseRevenueMember', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234841032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM Facility</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (9,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (315,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercises of common stock warrants</a></td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under ATM Offering, net of issuance costs of $2.2 million (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,645,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under ATM Offering, net of issuance costs of $2.2 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,978,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">9,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(371,433)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">171,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">$ 1,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 172,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 489,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (317,064)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Exercise Of Warrants, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234025336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232879288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (807)<span></span>
</td>
<td class="num">$ (55,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,894<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(12,900)<span></span>
</td>
<td class="nump">48,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable (net)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="num">(2,886)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,682<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Long term prepaid expenses</a></td>
<td class="num">(10,109)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(2,187)<span></span>
</td>
<td class="num">(1,098)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(908)<span></span>
</td>
<td class="num">(468)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided (used in) operating activities</a></td>
<td class="nump">7,154<span></span>
</td>
<td class="num">(18,475)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">7,154<span></span>
</td>
<td class="nump">54,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of period</a></td>
<td class="nump">162,656<span></span>
</td>
<td class="nump">55,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end of period</a></td>
<td class="nump">169,810<span></span>
</td>
<td class="nump">109,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Related To Adoption of Accounting Standard</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234186776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). The Company is in the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bacillus Calmette-Gu&#233;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#8220;CMC&#8221;) issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares.</span></div>In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of March&#160;31, 2022, none of these individuals are active employees or members of the Company's board of directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234178696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234173992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234067496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023237737336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of March&#160;31, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the quarter ended March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 9.0% to 9.7% as of March&#160;31, 2022 and 8.0% to 9.3% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the three months ended March 31, 2022. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the quarter ended March&#160;31, 2022, (in thousands).</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#8217;s weighted-average cost of capital (&#8220;WACC&#8221;), which has fluctuated from 9.3% as of December&#160;31, 2021 to 9.0% as of March&#160;31, 2022. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.0% as of December&#160;31, 2021 to 9.7% as of March&#160;31, 2022. The decrease in the fair value of contingent consideration of $12.9 million for the three months ended March 31, 2022 was driven by changes in underlying assumptions used to develop the revenue projections.</span></div>In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company's proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company also learned during the meeting that the FDA is trending away from accepting single arm trials across therapeutic areas, including NMIBC, and has a strong preference for randomized controlled trials. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Incorporating the FDA feedback from the Type C meeting, plans for further discussions with the FDA prior to initiation of the additional Phase 3 clinical trial, as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company&#8217;s revenue projection models are timing of potential commercial product launch, probabilities of clinical and regulatory success, and market share. The Company anticipates further delays in the start of commercialization due to the likelihood of the requirement to conduct a randomized controlled trial which will require more patients to be enrolled, lengthen the duration of the study, and increase study costs. The company is also projecting lower estimated market share as a result of recent clinical and regulatory progress made by competitors. The Company has assessed a commercialization timeline assumption and applied a probability to each outcome based on management&#8217;s best estimate. The Company continues to assume a POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234077928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">RECEIVABLES</a></td>
<td class="text">RECEIVABLES <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of March&#160;31, 2022 is $1.0&#160;million compared to $21.0&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $20.0&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of March&#160;31, 2022 is $1.0&#160;million compared to $3.5&#160;million as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The decrease is driven primarily by the receipt of $1.8&#160;million for German VAT recovery related to drug substance sent to Baxter in 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023237735896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLES AND GOODWILL</a></td>
<td class="text">INTANGIBLES AND GOODWILL<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's condensed consolidated balance sheet are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#8217;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there is more clarity from the FDA on next steps for Vicineum in the United States. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current range of commercialization timelines and POS assumptions. This was primarily due to the fact that the EU asset is burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company's proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company also learned during the meeting that the FDA is trending away from accepting single arm trials across therapeutic areas, including NMIBC, and has a strong preference for randomized controlled trials. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Based on the outcome of the Type C meeting as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of the indefinite-lived intangible asset. Management updated the revenue forecast models based on further launch delays in both US and OUS regions as well as slightly lower market share. The Company anticipates further delays in the start of commercialization due to the likelihood of the requirement to conduct a randomized controlled trial which will require more patients to be enrolled, lengthen the duration of the study, and increase study costs. The company is also projecting lower estimated market share as a result of recent clinical and regulatory progress made by competitors. Accordingly, the Company identified this as a potential impairment indicator and performed an interim quantitative impairment assessment during the first quarter of 2022. The Company concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of March&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's condensed consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $13.1&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. Based on the outcome of the Type C meeting as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both US and OUS regions as well as slightly lower market share. Accordingly, the Company identified these changes to the revenue forecast, as well as the decline in the Company&#8217;s stock price and market capitalization during the first quarter of 2022, as potential impairment indicators and performed a quantitative impairment analysis during the first quarter of 2022, in advance of the Company's typical annual assessment date of October 1. The Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of March&#160;31, 2022, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately 29%.</span></div>The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#8217;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in the Company's current development profile (ranging from 45% to 55% globally) and underlying discount rates also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of NMIBC. Further reductions to probabilities of success, decrease in market share, additional development and commercial launch delays, increases in underlying discount rates, or any decision to undertake any strategic alternative as a result of the review process that the Company has initiated, have the potential to result in future goodwill impairment.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234048456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234021256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. The court has not yet ruled on the motion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as nominal defendant. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. Defendants intend to seek a similar stay of the state court derivative litigation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023238043416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for operating leases under ASC Topic 842,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Leases. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022, with a right to extend the lease for one subsequent three-year term. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,500 at exchange rates in effect on March&#160;31, 2022). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,500 at exchange rates in effect on March&#160;31, 2022). Operating lease cost under this lease, including the related operating costs, were $0.1&#160;million for the three months ended March&#160;31, 2022 and March&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_70e2c78d-7000-4550-b39c-7708486d9514"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_a608af25-a8c3-43f1-bc13-bde655007b13">other assets</span></span> on the Company's condensed consolidated balance sheets. The right of use asset total was $0.1&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_257c3c35-2b5f-4801-99d1-da6db072ebc5"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_870e15ab-96b9-4644-93c8-e07c8cee8f3a">other current liabilities</span></span> and the long-term lease liability is recorded in other liabilities on the Company&#8217;s condensed consolidated balance sheets. The short-term lease liability was $0.1&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. There was no long-term operating lease liability as of March&#160;31, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIxOTkwMjMyNTg5Mjc_107f62f1-7e63-49b3-8b18-5cce5a5aebdc">six</span> to twelve months and currently extend through June 2023 and May 2023, respectively. The minimum monthly rent for these office spaces is $2,100 and $18,400, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234187608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS' EQUITY <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time through Jefferies (the &#8220;ATM Offering&#8221;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement of which $97.8&#160;million of common stock remain available for future issuance as of March&#160;31, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the three months ended March 31, 2022. The Company raised $72.6&#160;million of net proceeds from the sale of 30.6&#160;million shares </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of common stock at a weighted-average price of $2.44 per share during the three months ended March 31, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of March&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">199&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">227,275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (&#8220;ASC 815-40&#8221;). The following table sets forth the Company's warrant activity for the three months ended March 31, 2022 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note. 12 Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234012280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of March&#160;31, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"/><td style="width:61.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,774</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023238057352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations and Comprehensive Loss for three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:433.50pt"><tr><td style="width:1.0pt"/><td style="width:277.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 3.6&#160;million shares of common stock available for issuance under the 2014 Plan as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 13.2&#160;million stock options outstanding under the 2014 Plan as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of March&#160;31, 2022 achievement was deemed probable for only the cash management milestone, representing  20% of the PSU awards.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of March&#160;31, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately 3.5 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of March&#160;31, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the three months ended March 31, 2022:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.68</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense of $1.9&#160;million for the three months ended March 31, 2022. The stock option related expenses were</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.0 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three months ended March 31, 2022 and 2021, respectively. As of March&#160;31, 2022, there was $9.6 million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of 2.56 years. The weighted-average grant-date fair value of stock options granted during the three months ended March 31, 2022 and 2021 were $0.45 and $2.05, respectively. No stock options were exercised during the three months ended March 31, 2022. The total intrinsic value of stock options exercised for the three months ended March 31, 2021 was de minimis.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:64.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.15</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the three months ended March 31, 2022:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"/><td style="width:60.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.67</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any RSUs or PSUs during the three months ended March 31, 2021. </span></div>The share-based compensation expense related to RSUs and PSUs for the three months ended March 31, 2022 was $0.6&#160;million. There was no shared-based compensation expense related to RSUs and PSUs for the three months ended March 31, 2021. As of March 31, 2022, there was $5.0&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs which the Company expects to recognize over a weighted-average period of 2.94 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234052232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of March&#160;31, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP for the three months ended March 31, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The expenses incurred for the periods presented were de minimis amount for each of the three months ended March 31, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div>The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the three months ended March 31, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234187608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text">LICENSE AGREEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $0.5&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million related to meeting a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of March&#160;31, 2022, the Company may be obligated to pay up to &#8364;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.7&#160;million at exchange rates in effect on March&#160;31, 2022). The Company is also required to pay up to a 3.5% </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;50,000 (approximately $55,559 at exchange rates in effect as of March&#160;31, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#8217;s clinical development pathway. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $7.5&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase III clinical trial, (ii) $50&#160;million in regulatory milestones and (iii) $75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the provisions of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification 606, Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606&#8221;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for two &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30 days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#8220;Qilu License Agreement&#8221;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained and recorded as deferred revenue. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of March&#160;31, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of March&#160;31, 2022, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was estimated by management</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, therefore no revenue was recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;31, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of March&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234178136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING AND RELATED ACTIVITIES</a></td>
<td class="text">RESTRUCTURING AND RELATED ACTIVITIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;Restructuring Plan&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Restructuring Plan included a reduction in the Company&#8217;s workforce by 18 positions (or approximately 35% of the Company&#8217;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the Restructuring Plan, (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that substantially all of the accrued restructuring costs as of March&#160;31, 2022 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023237740504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTSOn May 3, 2022, Sesen Bio, Inc., (the &#8220;Company&#8221;) announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of the Company&#8217;s proprietary technologies. The Company is actively working with an investment bank in this process. Pending any decision to undertake any strategic alternative, the Company is continuing its development activities in accordance with its existing business strategy.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023235012280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of March&#160;31, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div>Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023238041544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Summary of Contingent Consideration Liability</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the quarter ended March&#160;31, 2022, (in thousands).</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234070712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Composition of Intangible Assets</a></td>
<td class="text">The following table sets forth the composition of intangible assets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023237758632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023233995192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Common Stock</a></td>
<td class="text">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,783&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">227,275</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Outstanding and Warrant Activity</a></td>
<td class="text">The following table sets forth the Company's warrant activity for the three months ended March 31, 2022 (in thousands):<div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note. 12 Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234059288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of March&#160;31, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"><tr><td style="width:1.0%"/><td style="width:61.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.640%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,537</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,774</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023238359416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations and Comprehensive Loss for three months ended March 31, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:433.50pt"><tr><td style="width:1.0pt"/><td style="width:277.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:73.00pt"/><td style="width:1.0pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,894</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">958</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the three months ended March 31, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.68</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:64.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.71</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.15</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of the Status of Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the three months ended March 31, 2022:</span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"/><td style="width:60.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,960&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.67</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at March&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,005</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023238035160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text">The following is a summary of accrued restructuring costs related to the Restructuring Plan, (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(507)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023233145800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>patient</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberOfPatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare', window );">Shares of common stock issued to the selling shareholders (in shares) | shares</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales', window );">Period during which quarterly earn-outs are payable after date of net sales</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations', window );">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods', window );">Percentage of net sales of quarterly earn-out payments during earn-out periods</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Viventia Bio Inc. | Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232487208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 39,100<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,378<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">39,100<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,378<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">39,100<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">16,378<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 39,100<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023233222968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="nump">0.097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Decrease in the fair value of contingent consideration</a></td>
<td class="num">$ (12,900)<span></span>
</td>
<td class="nump">$ 48,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage', window );">Probability of achieving clinical and regulatory milestones</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage', window );">Probability of achieving clinical and regulatory milestones</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WeightedAverageCostOfCapital', window );">Weighted-average cost of capital</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="nump">0.090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="nump">0.097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Probability of Achieving Clinical and Regulatory Milestones, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Cost of Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023319792568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details) - Significant Unobservable Inputs (Level&#160;3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(12,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 39,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023233207496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">1,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="nump">2,441<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember', window );">German VAT recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023238286264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details) - IPR&amp;D intangible assets: - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">European Union | Vicinium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232886200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLES AND GOODWILL - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 13,100<span></span>
</td>
<td class="nump">$ 13,064<span></span>
</td>
<td class="nump">$ 13,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount', window );">Percentage of fair value in excess of carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fair value of reporting unit in excess of carrying amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232517672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Components of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 981<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll-related expenses</a></td>
<td class="nump">2,675<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccruedRestructuringChargesRelatedCurrent', window );">Restructuring charge related</a></td>
<td class="nump">990<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">2,582<span></span>
</td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 7,278<span></span>
</td>
<td class="nump">$ 8,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedRestructuringChargesRelatedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Restructuring Charges Related, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedRestructuringChargesRelatedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234063608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberOfLawsuits', window );">Number of lawsuits</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232136440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>CAD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>term</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost, including related operating cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short term lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShortTermLeaseRenewalFrequency', window );">Short-term lease, renewal frequency</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShortTermLeaseRenewalFrequency', window );">Short-term lease, renewal frequency</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeasesAreaOfOfficeSpace', window );">Office space (in square feet) | ft&#178;</a></td>
<td class="nump">31,100<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption', window );">Renewal option | term</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="nump">$ 18,100<span></span>
</td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses', window );">Related operating expenses</a></td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="nump">14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Other Monthly Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseOtherMonthlyOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeasesAreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Area Of Office Space</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeasesAreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShortTermLeaseRenewalFrequency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-Term Lease, Renewal Frequency</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShortTermLeaseRenewalFrequency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232084152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Equity Financing (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 29, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance', window );">Shares reserved for future issuance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockCommissionFixedRate', window );">Commission fixed rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of units issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts', window );">Issuance of common stock, issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockCommissionFixedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Fixed Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockCommissionFixedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Sales Price In Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Shares Amount Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Issues, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023235029432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023233106984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 03, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_NumberofVotesEntitledForEachShare', window );">Number of votes | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberofVotesEntitledForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Entitled For Each Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberofVotesEntitledForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023235055384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockSharesIssuedAndReservedForFuture', window );">Total shares of common stock issued and reserved for issuance (in shares)</a></td>
<td class="nump">227,275,000<span></span>
</td>
<td class="nump">229,640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">16,783,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">4,965,000<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares available for grant under 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">3,564,000<span></span>
</td>
<td class="nump">8,933,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for sale under 2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockSharesIssuedAndReservedForFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Issued And Reserved For Future</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockSharesIssuedAndReservedForFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares Of Common Stock Reserved For Issuance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharesOfCommonStockReservedForIssuanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232282184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Warrants (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">Warrants, Expiring March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">Warrants, Expiring November 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member', window );">Warrants, Expiring November 2024, Issued May 2015</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member', window );">Warrants, Expiring November 2024, Issued November 2014</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued During The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Number Of Expirations During The Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023233185352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">23,537<span></span>
</td>
<td class="nump">15,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">16,783<span></span>
</td>
<td class="nump">14,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">6,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">6,555<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023232072328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 1,894<span></span>
</td>
<td class="nump">$ 958<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">502<span></span>
</td>
<td class="nump">178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 1,392<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023228920312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,894,000<span></span>
</td>
<td class="nump">$ 958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unvested stock to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 2.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,783,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan | Vesting on the First Anniversary of Date of Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan | Vesting at End of Each Successive Three-Month Period Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Stock Incentive Plan 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unvested stock to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested grant restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,960,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU | Retention Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unvested stock to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 11 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested grant restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Retention Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary', window );">Percent of base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent', window );">Achievement deemed probable, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_RetentionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023235051112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares under Option (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">16,783,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">8,513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">1.85<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Life (in years), Outstanding</a></td>
<td class="text">7 years 11 months 1 day<span></span>
</td>
<td class="text">8 years 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Life (in years), Exercisable</a></td>
<td class="text">7 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023238223592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue', window );">Fair market value (in dollars per share)</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.71<span></span>
</td>
<td class="nump">$ 3.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.90%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023235056232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares)</a></td>
<td class="nump">3,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares)</a></td>
<td class="nump">8,005,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested ending balance (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,960,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023228827496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution retirement plan, maximum employee contribution deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee', window );">Discretionary match per participating employee, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Common stock purchase price, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for sale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023222376552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS - Narrative (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="10">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>period</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationRoyaltyPaymentPercent', window );">Royalty payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_BusinessCombinationMilestonePayments', window );">Business combination, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember', window );">Micromet AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent', window );">License agreement, royalty payment, reduction, conditions not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,559<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember', window );">XOMA Ireland Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementUpfrontFee', window );">License agreement, up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAdditionalUpFrontFee', window );">License agreement, additional up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementOptionPeriods', window );">License agreement, option periods | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod', window );">License agreement, buyout amount under first option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised', window );">License agreement, period to pay buyout option once exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod', window );">License agreement, buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct', window );">Buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | IL-6</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | First Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on development milestone | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on commercialization milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Second Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember', window );">MENA License Agreement | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sesn_CollaborativeArrangementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccountsReceivablePaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccountsReceivablePaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Long-term Purchase Commitment, Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationRoyaltyPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Royalty Payment Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationRoyaltyPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CollaborativeArrangementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CollaborativeArrangementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAdditionalUpFrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Additional Up-Front Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAdditionalUpFrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Amount Payable Upon Achievement of Specified Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under First Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchievementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achievement Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchievementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementOptionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Option Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementOptionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty On Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty on Net Product Sales, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Period to Pay Buyout Option Once Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Proceeds From Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementProceedsFromMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Up-front Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Basis Of Presentation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RoyaltyRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty Revenue, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RoyaltyRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MicrometAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_EBI031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_EBI031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_IL6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_IL6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023234067496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Aug. 30, 2021 </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of positions eliminated</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, period percent</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140023238642248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 990<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>sesn-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sesn="http://www.sesenbio.com/20220331"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sesn-20220331.xsd" xlink:type="simple"/>
    <context id="i9f552561389a4839b36955112414fddd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i46864a0b0016476db02fe2e892f7cef9_I20220502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-05-02</instant>
        </period>
    </context>
    <context id="ia92debb44af54d02b67c7dd62a05fbfb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic3755f1139a340e2aade3663223c8a7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96da131196c74762907df64863032814_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f5e4b9652d54e48bf163ae90b636a83_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i2e633935010248e68ea0892b52e3708c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i5d598df14f84452c822d3e02466c66f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9d886c640194c0d8d40f577a2a0b6da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65986cee0a3f47009f98ae26909e02e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3bac899f8bff4b5e9d817fa13e651697_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60cbef6e654745cab2772e4470b57220_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ff0b9c4e94c4ca3a50ec38953dae726_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i267ce3744e594084b9adfe990aefe17d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i58548d968bce4d57bbbe97f3173fb16e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i801045fc75394914ab13f94f4ae1394c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i796d93487eea41168a8fd66cd90a9db5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40fdf0d0baf64a318b375f964064207f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40d094d92f884dde854fd3394639b343_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4281f2dc82c64e5bb1ce03499a4ff7dd_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia555869172ce4586aed28eb0644e17ac_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ibfb59442f67a48209291031525080d0a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i8df4db59df3a4f2399c13d3d26fe2f52_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i782b68f9a89b4a16b35f3ff27087d813_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i0bf8f5ab2d074836afe2b1f523782410_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if3c390b4af0e43b2adb9e8e3c0f80caf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9953df45c3614a88bc336cd3adb59e66_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i715f0bbb32d5441aa4c0c66f57e6c15d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idef1618b7f7c4e21924ddb1ad216ec24_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i04e13475210e4b4f8ded7256b0146395_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i526122db789843438c15c6cda35ca7ab_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="ib1fa9d23ba6f4ab397f6863c899cf391_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="ie71051d6bdb042b9928263d050777b62_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i3e5b79e7ff7b4732bf5be21b5ad315e9_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="ia625ecc78ac34ee7b9442e7a9ee6c67a_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="if0c08d92ea854817ba5024a4619ebab0_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="ie49f04215a514ffe9aa6de52f1449f7c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i29f65186d8914b83bd3a931c1ddffbf4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i487e4fc22ff1483fa5e2a198b37ce024_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibf2fde291dcd4b11bca4ee8ea8be676d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i352f1de5f4fc4ed299dd42039cae4d43_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia9d6eda91c70472c97ddbcf9c27c26f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id856a959b0b243f28a91153f115b51d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2f177ca553484a5e816e4b2458b15d0e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff3dd7d4481c4276acefb438f635d714_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i37b667a740a14082b1c2a0e4fe06a99d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i777b729b56654272aecb76e84444d371_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia85202389e8f434f9771578dd1116186_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6c8bda95fde40828c577fa8789c7d3f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied03436a4b954153b51104e07b4308a5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if5c3d72e64284343ad41bbaabad2492e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0974e9a0eac4b9a943068d81c400af6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4024043b56ba43449e39178a89ef2a79_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ida5defd37759486088c2d5f6a80ad271_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icc5ad7341ef44d9e9d0eb812d5d6aef7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i789b708b5a4b4f70b35c83d05b643756_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id5b7224c57a349dd8417b26074fdfea8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i37a86bcaa5c4400cb485d8e214b15877_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie4d8a28b63694dfca536772f228dfd1f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6cc771771ec447eb817fedfab04c5064_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:GermanVATRecoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i545bec4894b147faa5be77fb0ce698df_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="idf4f0077ab4d4c7e8baa7cd8eac1afbe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5e2f3183009408a88a2121d2f8320de_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia9c6211a35774d058c2bc34135cd81cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if355f8cd711e40d5bb37354a4ec90cf0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie489efabccd5453ea2dc7e35706cfaa4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie0b15da2342248bf8f341d5a7661bd17_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63ed6a9dc3044356a0f726f687f89398_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i91a2e679410d42bd9b578b3fe11ffb4a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i145c98efedcf4ac6a1bfc225996ebb5c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib4acdf8e88564bcaa3b39b640d7f099c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4321e3e7de5f473b81eb3f2fa81fef3b_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i38aea9f975c9437f993d25b7b3b9c71b_D20210601-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="ibb19d0c9c4ac4cbaac6c9dc28bf97c0d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5bc89768d7574532a2c9411e20751c77_D20211129-20211129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-29</startDate>
            <endDate>2021-11-29</endDate>
        </period>
    </context>
    <context id="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iad87f2a2e4064dc8babf6447190779eb_I20210502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-05-02</instant>
        </period>
    </context>
    <context id="ib6a9e7c16bd84278a88fc26407cd68a3_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i21ceb143543841428ec32f3c9ad4b0be_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0fe2c623a9d74a7389296573a31bbb22_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3baa1439c0ea43b08add2b44f358ac2d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i221c8962daf4444ebdf4d3c88988461b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id2d1253ec7414a4b84ffbe87119b85ff_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id98165c78fa5475887c60e7c8804b011_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if3c6c33e3cf54dd39de56d11701d0b0d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iefba41b22eac4b17ad9b01a9511c163f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b8342820bc14fc18dcb66343e2d8dbb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i60a06969725e4e0ab841501477d0ab94_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i46b9def9cc834e2e9e98a5e65496e75a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i874e45992d94489c9ad7c98356670dc7_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i900115e3ca494438812c53a74b2e941e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie30fcbf9c3814ac980e2533dce4fe035_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3779abea087b4610ba82ce1d85f2bf38_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic2a61ca27ef84e2aa470147840bc3c1a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87c1ad53e5a84769a79cc00b7c419f7f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1240079e3b784011876aef3004337651_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id2db8bf0bb154bf988c5f0cbf4b1fa14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8543e2bf0407481b92ce314c98882350_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7b139b5a19b94648b6cd590da2967190_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0474ce6e41f94994aa5166f4cef01656_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i491f8467f7ff45e0b2e6a6bc33dabb45_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6ad7b614817843a2a51daa8dac6c033e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id1d7e92567284313b0215206d23cf138_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i01f86ee5c7454a6daf1539b8ff9154fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1d1313b2a80c4a2b83d39bef2b31ff64_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6df6b49ba9af4253b2980614997544b3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i442503d958e94d1cbb92a12c86bfd18d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i638a4bc304a64fefb58743f705706eb0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ifb83446dcd9e42a599260539ad1c0a9e_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i08791a0aa370455b99495a2b83190943_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7b72109f9aee425d9d32f4948d46c658_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i548c92c454ec4c8eb027f6787d1601b5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i064bfd4b1d304882b1628ad085b4d6c2_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icf9f504438bf430eb66685abf363cbbe_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="id04c1f00c3054d6b86cd44222571b020_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i0ed5641b729d40d8b652fe7425a4c97c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i3414053ba29c49659486e8317c638717_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3644a46ac29a4cd088a111e400276c65_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i843c8c42b555485e8edc0700629c070d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7b5fbafca91d4ed69dc2dd77e2c3d271_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i070828932cb7457b89a6d3428bf1884e_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="ibe0c595a8b504aa7a9ef9bed9511cc7c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i20b6c5aa1a3c4bd7a85f15364a9f7f10_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8efee58bbcb34cfeb4ebe4d44af7870e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4a6dde7845004b009c604f58eaaf54f2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i14ad2e265e504b4994de4346a904f964_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i721f2630aa8b4812af090675ea7c48d8_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if6795b392d224fd1958f431310a8ae42_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1c321cdcae954377903223a91776e0b9_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i41cd54bf6e0e43108d5f54b38cbcef44_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie9646b6fad074c349a38b736d334913f_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="if180a9498a6049c5a369d46136508c69_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i249eb5f45f4a43748f1453177c588a6e_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="ia471201fe4bb48848f6167bcc65d599c_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i015e286376344c4c9c156e22c95fc9c6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i703ddc2f34bf4c4fa0e273c40ad0142a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1448067179f94f71ac95826b8ee7a5be_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i719e07b970f244aaa770a65739f6261a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i75fda142f1274858950bc952a648690a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id114c77b04144d64bd3d93db2ab92506_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e725e6c9c5548a683b0b8cd8414f46c_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6f0b7b32437649f0aebbff5cb5bced22_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3170a4ca7c3743c2af7e5c8f5d4ce2eb_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b8e64e250af4d2790f73c3b79426507_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5115ded926c24cf0bfdc639b4a65bd23_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i35b7f963b9974be1ae64730ce05532ff_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i0f201162abfc475998aec36e2f378832_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i860ae1f5203e49a08aa91ee83b20d7e5_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i8aab7a1843994c3488d3876ab37fc007_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i425a0d3a4bfe493e99909f42b47fd556_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="ide74b46daaba4a75ad68f84d5d0e6d0f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i607e98a9eea546b983ca1b261b279229_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i4aafe20143b64883857f4e9a3c846e12_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i05e3cb0224f54a1186393da585df2efb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i2fba7eecc61a49598234f514785e0ed0_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic5ec8b79f17f43bbb84e97e2a5566d46_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i4b8e98722c2b4cdcb4f305e34994b6e7_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="id273db7a5ed6402bb34a4872220bae45_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i17d89aea5f0f47dd8400fd0b5a4720c9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icf94f20a694b4bee91f6f6da52f38a93_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:IL6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="iea001a4f9d934dd893e45269b2383c74_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i6f42a6de33704f62b0e682799149f0e6_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="id8142289592f45f3ac1543eeb3a12d8f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd649cc1b18c474ab1dd1aab76c6641c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7ad5cac1a07b45d6ba8c79753fc4a02f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibcc08ea5943f404b9c1b2ff1c2b62d78_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6380f74d6af34e0fb121780679e0dbd2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7ab08b81f1a8468bb8602311426ac4a5_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i0473c8cf700e465d8a8670d029d1a17e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d312124644e44a09f50ee532d536d0c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2dcc52dfed04067b81a5e2472d5ab8d_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="ib2f514ca47c14bcc81a567e7c8ee3089_D20210805-20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="ib0ea7fa933c347ecacaa65b87757c77a_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="i35e5be36237a414280b903dade9eff3e_D20210830-20210830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="patient">
        <measure>sesn:patient</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lawsuit">
        <measure>sesn:lawsuit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="term">
        <measure>sesn:term</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="vote">
        <measure>sesn:vote</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="period">
        <measure>sesn:period</measure>
    </unit>
    <unit id="position">
        <measure>sesn:position</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF81LTEtMS0xLTU3MzM3_30560051-477c-436d-acfb-bff8c2cc8e50">0001485003</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF82LTEtMS0xLTU3MzM3_32260a81-7ccb-4b89-aec3-f64f884c36d2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF83LTEtMS0xLTU3MzM3_05630365-f4e3-41a0-adbc-eb82bf7fe5d4">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF84LTEtMS0xLTU3MzM3_bcf8896d-52ff-4790-8ce0-ccde3ac0936a">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl80L2ZyYWc6OWNkNmQzNDIyOThmNDU1NWFmMGE3MzM0Y2I1NjRjY2EvdGFibGU6MThiNWFlNjVmMDMwNGIzNmI4MTNmOTJjNzMxNDNkMzgvdGFibGVyYW5nZToxOGI1YWU2NWYwMzA0YjM2YjgxM2Y5MmM3MzE0M2QzOF85LTEtMS0xLTU3MzM3_063a7201-046f-47bb-a281-9dc3fb4b2019">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_70e2c78d-7000-4550-b39c-7708486d9514">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_a608af25-a8c3-43f1-bc13-bde655007b13">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_257c3c35-2b5f-4801-99d1-da6db072ebc5">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_870e15ab-96b9-4644-93c8-e07c8cee8f3a">http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <sesn:ShortTermLeaseRenewalFrequency
      contextRef="i63ed6a9dc3044356a0f726f687f89398_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIxOTkwMjMyNTg5Mjc_107f62f1-7e63-49b3-8b18-5cce5a5aebdc">P6M</sesn:ShortTermLeaseRenewalFrequency>
    <dei:DocumentType
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjQx_f3b09cd7-0830-4cc6-82aa-c0c0c41e96ce">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6MWM4MDkxODZiNDg0NDkyYzhhNGZiNDc4ZDM1OWQyZmIvdGFibGVyYW5nZToxYzgwOTE4NmI0ODQ0OTJjOGE0ZmI0NzhkMzU5ZDJmYl8wLTAtMS0xLTU3MzM3_a0c595e7-462c-4fea-8b86-bd66ebdecc2b">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8xMzE_5064e231-3bf3-48ad-8e26-5f7392406969">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6MWRkMzU0MzY3ODJjNGRlZGIwNmJkZjgxMzcxZTdkMzkvdGFibGVyYW5nZToxZGQzNTQzNjc4MmM0ZGVkYjA2YmRmODEzNzFlN2QzOV8wLTAtMS0xLTU3MzM3_9a29744d-e8a1-4cd8-8fae-daa6e8663fc3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjQy_6788a3e2-510d-4da5-90e3-668ba7db8983">001-36296</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjM1_19b43f81-b448-4a2e-b36e-2b7555908b39">Sesen Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6MzQwNjllZTA2NDkwNDZjODgzMjAxODFlNGI2YmNhZWQvdGFibGVyYW5nZTozNDA2OWVlMDY0OTA0NmM4ODMyMDE4MWU0YjZiY2FlZF8wLTAtMS0xLTU3MzM3_9664fafa-56d5-423a-a67f-f585744c63fb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6MzQwNjllZTA2NDkwNDZjODgzMjAxODFlNGI2YmNhZWQvdGFibGVyYW5nZTozNDA2OWVlMDY0OTA0NmM4ODMyMDE4MWU0YjZiY2FlZF8wLTEtMS0xLTU3MzM3_ab40d022-45f7-4788-b738-e67e85e4b464">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTAtMS0xLTU3MzM3L3RleHRyZWdpb246MmMzZGVhOWMzNGVmNGMzZGE0MGNlY2E1OWI4NTg3ZjJfNA_eb686097-96b1-4686-a506-440550cf8e13">245 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTAtMS0xLTU3MzM3L3RleHRyZWdpb246MmMzZGVhOWMzNGVmNGMzZGE0MGNlY2E1OWI4NTg3ZjJfOA_221867cc-fa47-4ff0-9718-a6f3b16ae3fd">Suite 1800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTAtMS0xLTU3MzM3L3RleHRyZWdpb246MmMzZGVhOWMzNGVmNGMzZGE0MGNlY2E1OWI4NTg3ZjJfMTE_d46954b2-8474-41b9-b2ff-55b2ce9ab33d">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTAtMS0xLTU3MzM3L3RleHRyZWdpb246MmMzZGVhOWMzNGVmNGMzZGE0MGNlY2E1OWI4NTg3ZjJfMTU_f2319aa3-c773-4e95-8e62-8fca946f17fc">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6ZDU2ODdjMjYwZDQzNDY4YzgyNmMyYzliZjBjNTNmMDEvdGFibGVyYW5nZTpkNTY4N2MyNjBkNDM0NjhjODI2YzJjOWJmMGM1M2YwMV8wLTEtMS0xLTU3MzM3_f0747755-fe50-4fe1-bcc3-e042fcb32b39">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zNTE_b423a194-a35a-4bb0-8966-5fa225459e34">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjM2_e2a63062-a65e-4037-aa5f-1709c395019e">444-8550</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6NjBlNmY0NzVlNWRhNGRlZThmNmM1N2RmYmJkNjU1YjEvdGFibGVyYW5nZTo2MGU2ZjQ3NWU1ZGE0ZGVlOGY2YzU3ZGZiYmQ2NTViMV8xLTAtMS0xLTU3MzM3_80d75d9e-0278-4529-8366-9bd64904aaa9">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6NjBlNmY0NzVlNWRhNGRlZThmNmM1N2RmYmJkNjU1YjEvdGFibGVyYW5nZTo2MGU2ZjQ3NWU1ZGE0ZGVlOGY2YzU3ZGZiYmQ2NTViMV8xLTEtMS0xLTU3MzM3_b2c13e4d-4453-4844-97d0-a5bc4483bc17">SESN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6NjBlNmY0NzVlNWRhNGRlZThmNmM1N2RmYmJkNjU1YjEvdGFibGVyYW5nZTo2MGU2ZjQ3NWU1ZGE0ZGVlOGY2YzU3ZGZiYmQ2NTViMV8xLTItMS0xLTU3MzM3_2e898299-f31f-450f-95d4-f750e7514ea1">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjM3_702de1b0-be9a-4d19-bf2d-4e7ba8bd1f6b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjM4_85f4d6ff-554f-496e-a40a-13fb32ca45a9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6YTU0MjBlMTI3YjNlNGMzM2EzYmU0OGYwN2FlZmVhM2IvdGFibGVyYW5nZTphNTQyMGUxMjdiM2U0YzMzYTNiZTQ4ZjA3YWVmZWEzYl8wLTAtMS0xLTU3MzM3_6e109ac7-fc0f-4723-bc5b-a7dd3602cd08">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6YTU0MjBlMTI3YjNlNGMzM2EzYmU0OGYwN2FlZmVhM2IvdGFibGVyYW5nZTphNTQyMGUxMjdiM2U0YzMzYTNiZTQ4ZjA3YWVmZWEzYl8wLTMtMS0xLTU3MzM3_fd217707-c97e-4356-ae11-ae12a3982fbb">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGFibGU6YTU0MjBlMTI3YjNlNGMzM2EzYmU0OGYwN2FlZmVhM2IvdGFibGVyYW5nZTphNTQyMGUxMjdiM2U0YzMzYTNiZTQ4ZjA3YWVmZWEzYl8xLTMtMS0xLTU3MzM3_c1e43590-31a5-44a6-82e0-09cd17f28e38">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8zMjQ1_1676b058-d548-467f-96b8-3b366e16e1b2">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i46864a0b0016476db02fe2e892f7cef9_I20220502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xL2ZyYWc6MjdmNjQ4MjE1ZjBlNGMwNjljZTk1NTQ4MjI5YTllZWQvdGV4dHJlZ2lvbjoyN2Y2NDgyMTVmMGU0YzA2OWNlOTU1NDgyMjlhOWVlZF8yNzg1_f7a33ee3-7707-4bcf-978e-ffcdb418d366"
      unitRef="shares">199463645</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNC0xLTEtMS01NzMzNw_e5548060-e185-4db9-bc19-524b5d64dc96"
      unitRef="usd">169790000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNC0zLTEtMS01NzMzNw_70e96ce7-6f8c-4846-9740-b3085b23a50f"
      unitRef="usd">162636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNS0xLTEtMS01NzMzNw_62a63408-e3d3-4ca3-90c2-3e51a9d46cbe"
      unitRef="usd">1011000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNS0zLTEtMS01NzMzNw_86a05a23-8d72-4ad3-8a3f-7dc1ed695887"
      unitRef="usd">21011000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNi0xLTEtMS01NzMzNw_cd2dfe2b-7158-4a8f-bc04-0795e5ea2ebe"
      unitRef="usd">1041000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNi0zLTEtMS01NzMzNw_2640699c-fed4-4013-92c1-890645267a6b"
      unitRef="usd">3482000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNy0xLTEtMS01NzMzNw_18fe83cf-93d1-4a61-a415-3952de31563c"
      unitRef="usd">8795000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNy0zLTEtMS01NzMzNw_876b46ad-8af7-436d-a62e-3853ce287720"
      unitRef="usd">18476000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfOS0xLTEtMS01NzMzNw_13675fec-4a90-4d34-bf3a-032bf76f1475"
      unitRef="usd">180637000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfOS0zLTEtMS01NzMzNw_c346bb85-2f0e-4a16-89aa-0647f307ed28"
      unitRef="usd">205605000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTItMS0xLTEtNTczMzc_e99822a8-ba43-4c6f-b290-0f1eae8da215"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTItMy0xLTEtNTczMzc_dbcd9d9d-bff2-4270-bb52-2bbda85c67ab"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTMtMS0xLTEtNTczMzc_825b908f-7301-485d-9a7b-0450d357b9b7"
      unitRef="usd">33000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTMtMy0xLTEtNTczMzc_54e46161-e460-4dc6-9eba-0dfb91c43fb1"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTQtMS0xLTEtNTczMzc_562d9104-62ee-429e-92e0-0663da46c4b7"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTQtMy0xLTEtNTczMzc_bb932bcf-b0fb-41b6-b88e-a1777ba378b8"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTUtMS0xLTEtNTczMzc_581546e3-4339-4cbb-a937-f349b09d2665"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTUtMy0xLTEtNTczMzc_ee783ca2-83f5-4a80-a23d-b605efbd788c"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTYtMS0xLTEtNTczMzc_24d15e3c-e39b-46c1-9a9e-d9aeaca1cefd"
      unitRef="usd">17301000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTYtMy0xLTEtNTczMzc_9e8c9d94-45ca-4d87-a431-6b6897887437"
      unitRef="usd">7192000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTctMS0xLTEtNTczMzc_9bf54941-bb10-4ed8-bf3e-3ac0294785b4"
      unitRef="usd">85000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTctMy0xLTEtNTczMzc_b021ea10-846d-4e72-b5d5-617673000b06"
      unitRef="usd">123000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTgtMS0xLTEtNTczMzc_9210ddc0-1c3d-41a4-9c24-fb7515d34b77"
      unitRef="usd">45203000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTgtMy0xLTEtNTczMzc_bd8587d6-c444-434b-85c8-9b460706fb1f"
      unitRef="usd">35142000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTktMS0xLTEtNTczMzc_79c10e92-c79c-4112-903a-de8b51eaa8c1"
      unitRef="usd">225840000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMTktMy0xLTEtNTczMzc_69f53e6c-c6c4-4b2f-89b9-f30d946c5b30"
      unitRef="usd">240747000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjMtMS0xLTEtNTczMzc_b9123f93-5ada-492c-b53d-b3ee9a084058"
      unitRef="usd">666000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjMtMy0xLTEtNTczMzc_8a5bfc72-25c4-4ebd-a14a-67e4f86659d9"
      unitRef="usd">2853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjQtMS0xLTEtNTczMzc_2fc662e2-3352-417e-8a57-91249c2f578f"
      unitRef="usd">7278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjQtMy0xLTEtNTczMzc_8577eb7a-db3c-47ac-bb3b-d6b434a096af"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjctMS0xLTEtNTczMzc_25192d9e-68b6-4dae-8038-1f39deea3d8f"
      unitRef="usd">530000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjctMy0xLTEtNTczMzc_faae3845-f457-4a63-bb75-2e28bb33d37c"
      unitRef="usd">460000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjgtMS0xLTEtNTczMzc_7e9e9823-a46c-4554-8ab3-f5041d344482"
      unitRef="usd">8474000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMjgtMy0xLTEtNTczMzc_71f5d354-9edc-4a7b-8cd0-5bae45a98dc5"
      unitRef="usd">11568000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzEtMS0xLTEtNTczMzc_2f16ed32-e614-4c62-bdfd-761a69c879f0"
      unitRef="usd">39100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzEtMy0xLTEtNTczMzc_e3fe1285-4910-4551-b2e1-3c1662f7c68b"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzItMS0xLTEtNTczMzc_d5272d13-537e-46de-93fe-c0354d89debf"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzItMy0xLTEtNTczMzc_8998d6fe-3339-4e5f-9545-dec34f8bf21d"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzMtMS0xLTEtNTczMzc_5f85f69f-fd29-4653-8cdc-f6c9e3faf9f7"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzMtMy0xLTEtNTczMzc_1c8630b5-826c-438e-8efe-5c968782ae7e"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzUtMS0xLTEtNTczMzc_d6cc7723-bfac-4a5e-ac2c-9fed9204da2f"
      unitRef="usd">44569000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzUtMy0xLTEtNTczMzc_dd7992c6-8ec7-4c3a-a2af-089d0ea54564"
      unitRef="usd">57469000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzYtMS0xLTEtNTczMzc_0bfc871c-494b-45f2-beae-c9de56dacaff"
      unitRef="usd">53043000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzYtMy0xLTEtNTczMzc_94185446-7b35-4465-b68a-c955da3a3c06"
      unitRef="usd">69037000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN18yMQ_5cc46fee-8b75-41d3-bff6-9a53c2d0f210"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN18yMQ_aaa691c4-794f-4a31-b0d9-824b122d10f4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN180NQ_a2ee158d-7983-43a9-b51f-5aa47efa0cdb"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN180NQ_d94a625c-6e13-46f8-af64-d5a2593b42fb"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN185OA_66bda149-1205-43bc-baab-8d3fb7db6b04"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN185OA_a6e34bd8-c089-4deb-b21b-9cb6c3259184"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN185OA_aafb27e6-21cd-455b-9d29-6d7f1759ad68"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjpmZGI0N2IxMDNmN2M0YWJlODI2Y2ZiYWNkZGZhMzZjN185OA_d5da9766-bde3-4691-a714-876c187a9ad3"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMS0xLTEtNTczMzc_a5d1283c-94ac-4158-8d49-c1aad668d0f5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfMzktMy0xLTEtNTczMzc_b1bc4713-ee91-47ef-850b-44c4c80dfb8b"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xOA_06b46a3d-5ecb-4487-ad81-0366d2c37fd1"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xOA_719e92d4-47c1-4a67-9b75-5cec05ec24fb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV80Mg_3f10894c-4d6d-4c30-84af-9ac3c4676536"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV80Mg_b81a0aae-b3d4-4d53-9f6f-1f5f3855886f"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xMDE_111b222e-3a07-4bba-b32f-77382a1d6d3c"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xMDE_161906aa-69c8-4ff1-8354-9b7c6339cf08"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xMDE_20961428-0725-43f9-914c-d696cb22de4b"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo0ZGIwNTA0NjIwZTU0ZGI1OGY3NzQ5YmM0MTM3Zjk3YV8xMDE_2fc36e55-f4e0-4fc6-93bf-abe175b50117"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMS0xLTEtNTczMzc_33086369-3fa4-4de5-92ef-25cc64b74562"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDAtMy0xLTEtNTczMzc_ce0e3c7b-6cf9-41df-8841-07d1cd66fd0d"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDEtMS0xLTEtNTczMzc_2b3c5a7c-3260-44da-a8a6-4663420e5761"
      unitRef="usd">489662000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDEtMy0xLTEtNTczMzc_f454f251-aa11-4da5-b57f-14117579aad9"
      unitRef="usd">487768000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDItMS0xLTEtNTczMzc_47a2b5ea-58b6-4403-bf8c-de0878d9480f"
      unitRef="usd">-317064000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDItMy0xLTEtNTczMzc_2469d2f4-5eb9-4e65-9c05-4631f046fa69"
      unitRef="usd">-316257000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDMtMS0xLTEtNTczMzc_4fcfc894-dae1-4e85-99f3-0b803d6b0f5f"
      unitRef="usd">172797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDMtMy0xLTEtNTczMzc_d05e10ed-0d48-4541-8497-38ebe2fb8cc3"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDQtMS0xLTEtNTczMzc_17d12d3e-6d97-42ac-a0b2-82573fb31a2b"
      unitRef="usd">225840000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82NC9mcmFnOjU0Y2YzODE3ODc2NzQ3OTg4OTc5ZTIzNWFmYWE1ZWRmL3RhYmxlOjExY2E4OTI4NTI1NTQ1YThiZTQyNGIzY2M0ZDVkY2JhL3RhYmxlcmFuZ2U6MTFjYTg5Mjg1MjU1NDVhOGJlNDI0YjNjYzRkNWRjYmFfNDQtMy0xLTEtNTczMzc_4fff433d-82f1-4f9a-a083-d51e018eece5"
      unitRef="usd">240747000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i96da131196c74762907df64863032814_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfNC0xLTEtMS01NzMzNw_deb93049-ef0c-407e-9af4-e32f34a9cd72"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i3f5e4b9652d54e48bf163ae90b636a83_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfNC0zLTEtMS01NzMzNw_e335b44a-a452-44e5-832b-f2e76c74cdba"
      unitRef="usd">4310000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfNS0xLTEtMS01NzMzNw_8335e648-e3b8-4d25-9c30-f4798caa4d9e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfNS0zLTEtMS01NzMzNw_69a74ab4-6355-4cd8-88da-fde6a94c23cc"
      unitRef="usd">4310000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfOC0xLTEtMS01NzMzNw_180df177-8772-45ac-88af-46dba954a3f8"
      unitRef="usd">4760000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfOC0zLTEtMS01NzMzNw_ffca905d-3743-4987-8501-dfa4b2e47614"
      unitRef="usd">6078000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfOS0xLTEtMS01NzMzNw_0f395886-87af-444e-a7eb-afcb56dbc1f0"
      unitRef="usd">8975000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfOS0zLTEtMS01NzMzNw_d7c1d42f-147b-46ea-9bd0-dc0ace85421e"
      unitRef="usd">5293000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTItMS0xLTEtNTczMzc_ba71d98b-8fd8-4fa9-ba90-8eafb31b5995"
      unitRef="usd">-12900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTItMy0xLTEtNTczMzc_c45cd241-ae4a-47db-acb7-f95d62682722"
      unitRef="usd">48160000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTMtMS0xLTEtNTczMzc_396fbebd-923e-456a-8ac2-fda9896abb03"
      unitRef="usd">835000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTMtMy0xLTEtNTczMzc_3e79547c-72b9-4a09-9f6c-6b92dd377483"
      unitRef="usd">59531000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTUtMS0xLTEtNTczMzc_445ad8e4-a5a6-4774-be46-edb46baf98d7"
      unitRef="usd">-835000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTUtMy0xLTEtNTczMzc_2f6ee948-73c8-4533-a312-10e6bba2906a"
      unitRef="usd">-55221000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTYtMS0xLTEtNTczMzc_e7f3d8a8-9668-467f-9d51-2a9c4bf26a73"
      unitRef="usd">28000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTYtMy0xLTEtNTczMzc_85abd35a-ab4c-4015-9e32-d7fe7b1a6c36"
      unitRef="usd">-3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTctMS0xLTEtNTczMzc_85c76de3-c230-4da7-8c08-339440f1d974"
      unitRef="usd">-807000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTctMy0xLTEtNTczMzc_cf7284ae-216c-4511-b3ee-20f656c66d11"
      unitRef="usd">-55224000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTgtMS0xLTEtNTczMzc_e27aa945-476f-4790-9e86-c262a030da12"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTgtMy0xLTEtNTczMzc_8d9c5771-1bec-4601-8499-efd876f09c33"
      unitRef="usd">288000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTktMS0xLTEtNTczMzc_59d03f74-4a64-49fc-a7ac-a742bca96e14"
      unitRef="usd">-807000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTktMS0xLTEtNTczMzc_a0b86604-55f8-4358-b1c3-9663a4fc036a"
      unitRef="usd">-807000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTktMy0xLTEtNTczMzc_63bdf2f6-ee7f-49dc-9e6e-5c12e090f624"
      unitRef="usd">-55512000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMTktMy0xLTEtNTczMzc_880d1fa1-b49e-4d3c-9b13-3010702f59c0"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjMtMS0xLTEtNTczMzc_962d12b4-8d3f-4f2e-87a3-e1e1254afd03"
      unitRef="usd">-807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjMtMS0xLTEtNTczMzc_e2683da8-3ceb-4e2a-8a48-a50be3d5386e"
      unitRef="usd">-807000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjMtMy0xLTEtNTczMzc_3865bc2f-cd1a-4c76-8616-4c3440ec52bb"
      unitRef="usd">-55512000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjMtMy0xLTEtNTczMzc_54799d24-da33-415b-9941-e3fd3474c823"
      unitRef="usd">-55512000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjQtMS0xLTEtNTczMzc_8e525fcd-54e4-4fbb-84b7-105b145f35a9"
      unitRef="usdPerShare">-0.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjQtMS0xLTEtNTczMzc_91a81c08-67b6-4f4c-9873-f2409c9a69b2"
      unitRef="usdPerShare">-0.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjQtMy0xLTEtNTczMzc_c1e788ef-be6d-4214-81c0-912f27503de4"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjQtMy0xLTEtNTczMzc_fdbbb918-3832-4a24-a2c8-8ef30fc3877c"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjUtMS0xLTEtNTczMzc_79f96683-d8cd-4a31-b19d-77aab21ac3ef"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjUtMS0xLTEtNTczMzc_b6722d95-b8bb-4c60-820e-b6807b4c8f91"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjUtMy0xLTEtNTczMzc_b3e2728a-d859-4d4b-ab36-9dc0f088f08e"
      unitRef="shares">157033000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl82Ny9mcmFnOjE3MWNjNzM5NmYyNjRjZjdiNDA1M2VlOWJiNjMxMzczL3RhYmxlOjZmZWRlOTMyZGE5YTQxOGM4YjA0YmQ1OTJkMTgwNzhiL3RhYmxlcmFuZ2U6NmZlZGU5MzJkYTlhNDE4YzhiMDRiZDU5MmQxODA3OGJfMjUtMy0xLTEtNTczMzc_e5496eb3-2642-4fe9-8e91-5eeefe39763c"
      unitRef="shares">157033000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="i5d598df14f84452c822d3e02466c66f4_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi0xLTEtMS01NzMzNw_22ca032d-5d66-49ce-abf7-c63d985b087f"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i5d598df14f84452c822d3e02466c66f4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi0zLTEtMS01NzMzNw_0511f059-98d8-4ab9-9dcf-eea293fbe33f"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie9d886c640194c0d8d40f577a2a0b6da_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi01LTEtMS01NzMzNw_3e19cf53-866c-4f40-b95f-da809c48ee29"
      unitRef="usd">487768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i65986cee0a3f47009f98ae26909e02e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi03LTEtMS01NzMzNw_570b4f2b-9873-4f3e-bb6c-034ebbae07a7"
      unitRef="usd">-316257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMi05LTEtMS01NzMzNw_ddb757b3-a24b-4331-b739-5d11550573f1"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i3bac899f8bff4b5e9d817fa13e651697_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMy03LTEtMS01NzMzNw_fbe7343e-6fe9-42d4-987a-53c941187867"
      unitRef="usd">-807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMy05LTEtMS01NzMzNw_00fbdc62-bece-4184-9388-dd398c10d854"
      unitRef="usd">-807000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i60cbef6e654745cab2772e4470b57220_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfNC01LTEtMS01NzMzNw_c756e4d7-dc1b-4cc9-85d0-4932cc13d51b"
      unitRef="usd">1894000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfNC05LTEtMS01NzMzNw_05724157-9e20-42ba-908d-4ad3c5c60275"
      unitRef="usd">1894000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i8ff0b9c4e94c4ca3a50ec38953dae726_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtMS0xLTEtNTczMzc_c80a3310-7061-46bd-af55-2b6a5479099e"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8ff0b9c4e94c4ca3a50ec38953dae726_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtMy0xLTEtNTczMzc_494d7881-c50f-431a-9e3e-c6a739a1414d"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i267ce3744e594084b9adfe990aefe17d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtNS0xLTEtNTczMzc_f33503c9-3f27-40aa-9a6d-81a51779d12c"
      unitRef="usd">489662000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i58548d968bce4d57bbbe97f3173fb16e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtNy0xLTEtNTczMzc_11cf214e-bf43-4be9-9b01-f78bab6aff4a"
      unitRef="usd">-317064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTAtOS0xLTEtNTczMzc_895dab63-b55b-4f89-80ef-9eef8d682065"
      unitRef="usd">172797000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i801045fc75394914ab13f94f4ae1394c_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctMS0xLTEtNTczMzc_d4ea3dda-93ec-4e7f-ab08-a5fbaaee9a13"
      unitRef="shares">140449647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i801045fc75394914ab13f94f4ae1394c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctMy0xLTEtNTczMzc_5cf2fe09-9001-4698-b80b-578030090fd5"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i796d93487eea41168a8fd66cd90a9db5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctNS0xLTEtNTczMzc_7e5b255a-40a4-4193-a8e6-eb72246fb033"
      unitRef="usd">306554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40fdf0d0baf64a318b375f964064207f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctNy0xLTEtNTczMzc_bcfe5feb-e52c-4133-af4f-ca038649312d"
      unitRef="usd">-315921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40d094d92f884dde854fd3394639b343_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTctOS0xLTEtNTczMzc_ed684b61-3908-4442-8cd4-0298c59af531"
      unitRef="usd">-9227000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4281f2dc82c64e5bb1ce03499a4ff7dd_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTgtNy0xLTEtNTczMzc_d2a850e6-dcbe-410a-94d3-31922e3cbecf"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTgtOS0xLTEtNTczMzc_fffa8bda-1789-4fa1-8db1-b7ebbcf75cd1"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia555869172ce4586aed28eb0644e17ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTktNS0xLTEtNTczMzc_11efbada-c707-473b-b176-bcc25cd81e9a"
      unitRef="usd">958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMTktOS0xLTEtNTczMzc_77cc05b8-9a41-46c9-a816-99d36be55b55"
      unitRef="usd">958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibfb59442f67a48209291031525080d0a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjAtMS0xLTEtNTczMzc_1e285121-5fea-4a14-b3d8-f2f7c75c97c0"
      unitRef="shares">30610</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ia555869172ce4586aed28eb0644e17ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjAtNS0xLTEtNTczMzc_6d30c26c-3122-4109-a561-a0a6f54a8387"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjAtOS0xLTEtNTczMzc_b20f29a8-4aab-4dd0-b9ef-85df56225974"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ibfb59442f67a48209291031525080d0a_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjItMS0xLTEtNTczMzc_912571a4-0530-40d2-9d8c-1b9165daa292"
      unitRef="shares">852840</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="ibfb59442f67a48209291031525080d0a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjItMy0xLTEtNTczMzc_b4b35bac-a55a-4ada-9d0a-bcd5a15aa54e"
      unitRef="usd">1000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="ia555869172ce4586aed28eb0644e17ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjItNS0xLTEtNTczMzc_8d0403d9-f6ac-4207-86dd-cf3b9ecaf691"
      unitRef="usd">468000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjItOS0xLTEtNTczMzc_14136856-c9fd-4ada-b299-279052b716fd"
      unitRef="usd">469000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtMC0xLTEtNTczMzcvdGV4dHJlZ2lvbjo3NmRjNDliNTA1OWM0Zjc0OTcxNTJkMWNkNjY4NjFhYV83NA_8175de32-79a5-4b23-8460-0abd7f870137"
      unitRef="usd">2200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i8df4db59df3a4f2399c13d3d26fe2f52_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtMS0xLTEtNTczMzc_4feccc91-a392-47e0-be25-f1ccb456c65b"
      unitRef="shares">30645702</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8df4db59df3a4f2399c13d3d26fe2f52_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtMy0xLTEtNTczMzc_4790823b-dbe3-4243-8ed0-acdff4e10f2f"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i782b68f9a89b4a16b35f3ff27087d813_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtNS0xLTEtNTczMzc_bc1f0a78-ebd9-432c-ae03-872719c15583"
      unitRef="usd">72512000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i0bf8f5ab2d074836afe2b1f523782410_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjMtOS0xLTEtNTczMzc_36b4c3b9-d36d-4700-8619-35e098f9f47a"
      unitRef="usd">72543000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="if3c390b4af0e43b2adb9e8e3c0f80caf_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtMS0xLTEtNTczMzc_8eda3102-9069-426b-9069-ae5d6dadc8ec"
      unitRef="shares">171978799</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if3c390b4af0e43b2adb9e8e3c0f80caf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtMy0xLTEtNTczMzc_b13bc8cb-691e-4eef-aad3-254d92069235"
      unitRef="usd">172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9953df45c3614a88bc336cd3adb59e66_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtNS0xLTEtNTczMzc_3b470845-4e01-4593-ba83-caf21134e082"
      unitRef="usd">380531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i715f0bbb32d5441aa4c0c66f57e6c15d_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtNy0xLTEtNTczMzc_c378a3a8-9edd-4493-930e-2d5662f57cb2"
      unitRef="usd">-371433000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idef1618b7f7c4e21924ddb1ad216ec24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83MC9mcmFnOmUzYzJiYWMxMTcwZjQ4ODRhNjM2ZTQ4ZTIyZDE4ZTdjL3RhYmxlOjU4Yzk4MzNiYzJhNjRiM2ZiMzQwMzcyZjJhODQ2ZWYwL3RhYmxlcmFuZ2U6NThjOTgzM2JjMmE2NGIzZmIzNDAzNzJmMmE4NDZlZjBfMjQtOS0xLTEtNTczMzc_cac96922-6ed2-417f-8617-16a4c6d0db69"
      unitRef="usd">9270000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMy0xLTEtMS01NzMzNw_4833a359-2ee3-4a30-ab27-947bc7b47ec8"
      unitRef="usd">-807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMy0zLTEtMS01NzMzNw_7a0d278c-5afe-47cf-a1a2-0790d0802522"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNS0xLTEtMS01NzMzNw_3eaa1752-dfbd-4820-9622-756a5afb6b56"
      unitRef="usd">10000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNS0zLTEtMS01NzMzNw_69646cae-76c2-4c69-9edb-e4d8169f975d"
      unitRef="usd">30000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNi0xLTEtMS01NzMzNw_e9a271bf-adc5-47d4-89c3-12c6081b69a4"
      unitRef="usd">1894000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNi0zLTEtMS01NzMzNw_8e3e62c6-7a30-4c74-925f-abdb076c12b0"
      unitRef="usd">958000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNy0xLTEtMS01NzMzNw_ba71d98b-8fd8-4fa9-ba90-8eafb31b5995"
      unitRef="usd">-12900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfNy0zLTEtMS01NzMzNw_c45cd241-ae4a-47db-acb7-f95d62682722"
      unitRef="usd">48160000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTEtMS0xLTEtNTczMzc_f4e6c9ec-cf14-4086-b69c-493958c72142"
      unitRef="usd">-20000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTEtMy0xLTEtNTczMzc_5e14a35d-06b3-4b64-8b04-7c6063256322"
      unitRef="usd">2886000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTItMS0xLTEtNjUxNDk_3f2cf2c9-a9b2-4db3-b8a9-ecba5471ab72"
      unitRef="usd">-2441000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTItMy0xLTEtNjUxNDk_e07ee806-fe64-4833-bc2a-d1716efb338e"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTItMS0xLTEtNTczMzc_37e0394c-2ed5-469c-85ce-3863e805a506"
      unitRef="usd">-9682000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTItMy0xLTEtNTczMzc_9b56b297-6ad3-4101-8e9f-7fdb06d38887"
      unitRef="usd">6250000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTUtMS0xLTEtNjk0NTk_d676ea96-fada-4e20-9b58-a206f9b82113"
      unitRef="usd">10109000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTUtMy0xLTEtNjk0NzM_056038a1-707e-47c2-9178-283f48a4bca3"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTYtMS0xLTEtNjk1Mzg_129b9d28-c53c-4e9b-879a-b45f367da9fe"
      unitRef="usd">-38000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTYtMy0xLTEtNjk1Mzg_41890140-f6ce-4ec5-8a0c-044eab742129"
      unitRef="usd">-91000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTQtMS0xLTEtNTczMzc_2927abf7-5971-4262-89ed-5879a98fb4dd"
      unitRef="usd">-2187000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTQtMy0xLTEtNTczMzc_88e67860-f8aa-4d08-92ff-2baf3cb9efe5"
      unitRef="usd">-1098000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTUtMS0xLTEtNTczMzc_bd0d37dd-910c-4932-8c62-6d6d5ed28fad"
      unitRef="usd">-908000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTUtMy0xLTEtNTczMzc_eb14df53-e74f-4ea8-b241-2cf482dfcd2a"
      unitRef="usd">-468000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTYtMS0xLTEtNTczMzc_307a904d-7d6f-470e-825a-1e858636df90"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTYtMy0xLTEtNTczMzc_c799d0b6-7d0e-4468-8915-aa49d4c05354"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTctMS0xLTEtNTczMzc_e04424f9-8743-4a92-a82a-88383c0c848f"
      unitRef="usd">7154000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMTctMy0xLTEtNTczMzc_ef6c2a4c-f7ea-4e07-aade-1fa816c2fd6f"
      unitRef="usd">-18475000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjAtMS0xLTEtNTczMzc_f125e1bd-ce76-496c-bfb2-eb50800eb85c"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjAtMy0xLTEtNTczMzc_72c6be55-96ac-4d3b-9c28-7aff318b275e"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjMtMS0xLTEtNTczMzc_53f3396b-7472-47e2-a2b7-cf25d9cb810c"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjMtMy0xLTEtNTczMzc_264d4ae2-41c4-4aff-add0-3969718291e8"
      unitRef="usd">469000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjQtMS0xLTEtNTczMzc_f79c876c-b60a-4386-bd3b-a91633c891ce"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjQtMy0xLTEtNTczMzc_8e204ef4-a1d8-46a2-aa46-9b2a06e18b74"
      unitRef="usd">72543000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjUtMS0xLTEtNTczMzc_ae5720d9-008f-4c2c-981e-93e178a42d57"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjUtMy0xLTEtNTczMzc_4fccef20-3788-4450-ab68-481260d9217d"
      unitRef="usd">39000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjctMS0xLTEtNTczMzc_200735f8-21ea-4c8f-bea7-999c5a060ca9"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjctMy0xLTEtNTczMzc_0a649c49-3409-4074-ac78-09c23e9ec1d2"
      unitRef="usd">73051000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjgtMS0xLTEtNTczMzc_7970160c-669e-4d9f-ab34-bb3d7143a59c"
      unitRef="usd">7154000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjgtMy0xLTEtNTczMzc_090fbd79-e421-4143-9397-35c0f30b27cf"
      unitRef="usd">54576000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjktMS0xLTEtNTczMzc_3278e0d6-043b-4408-8ed7-6b9078d11b03"
      unitRef="usd">162656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i40d094d92f884dde854fd3394639b343_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMjktMy0xLTEtNTczMzc_e6cbcea4-8507-4b7a-ba0a-3b3135a7d748"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMzAtMS0xLTEtNTczMzc_3b95125f-080a-4f76-a817-1bcd6bb9e332"
      unitRef="usd">169810000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="idef1618b7f7c4e21924ddb1ad216ec24_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMzAtMy0xLTEtNTczMzc_131c5c19-4dbd-45d0-ab32-f96be640ca6a"
      unitRef="usd">109985000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMzktMS0xLTEtNTczMzc_5e69866e-5680-4304-9b99-2d604e350d7b"
      unitRef="usd">43000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl83Ni9mcmFnOjU1OTk2ZDQ1Nzg4ZDRkNzc5N2U5ODM2MmNiZDJmOGU2L3RhYmxlOmFhYTNiMzY5MjI1ZDQ5ODY5YzE1NmM3Zjk3NTVlYjU1L3RhYmxlcmFuZ2U6YWFhM2IzNjkyMjVkNDk4NjljMTU2YzdmOTc1NWViNTVfMzktMy0xLTEtNTczMzc_7270342b-d3f5-4185-9696-480d3f7a003f"
      unitRef="usd">43000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <us-gaap:NatureOfOperations
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfMTY1NDM_f06e5032-3d48-4d64-8e3c-f9617d2b2eb1">DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sesen Bio, Inc. ("Sesen" or the &#x201c;Company&#x201d;), a Delaware corporation formed in February 2008, is a late-stage clinical company advancing targeted fusion protein therapeutics ("TFPTs") for the treatment of patients with cancer. The Company&#x2019;s most advanced product candidate, Vicineum&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#x201c;NMIBC&#x201d;). The Company is in the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;bacillus Calmette-Gu&#xe9;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#x201c;CRL&#x201d;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#x201c;CMC&#x201d;) issues pertaining to a recent pre-approval inspection and product quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed will be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#x2019;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Viventia Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#x201c;Selling Shareholders&#x201d;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#x201c;Clairmark&#x201d;) (the &#x201c;Share Purchase Agreement&#x201d;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#x201c;Viventia Acquisition&#x201d;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares.&lt;/span&gt;&lt;/div&gt;In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#x201c;Purchased Product&#x201d;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that became employees or members of the Company's board of directors. However, as of March&#160;31, 2022, none of these individuals are active employees or members of the Company's board of directors.</us-gaap:NatureOfOperations>
    <sesn:NumberOfPatients
      contextRef="i04e13475210e4b4f8ded7256b0146395_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfOTA2_60b6e027-f626-4234-bc36-81ab28e3bf3e"
      unitRef="patient">133</sesn:NumberOfPatients>
    <sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare
      contextRef="i526122db789843438c15c6cda35ca7ab_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNDI0Ng_d3012cbc-1ed8-42a4-9834-118ac07c5fb5"
      unitRef="shares">4000000</sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ib1fa9d23ba6f4ab397f6863c899cf391_I20160930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNDM1MA_f626b25f-65ea-4ace-bb1b-e296545b8c8e"
      unitRef="number">0.199</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="ie71051d6bdb042b9928263d050777b62_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNDkxNA_b03c3774-850f-4627-9398-96322fde12e1"
      unitRef="usd">12500000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i3e5b79e7ff7b4732bf5be21b5ad315e9_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTA0Mw_4226aeac-22b5-49fe-bc0d-4eb33b2c82cc"
      unitRef="usd">7000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="ia625ecc78ac34ee7b9442e7a9ee6c67a_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTE4OQ_55daadd2-7068-4afe-ba36-e4152c76ef87"
      unitRef="usd">3000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods
      contextRef="if0c08d92ea854817ba5024a4619ebab0_D20160901-20160930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTMwMQ_6d23f7f5-936b-4106-a879-0f6f8633ff1a"
      unitRef="number">0.02</sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods>
    <sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales
      contextRef="i526122db789843438c15c6cda35ca7ab_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTU2OA_14fe9375-9d56-49df-9ded-60f5eb46a39a">P15Y</sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales>
    <sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations
      contextRef="i526122db789843438c15c6cda35ca7ab_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84Mi9mcmFnOmFjMjk3MGQ2ZTUxYTRhMzliZDcyNGFjZmIyNDZjNjhhL3RleHRyZWdpb246YWMyOTcwZDZlNTFhNGEzOWJkNzI0YWNmYjI0NmM2OGFfNTg4Mw_c98eb497-adca-4d96-9412-9789a0dfd9ca">P7Y</sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations>
    <us-gaap:BasisOfAccounting
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84NS9mcmFnOjY5MjM0ZTllY2I2NTQzZjlhNmZiNGMwOWUyMjkxYzc4L3RleHRyZWdpb246NjkyMzRlOWVjYjY1NDNmOWE2ZmI0YzA5ZTIyOTFjNzhfMjM2MA_fd57e6a1-7375-4d0c-88f7-3bef56068c47">BASIS OF PRESENTATION&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interim Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#x2019; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the three months ended March 31, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the US dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84NS9mcmFnOjY5MjM0ZTllY2I2NTQzZjlhNmZiNGMwOWUyMjkxYzc4L3RleHRyZWdpb246NjkyMzRlOWVjYjY1NDNmOWE2ZmI0YzA5ZTIyOTFjNzhfMjM2MQ_56c1a99a-cbc2-4a8d-b5c0-4097db759f6e">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84NS9mcmFnOjY5MjM0ZTllY2I2NTQzZjlhNmZiNGMwOWUyMjkxYzc4L3RleHRyZWdpb246NjkyMzRlOWVjYjY1NDNmOWE2ZmI0YzA5ZTIyOTFjNzhfMjM2Mg_0a10c04d-e655-468b-a340-5b765b2fc142">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiaries, Viventia Bio USA&#160;Inc. and Viventia Biotech (EU) Limited. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84NS9mcmFnOjY5MjM0ZTllY2I2NTQzZjlhNmZiNGMwOWUyMjkxYzc4L3RleHRyZWdpb246NjkyMzRlOWVjYjY1NDNmOWE2ZmI0YzA5ZTIyOTFjNzhfMjM2Mw_09546163-7fab-4ec9-9d11-affa81dce2a1">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the US dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl84OC9mcmFnOjMzZTkwNzU2ZjY2ZTRkNmM5OTgzMjVmNzdkYTI5ZDc0L3RleHRyZWdpb246MzNlOTA3NTZmNjZlNGQ2Yzk5ODMyNWY3N2RhMjlkNzRfMjgwMjc_809220bf-d163-4eba-b703-b3c6d4443d12">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85MS9mcmFnOjBkZDQwZGJhMjExOTRhOTliNmUwM2JjNDUxZmFhYTY3L3RleHRyZWdpb246MGRkNDBkYmEyMTE5NGE5OWI2ZTAzYmM0NTFmYWFhNjdfOTM1_3b740a41-9880-4ca3-a9af-b5e2fd5c0719">RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#x2019;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2021-04")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-04 clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85MS9mcmFnOjBkZDQwZGJhMjExOTRhOTliNmUwM2JjNDUxZmFhYTY3L3RleHRyZWdpb246MGRkNDBkYmEyMTE5NGE5OWI2ZTAzYmM0NTFmYWFhNjdfOTM3_cc6a704d-9022-4900-93bf-dcf1c03734d9">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-06 simplifies the complexity associated with applying US GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#x2019;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2021-04")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-04 clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNjAyNQ_f6cc6dd8-f9bf-461e-ab5d-570213bba97a">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of March&#160;31, 2022 and December&#160;31, 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the quarter ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 9.0% to 9.7% as of March&#160;31, 2022 and 8.0% to 9.3% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the three months ended March 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the quarter ended March&#160;31, 2022, (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s contingent consideration is determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts are determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout is derived from the Company&#x2019;s weighted-average cost of capital (&#x201c;WACC&#x201d;), which has fluctuated from 9.3% as of December&#160;31, 2021 to 9.0% as of March&#160;31, 2022. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate is applied to the milestones in order to determine the estimated fair value. This index rate changed from 8.0% as of December&#160;31, 2021 to 9.7% as of March&#160;31, 2022. The decrease in the fair value of contingent consideration of $12.9 million for the three months ended March 31, 2022 was driven by changes in underlying assumptions used to develop the revenue projections.&lt;/span&gt;&lt;/div&gt;In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company's proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company also learned during the meeting that the FDA is trending away from accepting single arm trials across therapeutic areas, including NMIBC, and has a strong preference for randomized controlled trials. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Incorporating the FDA feedback from the Type C meeting, plans for further discussions with the FDA prior to initiation of the additional Phase 3 clinical trial, as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop the revenue projections upon which the fair value of its contingent consideration is based. The most significant and impactful assumptions in the Company&#x2019;s revenue projection models are timing of potential commercial product launch, probabilities of clinical and regulatory success, and market share. The Company anticipates further delays in the start of commercialization due to the likelihood of the requirement to conduct a randomized controlled trial which will require more patients to be enrolled, lengthen the duration of the study, and increase study costs. The company is also projecting lower estimated market share as a result of recent clinical and regulatory progress made by competitors. The Company has assessed a commercialization timeline assumption and applied a probability to each outcome based on management&#x2019;s best estimate. The Company continues to assume a POS in achieving certain clinical and regulatory milestones in the range of approximately 45% to 55% globally. Any changes in these assumptions and estimates, or other information obtained, may have a significant impact on the remeasurement of the contingent consideration liability in the future.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNjAyNg_a4c30958-ffd0-4461-a1b2-90147dbd46fe">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of March&#160;31, 2022 and December&#160;31, 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNjAyNw_089a6db5-cff7-45a3-8754-069360e19d0c">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie49f04215a514ffe9aa6de52f1449f7c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC0xLTEtMS01NzMzNw_a9c3d085-4407-41c5-b2de-a9a591becaf0"
      unitRef="usd">16378000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i29f65186d8914b83bd3a931c1ddffbf4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC0zLTEtMS01NzMzNw_2dbc649f-ef77-42ba-b5f5-24fb18268af2"
      unitRef="usd">16378000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i487e4fc22ff1483fa5e2a198b37ce024_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC01LTEtMS01NzMzNw_aceb5f96-47a8-4cf7-b20b-ea67f6b4198f"
      unitRef="usd">16378000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ibf2fde291dcd4b11bca4ee8ea8be676d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC03LTEtMS01NzMzNw_a648e4a7-0dc8-4edb-b576-3e1c7a2d114a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i352f1de5f4fc4ed299dd42039cae4d43_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNC05LTEtMS01NzMzNw_364fb145-1b6a-4415-801d-fccc25424d3f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ie49f04215a514ffe9aa6de52f1449f7c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy0xLTEtMS01NzMzNw_cbdb6874-f359-4c03-9ea1-93f23630074e"
      unitRef="usd">39100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i29f65186d8914b83bd3a931c1ddffbf4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy0zLTEtMS01NzMzNw_3ca80efe-dbd6-4c92-b2fe-dbf7f68ec460"
      unitRef="usd">39100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i487e4fc22ff1483fa5e2a198b37ce024_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy01LTEtMS01NzMzNw_ab80364f-1277-4ae3-9327-0f1d20243fec"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ibf2fde291dcd4b11bca4ee8ea8be676d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy03LTEtMS01NzMzNw_6608c209-ed80-498a-8557-a0fb851d692d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i352f1de5f4fc4ed299dd42039cae4d43_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjE4OTAyM2ZjN2IyNjQ4NTc5NGZiYWRhZGIxMjc0OGY2L3RhYmxlcmFuZ2U6MTg5MDIzZmM3YjI2NDg1Nzk0ZmJhZGFkYjEyNzQ4ZjZfNy05LTEtMS01NzMzNw_2db040c7-841d-4f8e-9d61-29f176a97d7e"
      unitRef="usd">39100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia9d6eda91c70472c97ddbcf9c27c26f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC0xLTEtMS01NzMzNw_6538b298-dd92-4b33-b5fa-8059e75f6ef1"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id856a959b0b243f28a91153f115b51d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC0zLTEtMS01NzMzNw_5bc6b6b5-1847-44e9-aa45-7f41fa2db43c"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f177ca553484a5e816e4b2458b15d0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC01LTEtMS01NzMzNw_72986ccd-6860-467a-b8d7-bd6028c0c84a"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iff3dd7d4481c4276acefb438f635d714_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC03LTEtMS01NzMzNw_0a32a024-4a17-423e-9283-42feaf77448d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i37b667a740a14082b1c2a0e4fe06a99d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNC05LTEtMS01NzMzNw_e6abe676-62d3-4720-8275-6ebdcd37b595"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia9d6eda91c70472c97ddbcf9c27c26f9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy0xLTEtMS01NzMzNw_7d672c0d-d303-4c68-9832-05c99fe89824"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id856a959b0b243f28a91153f115b51d1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy0zLTEtMS01NzMzNw_43a77027-1361-4c3d-9f3c-e0a0d05ff888"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2f177ca553484a5e816e4b2458b15d0e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy01LTEtMS01NzMzNw_f2fd42f7-1b69-464a-9f22-e73a5aaeff10"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iff3dd7d4481c4276acefb438f635d714_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy03LTEtMS01NzMzNw_f1b22661-a830-49f7-a184-662b09c7174b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i37b667a740a14082b1c2a0e4fe06a99d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjY0M2FlMjk5NGZmNjQzYzliNWEyZDU4NzI5NDI1YjQwL3RhYmxlcmFuZ2U6NjQzYWUyOTk0ZmY2NDNjOWI1YTJkNTg3Mjk0MjViNDBfNy05LTEtMS01NzMzNw_195c4973-27d1-43ef-8577-1c5b5297a3b9"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i777b729b56654272aecb76e84444d371_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMTA5OTUxMTYyOTcwMjU_3a477643-ac3b-4361-87ec-ce612884f5db"
      unitRef="number">0.090</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia85202389e8f434f9771578dd1116186_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNzY5NjU4MTQxMjUyNQ_3dfac151-c911-4a23-9088-10861975294f"
      unitRef="number">0.097</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia6c8bda95fde40828c577fa8789c7d3f_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNzY5NjU4MTQxMjQzOA_807fc940-06bc-4431-b9d6-149102eabf94"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ied03436a4b954153b51104e07b4308a5_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNzY5NjU4MTQxMjQ0NA_9bebe03b-6eed-41e2-b695-68ee1ea4735e"
      unitRef="number">0.093</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNjAyOA_690e30de-e7ab-4591-a7b8-915301c71eda">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period, for the quarter ended March&#160;31, 2022, (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,900)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if5c3d72e64284343ad41bbaabad2492e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjQyOWRlODdhMTdmMjQxYWZhYTUxYzk5MTExMjRjYmFmL3RhYmxlcmFuZ2U6NDI5ZGU4N2ExN2YyNDFhZmFhNTFjOTkxMTEyNGNiYWZfMC0xLTEtMS01NzMzNw_7ed169d0-0997-4e8d-9b7d-9e048219e274"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent
      contextRef="ie0974e9a0eac4b9a943068d81c400af6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjQyOWRlODdhMTdmMjQxYWZhYTUxYzk5MTExMjRjYmFmL3RhYmxlcmFuZ2U6NDI5ZGU4N2ExN2YyNDFhZmFhNTFjOTkxMTEyNGNiYWZfMi0xLTEtMS01NzMzNw_9299d79d-24e4-45b3-9964-63667a0877d3"
      unitRef="usd">-12900000</sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4024043b56ba43449e39178a89ef2a79_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RhYmxlOjQyOWRlODdhMTdmMjQxYWZhYTUxYzk5MTExMjRjYmFmL3RhYmxlcmFuZ2U6NDI5ZGU4N2ExN2YyNDFhZmFhNTFjOTkxMTEyNGNiYWZfMy0xLTEtMS01NzMzNw_07ab3dd7-09be-427b-8737-f41d22663b19"
      unitRef="usd">39100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMjkwMg_a97c0d10-70ec-4f41-a030-d2521afbf6ac"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMzAwMQ_c4ec203d-0a49-4fe2-a361-339756b43996"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="ida5defd37759486088c2d5f6a80ad271_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMzE3Mg_5d363061-0958-4071-8dee-4ba34e9f9f48"
      unitRef="number">0.093</sesn:WeightedAverageCostOfCapital>
    <sesn:WeightedAverageCostOfCapital
      contextRef="icc5ad7341ef44d9e9d0eb812d5d6aef7_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfOTg5NTYwNDY2ODEwMA_e1c90691-1d93-4bca-aa5a-90025fb1f0e3"
      unitRef="number">0.090</sesn:WeightedAverageCostOfCapital>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMzQ4NQ_523ff1da-a94e-405f-8c08-508e1e508fbc"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNzY5NjU4MTQxMjU1Ng_7f3b4656-ab72-4c54-a895-e3fb323c7b7b"
      unitRef="number">0.097</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfMzU2MA_a9e1eb46-d0e5-4737-be53-cc5edd684605"
      unitRef="usd">-12900000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage
      contextRef="i789b708b5a4b4f70b35c83d05b643756_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNTc5MQ_ace41006-6dda-4cfb-8e62-478c04a1499b"
      unitRef="number">0.45</sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage>
    <sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage
      contextRef="id5b7224c57a349dd8417b26074fdfea8_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85NC9mcmFnOjQ1OGM1ZDY5ODQwMTQ5ZWI4YjlhOWMwYWQwYjQ4YWZmL3RleHRyZWdpb246NDU4YzVkNjk4NDAxNDllYjhiOWE5YzBhZDBiNDhhZmZfNTc5Nw_541d7968-c29d-4112-b521-ec951d08eb21"
      unitRef="number">0.55</sesn:ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfMTIzNw_7dd5be35-d5bb-4dcd-ad2e-33552a5df164">RECEIVABLES &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounts receivable balance as of March&#160;31, 2022 is $1.0&#160;million compared to $21.0&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $20.0&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#x201c;Roche&#x201d;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other receivable balance as of March&#160;31, 2022 is $1.0&#160;million compared to $3.5&#160;million as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The decrease is driven primarily by the receipt of $1.8&#160;million for German VAT recovery related to drug substance sent to Baxter in 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i37a86bcaa5c4400cb485d8e214b15877_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfODA_68c8d31d-5b21-46d0-aee1-4a9e574fa86c"
      unitRef="usd">1000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfMjE5OTAyMzI2MzIyMw_ab9479fd-9995-464c-86ea-1ca7da948b0d"
      unitRef="usd">21000000</us-gaap:AccountsReceivableNetCurrent>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="ie4d8a28b63694dfca536772f228dfd1f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfMTY0OTI2NzQ0OTMwNQ_7089d413-21a7-4c93-ab7b-55bfe8325e4e"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfODk5_75ce1e56-0fc0-466d-b070-6bb7b62d75a8"
      unitRef="usd">1000000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfMTA5OTUxMTYyODU0NjI_3cfb703c-7f9b-44f1-a527-1ebf810d8daf"
      unitRef="usd">3500000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i6cc771771ec447eb817fedfab04c5064_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl85Ny9mcmFnOjMxYzE1MDZhZTFkNDRkYWQ5ZWNlYTFjZDY5YjQwNGIzL3RleHRyZWdpb246MzFjMTUwNmFlMWQ0NGRhZDllY2VhMWNkNjliNDA0YjNfNTQ5NzU1ODE0NjQ2OA_158b8d62-18bc-438b-a4f1-45c54f07dc18"
      unitRef="usd">-1800000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzY5MjA_f500c6a7-0b64-4100-86ed-21ebff50e69c">INTANGIBLES AND GOODWILL&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets on the Company's condensed consolidated balance sheet are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the acquired intangible assets for the EU rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#x2019;s lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its MAA to the EMA for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there is more clarity from the FDA on next steps for Vicineum in the United States. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#x2019;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum United States rights was fully impaired as of September 30, 2021. The $31.7&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;current range of commercialization timelines and POS assumptions. This was primarily due to the fact that the EU asset is burdened with significantly less expense than the US asset, as the Company&#x2019;s strategic operating plan is to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company's proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for potential resubmission of a BLA for Vicineum for the treatment of NMIBC. The Company also learned during the meeting that the FDA is trending away from accepting single arm trials across therapeutic areas, including NMIBC, and has a strong preference for randomized controlled trials. The Company plans to further engage the FDA in the coming months to align on the remaining outstanding items related to the additional Phase 3 clinical trial. Based on the outcome of the Type C meeting as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of the indefinite-lived intangible asset. Management updated the revenue forecast models based on further launch delays in both US and OUS regions as well as slightly lower market share. The Company anticipates further delays in the start of commercialization due to the likelihood of the requirement to conduct a randomized controlled trial which will require more patients to be enrolled, lengthen the duration of the study, and increase study costs. The company is also projecting lower estimated market share as a result of recent clinical and regulatory progress made by competitors. Accordingly, the Company identified this as a potential impairment indicator and performed an interim quantitative impairment assessment during the first quarter of 2022. The Company concluded that the carrying value of the Company's intangible asset of Vicineum EU rights was not impaired as of March&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's condensed consolidated balance sheet is the result of the Viventia Acquisition in September 2016. Goodwill had a carrying value of $13.1&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. Based on the outcome of the Type C meeting as well as updates to the competitive landscape, the Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both US and OUS regions as well as slightly lower market share. Accordingly, the Company identified these changes to the revenue forecast, as well as the decline in the Company&#x2019;s stock price and market capitalization during the first quarter of 2022, as potential impairment indicators and performed a quantitative impairment analysis during the first quarter of 2022, in advance of the Company's typical annual assessment date of October 1. The Company concluded that the carrying value of its goodwill of $13.1&#160;million was not impaired as of March&#160;31, 2022, with the fair value of equity of the reporting unit exceeding the estimated carrying value of the reporting unit by approximately 29%.&lt;/span&gt;&lt;/div&gt;The Company believes it has sufficient future cash flows from additional geographic regions outside the US to support the value of its goodwill. The Company projects future cash flows based on various timeline assumptions and applies a probability to each outcome based on management&#x2019;s best estimate. In addition, probabilities of success in achieving certain clinical and regulatory success in the Company's current development profile (ranging from 45% to 55% globally) and underlying discount rates also have a material effect on the estimated fair value of its reporting unit as of the impairment assessment date. The Company will continue to evaluate its timelines for commercialization and probability of success of development of Vicineum for the treatment of NMIBC. Further reductions to probabilities of success, decrease in market share, additional development and commercial launch delays, increases in underlying discount rates, or any decision to undertake any strategic alternative as a result of the review process that the Company has initiated, have the potential to result in future goodwill impairment.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzY5MjE_5e3cceab-bc1b-4709-850e-e822b2e31cf2">The following table sets forth the composition of intangible assets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i545bec4894b147faa5be77fb0ce698df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90YWJsZTozM2MxMzhmYTdkOTQ0NjIwOWI5NjM4ODk5OGY3NGZiOC90YWJsZXJhbmdlOjMzYzEzOGZhN2Q5NDQ2MjA5Yjk2Mzg4OTk4Zjc0ZmI4XzQtMS0xLTEtNTczMzc_e92f618c-799d-48ca-9050-103ff9ea62da"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="idf4f0077ab4d4c7e8baa7cd8eac1afbe_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90YWJsZTozM2MxMzhmYTdkOTQ0NjIwOWI5NjM4ODk5OGY3NGZiOC90YWJsZXJhbmdlOjMzYzEzOGZhN2Q5NDQ2MjA5Yjk2Mzg4OTk4Zjc0ZmI4XzQtMy0xLTEtNTczMzc_2b8614be-504d-41f0-b1dc-69d6472781df"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ie5e2f3183009408a88a2121d2f8320de_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90YWJsZTozM2MxMzhmYTdkOTQ0NjIwOWI5NjM4ODk5OGY3NGZiOC90YWJsZXJhbmdlOjMzYzEzOGZhN2Q5NDQ2MjA5Yjk2Mzg4OTk4Zjc0ZmI4XzUtMS0xLTEtNTczMzc_7c74e13c-97c5-4c0c-abb9-41d3a53968c1"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ia9c6211a35774d058c2bc34135cd81cd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90YWJsZTozM2MxMzhmYTdkOTQ0NjIwOWI5NjM4ODk5OGY3NGZiOC90YWJsZXJhbmdlOjMzYzEzOGZhN2Q5NDQ2MjA5Yjk2Mzg4OTk4Zjc0ZmI4XzUtMy0xLTEtNTczMzc_9cb0a48f-37a1-43bc-86aa-599bc141f361"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="if355f8cd711e40d5bb37354a4ec90cf0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzU0OTc1NTgxNjQ4MjY_137774e5-b591-4db9-9295-d900164ebde3"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzQyNDQ_aa233855-905b-49b8-a8df-3109d47b8f04"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzQyNDQ_af5bb69b-48cc-40d6-99eb-e55d3b4edb62"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie489efabccd5453ea2dc7e35706cfaa4_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzQ3MDc_d112a134-1d03-405b-ab6b-7a5a64f23c38"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzc2OTY1ODE0MjYzMjY_f2a89dd6-b998-43a8-a11e-b99a215755c8"
      unitRef="number">0.29</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="i789b708b5a4b4f70b35c83d05b643756_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzYzNzk_93d42297-3529-4362-8a08-a94c414b9a16"
      unitRef="number">0.45</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount
      contextRef="id5b7224c57a349dd8417b26074fdfea8_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDMvZnJhZzpiMWMxYWNiZDYwYWU0ZTI1OWZmOTQ2NDJkMzM4NmQwZC90ZXh0cmVnaW9uOmIxYzFhY2JkNjBhZTRlMjU5ZmY5NDY0MmQzMzg2ZDBkXzYzODU_92ae78cb-7ed3-44c0-aace-0c14bbdaf5f6"
      unitRef="number">0.55</us-gaap:ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90ZXh0cmVnaW9uOmY4MGEzMGEwNDhkYzQyNTU5Yzk4MWYxNzYzMTIxZGQ2XzEzMg_0f682b2a-1629-45c4-8de6-139e08b04718">ACCRUED EXPENSES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90ZXh0cmVnaW9uOmY4MGEzMGEwNDhkYzQyNTU5Yzk4MWYxNzYzMTIxZGQ2XzEzMw_d63ef213-2596-43ea-a8c0-dced06faec72">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzItMS0xLTEtNTczMzc_8ad646a2-b867-42bd-bd25-bb5596c7d647"
      unitRef="usd">981000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzItMy0xLTEtNTczMzc_390e0916-4bb2-48dd-b452-1abc96e0075c"
      unitRef="usd">1841000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzMtMS0xLTEtNTczMzc_446684ce-4816-4914-b951-c57473bbc3e9"
      unitRef="usd">2675000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzMtMy0xLTEtNTczMzc_5df291fe-540f-4ea7-b1ca-fc81b553d7d6"
      unitRef="usd">2967000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzQtMS0xLTEtNTczMzc_4233a927-37bc-4c71-9f4a-ada6b09d9b6c"
      unitRef="usd">990000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzQtMy0xLTEtNTczMzc_9ba7663c-7f7c-499c-bade-3adf4468a1ff"
      unitRef="usd">1497000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzUtMS0xLTEtNTczMzc_abb7f3c2-5200-4f15-815d-449f659783ab"
      unitRef="usd">2582000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzUtMy0xLTEtNTczMzc_782bdd7e-6a87-4e08-b618-2b3d67a17cd0"
      unitRef="usd">1941000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzYtMS0xLTEtNTczMzc_7a548593-23a2-437f-8056-4912a7a66fdb"
      unitRef="usd">50000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzYtMy0xLTEtNTczMzc_9123781f-c410-464c-a8b1-7967c870cebc"
      unitRef="usd">9000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzctMS0xLTEtNTczMzc_4d850775-55a5-422d-9754-af6bf8bcb6ab"
      unitRef="usd">7278000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDYvZnJhZzpmODBhMzBhMDQ4ZGM0MjU1OWM5ODFmMTc2MzEyMWRkNi90YWJsZToxZGFmZTA2NTBkZWY0Yzg2OWRkNGRhMTExZmU3NWQ4OC90YWJsZXJhbmdlOjFkYWZlMDY1MGRlZjRjODY5ZGQ0ZGExMTFmZTc1ZDg4XzctMy0xLTEtNTczMzc_c0255bf0-9cd5-46ca-ab77-b79e8ee6d4cc"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzU0NDc_6ceb6a8b-ec6b-4bf0-bfcb-c7f8de9ff00c">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#x2019;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#x2019; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#x201c;Securities Litigation&#x201d;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#x201c;Lead Plaintiffs&#x201d;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#x201c;Amended Complaint&#x201d;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. The court has not yet ruled on the motion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#x2019;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#x2019;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#x2019;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as nominal defendant. The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#x2019;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#x2019; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#x201c;Federal Derivative Litigation&#x201d;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. Defendants intend to seek a similar stay of the state court derivative litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that these lawsuits are without merit and intends to vigorously defend against them. The lawsuits are in the early stages and, at this time, no assessment can be made as to the likely outcome or whether the outcome will be material to the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sesn:NumberOfLawsuits
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzEyMTU_12535ac6-2bc6-4f83-a74e-7dbe00521909"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzE1OTE_3e7e1ea2-4654-4baf-94d6-abd490f3af34"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzE4MzA_89f86dab-9e89-4dc2-93c5-00ded1229155"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMDkvZnJhZzpiODM4ZGVjNzdlMmI0YmYxYTk0MWM1OTBiNTUxYjc1Ny90ZXh0cmVnaW9uOmI4MzhkZWM3N2UyYjRiZjFhOTQxYzU5MGI1NTFiNzU3XzE5Njk_2bc8652a-30c0-4140-b22b-f7171c2ee076"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjU_6b336d7d-c114-4ac5-bf55-e96cfe8ede01">LEASES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for operating leases under ASC Topic 842,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Leases. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022, with a right to extend the lease for one subsequent three-year term. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,500 at exchange rates in effect on March&#160;31, 2022). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,500 at exchange rates in effect on March&#160;31, 2022). Operating lease cost under this lease, including the related operating costs, were $0.1&#160;million for the three months ended March&#160;31, 2022 and March&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The asset component of the Company&#x2019;s operating leases is recorded as operating lease right-of-use assets and reported within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_70e2c78d-7000-4550-b39c-7708486d9514"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjI_a608af25-a8c3-43f1-bc13-bde655007b13"&gt;other assets&lt;/span&gt;&lt;/span&gt; on the Company's condensed consolidated balance sheets. The right of use asset total was $0.1&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. The short-term lease liability is recorded in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_257c3c35-2b5f-4801-99d1-da6db072ebc5"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjM_870e15ab-96b9-4644-93c8-e07c8cee8f3a"&gt;other current liabilities&lt;/span&gt;&lt;/span&gt; and the long-term lease liability is recorded in other liabilities on the Company&#x2019;s condensed consolidated balance sheets. The short-term lease liability was $0.1&#160;million as of March&#160;31, 2022 and December&#160;31, 2021. There was no long-term operating lease liability as of March&#160;31, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases renew every &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIxOTkwMjMyNTg5Mjc_107f62f1-7e63-49b3-8b18-5cce5a5aebdc"&gt;six&lt;/span&gt; to twelve months and currently extend through June 2023 and May 2023, respectively. The minimum monthly rent for these office spaces is $2,100 and $18,400, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sesn:OperatingLeasesAreaOfOfficeSpace
      contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzE1Mw_46da70f3-a770-40fc-8828-23118c968097"
      unitRef="sqft">31100</sesn:OperatingLeasesAreaOfOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="ie0b15da2342248bf8f341d5a7661bd17_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzM2MQ_e2e5f4f8-3b57-47c7-9be8-9a74d0e5e1ca">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption
      contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzQyNg_83a8de09-258b-447e-80df-28b803172a73"
      unitRef="term">1</sesn:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie0b15da2342248bf8f341d5a7661bd17_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIwMjE_7cf3f2d9-6831-401e-abfb-f9a9a882ab29">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzUwMw_bdc73dbb-940f-4679-8417-d91922a1740b"
      unitRef="cad">18100</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzUyMQ_da709d17-d202-4694-92cd-ed86be596f50"
      unitRef="usd">14500</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzYyMg_7d0f0f37-40af-450b-97c7-b95419948bf4"
      unitRef="cad">18200</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="ibb10ae2816e5438499b0783f31fa6094_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzY4MA_3d6cce09-cdf3-4d7d-9696-16d3ad767797"
      unitRef="usd">14500</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <us-gaap:OperatingLeaseCost
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzgwOQ_20167ad8-1c04-4c70-9c12-daee0a484353"
      unitRef="usd">100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzgwOQ_4240b0b8-0c6f-4abd-a810-a9282d3dcacb"
      unitRef="usd">100000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzMyOTg1MzQ4ODYyOTQ_95e73548-4eed-4250-b9f2-6b46af1ed698"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzMyOTg1MzQ4ODYyOTQ_ca2c6cd1-9b0e-4a77-9044-0ce2913d0044"
      unitRef="usd">100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzMyOTg1MzQ4ODY1MDk_1b5cff73-9acd-4e38-8496-78788fd01e2e"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzMyOTg1MzQ4ODY1MDk_c98b4303-f891-46b7-b6a6-6750d0a00738"
      unitRef="usd">100000</us-gaap:OperatingLeaseLiabilityCurrent>
    <sesn:ShortTermLeaseRenewalFrequency
      contextRef="i91a2e679410d42bd9b578b3fe11ffb4a_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzIxOTkwMjMyNTg5MzI_f9b33f74-a062-4e80-a3b9-898bc1610006">P12M</sesn:ShortTermLeaseRenewalFrequency>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i145c98efedcf4ac6a1bfc225996ebb5c_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzE2Nzc_ac81a024-8943-4a4d-bb3b-41fd98b99a6c"
      unitRef="usd">2100</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="ib4acdf8e88564bcaa3b39b640d7f099c_D20220101-20220331"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTIvZnJhZzoyZDIxYjExYTVkMjg0ZWU3YTg1MDM0YmM4N2MzNGJkNS90ZXh0cmVnaW9uOjJkMjFiMTFhNWQyODRlZTdhODUwMzRiYzg3YzM0YmQ1XzE2ODQ_0f06a4ae-65ea-4d7a-9570-a40b03088a88"
      unitRef="usd">18400</sesn:OperatingLeaseMonthlyRent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzExMTY3_8c9e2114-a961-4e29-8691-8e446e73acf8">STOCKHOLDERS' EQUITY &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into an Open Market Sale Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time through Jefferies (the &#x201c;ATM Offering&#x201d;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement of which $97.8&#160;million of common stock remain available for future issuance as of March&#160;31, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Global Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#x2019;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the three months ended March 31, 2022. The Company raised $72.6&#160;million of net proceeds from the sale of 30.6&#160;million shares &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of common stock at a weighted-average price of $2.44 per share during the three months ended March 31, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.2&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the three months ended March 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of March&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following approval by the Company&#x2019;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;199&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares were issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;227,275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#x2019;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (&#x201c;ASC 815-40&#x201d;). The following table sets forth the Company's warrant activity for the three months ended March 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#x201c;Item 15. Exhibits and Financial Statement Schedules - Note. 12 Stockholders&#x2019; Equity (Deficit)&#x201d; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4321e3e7de5f473b81eb3f2fa81fef3b_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2NTQ0OTU_f4e93e38-2827-43f0-910c-52bc1cdc2db8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="i38aea9f975c9437f993d25b7b3b9c71b_D20210601-20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2NTQ1ODg_2afa4c56-2a1b-44b9-b9a9-68f3dd3a3277"
      unitRef="usd">200000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance
      contextRef="ibb19d0c9c4ac4cbaac6c9dc28bf97c0d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2NTQ2Mjc_0187e4ec-e077-4cd1-90b2-9b71ea3d1779"
      unitRef="usd">97800000</sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance>
    <sesn:SaleOfStockCommissionFixedRate
      contextRef="i5bc89768d7574532a2c9411e20751c77_D20211129-20211129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2NTQ0ODk_d601e7a7-f146-4491-9543-0f1782195e8a"
      unitRef="number">0.030</sesn:SaleOfStockCommissionFixedRate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2MzkwMjE_80cd3e7a-f987-49a8-87ac-7eff6273d8f7"
      unitRef="usd">72600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2MzkwMjk_0a09aeb5-c615-4f0f-ac53-f8f5ac50574b"
      unitRef="shares">30600000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2MzkwMzY_11d5fe7a-bc2d-4608-917a-ac4b90f8b652"
      unitRef="usdPerShare">2.44</sesn:SaleOfStockWeightedAveragePricePerShare>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="i933bb46d00bc455d8751660a39f9f3db_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzEwOTk1MTE2MzkwNDE_5219c350-4c26-4373-b72a-c22ed51e7655"
      unitRef="usd">2200000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM0NTU_3944a07f-e248-445f-9ffa-98acb836f61b"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM0OTk_50691a6a-95ba-46e1-ab97-4197e0edf289"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM5NDM_3563ac6a-63ca-4833-952c-bfa127c0fadf"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM5NDM_53d531ff-1e8d-4a8d-9c37-05a04dcda56b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM5NDM_849f35a3-f37c-4630-8ae0-5ca9d420f74f"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzM5NDM_af309297-051d-4704-8615-88d2f23b0763"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iad87f2a2e4064dc8babf6447190779eb_I20210502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyMTQ_9daa4122-16f8-4ec9-b2cb-9d00fa3db834"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ib6a9e7c16bd84278a88fc26407cd68a3_I20210503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyMjA_d1be7f97-15d2-480d-9f01-3fd51db8c013"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyNDA_36d4efd8-14d9-4c24-9ecf-39d2b75f7282"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyNDA_5547cbde-5175-49de-b6c9-cc6ffa44638b"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyNDA_9d611f14-2402-427c-b807-ae6e42447569"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQyNDA_b69ff116-2c3e-4daa-9dfa-1dd441e0e714"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzExMTY0_e17dbf95-7cbf-4f7f-beb3-b111ff833a77">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;227,275&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzItMS0xLTEtNTczMzc_caaf6bfa-a05f-41ac-909a-32989ca8edc4"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzItMy0xLTEtNTczMzc_8aeeb8ee-c65f-4571-8b97-4d6bfcb0048f"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i21ceb143543841428ec32f3c9ad4b0be_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzQtMS0xLTEtNTczMzc_a8ebc42b-2e30-4e64-b98c-1ccddf638d0d"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0fe2c623a9d74a7389296573a31bbb22_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzQtMy0xLTEtNTczMzc_2ddd350c-7a37-44a1-bdd7-5228c8f27765"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3baa1439c0ea43b08add2b44f358ac2d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzUtMS0xLTEtNTczMzc_49e20a66-ad01-48ad-871d-1143a94225f9"
      unitRef="shares">16783000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i221c8962daf4444ebdf4d3c88988461b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzUtMy0xLTEtNTczMzc_932191bf-9992-4e2b-8893-d41c7fdd98c4"
      unitRef="shares">15703000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id2d1253ec7414a4b84ffbe87119b85ff_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzYtMS0xLTEtNTczMzc_e6125035-a6b0-49cc-92a7-1f79a491f9d6"
      unitRef="shares">4965000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id98165c78fa5475887c60e7c8804b011_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzYtMy0xLTEtNTczMzc_8ccb00ad-a142-45e5-b0c7-ebbef8a1111e"
      unitRef="shares">3041000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if3c6c33e3cf54dd39de56d11701d0b0d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzctMS0xLTEtNTczMzc_54c75f37-9d92-45f5-b8c1-bddf5456726c"
      unitRef="shares">3564000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="iefba41b22eac4b17ad9b01a9511c163f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzctMy0xLTEtNTczMzc_c9692134-7014-4797-bd17-dd22aed6572c"
      unitRef="shares">8933000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1b8342820bc14fc18dcb66343e2d8dbb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzgtMS0xLTEtNTczMzc_4b316c63-7649-4e39-ba31-29a847f80396"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i60a06969725e4e0ab841501477d0ab94_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzgtMy0xLTEtNTczMzc_e3c3018b-d2ad-4b26-af1b-f27f987216c7"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzktMS0xLTEtNTczMzc_925539c6-2263-4bf2-af7d-8e46b1365cd9"
      unitRef="shares">227275000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo0NzNjNjA1YTYwNjM0MjMzOTRkNTVkZDFiMDU3ZjNlOS90YWJsZXJhbmdlOjQ3M2M2MDVhNjA2MzQyMzM5NGQ1NWRkMWIwNTdmM2U5XzktMy0xLTEtNTczMzc_d8066f23-def4-4c90-bd27-0c1dc7417f3f"
      unitRef="shares">229640000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:NumberofVotesEntitledForEachShare
      contextRef="i46b9def9cc834e2e9e98a5e65496e75a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzQ3MTg_6aa423b1-fb29-4d46-8cf4-9f8936163437"
      unitRef="vote">1</sesn:NumberofVotesEntitledForEachShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90ZXh0cmVnaW9uOjE2YzZlMGM3MmUxYTQwNWNiOGU3OGZjYjA1MTg0YzhlXzExMTY2_34fcb045-cd53-44a8-9596-79107ca0e11b">The following table sets forth the Company's warrant activity for the three months ended March 31, 2022 (in thousands):&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#x201c;Item 15. Exhibits and Financial Statement Schedules - Note. 12 Stockholders&#x2019; Equity (Deficit)&#x201d; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i874e45992d94489c9ad7c98356670dc7_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItMi0xLTEtNTczMzc_c1bad728-b381-416c-b33a-1f63b2abca63"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i900115e3ca494438812c53a74b2e941e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItNi0xLTEtNTczMzc_8ccb58b6-1a39-4dc8-ac26-c3b30af1e860"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="ie30fcbf9c3814ac980e2533dce4fe035_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItOC0xLTEtNTczMzc_29dd1334-ebfb-4f34-88a6-b9ac8a65ceea"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ie30fcbf9c3814ac980e2533dce4fe035_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItMTAtMS0xLTU3MzM3_314f4f48-4cbc-40c7-93ef-911b5d816978"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="ie30fcbf9c3814ac980e2533dce4fe035_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItMTItMS0xLTU3MzM3_0c158ad9-b0d6-43bb-a312-b1564072b344"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i874e45992d94489c9ad7c98356670dc7_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzItMTQtMS0xLTU3MzM3_94b03bef-e6b1-4422-bc4b-e7f83cf26f28"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i3779abea087b4610ba82ce1d85f2bf38_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtMi0xLTEtNTczMzc_168187a6-1bd6-4c73-b541-65c7833d2b74"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic2a61ca27ef84e2aa470147840bc3c1a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtNi0xLTEtNTczMzc_a31fd6a0-d256-4810-bab3-ef815f1e2ed1"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i87c1ad53e5a84769a79cc00b7c419f7f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtOC0xLTEtNTczMzc_13aa74dd-0b49-478e-8786-a1ad1260f7da"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i87c1ad53e5a84769a79cc00b7c419f7f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtMTAtMS0xLTU3MzM3_866a88e8-5a28-4020-a20d-f5d7a1145293"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i87c1ad53e5a84769a79cc00b7c419f7f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtMTItMS0xLTU3MzM3_41636cec-5c02-46d2-943d-cbe1c0bd7c43"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i3779abea087b4610ba82ce1d85f2bf38_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzMtMTQtMS0xLTU3MzM3_537ce7cd-b071-49e0-aa60-55c3c6caca69"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i1240079e3b784011876aef3004337651_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtMi0xLTEtNTczMzc_1723de1a-c893-4e65-b07a-72a13c8555ee"
      unitRef="usdPerShare">11.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id2db8bf0bb154bf988c5f0cbf4b1fa14_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtNi0xLTEtNTczMzc_86fc3fd8-7982-4c61-acdc-76f9fa240a68"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i8543e2bf0407481b92ce314c98882350_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtOC0xLTEtNTczMzc_b2399c89-c612-470b-b657-f395247ecdf1"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i8543e2bf0407481b92ce314c98882350_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtMTAtMS0xLTU3MzM3_f345c056-2bde-45f4-921f-67eb806bb90c"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i8543e2bf0407481b92ce314c98882350_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtMTItMS0xLTU3MzM3_90d14c67-b7ef-4074-a78c-f83e209b4dee"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i1240079e3b784011876aef3004337651_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzQtMTQtMS0xLTU3MzM3_e3ca020e-7c8a-4976-989d-00e1f73a27db"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7b139b5a19b94648b6cd590da2967190_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtMi0xLTEtNTczMzc_dec0630b-cc05-4266-a786-f45aaad74f13"
      unitRef="usdPerShare">11.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i0474ce6e41f94994aa5166f4cef01656_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtNi0xLTEtNTczMzc_c456632e-b563-460d-8f92-65f8633b84ac"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i491f8467f7ff45e0b2e6a6bc33dabb45_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtOC0xLTEtNTczMzc_675c216c-33bf-455a-86dd-45ebd9180e8e"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i491f8467f7ff45e0b2e6a6bc33dabb45_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtMTAtMS0xLTU3MzM3_d8b7b2eb-4627-40ef-a813-14f4bc9218fc"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i491f8467f7ff45e0b2e6a6bc33dabb45_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtMTItMS0xLTU3MzM3_21316b5c-7347-4edf-bf1a-8b65717a75a1"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7b139b5a19b94648b6cd590da2967190_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzUtMTQtMS0xLTU3MzM3_2929b52c-d484-42d3-9221-00720a47f535"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtNi0xLTEtNTczMzc_ee8857fc-576b-41b1-8014-37698a2241f9"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtOC0xLTEtNTczMzc_e6827987-8b19-4b22-b83d-b31bbab58896"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtMTAtMS0xLTU3MzM3_d07dd146-11a0-4a85-b209-f0abeae02aba"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtMTItMS0xLTU3MzM3_c12bba18-c974-4971-b905-e43aadd769d7"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTUvZnJhZzoxNmM2ZTBjNzJlMWE0MDVjYjhlNzhmY2IwNTE4NGM4ZS90YWJsZTo3OWE2N2Q5ZTMzOTc0YWRhYThiNDU4YjNkYmU0OTFhMC90YWJsZXJhbmdlOjc5YTY3ZDllMzM5NzRhZGFhOGI0NThiM2RiZTQ5MWEwXzYtMTQtMS0xLTU3MzM3_b5e4811e-23a0-4927-ba6e-d1f4c6bf7139"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90ZXh0cmVnaW9uOjNjNDcxOTZjMmZlYzQwOGI5ZmUyNzlmY2I4NjMzOWZlXzI4MDA_544314c0-c5ca-4606-8812-f4a35c1635de">EARNINGS (LOSS) PER SHARE&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#x2019;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of March&#160;31, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,537&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,774&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90ZXh0cmVnaW9uOjNjNDcxOTZjMmZlYzQwOGI5ZmUyNzlmY2I4NjMzOWZlXzU0OTc1NTgxNDMwNzU_056946f6-6cf8-462d-b1cb-7592f5dc6981">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of March&#160;31, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.988%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.051%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23,537&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,774&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6ad7b614817843a2a51daa8dac6c033e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzItMS0xLTEtNjY5NTY_63449a8c-08a3-4a05-8877-d2a2735f3c2c"
      unitRef="shares">199000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id1d7e92567284313b0215206d23cf138_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzItMy0xLTEtNjY5NTY_baa1835a-d7a6-4199-80ef-68583d9c196b"
      unitRef="shares">1394000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i01f86ee5c7454a6daf1539b8ff9154fd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzMtMS0xLTEtNjY5NTY_e22058c4-12e4-4fdb-96d6-494378aa01a6"
      unitRef="shares">16783000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1d1313b2a80c4a2b83d39bef2b31ff64_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzMtMy0xLTEtNjY5NTY_37c161d9-7a42-4391-a9fe-3bbdf9bdf1e3"
      unitRef="shares">14380000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6df6b49ba9af4253b2980614997544b3_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzQtMS0xLTEtNjY5NTY_4a2170b6-e5f0-4c37-8731-7173cbad3987"
      unitRef="shares">6555000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i442503d958e94d1cbb92a12c86bfd18d_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzQtMS0xLTEtNjY5NTY_8c0ac15e-7400-4d56-a40d-74f33ebfdc86"
      unitRef="shares">6555000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i638a4bc304a64fefb58743f705706eb0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzQtMy0xLTEtNjY5NTY_15befb67-bc52-436c-8e75-e1e89c7e9f05"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifb83446dcd9e42a599260539ad1c0a9e_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzQtMy0xLTEtNjY5NTY_95b1cd95-50f9-449b-ad14-94576d0fd348"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzUtMS0xLTEtNjczNzA_8e6b32e1-d9b6-45d8-bc54-af9eb70ddc6a"
      unitRef="shares">23537000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMTgvZnJhZzozYzQ3MTk2YzJmZWM0MDhiOWZlMjc5ZmNiODYzMzlmZS90YWJsZTphMGIwOWI5NTIzNjI0MzI2YmM1ZTM5OTZjNDMyYzMyNy90YWJsZXJhbmdlOmEwYjA5Yjk1MjM2MjQzMjZiYzVlMzk5NmM0MzJjMzI3XzUtMy0xLTEtNjczNjg_30f70133-10fd-428e-8645-75150316a0e8"
      unitRef="shares">15774000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyNDc_9c8814ac-b73a-4fd5-b005-8f93fe184e8b">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations and Comprehensive Loss for three months ended March 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:433.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:277.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;958&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#x201c;evergreen&#x201d; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#x2019;s stockholders in May 2021, the Company&#x2019;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 3.6&#160;million shares of common stock available for issuance under the 2014 Plan as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 13.2&#160;million stock options outstanding under the 2014 Plan as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#x201c;Retention Program&#x201d;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#x201c;PSU&#x201d;) award equal to the value of approximately fifty percent of current base salary. Each PSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of March&#160;31, 2022 achievement was deemed probable for only the cash management milestone, representing  20% of the PSU awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2009 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of March&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-of-Plan Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;here were approximately 3.5 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense of $1.9&#160;million for the three months ended March 31, 2022. The stock option related expenses were&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.3 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.0 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three months ended March 31, 2022 and 2021, respectively. As of March&#160;31, 2022, there was $9.6 million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of 2.56 years. The weighted-average grant-date fair value of stock options granted during the three months ended March 31, 2022 and 2021 were $0.45 and $2.05, respectively. No stock options were exercised during the three months ended March 31, 2022. The total intrinsic value of stock options exercised for the three months ended March 31, 2021 was de minimis.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units and Performance Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company's RSU and PSU activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;      &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not grant any RSUs or PSUs during the three months ended March 31, 2021. &lt;/span&gt;&lt;/div&gt;The share-based compensation expense related to RSUs and PSUs for the three months ended March 31, 2022 was $0.6&#160;million. There was no shared-based compensation expense related to RSUs and PSUs for the three months ended March 31, 2021. As of March 31, 2022, there was $5.0&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs which the Company expects to recognize over a weighted-average period of 2.94 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyNDA_5f476810-fdb8-4f19-8e18-5b27199cee39">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations and Comprehensive Loss for three months ended March 31, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:433.50pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:277.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:73.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,894&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;958&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i08791a0aa370455b99495a2b83190943_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzItMS0xLTEtNTczMzc_c366e0eb-8ef2-4f24-8444-2a9db365dc52"
      unitRef="usd">502000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b72109f9aee425d9d32f4948d46c658_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzItMy0xLTEtNTczMzc_9d47beb0-1a39-4f95-9d55-6903ecf37bcb"
      unitRef="usd">178000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i548c92c454ec4c8eb027f6787d1601b5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzMtMS0xLTEtNTczMzc_f803c2e4-8720-47e1-ad40-d97ca6505ba3"
      unitRef="usd">1392000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i064bfd4b1d304882b1628ad085b4d6c2_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzMtMy0xLTEtNTczMzc_8dc1701a-bd59-4f0b-a8aa-27505d9f4e1a"
      unitRef="usd">780000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzQtMS0xLTEtNTczMzc_cbd5c0bb-3e2a-40d6-8f44-d09b6916febb"
      unitRef="usd">1894000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTpkNjcxOGRiODc1ODI0ZWI5OTkyMDEzZGU2MDEwZjBhNS90YWJsZXJhbmdlOmQ2NzE4ZGI4NzU4MjRlYjk5OTIwMTNkZTYwMTBmMGE1XzQtMy0xLTEtNTczMzc_c6ff2285-9c3c-425b-b3fb-aadaa1e4013e"
      unitRef="usd">958000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="icf9f504438bf430eb66685abf363cbbe_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzExMDA_17ae0bbd-1f56-4efd-849f-9a42072ad7dc"
      unitRef="shares">7900000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="id04c1f00c3054d6b86cd44222571b020_D20210501-20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzE1Njk_186d25f9-f402-4448-8e74-b3e72793a8d4"
      unitRef="shares">12000000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0ed5641b729d40d8b652fe7425a4c97c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzE2Nzc_197130e7-7bb4-456c-a0e3-5af4ff7039bc"
      unitRef="shares">3600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3414053ba29c49659486e8317c638717_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyMzk_e0976c9a-9e45-4a96-a6f1-e3cb2bf28409">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i3644a46ac29a4cd088a111e400276c65_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzE4NTQ_0b012fed-e7fb-4087-acd0-51536232d69d"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i843c8c42b555485e8edc0700629c070d_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzE5Mjg_9df13bc1-fcfd-4d62-9a4a-7ff6a8a2dd22"
      unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3414053ba29c49659486e8317c638717_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIwODc_bc8ff8d8-de03-48e8-bd21-55e1d810ff54">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i0ed5641b729d40d8b652fe7425a4c97c_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU0OTc1NTgxNTA4OTM_d76d9811-6fab-416c-ae83-0886a78463d3"
      unitRef="shares">13200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="i7b5fbafca91d4ed69dc2dd77e2c3d271_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzEwOTk1MTE2MzY4NDk_94854535-d587-469d-be57-a7e06c334e29"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary
      contextRef="i070828932cb7457b89a6d3428bf1884e_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMzNjA_02eb1e05-b6e3-4dd7-ae03-9e5573b8c2ec"
      unitRef="number">0.50</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="i070828932cb7457b89a6d3428bf1884e_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzM0NDU_b20e7da0-495c-4bb4-8a6e-9a656cd8eb39"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent
      contextRef="ibe0c595a8b504aa7a9ef9bed9511cc7c_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIxOTkwMjMyODAwNzQ_5db50417-6b15-46ea-88a5-da0ce5faf6ae"
      unitRef="number">0.20</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i20b6c5aa1a3c4bd7a85f15364a9f7f10_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzUzMzc_d33f41fb-dac6-4f14-af08-3dd0a5e7daa3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="i20b6c5aa1a3c4bd7a85f15364a9f7f10_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzUzODk_474771d6-dedf-46aa-8a75-4c4a582b3d96"
      unitRef="shares">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i8efee58bbcb34cfeb4ebe4d44af7870e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU4OTc_3ec9a96c-e542-4d4f-a3f0-352c09cc8ff0"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyMzQ_f3afa9e2-daea-46a6-b03c-3b3c2967769b">The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and 2009 Plan and inducement grants made outside of stockholder approved plans, for the three months ended March 31, 2022:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.68&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzktMS0xLTEtNTczMzc_63335b3e-8641-4b4d-8a00-7ac88de1d42d"
      unitRef="shares">15703000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzktMy0xLTEtNTczMzc_6650d19e-5169-40df-ab19-7ff5e417bc09"
      unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4a6dde7845004b009c604f58eaaf54f2_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzktNS0xLTEtNTczMzc_4223d77c-4c23-4d95-b7fb-8a6d84ae39ef">P8Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzktNy0xLTEtNTczMzc_b2aba3a2-e76a-4086-88ee-9795a009fa41"
      unitRef="usd">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEwLTEtMS0xLTU3MzM3_3a9345aa-e7fa-41d8-b303-16b4c4b9b340"
      unitRef="shares">1080000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEwLTMtMS0xLTU3MzM3_d0121aee-2d31-4c4f-9eb4-e1b51df5a599"
      unitRef="usdPerShare">0.71</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzExLTEtMS0xLTU3MzM3_80b0b06d-2913-49a0-a324-0defa81163b6"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzExLTMtMS0xLTU3MzM3_8051bf34-28a7-4abe-aeb0-48d4abb28ab8"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEyLTEtMS0xLTU3MzM3_c6519f6d-253b-459a-9fb1-bf0a0a3202bd"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEyLTMtMS0xLTU3MzM3_4e1955ac-6fcd-4b5d-be6c-5c6105e22e08"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEzLTEtMS0xLTU3MzM3_ee2122e7-d313-42d3-b65c-c715a8290c15"
      unitRef="shares">16783000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEzLTMtMS0xLTU3MzM3_4a5a99d3-dbec-4930-9d00-69be0c229be0"
      unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEzLTUtMS0xLTU3MzM3_063913eb-e7cb-484e-baf8-fe35354503a5">P7Y11M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzEzLTctMS0xLTU3MzM3_cb196aa0-883d-410b-a13f-da5a5e53d7d4"
      unitRef="usd">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzE0LTEtMS0xLTU3MzM3_1db4361e-f806-46ca-bcbc-42184dcd75b7"
      unitRef="shares">8513000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzE0LTMtMS0xLTU3MzM3_2fb7045d-08d7-408e-9817-bdf085952b6c"
      unitRef="usdPerShare">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzE0LTUtMS0xLTU3MzM3_01b6ee48-08d1-4cb9-88ab-832bd3c4df9e">P7Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToxZDBjNGYxZWQ1YjA0OWYzOTA4ZTJlNmQ5YzdjZTQxMy90YWJsZXJhbmdlOjFkMGM0ZjFlZDViMDQ5ZjM5MDhlMmU2ZDljN2NlNDEzXzE0LTctMS0xLTU3MzM3_1a79a733-732d-4f2d-8489-3231b92121f5"
      unitRef="usd">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ4OTMyNjY_cae28894-94e6-4d16-953a-757dc3903f19"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY0MDE_7532ad19-0217-4d97-b6fa-208a9a3e129a"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzEwOTk1MTE2MzUyMjA_e6b2eb88-d781-43cd-ac67-cd05b2b13668"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY2MzI_8609337d-9175-4e57-b4cb-bd16702abe65"
      unitRef="usd">9600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY3ODQ_3fcbcc96-dec0-4269-97a7-c4582eb96c59">P2Y6M21D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY5MDM_122fe888-456f-4f93-8bf1-337063f851be"
      unitRef="usdPerShare">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2e633935010248e68ea0892b52e3708c_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzY5MDc_4c4c8da1-ffb2-4cfa-ac45-8b4dd0ab3584"
      unitRef="usdPerShare">2.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIxOTkwMjMyODAwODI_ed694df5-cf62-40c9-a674-3c84335b8c26"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzcyNDQ_724a3b75-4ffd-44ab-b517-c90344a46e1c">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzItMS0xLTEtNTczMzc_77f1fe5e-890c-4ef7-8c93-a3062913fd78"
      unitRef="usdPerShare">0.71</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzItMy0xLTEtNTczMzc_82bf6ac4-e22d-487a-b91e-71f1464e0afa"
      unitRef="usdPerShare">3.15</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i3baa1439c0ea43b08add2b44f358ac2d_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzMtMS0xLTEtNTczMzc_2a52a63c-ad9d-4759-a00b-7c626e87b78f"
      unitRef="usdPerShare">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i721f2630aa8b4812af090675ea7c48d8_I20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzMtMy0xLTEtNTczMzc_7c28631a-9700-4110-8c4f-57cdf1f765ff"
      unitRef="usdPerShare">3.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzQtMS0xLTEtNTczMzc_39f784a9-8324-4057-914a-8c871d8a8edd">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzQtMy0xLTEtNTczMzc_74ac8209-a2b5-4752-8fb3-201f9f66db13">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzUtMS0xLTEtNTczMzc_a656431e-6011-46d6-998b-65d08637118e"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzUtMy0xLTEtNTczMzc_f3ed09a1-99bf-44a3-8944-087235931770"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzYtMS0xLTEtNTczMzc_48d679b9-cbe5-41af-921e-bd459a84d05e"
      unitRef="number">0.719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzYtMy0xLTEtNTczMzc_8eb8da68-96ff-4a0a-a0e9-d3d416c3e318"
      unitRef="number">0.750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i14ad2e265e504b4994de4346a904f964_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzctMS0xLTEtNTczMzc_48efc603-3898-4f12-83ae-638f6342b90e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="iebc1439c13884de8b705cf3adc018cef_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZTo1YTA3ODkzODEwY2Y0YTdmODhiYmM3NDc1OWM0ZTgwOS90YWJsZXJhbmdlOjVhMDc4OTM4MTBjZjRhN2Y4OGJiYzc0NzU5YzRlODA5XzctMy0xLTEtNTczMzc_9f4524e1-fe94-48eb-83a4-16c480564ad2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU0OTc1NTgxNjE4NTE_55c13a8f-a6ea-490a-a25e-9913c47ec891">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company's RSU and PSU activity for the three months ended March 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;      &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,005&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzEtMS0xLTEtNjc2MjY_ec02523e-7c75-4581-833c-fa157751a5e4"
      unitRef="shares">3041000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzEtMy0xLTEtNjk5Mzg_fea032d5-3632-423f-8f17-820d42cbbff1"
      unitRef="usdPerShare">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if6795b392d224fd1958f431310a8ae42_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzItMS0xLTEtNjc2MjY_2a7045a0-8012-4fe9-bbce-ce05e05530e1"
      unitRef="shares">3960000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if6795b392d224fd1958f431310a8ae42_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzItMy0xLTEtNjk3MTI_c61d5e2a-6c0c-4fe1-af83-3666ca7cb22f"
      unitRef="usdPerShare">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1c321cdcae954377903223a91776e0b9_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzMtMS0xLTEtNjc2MjY_83ab7b9f-31d4-4a0b-bde8-ff88eeb8c91c"
      unitRef="shares">1004000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i1c321cdcae954377903223a91776e0b9_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzMtMy0xLTEtNjk3MTI_b03ad00c-53f9-4524-8b7a-335f7cce455d"
      unitRef="usdPerShare">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzQtMS0xLTEtNjc2Mjg_da85325a-441b-41bd-a525-9e04434a13c9"
      unitRef="shares">8005000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90YWJsZToyOTI2YjBhYThjZjA0YTdmYjQ3MDkxZGI3M2M0ZDc0My90YWJsZXJhbmdlOjI5MjZiMGFhOGNmMDRhN2ZiNDcwOTFkYjczYzRkNzQzXzQtMy0xLTEtNjk5NDA_ad4ef1da-38bb-4a98-8233-ccaaf8dc3c8d"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i41cd54bf6e0e43108d5f54b38cbcef44_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU0OTc1NTgxNjA5NjA_e1735b19-3abc-487d-9e12-3cb5c11121a6"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie9646b6fad074c349a38b736d334913f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzU0OTc1NTgxNjA5NjA_e466559e-ea25-44b3-a3fa-4ec4c67d94bc"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if6795b392d224fd1958f431310a8ae42_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzEwOTk1MTE2NDkxMjk_3f0273bc-47c8-4354-aad7-67040b08208c"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1c321cdcae954377903223a91776e0b9_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzEwOTk1MTE2NDkxMjk_dce094e3-67ab-4d42-bb12-6585fcca4d34"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9646b6fad074c349a38b736d334913f_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIxOTkwMjMyODAwOTE_b0d4bb97-5770-4850-a23b-bd8ba2838178"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i41cd54bf6e0e43108d5f54b38cbcef44_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzIxOTkwMjMyODAwOTE_b79e8573-f5dd-4e60-a8e3-81a3c1977c83"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if180a9498a6049c5a369d46136508c69_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ5MDU5NDc_79653a1b-85db-4ff8-9a75-e3887254f7bd"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id2d1253ec7414a4b84ffbe87119b85ff_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ5MDU5NDc_f42828f8-0de9-4786-a7ce-ee14a503453e"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i1c321cdcae954377903223a91776e0b9_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ5MDU5NjI_04854ce1-c577-4b1a-9e80-a2293f953ecc">P2Y11M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if6795b392d224fd1958f431310a8ae42_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjEvZnJhZzo1YTAyZmI3MGM1OTU0MmEyOTllZWY1ZjdkZGFmNjI1Mi90ZXh0cmVnaW9uOjVhMDJmYjcwYzU5NTQyYTI5OWVlZjVmN2RkYWY2MjUyXzMyOTg1MzQ5MDU5NjI_bbd488fc-43e3-41a9-bf84-a786aaccdd2c">P2Y11M8D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzI2NTQ_8f06958c-42a4-4f21-818f-27f09fb76260">EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of March&#160;31, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP for the three months ended March 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States - 401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The expenses incurred for the periods presented were de minimis amount for each of the three months ended March 31, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canada - Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the three months ended March 31, 2022 and 2021, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i249eb5f45f4a43748f1453177c588a6e_I20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzM4Ng_1a9d040e-dd8f-4512-967d-3b61035440ca"
      unitRef="shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ia471201fe4bb48848f6167bcc65d599c_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzYxNg_b57cb2fb-6e95-4ca2-8a7a-4cd7e2328ca2"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i015e286376344c4c9c156e22c95fc9c6_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzk2Mw_4adea22b-8b77-4f36-adf1-10b07d56e208"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i703ddc2f34bf4c4fa0e273c40ad0142a_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzEzNzY_9dafa3e7-d853-4142-863d-0d6051cdc026"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i1448067179f94f71ac95826b8ee7a5be_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzE4NzE_3e04efaa-d7af-45ab-a709-8a75b71e3fca"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee
      contextRef="i1448067179f94f71ac95826b8ee7a5be_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzIwNzA_0d36f63f-8dfb-45e9-a005-4902d3cbc674"
      unitRef="usd">4000</sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i719e07b970f244aaa770a65739f6261a_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMjQvZnJhZzo2ZTNkYjJjYWYxZmU0OWU5ODI4YTUwMThjMGE5NzMzYi90ZXh0cmVnaW9uOjZlM2RiMmNhZjFmZTQ5ZTk4MjhhNTAxOGMwYTk3MzNiXzI0NjI_427aefee-2255-4b4a-90d4-26e32c09a7a7"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <sesn:LicenseAgreementTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzIwOTQw_ea782f0d-4d26-4520-b0ee-3a6ac524fc90">LICENSE AGREEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Zurich&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#x201c;Zurich License Agreement&#x201d;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $0.5&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million related to meeting a development milestone, (the submission of the Company&#x2019;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#x2019;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Micromet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#x201c;Micromet License Agreement&#x201d;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of March&#160;31, 2022, the Company may be obligated to pay up to &#x20ac;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.7&#160;million at exchange rates in effect on March&#160;31, 2022). The Company is also required to pay up to a 3.5% &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#x20ac;50,000 (approximately $55,559 at exchange rates in effect as of March&#160;31, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#x20ac;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ecember 2020. The Company recorded an expense of &#x20ac;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#x2122; in the first quarter of 2021. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the European Union.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with XOMA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#x201c;XOMA License Agreement&#x201d;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. Based on current clinical status, the Company anticipates that these milestones may be triggered by Vicineum&#x2019;s clinical development pathway. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#x2019;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Roche License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into the license agreement with Roche (the &#x201c;Roche License Agreement&#x201d;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#x2019;s monoclonal antibody EBI-031 and all other IL-6 anti-IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#x201c;Roche Licensed Product&#x201d;) and pursue ongoing patent prosecution, at its cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received from Roche an upfront license fee of $7.5&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase III clinical trial, (ii) $50&#160;million in regulatory milestones and (iii) $75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the provisions of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Codification 606, Revenue from Contracts with Customers ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606&#x201d;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in the previous quarter. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Buy-Out Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche License Agreement provides for two &#x201c;option periods&#x201d; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#x201c;Initiation&#x201d;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30 days after Roche&#x2019;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#x2019;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OUS Business Development Partnership Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qilu License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2020, the Company and its a wholly-owned subsidiary, Viventia Bio, Inc., entered into an exclusive license agreement with Qilu (the &#x201c;Qilu License Agreement&#x201d;) pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to develop, manufacture and commercialize&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Vicineum (the &#x201c;Qilu Licensed Product&#x201d;) for the treatment of NMIBC and other types of cancer (the &#x201c;Field&#x201d;) in China, Hong Kong, Macau and Taiwan ("Greater China&#x201d;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#x201d;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of value-added tax ("VAT"), which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#x201c;Royalty Terms&#x201d;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#x2019;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020.  As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MENA License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained and recorded as deferred revenue. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million has been recognized. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of March&#160;31, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;EIP License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2021, the Company entered into an exclusive license agreement with E&#x130;P Eczac&#x131;ba&#x15f;&#x131; &#x130;la&#xe7; Pazarlama A.&#x15e;., (&#x201c;EIP&#x201d;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#x201c;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The EIP License Agreement is subject to the provisions of ASC 606 and as of March&#160;31, 2022, none of these amounts have been received by the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; No initial transaction price &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was estimated by management&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, therefore no revenue was recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;March&#160;31, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of March&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt; none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</sesn:LicenseAgreementTextBlock>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i75fda142f1274858950bc952a648690a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY4Mw_81d82ca6-896c-4405-8a26-b1b3b86da105"
      unitRef="usd">500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="id114c77b04144d64bd3d93db2ab92506_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc2NQ_e641166e-0104-4a20-b274-2b63f02f523f"
      unitRef="number">0.04</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="id114c77b04144d64bd3d93db2ab92506_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzEwMzY_8d6ba2f9-7006-44de-8e24-cd8d7f82a0af"
      unitRef="number">0.10</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="id114c77b04144d64bd3d93db2ab92506_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzExMTM_f902e8dc-8c02-41f0-aebf-2e31520cd5b5"
      unitRef="number">0.02</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i2e725e6c9c5548a683b0b8cd8414f46c_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MDU_15f85c13-a135-4e9b-ae5b-494064d2c143"
      unitRef="usd">300000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i6f0b7b32437649f0aebbff5cb5bced22_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MTI_25c8bc14-be96-4120-ad3b-8c92eadd970c"
      unitRef="usd">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzIyODc_b89ffe97-7016-44e3-9000-8c8cc7eb4ce7"
      unitRef="eur">2400000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzI0MzQ_375b0df0-2f8d-4a10-8f79-eafa994d894e"
      unitRef="usd">2700000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzI1MTc_774c3aeb-d5a7-4c87-a3c4-f50cc0efc4b8"
      unitRef="number">0.035</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent
      contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzI2ODY_d465cdb7-3898-4b40-857d-d97c039cfb55"
      unitRef="number">0.015</sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent>
    <sesn:LicenseMaintenanceFees
      contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzMwNzk_a9e9c2a6-38e1-42e7-a51e-2e4b0534897f"
      unitRef="eur">50000</sesn:LicenseMaintenanceFees>
    <sesn:LicenseMaintenanceFees
      contextRef="i84bb5805030c4f2b8c07b1ce20bd75fd_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzMwOTc_837ad622-9049-4f61-88e0-93ad0947a899"
      unitRef="usd">55559</sesn:LicenseMaintenanceFees>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i3170a4ca7c3743c2af7e5c8f5d4ce2eb_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzMyNTQ_b92e2053-3ba8-4dd0-b1f1-7a1de18ddb67"
      unitRef="eur">700000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i3170a4ca7c3743c2af7e5c8f5d4ce2eb_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzMyNTg_c870a08d-8ee4-4943-8d07-150b02d6d7c1"
      unitRef="usd">900000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i6b8e64e250af4d2790f73c3b79426507_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzM0Nzk_3031afd6-91eb-4c33-b674-e88624977713"
      unitRef="eur">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i6b8e64e250af4d2790f73c3b79426507_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzM0ODM_aa2338d9-a273-42ab-9a59-ebf885b7b70e"
      unitRef="usd">600000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzQxOTI_5454d925-2e6a-4fc8-bfc7-937a0607e112"
      unitRef="usd">250000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzQ1MjI_537affa1-c5e4-43ac-ac12-ddb298955d39"
      unitRef="number">0.025</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzQ4NDA_9b1b9739-d757-442a-aaec-6d37bd1ed32b"
      unitRef="number">0.0175</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="ief2494fecc04479ea11ddf06db4b6649_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzQ5MTM_82897b9a-fc12-465a-9103-f55f507398d2"
      unitRef="number">0.50</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementUpfrontFee
      contextRef="i5115ded926c24cf0bfdc639b4a65bd23_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzYxMzM_03152e80-540a-4fa0-91ec-1c6f444e6864"
      unitRef="usd">7500000</sesn:LicenseAgreementUpfrontFee>
    <sesn:LicenseAgreementAdditionalUpFrontFee
      contextRef="i5115ded926c24cf0bfdc639b4a65bd23_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzYyOTk_47c46f7c-212e-4bd7-b142-9a10ba97266a"
      unitRef="usd">262500000</sesn:LicenseAgreementAdditionalUpFrontFee>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i35b7f963b9974be1ae64730ce05532ff_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY0ODU_6a1e3af4-b4a8-4fde-ab0e-ebca38b4f54e"
      unitRef="usd">197500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i0f201162abfc475998aec36e2f378832_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY2MTQ_8dd2bb7b-1cff-4169-81bc-f34b915b7328"
      unitRef="usd">72500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i860ae1f5203e49a08aa91ee83b20d7e5_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY2NjU_61ec173d-6451-4893-b5ff-964b15d590e1"
      unitRef="usd">30000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i8aab7a1843994c3488d3876ab37fc007_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY3Mjc_173861ef-85ed-4e63-a4ce-804e73fff412"
      unitRef="usd">50000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i425a0d3a4bfe493e99909f42b47fd556_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY3NjU_3294b4c5-acf1-42a7-b18e-8dc81148f91e"
      unitRef="usd">75000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ide74b46daaba4a75ad68f84d5d0e6d0f_D20220101-20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzY4Mjk_38b9bbde-bafd-4166-af12-d8e92ae9b84f"
      unitRef="usd">65000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i607e98a9eea546b983ca1b261b279229_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzcwMTg_9b1090b0-7791-4bfa-8862-50ba0714d2f1"
      unitRef="usd">22500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="i4aafe20143b64883857f4e9a3c846e12_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzcxNjE_64afd44b-f816-40a9-b442-0d94325ba6ce"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="i05e3cb0224f54a1186393da585df2efb_I20220331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc0NzU_b2d22bf8-9cff-41d1-887a-46647efd5ac8"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:AccountsReceivablePaymentTerms
      contextRef="i2fba7eecc61a49598234f514785e0ed0_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc1MDA_c8428466-54d8-4b05-88ac-b85d78703947">P30D</sesn:AccountsReceivablePaymentTerms>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic5ec8b79f17f43bbb84e97e2a5566d46_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc2MTY_ff9bb9d8-8573-4e93-b00e-16a988fd6236"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:LicenseAgreementProceedsFromMilestoneAchieved
      contextRef="i4b8e98722c2b4cdcb4f305e34994b6e7_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc3Mzk_d770ac7b-04f4-4ae9-817c-543fe882b489"
      unitRef="usd">20000000</sesn:LicenseAgreementProceedsFromMilestoneAchieved>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="id273db7a5ed6402bb34a4872220bae45_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc4OTQ_9e24854a-9139-4524-b186-a4f818c21c10"
      unitRef="number">0.075</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i17d89aea5f0f47dd8400fd0b5a4720c9_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc5MDA_b95baaaf-087c-4ec8-bfb7-2401d116ab99"
      unitRef="number">0.15</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="icf94f20a694b4bee91f6f6da52f38a93_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzc5NzQ_cd421653-ced8-473e-b2e0-cc451b3a9d23"
      unitRef="number">0.50</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementOptionPeriods
      contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzgyMzg_ad0613e8-f9b8-4cf2-86f9-c9db51864cca"
      unitRef="period">2</sesn:LicenseAgreementOptionPeriods>
    <sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod
      contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzg3Mzc_713e8b9d-ad31-4a3f-afc2-ed73d12ce395"
      unitRef="usd">135000000</sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzg3NDc_9c52cc27-0685-4353-947c-60ee43b617b9">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzkyNTM_276f41cc-ef8a-494b-9a37-642bada9921a">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod
      contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzkzNTE_f3326ac6-ea4c-48bf-8139-c55c17ebe54f"
      unitRef="usd">265000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct
      contextRef="i96fb9eefafbe40a7a5f40dae6de616be_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzkzODg_f6612019-4469-4633-ad7e-e80b7f0296c1"
      unitRef="usd">220000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="iea001a4f9d934dd893e45269b2383c74_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzExNjQx_8471dda9-1e81-43bd-95af-1d1c1d15531f"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount
      contextRef="iea001a4f9d934dd893e45269b2383c74_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzExNjgz_c8066d0b-9e1f-44ca-a400-e9fed33766b5"
      unitRef="usd">23000000</sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount>
    <sesn:BusinessCombinationRoyaltyPaymentPercent
      contextRef="iea001a4f9d934dd893e45269b2383c74_D20200730-20200730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzExOTg1_488227b5-6495-4fb1-b7ae-7307702dc93e"
      unitRef="number">0.12</sesn:BusinessCombinationRoyaltyPaymentPercent>
    <sesn:CollaborativeArrangementRoyaltyPeriod
      contextRef="i6f42a6de33704f62b0e682799149f0e6_D20200730-20200730"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzIxOTkwMjMyNzk0MTc_0bfd6ed5-ca7b-46e7-902c-1302df974960">P12Y</sesn:CollaborativeArrangementRoyaltyPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i40d094d92f884dde854fd3394639b343_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MDI1_a81e9226-9a90-43ad-ab79-767f52ec7cb0"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id8142289592f45f3ac1543eeb3a12d8f_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MDgx_2b8ec1d3-85a0-44ee-9907-e288e3bbd603"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ibd649cc1b18c474ab1dd1aab76c6641c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1Mjk2_a7d5641b-e33d-47ba-8c6a-24a12a3bee3d"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ibd649cc1b18c474ab1dd1aab76c6641c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1MzEy_3d9ecb38-4660-4ff6-a893-54312be5c64e"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7ad5cac1a07b45d6ba8c79753fc4a02f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1Mzgw_21f65d5d-2d5f-4531-b89c-bec1404bac39"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:BusinessCombinationMilestonePayments
      contextRef="ibcc08ea5943f404b9c1b2ff1c2b62d78_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1NjUy_5d6a3473-c59c-487b-a43b-ce347afd551b"
      unitRef="usd">3000000</sesn:BusinessCombinationMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="ibcc08ea5943f404b9c1b2ff1c2b62d78_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1NzIz_f4d073bf-43fb-4cf2-90a0-46c27df5dc63"
      unitRef="usd">23000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ibcc08ea5943f404b9c1b2ff1c2b62d78_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE1Nzgw_97fe8cca-802f-4500-b226-28fc979e7bcb"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6380f74d6af34e0fb121780679e0dbd2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE2MTg5_84b5e03c-81ec-4153-a13f-a047f0573dc8"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i7ab08b81f1a8468bb8602311426ac4a5_D20201130-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE3MDkz_1d9637bc-fc1d-4e0a-9251-8657c7b72c0f"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0473c8cf700e465d8a8670d029d1a17e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE3NTI0_0163c53c-654a-4484-8b41-6297fe9d99ab"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i0473c8cf700e465d8a8670d029d1a17e_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE3NTY4_1af5f7b3-a0ee-490f-a400-5a3f6f17cd19"
      unitRef="number">0.50</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i0473c8cf700e465d8a8670d029d1a17e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE3NzIy_5623fa36-727b-4f56-9a70-90bbeb6eb936"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4d312124644e44a09f50ee532d536d0c_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE4NDA5_9cc882bb-9dd3-4b20-89f8-5678108b50fb"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia2dcc52dfed04067b81a5e2472d5ab8d_I20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE5NDI3_c827158d-d170-472f-8a5a-df2881fcc170"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="ib2f514ca47c14bcc81a567e7c8ee3089_D20210805-20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE5Njg2_c5c6f48e-9e0e-4822-a7c7-a8227fe5a311"
      unitRef="usd">2000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RoyaltyRevenuePercentage
      contextRef="ib0ea7fa933c347ecacaa65b87757c77a_I20210805"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzAvZnJhZzpkMmQ1ZmIwMmFjODA0NzVmODJmMTU2MjU2ODQ1N2RiYS90ZXh0cmVnaW9uOmQyZDVmYjAyYWM4MDQ3NWY4MmYxNTYyNTY4NDU3ZGJhXzE5NzIz_a19f5ab3-3e5d-4013-9fd7-ede32c57b1b8"
      unitRef="number">0.30</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90ZXh0cmVnaW9uOjIxZjU2MWEzN2IwNzQ0YTM4NmY5YzM5MDNhOTcyMjQ2XzEwNzI_dc82289c-8c41-4dc2-b70d-eac6947f8759">RESTRUCTURING AND RELATED ACTIVITIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#x201c;Restructuring Plan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Restructuring Plan included a reduction in the Company&#x2019;s workforce by 18 positions (or approximately 35% of the Company&#x2019;s workforce as of the date of the Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the Restructuring Plan, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects that substantially all of the accrued restructuring costs as of March&#160;31, 2022 will be paid in cash by the end&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of September 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="i35e5be36237a414280b903dade9eff3e_D20210830-20210830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90ZXh0cmVnaW9uOjIxZjU2MWEzN2IwNzQ0YTM4NmY5YzM5MDNhOTcyMjQ2XzQxOQ_ab405c40-213e-45f0-9ed2-6369463a08d6"
      unitRef="position">18</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="i35e5be36237a414280b903dade9eff3e_D20210830-20210830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90ZXh0cmVnaW9uOjIxZjU2MWEzN2IwNzQ0YTM4NmY5YzM5MDNhOTcyMjQ2XzQ1MA_5825f03f-d6ae-4e42-89ca-46966747c586"
      unitRef="number">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90ZXh0cmVnaW9uOjIxZjU2MWEzN2IwNzQ0YTM4NmY5YzM5MDNhOTcyMjQ2XzEwNzM_fbee2a37-e44e-47f4-aada-e204f64ce580">The following is a summary of accrued restructuring costs related to the Restructuring Plan, (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(507)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ic3755f1139a340e2aade3663223c8a7a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90YWJsZTo4YTJjMDExYzRiYzA0MzJkYWUxZTAwODkwYzcwMGEwMy90YWJsZXJhbmdlOjhhMmMwMTFjNGJjMDQzMmRhZTFlMDA4OTBjNzAwYTAzXzItMS0xLTEtNTczMzc_e6b40f96-3e8f-4ddc-a284-ffa9df914d7f"
      unitRef="usd">1497000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90YWJsZTo4YTJjMDExYzRiYzA0MzJkYWUxZTAwODkwYzcwMGEwMy90YWJsZXJhbmdlOjhhMmMwMTFjNGJjMDQzMmRhZTFlMDA4OTBjNzAwYTAzXzMtMS0xLTEtNTczMzc_1141b181-dd15-4103-9e70-3b5fc1a67349"
      unitRef="usd">507000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="ia92debb44af54d02b67c7dd62a05fbfb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xMzYvZnJhZzoyMWY1NjFhMzdiMDc0NGEzODZmOWMzOTAzYTk3MjI0Ni90YWJsZTo4YTJjMDExYzRiYzA0MzJkYWUxZTAwODkwYzcwMGEwMy90YWJsZXJhbmdlOjhhMmMwMTFjNGJjMDQzMmRhZTFlMDA4OTBjNzAwYTAzXzctMS0xLTEtNTczMzc_c112f171-9ccd-42b4-a008-c266228d7376"
      unitRef="usd">990000</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i9f552561389a4839b36955112414fddd_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjVjMTI4MzMyYTdmYzRlMGE4MGUzNGIxYTE5Nzk2YmNmL3NlYzo1YzEyODMzMmE3ZmM0ZTBhODBlMzRiMWExOTc5NmJjZl8xNTIyL2ZyYWc6NzU3ZGJkMzYwMTI3NDQ1NDk3YWRmN2U2NjRhNTA1ZWEvdGV4dHJlZ2lvbjo3NTdkYmQzNjAxMjc0NDU0OTdhZGY3ZTY2NGE1MDVlYV8xMzc0Mzg5NTM1NDcyMA_3d6b2162-d1c0-4c15-84dd-42d181b097e0">SUBSEQUENT EVENTSOn May 3, 2022, Sesen Bio, Inc., (the &#x201c;Company&#x201d;) announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of the Company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of the Company&#x2019;s proprietary technologies. The Company is actively working with an investment bank in this process. Pending any decision to undertake any strategic alternative, the Company is continuing its development activities in accordance with its existing business strategy.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MH1\%D3,9/Q_FQ&2&?.PW9AVD;H/4M2*=Q3$O%#"U&V.J4#XEU BR]N(=SNY
MV(.H&Z&.50>AUR#TK COY8:*8_ \ SRW#T\WPFZ(S.C\!IUO1?<@Z):P): O
MBE-SFE=OG5>0X\ZR,J'V-4!A$'D]U+H1#-U@X+4'#>S "ON12Y*<@# P3.[X
M..AAU,V0X_F.9P89-B!#Z[Z\X]EY?/+>C!JOD37T;S27@L62UKO3%'5D"*<7
ML=6D@PLZ+0L[1]:2$F8A7ZLU5)+&5DFE/ ,9E4:.=?3UC'LP#38N'L!YH!;0
MBO-+)DFV9FHO6E;.WD=GZ;B!T\_C4;,NQI;2(;)B_)/SY8XEB1$:TN?$CN_V
MH1TSZT)KM0':Q>&69VL@J4C!MD<>1K!81Q%@I\]M!K, 1@/D!EMU@'9YJ,G7
M\I9UR@_[!&:P@6AH$;:J .VR4#-8IE&$$:7._*Z''&VS& 3"@^Y0$EN)@':-
MJ*'.AN'I%(^0%[K:7C'8N4[@!@, 6S& P4D%4,+($TN89-3*M+ E<!B>5EUL
MR6NIW<;H0RTJW_?[H>M&*/2&%E$K!="N!0J?*.B1#:A3?8""L ]0MPJ1-R"
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M38EL.\I WE\Q)EY/U/>GXB/KZ&]02P,$%     @ 4T"I5 O^/3!5 @  G 0
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M>2+ .:U*W0]2T'^YN_DO4$L#!!0    ( %- J507L4AYL (  .<%   9
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M^[T/IQ[H9JTT%ZO*>I2WRM)BJ(\Y;6+4SH'LF:(*MQ<GT.WVZ1]02P,$%
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MU-: ]8E2=+I8!\WTGOX"4$L#!!0    ( %- J50;2/RM" H  !@;   9
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MU*L@ ')JK4DJI5;C((_<0;W(+-.T#EJTB8V8=K6ELY8ZISCT0==!2BOG )&
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MUU_2%;/1#$KHZ4,%!IB,DU?'E$-%E2]C]A-U51@#XMB$"C5=HBQDID2R[7D
M909K#?<2++GX,&/[?M$IN@=XJ3$VH*JYAQ.FB\L?7U7&*5\"-/'YW>W-Q>4S
M)GM;84KC.Q@L9;!H4YDL,'[&<2"UOAX,T$"P0J$6M$GSBBL6E&Z=45M?U[)8
M*.6Y&IH\G[[>);KB!DC*C+<Y>DSME0:5I&J/#N+%,;6I7R%-GJ;6?%<9'UK>
M&"(9/8I8O$=2?9WJKV9__4F\(-F$=SI^NU<(/YN\?1FS6Y:EA:> ]&$K#5?9
M4#S8#%:+.1PEH?0#56 NKN#SE?S,VRZ4^2S1/MJ;+VJ5'W!0$/?L?;U8^$89
MG)+S8+Y6S*B1S6EMV:[M^.;>Z36UL;T&B =%G$CYR+&XLVM54#!:)@H;B]2S
MZ>/*YAF54RS"PL9$!Q]2%T3VD#[I'RG6N_@174:O@$$S(%/$IT_0QGR+&U8R
M,J^K\ICVF#9 "(TZ264/<J9!K ]X>M0@QKD"74*:T&"5]79N*FCC'BC$6IE*
M-6WF>6[H4@(2QLMT57D5<)@#:*"I)6\ >U$1(2=.0W]&<<&6*Y76_CQLX"55
MZ#BHL7>K>C:WDMG(5LH/W0IYDAZ-L>@Z*&^<(/IMH"WD7E;/ZJ67S=,FR6),
MOGI<\U[,.0]%_WT"M&:G#!?$.G7.ETXC2CN&BI@[X2_L.HX2F(X*[>.NKVV"
M!C0FC)FQTTZCG/*I9[%9 P[2V>LVG3HY@'\S0,KK*$W9OJNGR1BE.%52\S9(
M&L?C@J\@U[7SWRYA&^@,<MO(WE<R3U)(=3-HKLI0U\DXYA"CZ]P^ZA5\;\;P
MNL",Y.!9IA+J$WN&BMLML</WC0:3R?'A:?13W19F+MU^OY"3D]\8$-H!,K'2
M\<";:? 66I+_?;/#L_PPC*>);HLV2&$F!HEX@? QM+7)RE'ZBS05'?XFTQAE
MM!6B.P#NN'Y7R#O??T)-/>.UZ#3F)W8.+)I7I>+2B:9HTT?^_^^_/=[;32S[
M7-7,:V!G!0VD;*&S"@=0FF$J:HKLH\!G)ASJ4(O4,^FX$NI#>Y_H0/'*]:=N
MJHG_W;C6*Z!=CC3\TO!V93[324,9.'U%<F%<4OG:;A.<S8=BZ>@$"-K!K([Q
MCM7S@*/C*$>7"8)4]WJG[.*W(^ 53@Z5J0^C<%(].PY!ACBRA:H]S8'REM;5
M>H$+C6&A*0R),HJNZG&SGD.9>Q-*/SID13=WFL ?,9I.3O^3T13$V:1%O>2[
MQM2KG=NZ8RJW^6>8L]O*W]>J]XK9M?7N.#&=?FT6?(Z TM#TF<<VA*:L\OJH
M7=AZNJ/#,.5\H.%01I]_$P"\$- :Y8)&;DE]BCS/ =_NZ7:1JQ#,3B!K+MD[
MQ[)=U!\G#7.&?2U<8NQS,?MZX</8[50<</=3;:W[FR:.NLV>S@&&9P_.>]DV
M4797\V*&.*+V>[>Y=D1V7THD*M=JS<,7S\'(GUTCIG=CQ)@XRXH"LF+%1A@<
MI[5&4<6W,-&I79XOHJ:>M-IF)1W- *$YYPU[0_B0WI?%MSI<KO7K-:8\Z9OY
MFM\UP>PJ\)M2<-MFI>K7)*J]O=%Y'C?7+U?Z+X%&F!X1>W;1-0)CMZQQM@3G
M1*+M.HNFHB:7X04KU&Z+W&T!%$NG$AQ)XCM'[CI/VMDC#G"JT0WJ "&M(Q42
M37N%:HA)7LKM[O5XRU80U A,M4NK@F:KE 3Q^Z$%$U?M[1VTT;YWYP>=KQ6(
M\I*_R= [5I17_'#1WFT_^\SBUX[=\OC-""/O$N&'X0ML'8].C@?"Q>\P\4>P
M)7_[2"SXL>#+%;A(.5J YPMK0_.#%+0?P\[_#5!+ P04    " !30*E4)(15
M!R($   Y"0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6RM5EUOVS84
M_2L77K M@&/9LK,&G6/ <5.LP((%=;<^#'N@I2N+*$6J)%79_WZ'E.PXR1)L
MP%YL?MQ[[KF?U+PU]HLKF3WM*J7=]:#TOGZ;)"XKN1)N9&K6N"F,K83'UFX3
M5UL6>52J5)*.QS\EE9!ZL)C'LWN[F)O&*ZGYWI)KJDK8_0TKTUX/)H/#P4>Y
M+7TX2!;S6FQYS?[W^MYBEQQ1<EFQ=M)HLEQ<#Y:3MS>S(!\%_I#<NI,U!4\V
MQGP)FP_Y]6 <"+'BS <$@;]OO&*E A!H?.TQ!T>30?%T?4!_'WV'+QOA>&74
M9YG[\GIP-:"<"]$H_]&TOW#OSV7 RXQR\9?:3G8"X:QQWE2],AA44G?_8M?'
MX43A:OR"0MHKI)%W9RBR?">\6,RM:<D&::"%170U:H.<U"$I:V]Q*Z'G%[_>
M+M>WZWGB@15.DJS7N^GTTA?TIG1GM"\=W>J<\\?Z"3@<B:0'(C?IJX!WPHYH
M.AE2.D[35_"F1\>F$6_ZDF.,7#GZ<[EQWB+W?[V".3MBSB+F[#\'Z]_HT:>2
M:66J6N@]JC$SC?:.T%>$%K/"2[TEU;%N$%1+R_6*/IE:9G0U2X?4>30ZA?G!
M=1I4&^L+HZ0AJ3/5Y, 0^BENM"5A$V&>C,?H@$;8<&H\%2*32OH]].FSU%K6
MO!W2G=#2FXV@MI1929E!,SH F (UJ!LH^<8"?TA*; QL&;L?4@O4TC0P*'0.
MV4)F3*X6&8_H@Z8UUYZK#1Q$JL=#\B=A8>W9<@X6W@0/>.?[ 0"3OI3NQ!-<
MBSR7H;F%(M\:VK.P+@!:TVS+QX80P%;ZD@39T*@$_ B>1_L/J$:#:[-Q_+4!
MF8#%?!& "<RJ+OKH0UDU%56A!=0>PPF27<Y..&*Q6KZCL\E5C/:/HJZMV4E,
M$H;.V60VO,2Q\."1E4)OF1! ) X9X*+ U (79, B\(>^.(\!/'@=?(BF>8<9
M[?A)*'&8(5<^UD1CCV0PKPF%T;$'@(+5/(@]E$L/Z/XOTK\]*<3,N.<!&_:U
M&\2"(P=F#[2"&O+;HD3H;#R:(!%*A4"$Q 65F*W.,8=:PF1ZPB56Y*.C29=2
MX1Q>P RQ0P$@I+'<CL'\_KNK=/+F9_>\4T'><F9L,"6>W7>U=F&*B]@-P8:+
M%"R'CH5.J$G$SL"8/0AT&Z0L)E=)L0FM*6'M)/F/DUW"MBL!>1&JE) S$$$W
M]RQ#?"J3-PIE?-J/\6)R'H<"G*A#"S.5>-S#: !43.Q*5!LK\RTR=+>,]-/S
MQS 0NB^E$CFKNI1B2/?++JPGG'HJ\ E/-7]CNR<G=_\TE9.3YZQBNXV/=B"(
M@=F];,?3XW?!LGL.'\2[CPJD>BMU*+ "JN/1F\M!EY/#QILZ/HX;X_'4QF5P
MGVT0P'T8CH=-,'#\6EK\#5!+ P04    " !30*E4CZ!9SFP+  !9'@  &0
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MH?S=$_)6>W,5:NOE'5W P$N7=X6N*'6[U:DF[]6SDWVQ=T$5.$WI^\96>#Q
M%W!*)ZVCHU^KYQ%ZE?&(;V^'HV=;GS3VT2QIX4F],#Q#XO"1=;3?/2T[$D^&
MPSY:HFK91(Q.=R[#4+7;A)<-)IUE)[N7G7 GME,9C/W:^K2Z(4)%Q9E7[]-;
M-WI]!DXV27NS0Y#:TQC6KIMIL]*&NI'\63H?SA-\(J #/$FTZ)"34+C#?4]2
MO4AH"VK;#B/Z%0BOO,K0-:+?N.,[KH#IZMT($OJ&#O#AY09.T$E);<<!G.-5
MGYQ]TV&&"NL-S%\KNM+T^Q6ZA0Y,*,N$+VEEGM,-5(SNU:0ZO(F8-?NZ>E]7
M7\0EM8 V <Z#B,\*]=^3)^A=HA@.#GYO4N%>X6 ?4F +R/V'WE,==E[W9<K.
M^:4FT3K(-[SY:WYMWIN>A]>%[?3PTA5(!S.@=JH9E@[Z)T>]P(OU@S<%OSR<
M&N]-QE\7"C1F:0+&9P9^KAYH@^9M\LO_ E!+ P04    " !30*E4#+:<IGL$
M  !/"@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6RM5EMOVS84_BL'
M&C"T@.:+;,=):AMP+FL#K)UAM^O#L =:.K*X4*1*4G;\[W=(2HZ=U'G:0V)2
M.N?C]YV;.-DI_6@*1 M/I9!F&A765M?=KDD++)GIJ HEO<F5+IFEK=YT3:61
M9=ZI%-VDU[OHEHS+:#;QSQ9Z-E&U%5SB0H.IRY+I_0T*M9M&_:A]L.2;PKH'
MW=FD8AM<H?U6+33MN@>4C)<H#5<2-.;3:-Z_OADZ>V_P%\>=.5J#4[)6ZM%M
M'K)IU'.$4&!J'0*CGRW>HA .B&C\:#"CPY'.\7C=HO_NM9.6-3-XJ\1WGMEB
M&EU&D&'.:F&7:O<)&STCAY<J8?Q_V 7;02^"M#96E8TS,2BY#+_LJ8G#D</E
M.8>D<4@\[W"09WG'+)M-M-J!=M:$YA9>JO<F<ERZI*RLIK><_.SL?K[\\O#E
MXPK>_?'G:O4>%O=+6'V:+^\G74OPSJB;-E W 2HY S6 STK:PL"]S# []>\2
MK0.WI.5VD[P)^)GI#@SZ,22])'D#;W#0.O!X@W-:F99<;@PL4,.J8!KA[_G:
M6$VE\<\;^,,#_M#C#_^/6+X)Y5KQVE0LQ6E$O690;S$ZCP]SD-2_0AD#*9-2
M65@C9%S4%K,.?"V02EUIC&%7H 1;(-RJLF)R#]P I]YX]J^4X:Y?8E?L/ 4F
MLQ:I,:#@I:HLJ:6,CZ'[<Y"&E=B!A_P$GZ4%QRV2FU8YMVS-!;?[V-MD*!65
M-+-*@\J)1'L.MHEZ=5;*1%H+YAN:RU34&4&OE2T\X,[W(&:_L2UJ&BD@ZW*-
M'MR[&Z"Q9"Q)(G2OS'D]&[5'694^ OZH^98)E-;$P(,J?Z2?1PZR3HNS+C2,
M:I$=TD"3IP-WS>J\4Z4L_7(FQ+Z5!SNF-?,D@KVJG'KCZ=>20NLB1MJLYJE;
M!BM&;EEKQ F::)-F)\+2\#:UWC>6)=I"93$PH<A@QYM88I[3X/3**8\QY%J5
M)^%+%1VN+5\+2CVFM::R0>.KC0;4OXKV>Q>FHVKX]9?+I#_^<)J&5A]8!56M
MTX)F[&F$"DHG5(S.2GD5<J]=HKV+*[*,;SD5$^FU!;-T^MX''E-!2<]<@3L2
M>6UK5ZX4DJ9D0U<X)8;\G2D!KD_.(H+'XA9GW@2.SW%SPD/BR<S7Y^MN.JGR
M4-X9P9$#/>"*U! (58%R;77WZHUKQABD"EU)?4Q5HU)F@PI'Y9P,H%)( ]M"
M"1+>T"<L"H4?AS43H-:";T*X"3 0;$+ICD3S(KLA];DB&CO/]:B8VR8X9G'2
MBQZ,!CZU5#OQ?;!HT0_LUDBC"Y]\4V2A''\R1/RCE^,J<'_9X"?%?#17WGF1
MJC;TSKR_?LG*,_K>%FW_Z@KZ\>!J"*N3[NQ?Q./+ ?2'\>"R!\O5M]"+"[>X
MB$>C$?AF2#[ 5V4IV,D@'@W&T!_%X_$0?O8QZAY]Y$O4&W^5H7FO:FG#]_[P
M]'!;FH=+PK-YN&J1H@TGD@)S<NUUQJ,H=%2[L:KR5P:J7+J ^&5!-S[4SH#>
MYXIRVVS< 8<[Y.P_4$L#!!0    ( %- J53F1=HE]PL  - C   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;+U::7,;N1']*RC&SDI5),5#E"A?59(L
M[SIE6RQIO?LAE0_@#$@BFAG0P(PHYM?G=0-S4")U;'9398MS 'WWZVZ0[U;&
MWKB%4KFX2Y/,O6\M\GSYYN# 10N52M<U2Y7AS<S85.:XM?,#M[1*QKPI30X&
MO=[102IUUOKPCI]-[(=WIL@3G:F)%:Y(4VG79RHQJ_>M?JM\<*7GBYP>''QX
MMY1S=:WR[\N)Q=U!1276J<J<-IFP:O:^==I_<W9(ZWG!;UJM7.-:D"938V[H
MYG/\OM4C@52BHIPH2'S<JG.5)$0(8OP(-%L52]K8O"ZI?V+=H<M4.G5NDM]U
MG"_>M\8M$:N9+)+\RJQ^44&?$=&+3.+XKUCYM8?#EH@*EYLT;(8$J<[\I[P+
M=FAL&/=V;!B$#0.6VS-B*3_*7'YX9\U*6%H-:G3!JO)N"*<S<LIU;O%68U_^
MX?J7TZN+SMGI]<5'<7[Y=7+Q[?KTU\^7W]X=Y*!.:PZB0.G,4QKLH#047TV6
M+YRXR&(5;^X_@%25:(-2M+/!HP2_2ML5PWY;#'J#P2/TAI6J0Z8WW*7J0EK5
M(1?&8B+7B*Q<G%HKL[GBZW^>3EUN$2;_>H398<7LD)D=_@EV?9029>4;MY21
M>M]"VCEE;U5K)WGQZT*)F4F0:SJ;BUQ.$R6<RAT>VGPA<KR6J2F@KID)U[!(
M9%(DNI.<*^J.KA6R+C+S3/\'[Z=KWGR.93);TRT)*G2N4H$=&BS.#3R?$3%<
M.9/H6.:XN<[Q019VQ/-RJ2PS<4)F,=.S:D%9?JO$%^-84K"R2HG4!Y2B@!((
MAVA1Q0-OQD5?[.D,RTWA\,3MOX$%:&LS%N]OY6U7,"4_)D*QN@4\+3D,7HE1
M;X"__>.Q^%EED#;A-3)&^FF*$,(1T6\/3P;B>-P3OYH<2SBZQ)GTZC=L"4KM
M\<DA/D]&8_#N'\(B)KH1G[,(_(C6))$9>RY8]R>W>UU;2%@N]3;9(Y>T>"V]
M:^VWQ8I>QV:9>Y^17Z9&VIAL'VLX-#?6"=CLHXI4.E666 U90U=,G?I1@%FR
M%G*YM.:V)N)(EH5)8N6W_T-F!5"<!>VR\)488JHB2"C4;*88=(5.4Q5KA $(
M+ZTF!QL.IR@QC@(5PN4;^G^>7!*73VIJ*S8L)$FE8U6&B1)S9#!'LZ[L1.LR
MDW5^%#+1,PTE6'H!JU#@M1'7\*..\NJ-7,%$VUX4&2F_U[JZ_D[6#:MA&Q5I
M[U]+N.^#V4 >Z]>$K"KIKC22SR>>7YHKFW(^L/@.$4A/D%'W,^VGK?Z3.:_)
M41\K(NW2J/5.E2X3LU8*$IC93$?P7;NFTD;29P[E2Y92R?A6.[SIBE//X#2#
MEQ/Q%>5EJYL>1$61<2"<M!];6,468H5#F1,O2%^'4;Z FGMZGSR+AL-YVQQW
M3U (DX1L3^NS@J.XA#,V*L ,V!&\%4 SYHC1SA42@0+'0I1[#,D$>QH,5:+A
M"T8O6O'WOXT'@]Y;@(2= UPRON^_%: G"U1H! *07"T3!8!8L#(<IMRY!)M5
M7-IB65@2@C5>+72T>)X>8+4PEL'X24T8!4K19(*TJVU(O1#]8\\B3/4SW4U:
M]X_?/G3Z5[EF3&T_O?HEGM_P>G_P%SF=L0O(O:(_+-Z=3CU2#;M'%=-=/KF5
M.N$B^W1P\>[-4M0-$!^ 2:!K=LC&F(R_C<;<UR/(=@N@$K D(A"L"]M9HYH)
MU%9MXA(=4*D8'0:CUZ4K/5C29O:O-^9,6Q!#0  [K2.T#:OC0,#OHNPXZNXD
M%IBJC*%*2:CIBBA2CBL[%_0.%_122@)+)6? O?MF8,+PW58SPDWJ3ME(N\KN
MLB1)@JE,D"U0(*Q)'ZKQB+_[PVX=9>Y%CMGNW,M,7"M48H[5DW8C2<Y*2/]8
M0WH65_E3-0^X276>*W4O%QN)A%#/J>YA-1Y!Q]3;)$DP/UA+^=4H ^HN@D15
M\3Q?:#43%W<J*KAR7OHJL0NC2NXK&*FLQ +K<TQ_=?VE:N;TG&H9=D,\>HM8
M6-2"^,XEX.I5I<#$*Q#P=;\K)@TQ:,>#I6RVNM'P?KB$1<GD_?8CN$0-@JH4
MKR6#/Y3VED6J3ZD,!!C' ^D6*,=9X7QE]T43>:0Z7(K1)807WF9L)TY56&!6
MX,8T0V+8\Y'2IM;KWU"!U$1-1CX5$,#+Y!%R84TQ7VS9VQ47E&K$&16(8(^+
M>2 SI\W<H7A7L&HDKP>T70C?Q#@4A\29C8#XDSU1>Z%N4IX;IYS&)5XT/ %
MX!,+Q&1HQ;:V=F(OQ.#D^GL9=<&#BKK'4MM;F11LK4W$F.E9OB9>%/E<'$+&
M$4OA9 (P#0Z:_&4.$L4R #F!AIO)J Q8<.LT&LN&341D,;E9+0&]CX=>VV>N
M;V1#V=D2P\-:BI*CSYM&-[L;U1*:O]B\$1Q]Z^=Q,F> EANU)F &<UC&<=NJ
M7=FBP)081:G-$7 P_E8KV]1FE)G=P,EJ <<L)S6L(L,Y0,T(H;\%US>$I$8K
M5KCFR61:E223)5[QG=3;=3B0(H->55<G)8I @$&O=_+DO"CH](T,17&U<\?&
MY$B*4T9PCUN.D=A8C9&,7P'BX_]AV*HX;9FWMK_CD>O_.#+1@/?'!Z7O9=@W
M1EFBN&V W8 _!#?C$@O"#92W2;.]" [Q+%$]0A=*,]$S.L]J=^YSF%6O9IQ&
MR6EV-X](P5VYNEO"+&U1YKCB*8B0BOJYE2;<8Q#$?A7#<B160E>0<Z8T^1D[
M$/L%DHHM0)Z&"&(A;TF"*28L+I;KLM$KMY +:(4FBZPW07"J^ WL0!2I*D32
M6@I'[I+OCQC/:3DK^_UU+6>OVZ\Z3J\R(>R#'-K5?E82;F\_B[QC9AU>\3F+
MB\@CT,\^?3ZQK!029!M\;D8G7%,9!:50H\Z%T @IDZD5Q%T@&.)F^@ 8DH(%
MK<HZ/P5J1L;&'*2<VL3LFW2Q_!%< ?%O5"Z^?#D7>RW_IK7?;()TK8/'(7!(
MV4)B+U#Z$LK"50$_C8Z&H[UH?^]P?Y_*'&P3D(,<FDJTKF17:F'OS^@^X9 <
MA)A9DS'YC8M,"*A2<V .%$159 5I *KEKM0-MD4\B-TSY^@9(TCH+C=Z'[?#
M5,%KNU5]9"Z]#+R?.%66Y7<ZN]J5G(](F_KXKV,05<V(":(^.O[QL6\3%^]'
MA7O@VL8)1#TW+;'?M:O"]N2!\QOQK3ISN/8P[.7S-A*_\_<_*NZ< FY0[!\^
MN%)4IDG/T_G<JCE!Q&43>?/Z3#9P[8O^J'W<&XI7_>[)4(R[="G& Y_#D+'?
M[HU[XE6O>]RG[CB )=M]\+;Z/ \83"A:H_#]5?=DN=?T](_:QV,69#RB,S@^
M(B]Y<D \W#-NC_J\Y6B,+8,CWM+L6QK?+SSY703L3E:HX?*YGO.GTQO!9U7"
MC4^@[7PJ@?RP(D^AA0>]E_.KOIK@X^2EGX>2]?9FLNV/0;B/?'72.'"B3.*L
M*;*&E38L$QDTXZ4JP*,BVUH\'H[OI':4NS!Q>-KE8=*J#%L9PK:N<X/NZ,@7
M.F_2!TLY_SI<^V92VWIJ<EMK;5Q8AI,7&36XJM<]''D?#;J]T7U+?S/W;:#J
M&OY"SEY7[PMTV=CH=+1+M9K%<\.E'T8(^G)7IW06^^D/!%K5FS]M?<^N:IT+
M5UJB!O@'CM79LB@[7W18:2"E?>=[ELCHIG,= 6+IB'09SJ)T1+12$ZODV=_*
M?2+!4]\(>/D]MKT:=OLCCWJ5C9G%YH(+#FSE9P7^9I##=5\<(9'I_Y5V-YT9
MB0)7*AH]_"EIOWO\&LW8^'5-XM8@L71"C<\Q<.>U.!YU,:-]U#01P1!KK9(*
M1%_7%U?U/..+Z'?^"HEL-VD,X,UW?["\HN?@ R>B3)^AHKZDINT0MJQ=HJQ=
MWO(?R53LHM_8-]]+P-E:NH;MWF&?W(,*5=8KDG?8/CGBFG5T7#TG^5'+>H?A
M>9/R@Z+2ZXW8ZX.-6A)KFD/SZK!Z3<P<E;P)?;X@Y?M=L>T7  >-7UFDRL[Y
MMR1T&($)U?_@HGI:_5SEU/]*HU[N?^L"=G.:UA,UPU:H,FKY0Z#R)C=+_LW&
MU.2Y2?ERH=#66%J ]S-C\O*&&%0_XOGP7U!+ P04    " !30*E4Y7LG8JL%
M  !(#0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6RE5VUOVS80_BL'
M8T5;(+4=V]V*(@F09"[6H6F-NMTP#/M 2V>+"T6J)!7'^_5[CI)ENXV#8ON0
M6!1Y=\\]]T:=K9V_#05SI/O2V'#>*V*L7@\&(2NX5*'O*K;863I?JHBE7PU"
MY5GE2:@T@]%P^..@5-KV+L[2NYF_.'-U--KRS%.HRU+YS14;MS[OG?:V+S[J
M51'EQ>#BK%(KGG/\7,T\5H-.2ZY+MD$[2YZ7Y[W+T]=7$SF?#ORF>1WVGDD\
M63AW*XNW^7EO*(#8<!9%@\+/'5^S,:((,+ZT.GN=21'<?]YJ?Y-\AR\+%?C:
MF=]U'HOSWJL>Y;Q4M8D?W?H7;OUY*?HR9T+Z3^OF[!@6LSI$5[;"6)?:-K_J
MON5A3^#5\(C J!48)=R-H83R9Q75Q9EW:_)R&MKD(;F:I %.6PG*/'KL:LC%
MB^G-[-V'/Z93NIJ^G[YY^XEF[R[?S\\&$;KEQ"!K]5PU>D9'](SIQME8!)K:
MG/-#^0$P=<!&6V!7HT<5WBC?I_'I"8V&H]$C^L:=H^.D;WQ$WT>.VC/2*=(5
M6U[J&.C/RT6('HGQUR,&)IV!23(P^=],_A<]H.%T0M.R,F[#3//HLEN:U3XK
MD)(T,\K2IX+IVI65LINGX3O./^LU9^:S6>\YK54@E;LJ<DZ+#0D]"Z=\3FY)
M.9C+HO.!M*6?.>-RP5XLC$G9' 6]"/RE!K5F0ZJJO+O;*0EBN7 FYT;\5V5K
M5'_"UT^8.Q2TX$R53+Q<<BI6TF7)N5:1H;CRVGF*CB)D,N."MBL!%P_<?CO[
M(%;>\,)W9A)(#E$MC$:EY%CCC(Y:&?25P!Z6H&C8'Z'"C)%F$0J%G6_59ZXL
M93O1B99(.H1:V8P%6*5\U)FN5!1HW'(?^G09DYI+"]<-W:!6'\3^-54W2O"/
M4 ./G.OXAE,@S^8IQ5N:=M3&0D7HS-"X0Q.<47_<N2MG;9VB"E0[YP_<;:G*
M#_VN4>_^T%@3UJKVE0N\=7,'10>!Q[9(\EN: "XR3 C*)!#J+.,04O#@XLK+
MXI S<8-MYFJO5ON4DUM;<%/HZALG#A5\G8!"I<[A>Q<\M.-8)!%75<['&GFS
M2<'>UM(1MD"WHM.73U \ 0AW,<'LN\6P13I+UA3>U:L"J;/QSAC,D[Q.XPH*
M/9FZK&1<4J9" 5[N0(^$-_3WBUU26V,^ <2#<83=!:> 298TJ8@\D1/(&8=B
M\T)>A1^7)[I1[6YE]3]"Q#W&OT3QKHVR1Z7KH",<1S:(#XU@G^8'-7- QM:X
M- ODK9 GZ?- GD(%<"-^U*9EYI!@5G(63Q#6N9(6A6J.J9LWS".75IR*9K\X
MGI* 1;R>84ZC,N-SU&(2P'3)BFZ\I *#X;7\VZ^+8[&]4]J@FW JA:#,(V6P
M#5*N<[(N@C6$65ZTNG>"R7]1* LD!O*X;&8JRTS]"G,B4[I#'QUYB1F2PY2-
M7B_J=-V1%A_H,](5._.8TN,%38:GSVZ??S,O2*YO$7\HM^V9O-6:[6OUNRE:
MB8YUH8$ID^R *#P#5=+U/\_W^]^TJR8)+QN]TD+>0<OD;<"7VJ,)M%F4"  I
M!I='25*\TY[R='Q)!;#TX>.6P1:Y(#LYUHWAZD9\@TA="833X?!):PZJ<;-]
M$=6]!!7CXT1FV]\81G(P8R\4I=2K,0TW9'2IL9!RW3EY0%B@N]32=G.L;8Y"
MGA*O0@JY2FU"V'56QA;*&;RBLHZXT6)7<A74)3H$'/AA<C(<#I/0AN7V)(;:
M^I72R&KOV^XM9#5E&\3C@'AB)Z5_SG+-A&,(5IGZE@BP IPV)M^?FB<R,ZIF
MEHOGU\JJ7"$-CV;L0_>PP=[MMF2_2G=X&<4 UUQTN[?=9\)E<SO>'6^^,8!S
M)4EN> G18?^GESWRS;V]6417I;ORPD7<O--C@4\=]G( ^TOGXG8A!KJ/IXM_
M 5!+ P04    " !30*E4<.45YRX9  !A6   &0   'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6SE7&USVT:2_BLHKK.1JBA:I"P[63NNHA0EJUW+UEE*[NJN
M[L,0&)*(08#!BV3FU]_3W3.#&1"DJ217M5?W(;%( #,]_?KT"_CFL2@_54NM
MZ^CS*LNK[P;+NE[_[?GS*E[JE:I&Q5KGN#(ORI6J\;%</*_6I58)/[3*GD].
M3U\^7ZDT'[Q]P]_=EF_?%$V=I;F^+:.J6:U4N;G06?'XW6 \L%]\3!?+FKYX
M_O;-6BWTG:Y_6M^6^/3<K9*D*YU7:9%'I9Y_-YB._W;Q@N[G&WY.]6/E_1W1
M269%\8D^7"??#4Z)()WIN*85%/YYT)<ZRV@AD/&K67/@MJ0'_;_MZC_PV7&6
MF:KT99']>YK4R^\&WPRB1,]5D]4?B\>_:W.><UHO+K**_Q\]FGM/!U'<5'6Q
M,@^#@E6:R[_JL^'#(0],S ,3IELV8BJ_5[5Z^Z8L'J.2[L9J] <?E9\&<6E.
M0KFK2UQ-\5S]]MWUY=7[NZMH^N/'JZN;J_?W=V^>UUB7KCZ/S1H7LL9DQQIG
MT4V1U\LJNLH3G83//P<]CJB))>IBLG?!&U6.HK/Q,)J<3B9[UCMSASSC]<YV
MK/>A7*@\_4V1'@RCRR*OBBQ-E*A%GD2WI:YT7LL7Q3SZ(<U5'J<JB^[PI88.
MUE7T7]-959?0HO_>0]$+1]$+INC%'V+[4]>(KO.3=VD,D]'1=%%J0_G65]"Q
M>AG]9U.F\3*Z7VJP9+56^29:JBI246;N5^']-6[\*8<-E55:;XA/9H6C@?PQ
M.(X>E_3%HE2T;^VMK#_'65/A8;=Z2?92#=NU^8NH+N @9N:F(7U<J4_X8ZGP
M[$HE^+,AVB VV'86-="Y,HIU6<,#16N(B[9>ERE\3)IMHB0MX0!T0BMY!'T-
M\E2YT'6:+W!0/#2,TAPT)OQ%'EVM+Z<W4;R$!RH5;U?J3-%"Z6K5Y$5<Y+\T
M"WQ1\<65KI=%4A%7+'DKE3=SZ$M3:OJ:-J_42D=']-=?__+-9'+ZVG!P2T)\
M>?SZ>$3BP05[KK@ ^Z.JP#*?]"92U1J'XUU_3F/H1[,:^0+%*7%ZG:YK2\'E
MQW?X:J%*/B=]<_%N&L&YNP7X UVHX>1K%C^>O;C\\:3)82=K6 ^)\?W-]<4E
M[DD7"UV"*RIZ=CHZAXO*,K(B_*OAO'(B?<.+@/]RVA&TB&1&>^PZ_S!0GA0\
MSJHB*J 7"V6$B76C9DU_J>C%5U%9;%1&:IGSHSGBV;HLDB:NP770PL<RWQ@^
M8IT9'BA]2240'VN D:A_IXH>%/Q&%&<J74%;_!.(@%JE9CL0A<+>K7 ^,IDI
MOBL>Y1QF@4<P+IK!"C0H)"T3>=5%#3=D#U=B%WD0Y/@<:M<AS:-O"EPF'J=E
M N+*FKDX/OV*SKL@R>IR2/QX2!.B8ZEJ,4)_IW;5%9B=%S41"%Z2:<-$)E^1
M9A"GF<.B>49&I -&2*4[,EBFF)@T;C(%JRV:O"[).:QAI17$::3'7QAWC$/H
M$I'/>6>Z(5.54^D^"<B!6';BASP1BP/!ND0U+:*L7O )8*W@5%Y\^226?!&5
M>\Y7DBX95B6QN],P4-!29ZW2I\A)&;9<E"0N,!\L8I/!TS"\,V=X)/_ $JW;
M(D^JC;\#;GD 'ENS83I3'8IK@OM=I57E<=OL3TYI_.IUQ2[#N>T?OI\2.[Z'
MGUG-H'*(V:?'0VL>\Z(I<>.O#:2.BUB0K@]%3<D301'J DSL4M'=L\>/S<MB
MY9,P;18 3+3!N"5 +"#<'\B"/)EF1)AM1KLBY$T:8POH]W:,_-(3TQ\1%NVG
M <C) 1!(]8F$Z0H!9XAH'8^&8<A,:]R8M\$R")(VR+7QT5TGY_8)6YPLL0WQ
MU@8,E0%VD\RA+UF1MAC'+8:+,(-X21] 0SHKDDWK*/U@Y0[WIX:K-AB0G5=6
MP+LW@_+P74")8)R%B6'$('\UT[L"!L@]>_GB]63TPEE)VA.R*A<*YVE9M?$D
M!H,)/FHQ;P60 ',"K]=KR$7-,NTK-B,5\H\GE#TD_:8'1N/ILO@,V%)#):-G
MD]&KUJ9KPD]PN0O-CIG]CY[/-7F2O,.(X]!GV-A9ZE^;M-P.G6>C\][@N3]H
MTEVJ%<C.<'??#2DVZCGQ[HH)W7B(9\9$JG.V"O^%WM90V'&AX@C8#?/*?V*8
M(L=:6H7U8A;KAA^I_)#02R,IB9@ $BE\$IB-+-DN(QH8%RO 4<Y,;/#JG+1J
M( AW4DIDLFRSA::ZRN +1)$;R!ML89T,Y?8@#"D1Z-"\J[&@\]/AZ>GIENZ>
MGP_/S[_=J[9])GP\-((""9!\# )3L=U'X-6*88U5)H<JO8-!MRK_* <%3W.2
M4\_<CA _O[6?COT :DS=@N(=<;0-/3"0:"6YL:;<N(V2YLR(A$FC;6ZR,_)^
M76W#]*T '/D1^&EG/P_._K+W[/T$WDRG]N+5C:%P4VV(0JS^XIO):X<$6(,[
M@7CD[B:U-+J,Y$W7I/NSDNPBIZ2)%>-1D8G#^9*5D6)'K'@/K4^R-!3KHJR;
MWYJ5FI$ X(D_6SJN&NR@P0CDLD6^,_;_QP<L=7!NS'=?$[= \+MTQ7I[-*"O
MNUFQA/B3;HPG+MJ8S*N%>);6=0'>DXI]!%*%:V+)U#I>YD56+#9^2KN&(UJE
M";""=RL5--(<WYFK,/6U[&5<"M^TJ6J]"J$ 4W@P#/"S9W>(/X -^G?_HI>3
MD <%GYP?$/?5KG@/GA8E](L]FCM.XTAU*D(0MP<;Q%F:X\]L!Q(811>,$T!<
MW)0E771/5,!O314>E#!;G*Z9&IO&D=-NH84!0VVN#F.Q/';XNI<JK+I\5)O#
M$(6*)H=CB9:)I)PD4$>)K[][@85OF4$!23"#@)05Q4)2G'(K\V8U*KQ,[F2V
M.;'!'F -![50IV>5M4IYE6ZBC6N')-:\>6]:/1Z].N]FUM>@,A&_-S1Y%2!F
M0;SS%ZX8%5G(!.+/D?"S@S+Y#LO*RD#0*\.HNJ_.83Q04.ZP[ %Y1-K_)S#U
MH:G[JJL?BQA/;4<1B.P?#9S*Y'3\,K187&56 U45H<<(@XJL[+O='7M9OPN]
M:\JJ45)M$]OQ-^8(A(UE&<8")@@-J7F2)8_0V<C57MO@L:\\FU*Y]:!8U9?6
M(S@7<4;1O$T^KRZN3T[/QN) D06(A5V_.WG)]YS8O]2BR%,(LF^-UHG W//M
M@ME17&29+0"(> 8!=Q,($&B6[B$L?$N@H:PW@V,_*NV0Q]!<Z,0@0!=X.\ ]
MXV+!V2&!Y)1SJPJ/!2=W13RKD53];HL>AU!K$Y^<, ())NKRSC"TEX='?5I'
MW1(FQRJ=P 72.YA0+C[)Z ,(KW3<B-?R#CKR.BSW'-@[8%6GA.GXJ$Y7FS4^
M8U%K+"83>?9J%$1S5P0:O_3JB9QT8-&<O*PQ]%V&.R]LS430)8@,E0=H')$U
M_K0L,BA")<4L0R>MTLVQ6]^-I9Y-7DX\BAV)G=2"O'4Z3W7BE1*&06RF35L7
M9KI;?MCO^GVAIG[$7[GK90#9Q/PD@LR=[!E+RDAD+Q;4*ZC] &A U/C;@._D
M C:,;D([=Q64G<?;0W#KJELRAZ3-B,P,&[#047H,%9B$.M /K(8&CWQF"@RR
MJ*)G9Z?N6:(6,*A.@V*ST' +F*&CZ^OK%BH!4:EL"!J(B/-3GX2^RJ9X1MS-
M- <4[Q/D*)JVZB."J#Q)O&P7HEANY?!EQ>HJ4S_)'+]AQ4B[/#$P(KG3Z]IF
MG!3CQ 0$%_F]"<?"_FR9C'CB2Y 3+>A!D[ER[W4.$%T;D $VO->/T?=EL["X
MNK;2LQYT!HI77/>TIA]),V&F"3IYM(_/ATP_'\FO8B-#5Z"L%6M+,B6BAJ^)
M3>"-RS?:PU5VJS(=C1E%-RI7"Q&)AG]I)$(N/=3NY1.,)2E=8ZE/8P8DM,%=
M#;%Q9>2R2-APF0TO3TD6((U"#?O02_A-ZEP;$[ODL0)J21P-HNG=)3W10@A2
MA41+SX4\1,W6718S,6_&C%&5+G+>D:*^V8K^!<S*I'1'F+*(D<&0!LT;[H(B
M)J5%XMICQ$6ZC7$E<<I@3*2G#VG15+98,.)#<\=RJY:5/Q1I[""-+RT^JBL3
MV?01QIZH3>4Y^1X;$:!;2K>3 5 K%SIL'0*M?<&$VS$^5:KRJC%5VPTW3)2D
M,18CETA(?*_V]E/&K+O_4'E#(+>MAMO3LX5MT<!!MB>U\/(\/)S6F00T\T2W
M B<>@N7#!4)FNXJ _0GU!%E/!0O0II<AV0KPZ(+8RUKZBK)'*O-VLA_ZL"X(
M4!!>L*K4%J49W- J/GH2YTCIC\BSLB5(<A)/7]J#H/ K:X@GL5T9#>6Q2M.F
M/0#)OY@PQND86V8XJQ"G9=RLD-*#;1(:C"[-FLU)T4!LZ]I:/:O7*+K %:0A
MT0=SY7Z/YID4U#0Q'@N;0\BJUA:-W<.)<1HEABE+4G+*TU-V" -BA06<U.DJ
MZ.J'Q8A$.F]-2=ID&K>:D5^2(DO4..S0,R<./)V:;IM.5IX;W''.+FPA0.#1
M_YFB*J56':YV'(")3P7W_BWNO79(P&'=H)8I[GT",-@D&U,SZL?*$7GLC!]-
MN!C#,>AZ+](X.V!=YK7(C!UH;]K!!7Y/1L_&9^>!E\0:UBVJ.7D57@8HUW&/
M< /EPAT>"FIP?5F56W_<9BEFTR&%7L9)3Y<-<4SH^N,,ZQ>$A( 8D$!Z'%B
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MK1V]4'Z8T%\"-&Q ^QNM73UA!\V?C-$_4$L#!!0    ( %- J52?72S880,
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M$R&WKY+MAQ8K^Q*8"TWO"CN,Z2&'TAC0^D*09(L/ U ^#;O_ 5!+ P04
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M09/CTY.HUKLQG"[#,,ZUH]$.QX)V*1H?0/<+K=W&\ F:[3SX!U!+ P04
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M[1S(OE)TM]N#2]!M[^E?4$L#!!0    ( %- J53WNM&Z8@4  '\-   9
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M+5/6 -\OI#1O-S9 /B-W_P=02P,$%     @ 4T"I5+URW(?M @  808  !D
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MQC)NARFV9B#-!OP^$GC.Y<08J)J]SG]02P,$%     @ 4T"I5!![@ 1F @
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MXB!M@-E?"J%?)K9/M+^%^ ]02P,$%     @ 4T"I5&<=-8," P  J0D  !D
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MFZ).36?S^?IQN2#+'ZOEE\UR0V[(G&<%SR%7DO"8S,)0E!"1Y3,N' F27"U
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M?>Q/5$="-5&\,+OJEBO<H\TPP5,4A [ ]S'GZG6B-^KF7)[^ 5!+ P04
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M/S7(N,+%R4\P/LQ/89R>SH@SQ@J6F9]E"F$-2RF![;R^;4?;/E9?4 J@B6[
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M14^4,^J+HQ!0<OG>.2L4C_A%JS9G%8U@O_,J:<'!(8;IN%?N]$B9E\2$Z_3
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M-BJ[@=:74IJG@>V"JLY]^@-02P,$%     @ 4T"I5-R[R[5M @  I@8  !D
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M][;TF0ZS'#.#[KWI<QUG^<W<'.Z?B\#Q-0#R%<:PH,G1EKH-'$8#($;!# O
M) T<20,@2<$,"\ D#6H'GS]S\OG_&!8TV=K($Z]V5)YRN<I?""BT$)M,%Z?F
M56OUTN%=<=3N'B_>6%PP:1)9H80O35?_:&B$9?$2H+C18IT?O,^%UB+-+R/.
M0B[M ^;WI1!Z=V,%JE<QLQ]02P,$%     @ 4T"I5)CAS' Z P  ^ P  !D
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MQO3[@-(8T/Y<"+V=F /*'Y+./U!+ P04    " !30*E4-HC%)QT'  !4)0
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M*JFNN:9'#RH;0/-+*<U]QWZ@>D:-?P-02P,$%     @ 4T"I5#LZO3=, P
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M&Q;FY4-I$\SZ1@A]"*Q ]Y8FOP!02P,$%     @ 4T"I5/I%B$Q* P  [!0
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M_RGKD[7KO_ZEH+_GK:F[]WPV_+=Q]0I02P$"% ,4    " !30*E4!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( %- J50>!GJX[@   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( %- J5297)PC$ 8  )PG   3
M          "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M4T"I5/T!9<4]!0  \!4  !@              ("!#0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( %- J50"*01%[ 4  .T8   8
M          " @8 -  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " !30*E4VBI)7PH#  #["@  &               @(&B$P  >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ 4T"I5/ING*[(!   EA$
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M965T."YX;6Q02P$"% ,4    " !30*E4N2ZZZ/('  #%$P  &
M    @(%#,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
M4T"I5!>Q2'FP @  YP4  !D              ("!:SH  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " !30*E4T I:VYL%  !S#@  &0
M            @(%2/0  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( %- J51<KNI?HPD  )P;   9              " @21#  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ 4T"I5$=Z06KN @
MJ08  !D              ("!_DP  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " !30*E4,P3NDQP*   ?'   &0              @($C
M4   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %- J52.
MQ)RMN0(  ,D%   9              " @79:  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ 4T"I5!M(_*T("@  &!L  !D
M     ("!9ET  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %- J53E>R=BJP4  $@-   9              "
M@8&(  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 4T"I
M5'#E%><N&0  85@  !D              ("!8XX  'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " !30*E411F0D-8#  !P"   &0
M        @('(IP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( %- J52?72S880,  #<'   9              " @=6K  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ 4T"I5#K9;X%9"@  &AP
M !D              ("!;:\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " !30*E4")I75<D#   F"@  &0              @(']N0
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %- J52F-6H&
MF0(  *D%   9              " @?V]  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ 4T"I5()EZP_% @  SP4  !D
M ("!S<   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !3
M0*E4)M62P[T$  #I"@  &0              @(')PP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( %- J50[UD6[U@(  ,D%   9
M          " @;W(  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ 4T"I5/>ZT;IB!0  ?PT  !D              ("!RLL  'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " !30*E4?"7_WY<"  !L
M!0  &0              @(%CT0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( %- J51=ZU(1700  +0/   9              " @3'4
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 4T"I5,E>
M.'[J P  T1   !D              ("!Q=@  'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    " !30*E4D?I48_0#   O#P  &0
M    @('FW   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M %- J52]<MR'[0(  &$&   9              " @1'A  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ 4T"I5&2VIUW_ @  ^ D  !D
M             ("!->0  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " !30*E4$'N !&8"   B!@  &0              @(%KYP  >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( %- J51G'36# @,
M *D)   9              " @0CJ  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ 4T"I5&_,9Q3+ @  HP<  !D              ("!
M0>T  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " !30*E4
MM'&/V?4!  #8 P  &0              @(%#\   >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( %- J51?D6S4FP0  -L3   9
M      " @6_R  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ 4T"I5%ZAXT^= P  Q0L  !D              ("!0?<  'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " !30*E4W+O+M6T"  "F!@
M&0              @($5^P  >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+
M 0(4 Q0    ( %- J51P?0T8T@(  /T(   9              " @;G]  !X
M;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 4T"I5.<8]/J%
M P  6PX  !D              ("!P@ ! 'AL+W=O<FMS:&5E=',O<VAE970T
M-BYX;6Q02P$"% ,4    " !30*E4(66Q_IT$  "6&0  &0
M@(%^! $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( %-
MJ528X<QP.@,  /@,   9              " @5() 0!X;"]W;W)K<VAE971S
M+W-H965T-#@N>&UL4$L! A0#%     @ 4T"I5(Y'6H/; @  G @  !D
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M=#4S+GAM;%!+ 0(4 Q0    ( %- J50:?.0HP ,  )X+   9
M  " @:<B 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @
M4T"I5)FX(V9@"@  L4(  !D              ("!GB8! 'AL+W=O<FMS:&5E
M=',O<VAE970U-2YX;6Q02P$"% ,4    " !30*E45)4=<RD"  ">!   &0
M            @($U,0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4
M Q0    ( %- J52;PI0D7 (  %<%   9              " @94S 0!X;"]W
M;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ 4T"I5/I%B$Q* P
M[!0   T              ( !*#8! 'AL+W-T>6QE<RYX;6Q02P$"% ,4
M" !30*E4EXJ[',     3 @  "P              @ &=.0$ 7W)E;',O+G)E
M;'-02P$"% ,4    " !30*E4I_)83MH$  #R)0  #P              @ &&
M.@$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 4T"I5/,@BWGI 0  $B(
M !H              ( !C3\! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS
M4$L! A0#%     @ 4T"I5+)H2=C5 0  OR$  !,              ( !KD$!
J %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $$ 00"^$0  M$,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>179</ContextCount>
  <ElementCount>266</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2112106 - Disclosure - RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLES</Role>
      <ShortName>RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - INTANGIBLES AND GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL</Role>
      <ShortName>INTANGIBLES AND GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2118108 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2121109 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2123110 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2125111 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2132112 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2135113 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2142114 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2144115 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTS</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2146116 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2150117 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2315302 - Disclosure - INTANGIBLES AND GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables</Role>
      <ShortName>INTANGIBLES AND GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2319303 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2326304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2333305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2347307 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLESDetails</Role>
      <ShortName>RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RECEIVABLES</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails</Role>
      <ShortName>INTANGIBLES AND GOODWILL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2420408 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES - Components of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2422409 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2424410 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Equity Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2428412 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2429413 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2430414 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2431415 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434416 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437417 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438418 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439419 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440420 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2441421 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2445423 - Disclosure - LICENSE AGREEMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails</Role>
      <ShortName>LICENSE AGREEMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2448424 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sesn-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="sesn-20220331.htm">sesn-20220331.htm</File>
    <File>sesn-03312022x10qex3111.htm</File>
    <File>sesn-03312022x10qex3121.htm</File>
    <File>sesn-03312022x10qex3211.htm</File>
    <File>sesn-03312022x10qex3221.htm</File>
    <File>sesn-20220331.xsd</File>
    <File>sesn-20220331_cal.xml</File>
    <File>sesn-20220331_def.xml</File>
    <File>sesn-20220331_lab.xml</File>
    <File>sesn-20220331_pre.xml</File>
    <File>sesn-ex101xzurichlicenseag.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="430">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sesn-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 179,
   "dts": {
    "calculationLink": {
     "local": [
      "sesn-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sesn-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sesn-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sesn-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sesn-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sesn-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 449,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 4,
    "http://www.sesenbio.com/20220331": 1,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 10
   },
   "keyCustom": 60,
   "keyStandard": 206,
   "memberCustom": 30,
   "memberStandard": 33,
   "nsprefix": "sesn",
   "nsuri": "http://www.sesenbio.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sesenbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112106 - Disclosure - RECEIVABLES",
     "role": "http://www.sesenbio.com/role/RECEIVABLES",
     "shortName": "RECEIVABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - INTANGIBLES AND GOODWILL",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL",
     "shortName": "INTANGIBLES AND GOODWILL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118108 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121109 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123110 - Disclosure - LEASES",
     "role": "http://www.sesenbio.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125111 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132112 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135113 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142114 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144115 - Disclosure - LICENSE AGREEMENTS",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTS",
     "shortName": "LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146116 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150117 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2205201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315302 - Disclosure - INTANGIBLES AND GOODWILL (Tables)",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables",
     "shortName": "INTANGIBLES AND GOODWILL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2319303 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2326304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2347307 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i04e13475210e4b4f8ded7256b0146395_I20180430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patient",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i04e13475210e4b4f8ded7256b0146395_I20180430",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patient",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i487e4fc22ff1483fa5e2a198b37ce024_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "if5c3d72e64284343ad41bbaabad2492e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "if5c3d72e64284343ad41bbaabad2492e_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - RECEIVABLES (Details)",
     "role": "http://www.sesenbio.com/role/RECEIVABLESDetails",
     "shortName": "RECEIVABLES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i6cc771771ec447eb817fedfab04c5064_D20220101-20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInOtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ie5e2f3183009408a88a2121d2f8320de_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
     "shortName": "INTANGIBLES AND GOODWILL - Composition of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ie5e2f3183009408a88a2121d2f8320de_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "if355f8cd711e40d5bb37354a4ec90cf0_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - INTANGIBLES AND GOODWILL - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
     "shortName": "INTANGIBLES AND GOODWILL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "if355f8cd711e40d5bb37354a4ec90cf0_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420408 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422409 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424410 - Disclosure - LEASES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/LEASESNarrativeDetails",
     "shortName": "LEASES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Equity Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i4321e3e7de5f473b81eb3f2fa81fef3b_I20191129",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428412 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429413 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i46b9def9cc834e2e9e98a5e65496e75a_D20220101-20220331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sesn:NumberofVotesEntitledForEachShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "us-gaap:CommonStockSharesOutstanding",
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430414 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "sesn:CommonStockSharesIssuedAndReservedForFuture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ic3755f1139a340e2aade3663223c8a7a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431415 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ic3755f1139a340e2aade3663223c8a7a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434416 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437417 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i08791a0aa370455b99495a2b83190943_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i801045fc75394914ab13f94f4ae1394c_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i801045fc75394914ab13f94f4ae1394c_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438418 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ia92debb44af54d02b67c7dd62a05fbfb_I20220331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ic3755f1139a340e2aade3663223c8a7a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439419 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i14ad2e265e504b4994de4346a904f964_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440420 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i14ad2e265e504b4994de4346a904f964_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ic3755f1139a340e2aade3663223c8a7a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441421 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ic3755f1139a340e2aade3663223c8a7a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i1448067179f94f71ac95826b8ee7a5be_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i1448067179f94f71ac95826b8ee7a5be_D20220101-20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445423 - Disclosure - LICENSE AGREEMENTS - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
     "shortName": "LICENSE AGREEMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ibd649cc1b18c474ab1dd1aab76c6641c_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i35e5be36237a414280b903dade9eff3e_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448424 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i35e5be36237a414280b903dade9eff3e_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ic3755f1139a340e2aade3663223c8a7a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "ic3755f1139a340e2aade3663223c8a7a_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i2e633935010248e68ea0892b52e3708c_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i2e633935010248e68ea0892b52e3708c_D20210101-20210331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://www.sesenbio.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220331.htm",
      "contextRef": "i9f552561389a4839b36955112414fddd_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 70,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "CANADA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_TR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TURKEY",
        "terseLabel": "TURKEY"
       }
      }
     },
     "localname": "TR",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sesn_A2014EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2014 Employee Stock Purchase Plan [Member]",
        "label": "A2014 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2014EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ATMFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Facility [Member]",
        "label": "ATM Facility [Member]",
        "terseLabel": "ATM Facility"
       }
      }
     },
     "localname": "ATMFacilityMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_AccountsReceivablePaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Payment Terms",
        "label": "Accounts Receivable, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "AccountsReceivablePaymentTerms",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedRestructuringChargesRelatedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Restructuring Charges Related, Current",
        "label": "Accrued Restructuring Charges Related, Current",
        "terseLabel": "Restructuring charge related"
       }
      }
     },
     "localname": "AccruedRestructuringChargesRelatedCurrent",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "terseLabel": "Shares of common stock issued to the selling shareholders (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "label": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "terseLabel": "Total milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Milestone Payments",
        "label": "Business Combination, Milestone Payments",
        "terseLabel": "Business combination, milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationRoyaltyPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Royalty Payment Percent",
        "label": "Business Combination, Royalty Payment Percent",
        "terseLabel": "Royalty payment, percentage"
       }
      }
     },
     "localname": "BusinessCombinationRoyaltyPaymentPercent",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ClassOfWarrantOrRightIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued During The Period",
        "label": "Class Of Warrant Or Right, Issued During The Period",
        "terseLabel": "Warrants Issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "label": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "negatedTerseLabel": "Warrants Cancelled (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone",
        "label": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on commercialization milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on development milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on regulatory milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue based on Specified Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalty Period",
        "label": "Collaborative Arrangement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyPeriod",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedforFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CommonStockSharesIssuedAndReservedForFuture": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Issued And Reserved For Future",
        "label": "Common Stock Shares Issued And Reserved For Future",
        "totalLabel": "Total shares of common stock issued and reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssuedAndReservedForFuture",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "label": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "terseLabel": "Discretionary match per participating employee, maximum"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_EBI031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EBI-031 [Member]",
        "label": "EBI-031 [Member]",
        "terseLabel": "EBI-031"
       }
      }
     },
     "localname": "EBI031Member",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_EczacibasiPharmaceuticalsMarketingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eczacibasi Pharmaceuticals Marketing Agreement",
        "label": "Eczacibasi Pharmaceuticals Marketing Agreement [Member]",
        "terseLabel": "Eczacibasi Pharmaceuticals Marketing Agreement"
       }
      }
     },
     "localname": "EczacibasiPharmaceuticalsMarketingAgreementMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_FirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Indication [Member]",
        "label": "First Indication [Member]",
        "terseLabel": "First Indication"
       }
      }
     },
     "localname": "FirstIndicationMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_GermanVATRecoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "German VAT recovery",
        "label": "German VAT recovery [Member]",
        "terseLabel": "German VAT recovery"
       }
      }
     },
     "localname": "GermanVATRecoveryMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_IL6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IL-6 [Member]",
        "label": "IL-6 [Member]",
        "terseLabel": "IL-6"
       }
      }
     },
     "localname": "IL6Member",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option",
        "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Option",
        "terseLabel": "Renewal option"
       }
      }
     },
     "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalOption",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_LicenseAgreementAdditionalUpFrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Additional Up-Front Fee",
        "label": "License Agreement, Additional Up-Front Fee",
        "terseLabel": "License agreement, additional up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalUpFrontFee",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "label": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "terseLabel": "License agreement, amount payable upon achievement of specified milestone"
       }
      }
     },
     "localname": "LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under First Option Period",
        "label": "License Agreement, Buyout Amount Under First Option Period",
        "terseLabel": "License agreement, buyout amount under first option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderFirstOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period",
        "label": "License Agreement, Buyout Amount Under Second Option Period",
        "terseLabel": "License agreement, buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "label": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "terseLabel": "Buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achieved",
        "label": "License Agreement, Milestone Achieved",
        "terseLabel": "Milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchievementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achievement Expense",
        "label": "License Agreement, Milestone Achievement Expense",
        "terseLabel": "Expenses related to achievement of development milestone"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchievementExpense",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementOptionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Option Periods",
        "label": "License Agreement, Option Periods",
        "terseLabel": "License agreement, option periods"
       }
      }
     },
     "localname": "LicenseAgreementOptionPeriods",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty On Net Product Sales",
        "label": "License Agreement, Percentage of Royalty On Net Product Sales",
        "terseLabel": "Royalty payment obligation, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSales",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "label": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "terseLabel": "Third party minimum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "label": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "terseLabel": "Third party maximum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "label": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "terseLabel": "License agreement, period to pay buyout option once exercised"
       }
      }
     },
     "localname": "LicenseAgreementPeriodToPayBuyoutOptionOnceExercised",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_LicenseAgreementProceedsFromMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Proceeds From Milestone Achieved",
        "label": "License Agreement, Proceeds From Milestone Achieved",
        "terseLabel": "Proceeds from milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementProceedsFromMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "label": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "terseLabel": "License agreement, royalty payment, reduction, conditions not met"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Rate",
        "label": "License Agreement, Royalty Rate",
        "terseLabel": "License agreement, royalty rate"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyRate",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Text Block]",
        "label": "License Agreement [Text Block]",
        "terseLabel": "LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sesn_LicenseAgreementUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Up-front Fee",
        "label": "License Agreement, Up-front Fee",
        "terseLabel": "License agreement, up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontFee",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Maintenance Fees",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Revenue [Member]",
        "label": "License Revenue [Member]",
        "terseLabel": "License and related revenue"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MENALicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MENA License Agreement",
        "label": "MENA License Agreement [Member]",
        "terseLabel": "MENA License Agreement"
       }
      }
     },
     "localname": "MENALicenseAgreementMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MicrometAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Micromet [Member]",
        "label": "Micromet AG [Member]",
        "terseLabel": "Micromet AG"
       }
      }
     },
     "localname": "MicrometAGMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Lawsuits",
        "label": "Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "NumberOfLawsuits",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberOfPatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Patients",
        "label": "Number Of Patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "NumberOfPatients",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberofVotesEntitledForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes Entitled For Each Share",
        "label": "Number of Votes Entitled For Each Share",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberofVotesEntitledForEachShare",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_OperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Rent",
        "label": "Operating Lease, Monthly Rent",
        "verboseLabel": "Monthly rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyRent",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeaseOtherMonthlyOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Other Monthly Operating Expenses",
        "label": "Operating Lease, Other Monthly Operating Expenses",
        "terseLabel": "Related operating expenses"
       }
      }
     },
     "localname": "OperatingLeaseOtherMonthlyOperatingExpenses",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeasesAreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Area Of Office Space",
        "label": "Operating Leases Area Of Office Space",
        "terseLabel": "Office space (in square feet)"
       }
      }
     },
     "localname": "OperatingLeasesAreaOfOfficeSpace",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Line Items]",
        "label": "Organization And Basis Of Presentation [Line Items]",
        "terseLabel": "Organization And Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationLineItems",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Table]",
        "label": "Organization And Basis Of Presentation [Table]",
        "terseLabel": "Organization And Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationTable",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probability of Achieving Clinical and Regulatory Milestones, Percentage",
        "label": "Probability of Achieving Clinical and Regulatory Milestones, Percentage",
        "terseLabel": "Probability of achieving clinical and regulatory milestones"
       }
      }
     },
     "localname": "ProbabilityOfAchievingClinicalAndRegulatoryMilestonesPercentage",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_QiluPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu Pharmaceutical Co., Ltd.",
        "label": "Qilu Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Qilu Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "QiluPharmaceuticalCoLtdMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RetentionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retention Program [Member]",
        "label": "Retention Program [Member]",
        "terseLabel": "Retention Program"
       }
      }
     },
     "localname": "RetentionProgramMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "label": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "label": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetRelatedToAdoptionOfAccountingStandard",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RoyaltyRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Revenue, Percentage",
        "label": "Royalty Revenue, Percentage",
        "terseLabel": "Royalty revenue, percentage"
       }
      }
     },
     "localname": "RoyaltyRevenuePercentage",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sesn_SaleOfStockCommissionFixedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Fixed Rate",
        "label": "Sale Of Stock, Commission Fixed Rate",
        "terseLabel": "Commission fixed rate"
       }
      }
     },
     "localname": "SaleOfStockCommissionFixedRate",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "label": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "terseLabel": "Aggregate sales price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateSalesPriceInTransaction",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Shares Amount Available For Future Issuance",
        "label": "Sale Of Stock, Remaining Shares Amount Available For Future Issuance",
        "terseLabel": "Shares reserved for future issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingSharesAmountAvailableForFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Weighted-Average Price Per Share",
        "label": "Sale of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_SecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Indication [Member]",
        "label": "Second Indication [Member]",
        "terseLabel": "Second Indication"
       }
      }
     },
     "localname": "SecondIndicationMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent",
        "terseLabel": "Achievement deemed probable, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "terseLabel": "Fair market value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "terseLabel": "Percent of base salary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "terseLabel": "Shares received per award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "label": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "terseLabel": "One-time milestone payment upon first sale of product"
       }
      }
     },
     "localname": "SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "label": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "terseLabel": "Percentage of net sales of quarterly earn-out payments during earn-out periods"
       }
      }
     },
     "localname": "SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "label": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "terseLabel": "Period during which quarterly earn-outs are payable after date of net sales"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "label": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "terseLabel": "Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharesOfCommonStockReservedForIssuanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "label": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "terseLabel": "Shares of common stock reserved for issuance for:"
       }
      }
     },
     "localname": "SharesOfCommonStockReservedForIssuanceAbstract",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_ShortTermLeaseRenewalFrequency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-Term Lease, Renewal Frequency",
        "label": "Short-Term Lease, Renewal Frequency",
        "terseLabel": "Short-term lease, renewal frequency"
       }
      }
     },
     "localname": "ShortTermLeaseRenewalFrequency",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_StockIncentivePlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2009",
        "label": "Stock Incentive Plan 2009 [Member]",
        "terseLabel": "Stock Incentive Plan 2009"
       }
      }
     },
     "localname": "StockIncentivePlan2009Member",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIncentivePlanTwoThousandFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "label": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "verboseLabel": "2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwoThousandFourteenMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Exercise Of Warrants, Value",
        "label": "Stock Issued During Period, Exercise Of Warrants, Value",
        "terseLabel": "Exercises of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfWarrantsValue",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, New Issues, Issuance Costs",
        "label": "Stock Issued During Period, New Issues, Issuance Costs",
        "terseLabel": "Issuance of common stock, issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewIssuesIssuanceCosts",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Exercise Of Warrants",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "negatedTerseLabel": "Warrants Exercised (in shares)",
        "verboseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_UniversityOfZurichMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Zurich",
        "label": "University of Zurich [Member]",
        "terseLabel": "University of Zurich"
       }
      }
     },
     "localname": "UniversityOfZurichMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViciniumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vicinium [Member]",
        "label": "Vicinium [Member]",
        "terseLabel": "Vicinium"
       }
      }
     },
     "localname": "ViciniumMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViventiaBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viventia Bio, Inc.",
        "label": "Viventia Bio, Inc. [Member]",
        "terseLabel": "Viventia Bio Inc."
       }
      }
     },
     "localname": "ViventiaBioInc.Member",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Or Right Outstanding [Roll Forward]",
        "label": "Warrant Or Right Outstanding [Roll Forward]",
        "terseLabel": "Warrant Or Right Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "WarrantOrRightOutstandingRollForward",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_WarrantsExpiringMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring March 2023 [Member]",
        "label": "Warrants, Expiring March 2023 [Member]",
        "terseLabel": "Warrants, Expiring March 2023"
       }
      }
     },
     "localname": "WarrantsExpiringMarch2023Member",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2022 [Member]",
        "label": "Warrants, Expiring November 2022 [Member]",
        "terseLabel": "Warrants, Expiring November 2022"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2022Member",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedMay2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "label": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued May 2015"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedMay2015Member",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedNovember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "label": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued November 2014"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedNovember2014Member",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Cost of Capital",
        "label": "Weighted Average Cost of Capital",
        "terseLabel": "Weighted-average cost of capital"
       }
      }
     },
     "localname": "WeightedAverageCostOfCapital",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_XOMAIrelandLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA Ireland Limited [Member]",
        "label": "XOMA Ireland Limited [Member]",
        "terseLabel": "XOMA Ireland Limited"
       }
      }
     },
     "localname": "XOMAIrelandLimitedMember",
     "nsuri": "http://www.sesenbio.com/20220331",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r49",
      "r51",
      "r83",
      "r84",
      "r204",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe",
        "verboseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r203",
      "r214",
      "r320",
      "r323",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r482",
      "r485",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r203",
      "r214",
      "r320",
      "r323",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r482",
      "r485",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r151",
      "r242",
      "r244",
      "r460",
      "r481",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r151",
      "r242",
      "r244",
      "r460",
      "r481",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r203",
      "r214",
      "r273",
      "r320",
      "r323",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r482",
      "r485",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r203",
      "r214",
      "r273",
      "r320",
      "r323",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r482",
      "r485",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r50",
      "r51",
      "r83",
      "r84",
      "r204",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r242",
      "r245",
      "r484",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r242",
      "r245",
      "r484",
      "r494",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LEASESNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r29",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r42"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r30",
      "r362",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r358",
      "r359",
      "r360",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r326",
      "r329",
      "r365",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r228",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r329",
      "r354",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Total Share Based Compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "netLabel": "Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r81",
      "r140",
      "r143",
      "r149",
      "r161",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r390",
      "r393",
      "r420",
      "r444",
      "r446",
      "r467",
      "r473"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r48",
      "r81",
      "r161",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r390",
      "r393",
      "r420",
      "r444",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r81",
      "r161",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r390",
      "r393",
      "r420",
      "r444"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r318",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r318",
      "r321",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r72",
      "r388"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Decrease in the fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r383",
      "r384",
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r383",
      "r385"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r37",
      "r75"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r70",
      "r75",
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r427"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r236",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price per warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r236",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r191",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "netLabel": "Shares of common stock reserved for issuance (in shares)",
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "verboseLabel": "Shares of common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r86",
      "r87",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Shares of common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r28",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r28",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 400,000,000 shares authorized at March\u00a031, 2022 and December\u00a031, 2021; 199,463,645 shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r250",
      "r251",
      "r324",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r61",
      "r470",
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "terseLabel": "Comprehensive Loss After Taxes"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r238",
      "r239",
      "r243"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r369",
      "r370"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' eligible compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution retirement plan, maximum employee contribution deferred"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r73",
      "r177"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r317",
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r62",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r106",
      "r109",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r402",
      "r403",
      "r471",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r62",
      "r95",
      "r96",
      "r97",
      "r98",
      "r99",
      "r109",
      "r116",
      "r117",
      "r118",
      "r122",
      "r123",
      "r402",
      "r403",
      "r471",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period unvested stock to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares available for sale under 2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r57",
      "r58",
      "r59",
      "r86",
      "r87",
      "r88",
      "r92",
      "r100",
      "r102",
      "r125",
      "r162",
      "r228",
      "r235",
      "r358",
      "r359",
      "r360",
      "r372",
      "r373",
      "r401",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r486",
      "r487",
      "r488",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r316",
      "r405",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r404",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r404",
      "r405",
      "r408",
      "r409",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r205",
      "r274",
      "r275",
      "r280",
      "r316",
      "r405",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r274",
      "r275",
      "r280",
      "r316",
      "r405",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r316",
      "r405",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r316",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r411",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r410",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Contingent Consideration Liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "auth_ref": [
      "r421",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.",
        "label": "Fair Value Option, Disclosures [Table]",
        "terseLabel": "Fair Value Option, Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r173",
      "r174",
      "r461",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r169",
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r317",
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r165",
      "r166",
      "r446",
      "r466"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLES AND GOODWILL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r325",
      "r327",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r73",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D intangible assets:"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r59",
      "r64"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss Before Taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r179",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r82",
      "r101",
      "r102",
      "r139",
      "r371",
      "r377",
      "r378",
      "r480"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable (net)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Decrease in other receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedTerseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Total Intangibles"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r168",
      "r171"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r41",
      "r81",
      "r144",
      "r161",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r391",
      "r393",
      "r394",
      "r420",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r81",
      "r161",
      "r420",
      "r446",
      "r468",
      "r475"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r81",
      "r161",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r391",
      "r393",
      "r394",
      "r420",
      "r444",
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r24",
      "r25",
      "r81",
      "r161",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r391",
      "r393",
      "r394",
      "r420",
      "r444",
      "r445"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "RECEIVABLES"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r128",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "terseLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r71",
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r52",
      "r54",
      "r59",
      "r60",
      "r74",
      "r81",
      "r91",
      "r95",
      "r96",
      "r97",
      "r98",
      "r101",
      "r102",
      "r114",
      "r140",
      "r142",
      "r145",
      "r148",
      "r150",
      "r161",
      "r192",
      "r193",
      "r194",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r403",
      "r420",
      "r469",
      "r477"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net Loss After Taxes",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r106",
      "r107",
      "r115",
      "r118",
      "r140",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r108",
      "r110",
      "r111",
      "r112",
      "r113",
      "r115",
      "r118"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r89",
      "r90",
      "r93",
      "r94",
      "r103",
      "r104",
      "r105",
      "r159",
      "r160",
      "r163",
      "r164",
      "r246",
      "r247",
      "r248",
      "r249",
      "r361",
      "r374",
      "r375",
      "r376",
      "r400",
      "r424",
      "r425",
      "r426",
      "r443",
      "r462",
      "r463",
      "r464",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r140",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r440",
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost, including related operating cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r12",
      "r42"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r42",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r69",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r67",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "verboseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r27",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r27",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at March\u00a031, 2022 and December\u00a031, 2021; no shares issued and outstanding at March\u00a031, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock under ATM Offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r68",
      "r357"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercises of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r19",
      "r20",
      "r178",
      "r446",
      "r472",
      "r476"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fair value of reporting unit in excess of carrying amount.",
        "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount",
        "terseLabel": "Percentage of fair value in excess of carrying amount"
       }
      }
     },
     "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r368",
      "r459",
      "r508"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r8",
      "r23",
      "r75",
      "r76",
      "r495"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSU",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r183",
      "r186",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING AND RELATED ACTIVITIES"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions eliminated, period percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r181",
      "r184"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r31",
      "r235",
      "r362",
      "r446",
      "r474",
      "r489",
      "r493"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r86",
      "r87",
      "r88",
      "r92",
      "r100",
      "r102",
      "r162",
      "r358",
      "r359",
      "r360",
      "r372",
      "r373",
      "r401",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r302",
      "r303",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r319",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r137",
      "r138",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r154",
      "r241",
      "r242",
      "r460"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "License and related revenue",
        "verboseLabel": "Total Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of units issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r300",
      "r301",
      "r304",
      "r305",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r329",
      "r353",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Carrying Amounts and Fair Values of Financial Instruments Measured"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r169",
      "r172",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Composition of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLESANDGOODWILLTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of the Status of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r181",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r330",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r334",
      "r343",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r44",
      "r79",
      "r126",
      "r127",
      "r208",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r221",
      "r226",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r209",
      "r210",
      "r211",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Summary of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r236",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrants Outstanding and Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Common stock purchase price, discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Unvested grant restricted stock units (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested, ending balance (in shares)",
        "periodStartLabel": "Unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested ending balance (in dollars per share)",
        "periodStartLabel": "Unvested beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Grant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock available for sale (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r336",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares under Option (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r328",
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on the First Anniversary of Date of Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting at End of Each Successive Three-Month Period Thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r327",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of original number of shares subject to the option vesting"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r348",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Life (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average Remaining Contractual Life (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested stock options outstanding (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r46",
      "r57",
      "r58",
      "r59",
      "r86",
      "r87",
      "r88",
      "r92",
      "r100",
      "r102",
      "r125",
      "r162",
      "r228",
      "r235",
      "r358",
      "r359",
      "r360",
      "r372",
      "r373",
      "r401",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r486",
      "r487",
      "r488",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r86",
      "r87",
      "r88",
      "r125",
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Shares available for grant under 2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r228",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under ATM Offering, net of issuance costs of $2.2 million (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r27",
      "r28",
      "r228",
      "r235",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r27",
      "r28",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under ATM Offering, net of issuance costs of $2.2 million"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r228",
      "r235"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercises of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r28",
      "r32",
      "r33",
      "r81",
      "r157",
      "r161",
      "r420",
      "r446"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r213",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r227",
      "r235",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r108",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r106",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "http://asc.fasb.org/topic&trid=2127225"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "http://asc.fasb.org/topic&trid=2197446"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r509": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r510": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r511": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r512": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r513": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r514": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001485003-22-000063-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001485003-22-000063-xbrl.zip
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M[P7"9446SUSC*(VMTF:F%=P+;#*.I;4 GTD=?85JA,J%1/]<(P>(<&1J0YD
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MU77.\NK+9E[GN%C4;A;=HC.Y!9=+3%92-B_ 7*7\]3,R@LGH>!,0SKPX5UK
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M KW3*WRR@WW@E6&ON]A8?;'RHD&QX.:[P[XJ8L#!9T*7.3%_O>V]'EFD]0O
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MW=[]]/YK>/.1AW_]W=ZE[:_NH'?2HCNTM;IWTMS^V(%QX9W39;KQJ=7>V/Y
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M=1I]DJ:.7F8'U@.&]!YN34Q/?-D:P-OLS:LD32>W'?M,6]L]A=:<1Q]$ISN
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MC9IZDVC])&IC.8,SKAZ(-[JM.]9G>I!M>>NCQS5CI)%%C^UMJ@8_EQ.LK_2
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MNA#8Y\A9$RN58XV 9C/$B*+4,_C0AK770C0$F<_ONSTOJQ5YB169^APL*29
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M".ARSS+8>W11';XVO/6)#AQY0#5XF/# VW5M4_>/L[?M[O=^%GK=TVSOS/>
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M1[135"@P)T4D&ZH(ACL7 U1(<9\2FK7S8GE5^W>RC%JU'U*U9W9Z"IA,6>1
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MO>CG:'WSKR*A0"S=/6O_ZKZ/#P VN/L@;;ZE9(&,M/O=[&NG^[V3Z7[V[QM
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M*DVPR'O'VS^,Q"U(QAHCU8%K-\4W_I+[Z#9B#R-7BO.GZ$V8E?A^O*L<NHT
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M9 7DRH28EJ9[C17BK1++JB:GY4?T =[;WZ6MJ_?P=_.B]?X0K%3E.&&($BW
M2E(LACL-RC(3O&0T\QS.0XIO)*<)!F%R^[W=;/QO+P0XXKKH+PV'G04Z^6OH
MD@*]^,UNUVXV?HFU\M'5\=5'D+DR7RQ=4"6,C3W L^Y 77H =W?G7<R5DMR+
MOJ19S$P@\]L" =PJTK"RC.A'J@.%-?*8NL#]LA463X-Y#;H^"V[2!$ZS0Y'9
MF)R2(QPL!NF?.V2PP"@WP+0Y=2+3\CFH O7FWU5R3P'I;7_"K9/=0V:#$9A9
M)(("2XL'@G06^X5Y$R3!3CH=7KUFFXL>CV6*P!,5RR3!=3U$QEK)V)6:T7D?
M"+0?ZS06=:2[<%ANK1 $_O-@:HF8V"J"=T$;S&V&<W[_I)W=,N2P70Y^MSO/
MA37O+>.]UOY[&.\GLK>] WSWGNYM'8+1:R0<>8C("%#'I$$Z\A_/;,8#%LZ2
M)(;E#:P7M9EW'I:\V_AG:S]ADG_U_<OI4*SKCXX:@Y&)P5H;89F*\-4?^MLP
MN1TCJ^"D50%1J%OET]S.#4@P>V9^0/'H?L!WO9Z+P<"MKMOM#B,V+;!-@EA;
M/P?@M^9V\^N7[I_'7Z[.X3O@E<^M-O#$Q<'G3W#?+MG[_.5L;_\];6W_>0I/
MY*VS]Q=?WBC\Y=_'V)[]T]6?U6CO#,9Q]?;X@/X)//$'\!F,\>13]N7L(&MM
M'^#FV?NKYM41_;+]Q^F_KPZRYLG68<@PMCE8$]CD',483+10'5@8<##!ESY7
M=L$#F'D+0HYX'#BG0BJBO"<LR[S"V*ALW@.XV]K?@C5*'L"MUG;CW=[>]N?=
MO_ZZCS?PQE?/#I5( J:1YEAHPIF0FE/O14Z(RC'6FJZ3]_".#3(F-#UXCOC=
MD^&/NZ',9$ 4>'0N>@Y2J#\5T"8Y6QE)@V,? =K[OCS!JV#ZRJX,[=E.&.3Q
M0Q$?P1IVHX[?"_,2"(12)9_6";#QB>30SF'FF;5>&V0L ?U88(4D2!_D):6&
M>D9LH//,+;QBBF:".6HXU4H:.!F5AELL,T*:>3ET W)BE6E4)HNF5)\%(KT>
MT'A%D<$LHN%OU\N]V_926@5PN%1NWKA4/QP846[R#-\'&#'/-C')'AX8,=OD
M5-[KL==_E]/\40;+;C>@&R!M5C4:O.;2)0@M!?&M%1[);$K\2B2O%[ 2XX+P
M!3C+.]#'79&-G@+&8_?O#_^//CO_?7M1;O]V"P)8B=@Q#=IQ!^JXQ:5W?^6C
M@@&N!<#@-<B):P\P.,Y]+]JIP  ^=5/KI'C-X+O05=<,&*L&D+W&+9CQS'C+
MI>*&<!&TAE^%" 9;,*>E"[<%N)HW&N[D=7]B$*M[6Q('G_\<?-GO735I\UOS
MZO@,QG8*UT4O^L7>Y]VL==+D,;RR]^Z M=Y]:>]5]_S[SV-SYCI[)\TK&.?5
MWKLOQRWZ'BR.][1YLI4=G)Q2L#KXWOXI_W)B\9>S7?[OJ_<1P"H!6;7V+5@E
M]M K&G(B+1(JIB9*&^OG,XP(9B$HKW/J]*O7A&^(M4*)O:=XO76#Z5HF/6^9
MY (/& NA#7?<"B^-UL(ZZ;6-^$.W!K6N9=*/D$F7LS*)&ID3;CS*,(_IT@$C
M0YQ%N7(Y%U1(XL(:RJ0' I>^"YSJG!*.XO6_L3S)N*<POO9[$4YII:_VMN"V
MUV(-7@LW^+,CK#[\ JV+R/]NG%6?>1H8D0QCQ;'44FI**'$T2$:Q\[4:NC8B
M_]."&BJLX)XPBY2P&>(66Z2-42#\'=,94[FT9*7(?T9@J@_.OX^M0,^=4;=6
MH&M)7DOR^TIRK6P.RKEFF1#<X4Q::BSCA&4VMEQPM?*^3I)\3GE7UF#-94!,
M:((X,[$(0&N4*64L 66>Y;4D?TA)/@N.O5AI>:<PZWH!URQ'R]8VH1VX)?'J
M*@5_YU/IA)[!#&XO:7VNX<+!*=(NSM1/FGS'-(P*+[NHM]<14Z( 72B@5/Q@
M!CV@>,0$9F:"OUVB6A05NKUS7X*2Q%[GW8$?S.)XEV 4)7@VS NVH4BW2]@$
M@UA0'6=5@GJDPMSXNO3MD>\=]?7Y<:HRZ/LCH(#?IY%&YJ"YYW H)R.>0(5'
M))7&UN@(II:B:?,X)#%!,P$IO/GPUP15)<*CP.MUO\1P&=P2+^>/-^_0J-OW
M@_-86/S55U UR[!".EZ[,>:'C7 Q+D$Q[):)-1_^FH +36U[PM=IQ]+E4<<U
MNKUAL;M?B[R:A6&VNVGX%;IZ/#G2-L9;VBYM;H*=Z+H""K0Q.(>#)+1M G^8
MP,!4M1__FL8J@GN*MO,%:%%1V%W=%!_PIOD&J'80:>>\@(M(N1R]HAEE'! ,
M#!432!4E\>UCE(MJ<?XSTI%"-QM;$;2C?<U^1GP;UP?FC7-N;FU5E+'3+)?E
M<G!YU]V;P30]UZ.8FCP<3#"#SD=]F. T\L5X/I%YJS>6U3+ V4"_[4Z!MAI9
M.H&>V(Y.@%$S%)@0Z[^!S!WZ\\'"ML:K/H$2 GOX<1C98;/Q+J5+%S4\\?$P
MK5&WQ.F85+5/<]X$+FC\Z#FPDY(6*X3817#JM.3ZHIANN>X1B"65XK?[Z35C
M4*N(=5?"PQ3 6P5$7KOOY@N(*ED5F^5&8>4FR%)6]_L)+.C:)@3STG5&E,XL
M7"5KX^#"J-.Y+(<>Y4*2P),\-(:GJ_CNDGP>6)8%:9T@Q',<*[B98!G7W%N%
M;< I/XU4^6D$*X:OK_/8'2_O8K[:SK<2*ZO*6GL6Z>=/D,[V"</[26O_Z%OK
MY#UOGAP<$B9 :_<9,K$/,7=@Q"NJ,N04QB3GWKB(RLS($FS2V03TR T3#K#'
MH*3XP4J"@B,N=HHH4)9F49GB.9O8Y1IXILB=!831 FK4&!W*)D31JF5&1'B.
MW+9XG(_?5P PM8ON:VZ"%[;P^HU27J3#LEMA*56/66S?,8%9JN38QQ)P"63\
ML&1T4,0VII"+&E.(8=?*@4E4_],T8Z>3<A;>*VI.<]LT _R1%JK\Y Y@FB\1
M 5,^4P3,I>F7-Z:ASV6V@CCG2GEC7* \8G1()@ECQ@N;9UJIF]+6U]9^*=LN
M3H"[5B.4%<9!! F;@O0I\=TC^TUJN*:0Y$*$ZAFS,_!K<5!'5+X1:%QC637%
MM/" 3C0O2FD5[QZ+D'1W0B9<I@\,AM%H. +-=B+S$L9F.ZEQ [!ZB]+WJ28M
M( !+..99K0GD<-?W"W6W4UDJ@P3\"$IU.9YIR,IB?AO%=-K#U/ZC,-]FH  K
MQ.>XUJ-S4 :[,)]Q^7<!;]<O^J^,T?W'X/W7CA4DN9Y@=4[ADT[KK5VW9(=+
M_+SG6;50 \#6 +#/$P#VCVFG2H7H6)+3'*D^ 11K>[@,['10&6U)F4U8G>E&
M&-@,1EOLAS!8;!&RZ"J+G4%"Q*/PJ)/\-/-&W28P^%A#+";O9G!B8S\3T#R'
M%0[KV%=5[72!MCJE<H,@.TZG"5#7'OQ="?>I51YTHI")1U'2=&O(U?6&7(W@
M2,F3%Z%/IFF_'5O^ 54FFFD/BI=.A.:,7>#@O<,D?%WT945S.E)VK%,#&FZ?
M1?\%W#9,*OZ,[R.Q5_IQ2EJ&=G\PG/-YT 4<UCMY/O[[!I_'HCTTY^98VE-C
M3<_].Y9?5GZ0-9W-M5I,-?9[EERV!]]1<3E^][%.",4+]/<4"">U4^MZI];[
MR];V^T,P5!F361;SH0WBRDBDI0N($:P<%T8&S.\8UGX8=*)Z^VZU?2$S)H_H
M,]):Q+'+4?0Q()]ECAGNG<GIJ]>$;9(E4>A;@-+<K2BVUD<;46&*0:@E"N?T
MVW^\PGD[]2:B+5?PR^5NS ]YIJE#$2FR"7U^1;># 1BPI]&S$S'0)JT'RJZD
M$S7V>J4GO?5ZI6LPKW6M5K8JX_GFMZ90Y==T4"[H4</+\U+-[(YT9T:%*_LU
M[]EA+QZ3Y!XZ6R27H_&A?K<SU'.I?-#&6I?QC'E-G16>90+G-FC-BS/TYNA1
M+81O$,*LN6T/'6@CFC".B,,L-C(T2)O<(*$SG?, >@N3*X3PK,R]O<:],?$\
M+9,_$_NO:CD>B:7AOUGOQY[&B4VUW&"8N]E<?E='AN]L,EU1Y(=J4#$V.P'?
MWPMO81G^B</?[>Y\BZ&LV$ZVF%;1[FYM\/F?@$XMW=L_2/A9S9.#JQC #%1+
M!<N/C%(2<:9![R/$QU\U)1FHX!9HEBZVKONOQ^H8MQ[]PFZ.TDP+<N,[$>UV
M$)WUT<<X& 70%MHIAV8AGEDX-2<^O4D:TXK00!%P.(\$GSY9>C3,N2@+K6:P
MY/5C%>.K[K=[H\&RMC&#J;XQ@X?K&[,[<44O:5A4Y8+=J6_,U$USUFX9C9J)
M;O1[H=WQC5]BB"H^_1Z-@[^SHTPMO[X+3^@*QGNHF..4*H%81A7(K)PBJ;&,
M_8,M)]PH3?(U:2A3;_?W;??>]J=#1;47TH(>Y1VH5=QBI+7U"%O8:^- CPCY
M#?UD?DUB8\HZG$\-C<[FLC],%%7)_^U#\)/F,,LZDE<R>$Y#*K2U%)%8[MA=
M:**5=/LJ32!)V/C\U#]].)B*FL<XU?)TGFD)/25+YU)GIQV\UT7PWI;6)^B>
MH[)MWK!W3;+0=!OE:7-S8_J<FQ[(;/!XULK=& <(YOO:SNY::OH35R_RW:#,
M(4U7#_6I3]],HOBZ [O:+2S )3F+8-RV09V &:9E&YMCT[W72J3S&.E(I)*2
MB,>6*+R[?&2[6YVZ8[-M0@=+V@.M=IJ_Q-P@]4QS@QZX/_)MH6'S9P8-*Q\=
ME[%J;O*WOHQ5(EM=!Y_T1]Y5[<S;:]@D"@[7@^IP/8-KCIM7\/_V>_[E71-L
MM4]PN#:SO>VW9\U]2YOPW.;G#Z>M]OSA>@#CV;F"_R]:V\>G!]$YO/\I.[@Z
MY<W/!]]:<*#"'+Y]>?>>_OL*KCLZQ"&7U%"-2!Y5J<QR))W/$6'*@Y*+N2!R
M/H'-DI";('*LK>"@_6I0B(123 BB:& +3:*VWKSY\&EGN['S[[]W6A]W/MX#
M&O;&5[[^86"?B\2T9AB?3T!'%X<N9S[0V+TD4SFHY%XC+4%1<]8[G ?MK:#S
M=+%V$NN:LJP[(8OJ@D0F.=(/ RQZNPXI*Y!#:P30&@'T)\*]K!% 7QP"Z <_
M\&G7H\R<LB57U3 _5ZB%.R*=/3O A.]&.[MG9@F;:5Q7JG$548&5L#TAJ9WB
MX!XC**P-2,+]=+L2) 'TM;=G7_:W:&O_C],OGP_PP=41W8O7O/MPW-S?^?;E
M[!-K?7[/%T$2WIX>?/[2@?>3YKL/G2\G'T[VM@\RT/_PEW<[WYK[\;F6?-D^
MXO^^VEV NY':Y3S7%!F9"\2I<<@XFB%C,M 68>]R+L#PEZO"HM]+^@^+&G,3
M.$PM=WY2N7//A,3OD#O/ [GEF0BE.>06IK#'BH"Q:@Q%7#H02CRCB&AC5>XQ
M%EGLY;LA^;J)I0="W5YK9>]O?1FK"E!5"5.9TBLU?7JW^2\5OL]:.GVO5E1Y
MNG;.SCN]2^\_%"L_Y>>JQ=*#BZ7F@J[$>9Y+;CU(I"B;%.'(J(P@FPDNF#&6
M>?7J-=W(Q:INDL\8H+KFYH?2-6IN?AINGE,R,A>H(L&CC.. N-<"&6(U"E82
M,'Z8 ]LG<K/*5^&#O 1HYR?R)@W[(SLL$K\+O)6J[O9>2L:2-?CYQ-(#NUXF
M._"F +PIQ53M>+F/^%EL=\$I8[!E C$1N^-:09 *7"/M=&ZP<LKD8.,H]=VX
M\LL%P%-"]=8\^TANBQMYMM8G'I"AY^%FC1:P=;'3O "&5LHB ]N)F'8!+ >I
M28B](C:X^FY]X@%9^D4X+/J]X!-@2D13\;6GXO$]%:5,FE[YM[XV;!Y!$"UV
M,-#&B, L11G%&/% ,B1)YA#G*N29$I)I$PV;3-(U,FQJ-\6:Z18U*S\!*\_I
M%$)2XYSP*-=2(.ZQ1"8G$E'#7"XT$=;AJ%.H.P=":A_%]S'B7JS!J)T1CZU'
MI&5>3.NMG1#WD2\'B\V.=,9EIABB3%/$F0A(XBS%-B@<$7D>'*@*6>V#^(E9
M]:'TA)I5'Y95Y]T+L -"DH L)Z#5Y]PB+0U!0H%HE0);;VRJT%H;3OW1KH55
M72B)?.(NE"53-';F$R5NUXJR7):Z@=F/6Z!U$>X/T,#L0?TY=8SZ,86^70P2
M.9EA(3*493I#G%*'E,@XTK'D3AIK\NC*$1M4R.?<P>S!&7C-F[G7HKP6Y4_M
MSZM%^2.+\CG]W6*:929@I*P#49Y;C;01 AFAO/0^=]R"_BXWZ!*PE%J4?V\S
MRC$,VDQM^U)8M-NB.ZC;H3NL04N8Y6@/ZM'1'M[TSL[:11_*K:Y[DU;ZR'?M
MFH(\G(X1E. >D"?_G+2N7*=YMHL/S@[@^:>X^;E)]O;_:+?V/WT[.+&D=;F
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MG%9=6PK&C%94L2I@6#D8F4]-#V9'6_76C#<<EZUE^J-.U: +C-WQZQ+L=;N
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M<&S%!P!;-Y^R'J^H5/G3)VJ)J Y_O6G\\FK\^ZM?-QJ%RW<"JI>P-B,6>(2
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MJ[$7I^YOW&DK?(:5 I1'$#*VU08TW<S? =':/0>(' "X=2.\1/V<4/'5_+-
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M5"FMW2-+G$6%T#0*[Z169%;H/A,QF* G=H$-+C.O3(!I#<*37# E"S(Q-PW
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M?3LU:LI [$ D?,Y4F+FLTJT_A:L&B$!X.&Q5/^<*M?IU3!TX#*1;BLLW0!3
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M4*1EX1&SDF F.,?.I/#!?*;-M+U;'OD\>;E\6B519U]@JSJ51)@7)F6JM2X
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M7J7TZ(L>J$4]V*PJ[Z9,IY]. 1C F919!* A=@:;2;2VAS[_HM/8O7BUW6R
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MYK$\RR*PE"7P[#$NER??2I')RY)@JQM< H>DS(!>RCE( J:RSW*Q6+VX7@Z
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MTS_@'5JVZZ_&YNBD-W"TN"?U!XY]*TFY&N6%+W\8<.V-N=D3 ?RK9!8L<<+
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M*I#P)1-E%1+HWR^?7&(32!04L\"UP<H84&*"8I9B7P1Q&T')-4%]$X+:/P/
M ^V2%,PCR05!7&F&K #2TI);DB:HXD V7K)YS^<T.>4V['ER\623J1*IWN31
MDGM[>^, YZ '(GL3D.J>4 649 M#%&=:<\>X4IZI0AK+BNAPF7:VIJSO3EFL
M>>:.@:H44%=$2@2/P'1AR' 7D,(\%"S&R,EBG_H<4"UJ=%-ZLH" [DE!G J#
M/3/<1L F%K366$=.+2^B%T*N*6@U*"AA$Z.:6^X$,BZF@BB3K P%%.2=(H2K
M"%(%A-T=1-U-=L)68VS_57I^_V&*O@^@WW/I :0,-X4P7JJHN!<>!^EQO"U[
M:4U;WZC_\MFG8U#FM;6@WEL3?5*D)#(Q)5VHH*D)VBH>-U[*VV@KQ?=J-?]V
M4W;6?%T,;#FFUP\IX75"RU_9/ENW!5K>AXM!79N0HBVE?ZA,Z)CLN#O2%Q;7
M>MS3G9D2T'2>$6$$EU8KY@RQ5,)_A:945SBO:YR_7U^^-2\^48_JR^;A2<KD
M@(.P&!6%!IRWT:!4NX $M@87A'L:00>EMQLU.6,8K.5A>]3J;B^/E:[BYP#P
MB:YW>L.3.AMP-$2H#N]88+SSW'JL=I4VRB:J-J2LD ER)F(SDW3.'YGLX$<V
M[]FXGQL30QJ6RZP$G98I440>M&%.<1D(S1.6R5Q!V\WR8K:(PJ^)< D1?MD_
MVSV6' 0!YQ9%E?IO8:.1Y9PB[#5G5%@C76IJ=)NZ.@:L5+1020)?%Y]5H<?*
M4,K-)&OK:,8XVFHT3<>4<[$;X;-I#\M([>E$6NE$PFM.@4LIYEEU6<D*M6V7
M<SW2JM\/0/KE,N-779\]KIE#)$[BH>S:50:X\A0UD[)ILB/L%<BR[GEJ!?QB
M8]$:O]E2WK]*+SL.[2=A[D/99CEYE0?9_=?KVM+_ES.!&GT0QWFQ*1I?K3+]
MW>O#H><6*BE3J.O<,-G2C3C,0TZJ261U=F:BJO2UG"V4**?*'+J .[6ZPWY=
M: -:K4MU?ZE/XFQ_B<[G;LN-4@WNY2H4@3D+NFMRA!I"E&2:>2.4\)&&:)>,
M@E\#U=, %=SWP[&EGE(;%=*E"]"G9@&%05Q*7@0P8HU3=P"JS%"CROZZVN.F
M(6PT6E.$X)PDAFNA%65 !H078.#CX/%M0]@J .B_RS'LQ!E50YX<F9\Z=&!,
M]ZL?]KRY^OE.F31WMH]!\E,0_A()[E,+GC0@1AF'++!:H0K,-"\F_7+U2+4&
M;%E_>M#WK#U2)AKVRK%#.85H+%$2+ VF4Y5NBA#?MUNV$\$I6^A(0,%AUH*5
M%701J!%"2L_+F06D+N&_0>.IIW%6TN(U"(M:5OP#A%T+BKTZ2VJ[#R38#_[0
M?%FCR[)Y,<W#H^,8P2S60'*@@[+41YTABW% 1!JM5/22,GD7=#']B<+S_G@^
M627WRL*<$@^JI)8$"/T;.U^3K&G_:3K#E&TZ[IQ;H]@]341NP=97!:6.6NZ\
MLSRR)."XUMS*4,SB&;F75'O3Z[H0?#^1YEK"W94&6?/ZT[%/(Q]=81'F,0TM
M"BG(53B 0A:#4G!:2M^=!G.^U+/UGDS7)4S4?Z7.M8-VF6)3K7*V84_I2LIJ
M8.X-ED6^:0Q:.<-UJD8F4US5L+LL=>B9SDF2#5D/O^=D&EHP;PLC@I<<4VL9
M-SPQ&@6#/G"Q6$N\8Q._5-SP,Q<L.'YP^/98!\J52/.3"=-I?BM/KG&)# ?S
M53E*',&+\\3^=?_NC*3P2IM@1,21%]XKH-;HL16&%Q0[O3[/QYRG2.J>U<(:
M8R+""H".AUQ,:PM$.08%'X2O31W R&VE3.D?%W57ZY$%.>X)FG.-$U=/)C.7
M@8[[D82+FD>*C4P1&AN")E%&"98@S9-YV9HD'D42^]=OCYWGE$C!$)CJ8 $4
M+"!+ T;.<4$L,]I3MJ0FJ53R^W4[N.3>3"2R[H]\<W_DXD?JCWQKO^/9Z=Z<
MXT"$!-&A.1&%,<#:S#*@0J6=?#[]D>\'A!/U*PZ4J^0?K0>7!+";:WMY7''7
M']JS*AFO5Y=6SLQ+=JV>&Y[W!TGI*O,4*C/:#J]0=PB&RL6@=M5FR_H'J[GX
M'99Y ,L\*)?Y_!97UEPL<WI4Y>8EKBX5FZ7?=D9L:AFM#B&:: /'!E1DX$IO
M@O1!$FE#%964=5123D<E;Y.?Y8:_*3W&\PXUD.278 OT0^<G[KAZ<M6\/CDV
M'DO"@D)16Q"N+E*D9-3(:6\%*-+<.;/Q<G#9G6^W6A5>E3Q<N^>K4$##EP,(
M2U]]24"I[4!H5Y"1QJZ#"=8%>AL O4Y.;9YN*.++&5S#7K+\JO&-(1=I^1;P
M1P!HV9SPV^5L@IEVK>.ZX?Y$I&@)5<]FOZ<DXHGW_Y*R9U(5Y R&S7@:JP!^
M-X_\K4O4]D9Y@:.RM*G68&4$C *+#_U5U?=E<5E;(\6/VOE2GQNJY(CLWHUY
MA^P.]\U[79Y9CJDLK!#,?;@GSN@^KJ9'\OTMKB; 6SB1,B<AUS^^3NN?!(.U
MOVD)&+#FM3LN$A)8[=.(0(*X81%4.T=1\ 7SA+K =&IWSVY+/TA:0ZMS8PSE
M081P<],'.-[#[AMS55)!>>H'  ^[%<_Z=61E=-K[.^Y8.T&=HP7"4@G$&5A8
MFH/1+7$(*0&#%%8OCZQDG;\$B'_WQ[B8TKQ2.X,9="R3O$:S%TVG#KZ.2X4K
M.-E,*28Y'_K^J)NPL'ROQT/A8H@MHT@N7 S*(0-P@Q1O!EVK*@A,O7%3^\6L
M34_.#!L.3KN]UN"J;..;FNNFN<$M8!G3F\O! 87P4S5DLRXXO/%=4Q^^5M41
M**2^CBE%XOT@&[TY(;UL_/CA(?B^N6;G%6?G3_#OYC$M9.3$.12B,JG]=&IY
MR@HD.;7&&ZTI,7=BYU';@Z=DZA56$M[G#-.UEG '0KO>/]P]CHQ1:9Q$P7"'
MN+(1J>1\=T(X4@0;1,H8IK>E#->)/%5%Z65WV/8SLY.>%=&D[-?];F>OGQ(&
M7#B(;W)_B7>YW<A!K\;L"K+7)+:,Q YV3HZCE 1.22/.)?PA&0.5M @H*&R+
MB*F6+B?"WEHS$_,\WF43J*<[PDPXPTSI RL=M^EJ.*F$CS/=H)+U4SO+DIQ=
M(IU3I\ 6D$4NLZXD\0_FZ3JL+'/X]?-;V,;+W;'R-)KKTIM40),'=.Q]N"D3
MJ!S[53?%,:F_37*2PY?+63) 3,EYD:83I?36)<X),Y59Y+NA3'9TR7M;BN)\
MSUHU,Q.U%6Z<++DUL82[O?U8GYYND&&O*F]?)GO_N0RC@SX+#)3>+ G]&==-
MRA2?O&KFVZTX&\CWP9H>H/]FP[?Z_QT"7:3U;,)Z87%IF,5FV0HJ_U3KV)=)
M/P&:!"TZLU> W6RE7-.L@M2.Z!A@8]-F]W+;VK2_H>-:I78,KWC2,^?]Z?:>
M=]^S5DR=-UNIF'VR+CVVVE4=NAG-TECN=QGD47&IG6UU=AFS+D/[\VB@QV7^
MRDAE+[OI=;+G'9[3'\;8@B5UINM&$BQ^;F6'_:(2^E$DX/YMFU8<P9;TI?OP
MOO'[L-_*1+TSL4]O@%,[H=<_;5T\XX9UBQ?]MM4>SM/M5\X;OV=3O6>9EG20
MNN>UKQH,U[-U9GS7&>H-<"[ *IA.N<=;?VC[@(@FM7'Y.^'KH 4 T>IN INY
MK<WIQGN3[>^6=>#+QSO9@&_Q>8]\SG=KOY=O,MU];]13+V4H;M9N=F2#R=K0
MJ-_>=!"P-0D>%W7/MW(O !)']X=];-> 8V<\$"M9QP';5R'M)L!G9Q@!:Y/L
MG>W'$[YGA<9X?-,R"IGOE5?W91F CC&H$TKWFWN_O\IKJUI/7UV4T667=('>
MU.U?MT+;3\8X7H&28C8;_[<+9/+_NJFC8-,X,\RW.S2M2]B7%QM_I,?!G?*7
MIR8ZC%DJ]7J?IM#IF1:W$NED7\AI.BV7M9A:EQ!FX\XDD*]:N.MI>Z96/CNT
MJNR*F,)0$W)]<TG7I\J4J<P,$/:C1/?<.K-2H-)&3#VS!*YFRWO0G'9-OU0[
M][LI]7@[]EHN51.>Y.%(&\W=_>VIMHJ'PUZ>HU&V(?AE8B-RW^CRC6:5CQ%9
MWN%5RVUYC@)BKU.V)$K:Y\BY.^I3VA^1\BS>E:0]U3EN-C Z#IW6/0^=Z9\^
M- 4\&(R)X5%[S;CW2K/ !97:4J:8*W@Y4A 7#*/ZAYOK$:J*EOYA=]MEUW*M
M=87^'[UN_XYS4'\^_\?NE_VSMU^.%2^(]T8C$A1!G%F/M# 1$4\<_"<$(W'C
M):&WN=@24RZ8*3+H)KT,6.L!DVF>BE*RGZVF"B!K6_D/_@+YD-P);X8]EZ(U
M\-%Y:S!='Y?]<&L26DY")]?'3F$I/;9(!Q(1Y\X@ RB%@@9KF+%"2BLV7E+V
MP+Z$M=B<Z&$\ #3KQ]";;T^XL+_#5F.[W1[3Y&6R;H$8;2A[.F>5%QZ42GX#
M,C[/M3!?0 +]O?W_L_>ES6T;V:)_!:6;S)5>D0P![O&;J9)E.Z-,)#N6G+S,
M%U<#:)"P0( !",GTKW]GZ<9"@A0ERQ)IX=Z:V";!1O?ILZ^7!T>-+(Y%<WM1
MODQD0*R4N"?M6RW.=("\EW^CTN"P+N=:JB[SZ%2!Y?,1->):^ $J$0];,O'D
M:BO+%E2DE@1,2;K<<:+#US$%ZS:>H/*AE5!1 QZ><V8TOG]L?NP.00\;V+UF
MOSOJ-;N>;3;M@9!-@.]@T+9<!RZB4DSD W-L&O!$U"+"$+7>4A)]I<Z:K%%:
M\^308CL8FG53N0Y.OEG1AQ6_@%WBUTKMY+DXI.^&#KG5BHE3%2,61*6BG:FQ
MK#U3VB^)P2S6C]U061-%C7M3R+OO=2W1=R6PTG;7ZUMV6_:'UF T,KLC#_Y>
MB?,%-#^) F OY$N_EL<QEAD5<_\K(I$ZQIWE+CXSI#^%]U_=G'TZ6\"^VV>7
MSD?L?]R7;J_IB('=[/;EH#EJ6T[3[ #R>Z-!=]1O8_8BN5$78 (F*]%O#GQO
MQ"62#6N--_J6T4HU\EN:++(Z5*0T\22+)D4JOJ2S62I#4&!GROE$N8>U?4[N
M\/SSHB5ZM^WGK>16SU"0X? V5\Q%YKO!M!:4KEN_J6JR0=;'G_D2U<*7O0"E
M0CW_[AGHQ6$1-Q,9YD[W,"J->R'^D=G\ZK;4E )L4[&.GZU,H5&GQ;*3B$$6
ME;*"B@"DE]YEV;VTB.F E'"$1?<)AVHP,@*J($Y=2(JS.(HC*");!V>+654Z
M.XK23\H.$4U&ZR48Y6NAJZI"G.7[S!.CTD06WA"@<T8D44A"3GIP"AZFFGF$
M$BFO*G<+CZXZ<"0.GP@D<@FTU=9BPJ9='QN?(G\I N20_327W(@'A!OLUT\F
MZ'60P!F9#$I.:WHUC0*AOBD4+R.A3(ENE!%7]$25_3W5?JE9 #A3&8&ZDX*Q
MLDO28^5GG-\A]30F[."AY#N7#"=,6TDZF^'$Y%)H56,;Q1OGQ6\WN\FI34V)
MT<;&1&"P+O_,I3>HU])VN? 8?ODWKLQA.24>JN\[E,"W:*84$HF^& 5^6KZN
M9=M<RS;\GFK9;JU-6ZIE<WL#V;,'[M!L>UW7\T9B8 Y[;=D#^ZQMMKM[4\MV
M!V?Z>OY84/.+0SQ1SPHD,H$R)ZOP;"#QJ<"86Q8^_'&)^/5$).7</=>=]\ZD
M2^W-,EYW[ )F^3@2>Z[:M/)V#P_.S][A&&_M-:X^,Y[!1C[.(E*Z#ZH8/+F_
MXG+IX*41[\!*><+? UJ9RK0L#@0L:\+(P LSE$L::\M0N42<^K.:1;+F*/J*
M"WE#^?@QG2NDDGX*XVB*V3XH@LB.SR.OP*2OP6!><#NC1*DU%9-KN6T&FL<>
MY;*I0ZHFP'KH;+EY&D/FFG7CM0?SDQP [B;MG"7\NE7T+%Z'&AJA0(PE3I/'
M09\LX_%&;P3:T3P,%U7U4.@I\#Z\>!KF+?:*:5><F4,TKKQ==.UH%P@DY6=#
M3V6;:K6=HFKW1]V'\GP'[N(8E  XBS''2RF<_E0K]/;=NNQUVVY[A+/5O>&P
MZ[IRV.MZ;J<SZN+(HTZ7FRNT5YIC]=8TQWHOIVQ"O),QN54P33?#@SJ<L,;5
M:)Z].C4_BJ$I1Y;5;X[$J(W#N=VFL >CYJ _\'J6= :.W09URVS=$I-2=)HH
MQZ-BMNFLR4%,S_\LW:6@Z1UCF:#M="W0AWJ -]V>UQ&.V>MVI+0[PK3<H:<<
M<ZJ=U2KZU+',!\2<\>>/ECV4CNEVFL.> ,SI2MD<C=J#IK2&0]FQ;;??[MP>
MR^11Y5HB9>$>Y-U_'%^6S4- !\X39:<-)6%E.7V%+-LU;#"3+(2?V*T@=+'!
MU"QG&Z59Q/B.B7!9"<LZW0IBF7F79)TDUC*,XX2<87>KB@$X=4>.8]KFT.D.
MNL(V7=?$,2!]I]_OF@XSP_7]NVMF^# H_>G*^B@&;@]@;C=EI^,VNP-;-(=.
M7S2M+K 8T0%$Z+A;,4.E7U(\OL:&/<0&V-_'CCN2CMT98N=98'">UV\*G!\$
M4L>T;-ES^C0K[79LJ-:@M# $GB)%'"JW4E$7SQI,W@6#!L+M.2 ;17M@=WMN
MWQ9#9S :]#J>TQ5M2XO)@1*36Z-2W8+T81!K?//1,KU^S^VY3<OM><UNKV,V
M[>'(:=H@3[OM+I@2G=&V;$8W'%6-.8CK3$#B-:FZ0)N05&=1*;3V,=B .L'6
M<P^RC$0P@<AAGN>2:-.7')GT,*WPFKO1%_@X^FM4OWNL$9=NL4+<+[5L-0L^
M)"X,.Q,Q&/<\-H%G-^!%4>SG3I+!<=I#*7JC;L=#)!F!D+ \SW0LNV^Y@R&W
M%M;JKWE+C_**9(PL#4OKQ345KZ/B\T\?%A^!MXI.=]!I.KT1ULL.[*;H=NRF
M(^%3@<.V3/O@7[?E8:UD\7&U#N)GHQ"^7GV,"K89/9\.C3(UPXG&H5_"HC.*
M6[_3/<IJ[-H>N[Z<?OGH==WVH&.#>.AX-C=P&K71SNH[UL#U>C@?>HLT/V S
M>9NXU8S1Y:3T>^@;7XM0M;[Q;7$)](W1P)-#QP%C!O0_T#?:[::-+A]KZ#FC
MP4@.; <XE=4:WH),AYA"!CP'#/.CJJ;GV^@@+ T[9D,U/%_"/VIF76IZ[H?\
MY'?EK,4V[RG0(6L%&WP6NL\\<-<OK+E<3$#!P(*;=^C#I39I+]-8BI3<$E@I
MZG!<_S*/<]'<J(/"!Y<J\'70,H[#0G"<_2I8LXO#7,B]2[^M^*F13#"68,M2
MIVY!N;RXK7"N$GT!6[*4W%;N(_EJ0Z??&;:]01>DL-?IRK9GFY8Y&+;[@-!M
MUW8MQ7BZFO$L=X:H&<\W9#S6V>6X]W'8M7NRW7&:0U."BF3V.DUA8O>Q=G?@
MM7N#CHNC7-JMT?WM'%U%S=R%B$H9-R8'@/+9ES-5>:!L\%P7SS2N_TU*#D!.
MH+Y GR&63*J.)A)S2O!+GT<[9+GF*_[*;.:1+8L!&"2(*)]_M$$\YSO;64/M
MCC7+6&7VK&J6GUS4O V-<T#1DME?YK[ERN1UY<@"0Z>QJP+@VQ4;[TJ=,26]
M%3--ELL4"2VS9-^#:BP].*JNX5RNBGG \LU"#2;NB2*T]ZH\Y,3C%&^:+U#Y
M/JI/>DN-8IC5)MZS+'$@[/;0'IJ>*8;=_M"VA_VVU3'-+C:@ZHH>^RA-4^78
MXU_J4-XWD=.=LU=77SZ:[JC? 2N@Z3DFCC)OB^;(ZIG-8;\W< ;VP'+:WJVN
MC&R"G^[X51!Y6549*(<4XXL"1/>$$+H\ J:$I1OQL$)>WE;51O4O30Y1%T>M
M8YD:)L;0?-4M*FA6V49>72_CJ:;N:NKZS@K/+M>SD:T33R[OD&]B8_I5-CH4
MOKK3@,?NH.,,'0^T$]GM]]RA&/8';;=MC5Q3F -9IYX\"M<YOSQM?VR;_8[3
M ^N@CX-^NMUAMSFTNV:S;Z'#8N2.1L(^^)>YS51DP*5L0+'R+;17,U+N5OQX
M/U0IUSSJ@2^,+:K $5#W6=<X=O#?'TWA];R!#19A6\IF=]3VN(ZY)SI>WS,'
MCFN.-HY_659"J%J*>#_;:6AX%;A/E@3IY^*@HHB#>#NQ,ZQUI(&U.OV6BY4T
MQ:_H0(<U']H_3/QRNOC8ZUL=3W3ZS8&%U89>#Y/A!NWFJ&W;TNY+>X0C(6_E
M0T=+XNZK$4XWXLV&3+K2DS&-MN-;KVBBLVV*U!J!74R1FM]$V+%O[H=PGNH<
MJ:08H@*J9 60NMW=DEQ5J ;CPJ/ UVX4*JK4MJ!(D@@L*7ST*HQNFI/HAFTL
M!5 W<M*I3A9F>"34PG7SBY.J%U=E^?.2?, U*QX^S.:/E@>J9WXN/22TRH'^
M O&"':K:0W;7*:%NQ[1,J]OO=F6W*]HCKP<,N=>QW%ZG[[:=.G[SA P*_G[<
M^SAR')P*:C='KMMI=FVKW1R.O&&SUQ\,33"D>VUO*T4IJRC)(PHMXSAWD%Z+
MV*?2AY*+H5&<_,[)WB(((H?P&EV7,?I>L@E03/;:B51-,PVU3E4!0L'L4AY2
M-KD"]+(D[%.U93$H0B$2QGU=_LN<+EA0:S#=\Z! FWD5#XVC7[9#JP%19%JX
M4[6](OGK52MVN3+QWE#E&OHW%':AI>A::,M$['R)BN*M1K'U,;KI\OO+LF@E
M=4%11:R+W/KFR\M93-;<E0LB. &-*]6UCI7#,6\YNJL5RG?T1;\^??>]N*)-
M:Y?RL]Z&QG$ZABT8O48AQ%GM;]ZB$^;K?_Q/I]U]\<YX[7P1#OZC]\(6\&?/
M?,'_,OB) #X$E?F%\4Y\$7$@IL(X;N%S[1>M1C:O">Y]0]-,?YXY41%!*O='
MM55CT(U *J_6>V?.Y<J&BR]/?FFFH:Z3OY:J R.09\'92RWZ9!P:)XM9G":E
M+HR5:(N^Z0^9=L?%THJ$*Y_?:MSRUSMZA>4Z3L]R/>FVN^W^P!Z:HB>M[@"T
M"V$/73)S0(2U>[69\^VTB-[YJ]/.1V=H#<S>T&VZ)A@W< 5><RAZHNEZUG!H
M>HX#'V^A1:Q6["."48T\7%GHJO2-55*F G=,'(#G_S<I8E2%,<\A&S ]0/HR
M$R!1F<5*<1Y/L5!7TUQY=XC7NG%X$:]SD5DTR$J$7.5=OB/RVY;7,[N.Z X<
MLVN##@>XWQ_(@3.4LM,>CI1F#<C?W$P%=:K=-R.,3V/KH]-S^EYW*)LCV9;-
M+C#9IA@X@Z; )ER>[(F.B5,I6K=-I:!ZU$3UKJABIW=T0-IM*0:>&'4Z3J<[
MD(YPA.CW[.%@@%&9@:AFGK4#<HMKQPQ+88*I*^Q.LR-[;K/;-CO-D><.FM*5
M'<OI#6S3'A8'*U4T68,K+,6$UDOPUF[VNKY<IQ]L&[KA;/>M;15EH)"TT)8H
MI_R5 ]:M)^VM?1YM"$;5C5DV-V89[6ECEGO85I6]7&[MS;+4RV5@6I[5D8[K
M>/UNNV<!.V^; ]-I=P;2LK'/XY/<XX:8ZTYR,C5JA:8YAE'N$%+YL^1"?TJF
MPCQR)T%7P;B?$E+;135 &DU]4'$*,8UJ0;9C(0TE,%<" ]\D=K'[OMW*#M)K
MG+Q+.3U@\\ FBGVG]\:'NY-LH)%)Q16=YBG80+5TO5U:[H1[?!F"%7Y<.D[/
M,:UAIV.!G>=@VMVP+3M=VP339##JVX[WT<30\Z[YV3=ZU<U^:_-(8:_7LWI]
MLS,<B>X0&_[T1[V>:5I=L^NYKDM>$4O'&RV.-RY[ Y-YG*I^;L>A^YYI^CB[
M@5=^X@11 G=V">]]"0SMZLFMW+^4E1LMSO[\RSS_]&9R]L7USUXY[?-?7G]Y
M^^J_T[=_GGUY>WG\Y:_+J\[9I]/VN;]DY7XZ_?Q?L()A[2_GUNG-^9??VW]=
MGG7/IW_U_OIRUCM[=3Z!=R[./OUN@94+WY]^=)TA]LQQFD.G:S:[KF,U[4';
M;4KA]$?=@3<<]$;+&FEOZ':<7GMD6D)TA2M'W@ (S;0LV?$ZGM4^ ,70$3,T
M.N(4*.[]ZXO+]Q].+C^\/SW_Q3@^?V6\?_W;\>7K5\;QR>7I'Z>7IZ\OEOLS
ME^FADM1OW<;N4<1MX1!=F;(T4$P7BPM*#<\PF[JK9EV0@:?-2(CA$,?/,Y3
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M0%# ]973J)+VU1=(UZ\XIG;[Z,\!?0OO1J=@X1NNM!D+/?F(*Q!5,R[MK4F
MC *44)\QESK9<P5K+2YNI0EI0=S VDQDJ(HUXVB 1DF[L*-T_O.68,*4T5+
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M.O?+_6A+36)43%('(L%61/>.GF14Z(WBP,O)*)['/HXKP%IRU4#%=5&%U3I
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M,.JT#>TT95\J?CU!\/'1>&H%!E9CGDN$R9B2+HW3J/(V,%NMIYH: JY$M-O
MSRL$UT.XP,E*G0!5'F96^%LW 'Q<<:BR5>LHYM[>7#1'^J;)]=5]&U=ZX52W
M8D3GQE)KQ:V*^%^>_%+N>\A9;W6KE5U#ATT=#,L] 5?Z$=:T_627Z4IL+NRC
M[8%^#;S7F0 M6HE:E<2JAI?EV0EK\E2U;^*&AA/,*)MJ;J0JHUHW\.!.DW6O
MO]W! CO+6/%2\EOK7N'$JPN3OM9T5X*OL?H&M4#4_W4S#5']/*N<KL1,25)
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M4**$+:UY!&R*8(7%,E1>BE47FEE35XYE*/+TYBW!>)=IWAMB3%0HIGN$[,I
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M#3;QI%MN3*9 2KH#JC).-)7*[1^Z N\!]ISE"I,1R3G$((6# *PS8F43[O:
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MI" )#ES4EPCVLPY.:'1.&L5N<+O9X7G7]8$UJFZ!5$:-37%#%14\JPB$%<.
M.;X5@CC(@E<#@\6NDH6HI'J#;BA9BK*M/J9"/6ZA=Q6*5'R3"DB6M\&1%QVX
M4KNN#+I41\;2&2KLE;$TLN(TDNIPDP!BP40'"D-D82Y8^P:QN"#<"L[40O\M
M%EYWCFP>NSE'10-E/B'+FBI-LR/G5Y&'*_.@JJ*Q58@;R]V6LV:=KH&1CW'&
M],F6R0L LC 6<<XL10%N)(>NVA<7]"Q5[N9Z%%E<^59U? ^L,R,%J889DM7[
M<\OC<("Z?=8Y5"PU:X&X7#2<U[S#E<5R0[Q;SQ=@^"7%!L)J+=PF[0!#UQ,_
MD'K-_,)QZ=8&PV?H]/I2?DO#9T^96687#!^"F3U$VD*9S2WE6"SQNH=/<;B<
MJ)X$^BQ+(638O3Y=W7+S<9,0050!IXBFL,SR.#FETF5]."H: A1+P9F9,GLJ
M-;M0BJCA3")4/N$W/G;7@"?8MSR1TXC=QG4+GT>^_<N8W=@Y-0* )^5Z7E(@
M<G/=!=I'+P 8B]_D-'W<V1;'60G'8O2PV:%?7\N8S'*%#-A,&A<X^)?YK7V-
M&Y& 2TG7@E:%!HFWYT#>EB3JK.P'(@DE]208B6DLQJ1/JE%44Y_546SXG:>*
M9":MEL-_@#4.TGU5"',:$:GS)95]I]2<;TN 3TE_Q^1[HZNRVN:0G:&I[^JI
MCZKE3I'ZT$J@*B9D?0F:(V!')7-.1O-4UH_N%FX<^D?Y(QYZT- AX'\VW"B1
M6G'3#A,_U.,J$=%010_2PAOF-Q&_(98R_SU5O\J0=JQD)J:S'/H/_^;RKXU$
MHH=LY;>[A;O;J^@JY7;8>(BTVSK?]DGR;>O4K6+J5O=[2]W:J9 E!<LR1,PM
M:*(TLG#,%\8?IQ>7Q_S9/K+%4Z91:HJ"OG9,-D,6 ,*RMWZT^ FP*U<T2HDS
M6?K7 KC+-7$@8K$<8'-4>)23<9HBGC:,*?8[;#(%-3!!-FQ2#Y9US$U/PBN
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ML0B=$ZG,$5N-3CJ//,_@HH$9]@8""2MH?#C?'2?\HHNW>)/\8VKA*[!9C:I
M4=HI*Y1TL2)1?O - ?S']Y15NW*6="CC-=6\8Q+0NVB6\BP(^LXZPC1 MEC?
M:ROT/8$000)(E!V69YYD7D1,ET7]*1"S1/ZL__("6\P&8O&S']*NZ$<ORAA5
M$3TAN/'7R@TWZ+9,RT)/W#R&_[GZQ<I)UR(GW4]SM^*[?JO=&ZW]NMTRU__T
M\9?M [\>6ELM^Q-!@J$!\,9;^>=!YV#I2E@*S.9&$@6^:VA<4]^B$W/U2R5!
M?K9FGPVS3.^XW,IM1;.G=A"OH+V),,3% ,.!JI>\L JT-=2JH%9@#DI>_)^'
M!5_,+WN>T*UFK[LL06C;AZ/>C]BLS,/D=0=GV,-> %&.*E"C9DP;]!:"9J?)
MVF#-EK:'&6HG-1]Z.!0<_6@<6L,?F[WVCS41WP>"_9J(:R)^6G!:?2!B<_!C
ML].OB?A>$!S51%P3\1,3<1N)V (B_AI)K)L_K8/A<T98T[HGE== ?5@N\'7P
M?-9< J0\<(GVCTUKL)Y+_$3^U>TZQ!72&+>8--?O?,N(VAW[U?P?[3MIRLQ7
M-<L=V:JP)Z&ZTNGIY:4.?%#<(T\QX5I^G3HVPYRQ]5&0'7#$%%WY*L*[UI,_
MJ!WYM2-_#YE?[<BO'?G[ =W:D?^L2*QVY#^<X3"HV="#0;-'=L'PQ^:H]N/7
M?OR:AO<1FC4-UV[\FH;W&YK=CO+/@=%?>_%K+_Z> /4>3*!VXM\?A;O )(!'
M](:U#_\9^_#?15$ >S]1Y00FE2*01W_4V9"</ZI]^K5/?P]Y8>W3KWWZ^P'=
MVJ?_K$BL]ND_8#+0J.9##^=,P)3 #AH*9NT0K)WZ-1'O(SBM(7H$1S\V.Z.:
MB&NO?DW$^PA.RT0B[@ 1?XTDKCW0M5M_Y[E [==_@.3\#75XM6/_FSGVGV7W
MZ][^=[_> 0<:!V14Q^4L,%/E!C2NDU;667CCDT\5ANFTK&[OGF$8J]][\'A)
MM]VR@#5^DV6'=1BF#L,\&=26&<;[]\9=G/"U-?8U8+?N"_::&]2QC\=WUM?$
M_A5P!8.JV:N;F]1!D%WQVM?4?$^XDHND]V.S^S7YT<\9,^MHR,.[[VMJOJ?#
M$[GD$,!:%SO449'] >HM;OHZ//*-X(YM"@>;&YS=%ATA"%EE(.Q"(QX]46-M
MVGYG>&2\ST9+-=_@9"IT$M.@D.Z+.F6_3MG?/3JN?<5UROY^0+>*M=8)^]\I
M"M1.ZX=+$.H,:R[T8. <H)^AU_VQ.>S5WJW:5UT3\3Z"LX=.K:[Y8W/0K8FX
M=E'71+R/X.SV,&H\^K'9KUW3M6MZ;X!Z'RY0>Z3OSR4LG5NRH39ORX3]SL9\
M?3[F[J;K*S=TP8WBH1LEQH1G/S%<Z=%<>I%01OY,QG@@,:91SMD\89H%+6*I
MYT%GR\#'^+.Q?RU#6".123+%7/\Y>A)IWNZV<X>K??^["]>G*(-XVDG-:P%4
M'3]YE<8,"D D#:LL&/(4 1WC<5Z^?JCX5+H^O%F/\,ZHRP^-;( S=HK*1D
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MBT])DZYI^,EI^%V.Y)R0=)'&USZ($./PX-V;BX.CY^OC&+4S'>U>*M]:;:'
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MQND8=4[ =33(X:<JO6UGE;S;P'\.-M%4P7]4!?\3$#HR=E XEM"-X'61SF;
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M%YDOT'G2 &77:366M*/0D)^=("7I $"65*M3H2*55=P&J,JPU&]SMP48A@\
MBJUJ4;!%4.M#1$=:I/BV!FZ4WRC(^QI'"Q',%TU;"F*0:C<-Q58=&<\Q60-Y
M2A!(8*,L\,$8!F66CPZDGZT/L%(K$)])P9ZH"FG;PKD:QZA=-]55>O1_+Q[K
M8BD"3"39*"H52A?1? P6?-+<F_OH&8R>F!9NS$'G2]C=3]$ S'Y%2FP8_\8R
MLO]$J B>"4>D]*-+X=_ (0\/2F1[<-0R0*B "(B6T,H(H["Y/69E7Z\@%^^V
M&L7*V&1L?6\EN5XZ$!TGEO3F0_](K\?Q@*5E6)VDLO=$*ULQVI3*+@$S)' 9
M^UT.(!5>Q$KVF>^ZH,:]QI@4+G\>Q4#=QUX,%(WJ9=&!=/;Z_#CS(-&5I#$F
MX^-?#WW8:UF94?M2MG<R ]B5U.Z[;GA7Y?7F_ >&185')R]H_,%L&_#J@*NH
MT7[42O9J_CE"B?#[-\67,].5Z2!6M( <?A[HC#9ZIY'.LK!4EJ/P@]7)WIW.
M5 Z%*MK4E*P)H<(OVUC!3\ 9K B/0&F&=>%NHY#<-AB8 \M98 6':?VXDVQ7
M,P6544+P$&&(%(^7DHA@52E?(EYTZ_ JON1BH)E8D,6909>3?XKJJ.#H:''9
MC/B4^8E!1D2D%/X6T#(8 V/*038Q!^C"%7/2$E?#;OTNJLSAUS68D/&G\O/,
MS^O9^8VP%MFQ&!_$"W<"X4]A^6O)YDO,GVB#%.UME;6!:TS%G/*H.&&J%.IL
M4)IP]GF1=V[:K.(\E3LN(")&$S$K0$L#[>E:LV[KR>OF-1[JGA4@G#XI]@E:
MFFJ=4)92CA\[Z92=1@6UID[$H4D==2+.-P1OGB-P,Y'$XV+"VC!2W(+9!*:U
MY J3XB#D<2(&DBSQ/W2P^@Z0<*Q9(5 L+$F4',5%^B[2]0H?75EG/STGEQ28
MT*DK++QQZ5?H&Q:S69"%^PY.SU^IL'8&B3PA$A15TA]4-OD)T24]3"MQ:^<B
MUR?!9ISK=YY)E_PN[]@=G1C'+I"$G\P5Y[U!"4\Q.7B91_=T[<,^_9(SC7M(
M: <-?GDF8F# [!CFD @B%-W@#[F*DJD4*%:YL@QC6WBB1D'@K3X6I9F2651Y
MT.L;S<D<#E9_E2AEW,$&4B[\L#7,?GF(&@$BV_'E$6HUVD[&W*$PE=K]2V81
MIM1PAS$,T_H@XV2("_*9.R8[Q!\6+Y]<F2I'8-;KK80Q".-QZ']A!+V8 ':@
M#0A(=NU3-<-+4 7 $ 2 7SB42\<&2*Z1PB('A7]>*@7UH&4<AP7G!6?N8IHV
M>G(Y-PY5THJ?&LE$<*RGJ$R#WBX^8^H1?GA-Z@F2C&QB9IM+7QX> %( !>*A
M.%'M."']0EL "IW:K5&&3J2P5&..[G;".$,P50X?L[&<<CQ+ :.X%@O@7""D
MC$S^%W.C L5#\$" Z\:%3+";58@=7$##-"1&U_%+?YYDQU#83C1!4; PFB-T
M"LH)?(UIULI'NXFR\&G<SGXR8^UXL]0]:+^;<FB%&#)6"1(RC*,@T*94SJ)T
M<RSM]6!6IY-/R^YMPCMJ-<9+>IC;X;#AG7#^]9+8*[?OJ7;%L+$2S638#(0M
M@X:!89P ,#F>@I*.B--DM<VP8]\=<V,=W [=/C<!F\MMMU1NG-#K+.W1 5[H
MAW UI(S[\]0X/#F]4-$40'+\$YEX7JZMBIX:5).MBKDOQ>H#7--=];E'$07Z
M92L;99!%>%6^0%XJ@EF*J+F@1,,LRMS=I:%,Y$CJ4**D"[O%LA(&(,MIJ0,.
MF8C%S)B\J1 I_X>X(K9?TM ZRM(4ECO3Y<_G1RW\"NQ7_W-6Q98Y$]:\=^-+
M*'";<Z:&OG'Z413(+ M%%<%4=OYY6:S:J!8-C1Q\R+,Y"SI.0QTY!O,##\!6
M,'&3'64F#Q:R0!?<=Z4EO"WD&FX(8QC?*(SQ;_]J*E92=7[[[:11\.5N<M_>
MQ?6-6B[<7^96M=JP*HA;S)&B+S?X8H\X=[7@B5TE%^V;?5K_!>A].^G<H]($
M(*1"20'R-W92Z]"!"@HQ6A"NN%I'HH U(E4Z V4JG&M5IJ'\@CHK/?=Z9LH.
M.ZIRMV 4%OR)2D@4,2-#*AE/M=; 6UKU^NX;-W@P5LC!AQUE^+?Q/)7SVVNL
M2U#;@G>]_L?_=-K=%^^,U\X7X> _>B]L 7_VS!?\+X.?".!#JV.^ !7GBX@#
M 7ATW,+GVB^ 9^KHSNO3=UEP9V/4%AZLWA]Y)\<^)>8_',LL!)F((<H8-.;%
M+$Y!A_B0)=<@J619G;PA2DC-58D;CHY4!496B9K#,JV>ML\XN!+RX;EN>,KV
M6/Z^X@61\$ ;4D'5'+Q(BFM3L=/2*['5%>A&#J9LY,53F0V%Z7#L,"D7I"W%
M?0"_?97@EATOMP\+3K/R#569: @#JY7'ILAELPZ$(+U_S/S6RPQNTQWN* 7?
ML0Q6Y0QC'C"ZNW;T4+>QI3?2CME%QYS)4JI8T:!5!H-R6@BT<EPYD]3:@:+D
M,2.:\OH!Y@DE65&=LR,1N]RR(L:F;G%24FQ>XM>E&'.>9$XK<$83JDV)#'(R
M >O85PFS6%"O/!(<<.("3,JP=CA55!D=:FGX!0MH\BR/98@Z CHOXVC:*-<.
M5B2;W2/'4N8=!U8MY2(T&)=RM0XM2/X,2"^Z,F:!<'@Q=9XT3E1_@>O<.//#
MZRA +RO6;\!#F+J@E"!T"N&M</TC<R$IX-1"7R &XR(R4>&F^^UV W PZW6K
M%)O.B.\=?\ )'60RLA*+12EX!X TT4+*+)\6'5."#,'CA%Z''VC6R(=DX!-*
MZ!"H),<1%Z)@%A_V2J-B _7&I8/0RVS@B:#(4SS"@6.,);5U( 8^5?6/&/M"
M]T9$JW$B,%9W!E&2QOQ2W,O%ZQ-#W3>RX^+O] 4V"ET,.L4\^J](S2UT'B@M
M@LSX1L0LE[\73OH^0[P+C"F 0N$8QX&JR(!KW-%3WL9:L4:]LX:I<DHYJ14Y
MPQ19ZCB)60)*DD%$%""2LT'==G,J/OM3_POE-8%M*\&&1D6)'-4MXUVF4ZQ9
MCTM*@&T"=%3QD?;VN47WM-J5WN=4+$J=FW6N 1$HIMZ'"^0LP [&F 8@G+]3
M7V<'Q"K-RM8IJ=P)7A4$B<).9YR?FDS\F7(.AC)K,D;!/HQ_*Y+)-,&&V@V2
M-071=&Y!$DVS36):%QCC<RIYUP$!*B_2*I8SYRQ"+/"@@"=N@&0@+DIT;(OP
MBHTZ/]&@ 9@#L^'RR 5HAHZ?*.\[&31S<27IF\K[R%370AH(^N5+F3>X,7^N
M' G"P1 #24.&4(I"T.<:K0S"ZF4;\J"?9:[ \M":[SM7H&H]7,EW_WG@]QS3
M&G8ZEAAX3E>VQ; M.UW;%.9H,.K;CO?1M+K#@UUEQ>N&G$]!NFK[YBU0AFI=
M0__4JE'RG0A3[2]"%OY>.:C><YQQ1P^XD3A_6PJRJW8C23%\6@@E%]T8R -W
MU"^YG-!;D'!/V_Y<NS/(B- Y/IO"->PKXK;)(&(PAY(\-,<7)\9E- .YUF_W
MJW/NGZ[1O*('X_#@2:<' (@ .)C/?JKR1"F*3M(?-2MMF&:(SMWABHH2DD$Z
M:Y;<2G!W%:Z=LC\:TP>C,%3-?3*5H2:7;THN>Q>L7&>O)9+RF!"G"H5D.WJZ
M6UA!X2Q%_1I=2"%V&E(21P7R?:[=QA TM4I"+X2;V?;%!6YU&2E37W%0MJ)^
MOG?S\TXU6)]9&]9-D:7*IJO:2Y6UF-+W7J1H,"1%3$:F#2S9\Y'>P92"N^;L
M%S2XFUQ!@%8O5AP1GU)KO:CO]''O5)-N1I^LD^3L6LTX>_\V43UPLBS;:RSX
MS@:;9/[B=*5+P#+'+X1<UJ1TW>X-)(Y08\L38<MRX95BYGC!Y3(W1\PXW0E8
M0GU;.W);NCXMWGQ?'',-N;WE4BN&>"Q"I6)BQ?S)V=M$9=7G*F@S<="KF/<@
MJQ'@<1% -2XB:>S*&=C^/@O;O,PX%^$EW4H%(#FH'0214Y+WJG)!Q;!P(,!<
MACJ\6'RI'R9IG#7JX3=2>PGD!K7ZMB/LH)CVD'G*7^"5W7?.07U##WM#.H4F
M]U5X4B:[:B+?UN-&'1.CVM7V)%N,(E=*LTHC<EW" BJ/8O5'6;=[S,%:J=;2
M4S]8LA4S-;  'YM"&G.17"6J:98?4M/(C&52"@3F&/FJ!56:Z,R-:QFZF*ZA
M$W,S?98TY+V\*<RGR'M;;M%J83LK'AV@6),0+ R,\%)]KNI0B)5'W!T:?QJF
ML#Y6$L0^7@EUW-8_X/KQ)2K1?1IOW>FR/9(OBPZ+>T_2K;G>O;@>!<.Q7U@^
ME:>!N4P.QI[Y_E00XR%,RT9!%5G+@ IBL$:&1T>&4KE4GN))(]+F8BRW2#%C
M3L,=#55E8IXRD#]:0A].,1!8BN-RXYVX=D<]P?4#9*^PC7'>NGB[ZZ[OZO'O
MBLK+*&^3^YHH/<M'U0HO)U,,5KP"*ZT=]0W7U_BXUQC9J/E0$AA9\OH?F*&O
ML[*P)!_;3E/+UD)SFZ0@3*M;@'$%47VGCWNG6+U/+>ZU!HR)O7AY8TR'YJ[?
MRNJOW7)/PCB!0PHGR^@^>?O'Z:NF.0+B JA-?:?VOCS-M; 8:W#ASDR)-ET\
MA0HB*R?$%56UT7X:]\<JV5\76&I[2QTSZW!]+<!HL@.YVJGP?C%\+,,(7&,J
ML9V&4>13Y?TH%U"N652U^KO[ZWEN@_PL4$&A-LBZ6H$:*&NS,/>'IO-)%&.Q
M/LT4H%QSZGN@^EGJH.=*#8S.V-:S'VRYB*B\!:=:9FW2N2Z#QH: ](0]80;3
M2H<%?9RRQRJ?]WB?1 JI+F*IDP.YYMS2O10L:L]'+[]/!4P)&...S*Y(YF5#
M#[3)O20K:K;*X1(=0EGK9,A#+RIMAAOB8XWC3 2<.Y-Y.HD>&MR'3R3D_@5A
MX=.EE6:V-8KE0_ /B?&[P B$C57"-'&$=D(!_36I;2L^%J9&G?8!KUR.!NK6
M.A1"+(?RL:5)/BN@:GH1?E[MX:8^ YEKMC#4:!R+*1<>N!%UVLF@KI-4LM:0
M&+V,XBQG10%2NYC+3(7*'. Y=/MR?98>_5&5ZE(*J644#P*6+UZ]:=,)@/QH
M>*UBMKPI3&>TD;G105P]-H9:SLSR>&J^"&=LK'=F8<-WH7LL8:E$(G'0 W6:
M 34^26!OZ&-'A^^<NG':\.,;[>E.;D?A<G;7-F)@-0*)GG0U%6=!-TL5/U0G
M3 NG5!E[-T9R<7+R[W-ZUQ\O^\UAMT?-U+#!% WXII)'KO_P/)IVJ=WW.7_#
MJX4/HG <\9TO ;;42?^^/O$-U6G/LLIDM/]5)KLDDER0$R4F>3M!4Y>%A0[9
MK^%?Q6HW;MV'-5W8+0TYZB&I<E$*FW>3HUNC*A5@SY"0N5*&V$B_F& =B%DB
M?]9_>>'Z"3#OQ<]^2%"@'[TH*PMX_6 !4R<;]1)Z'W^=8T:KS=@QC^%_KGZS
M^KI%7_TT=U>_ZP];_4Y_[=?MEKGVNTW+FIU6OW^_93=_U^NL?^E7;7:XU;(_
M$7P9QG"-B"#_/.@<Y!1.9MK/;<,D8U6OESTZ6GG4FGW&AU>Q:/G:^<8?O\RJ
MS:%5[ ]V%E'GPM?E;I<9G3P$@/)'%=4@E<&SV!P,F((^Z7Y!#ZN$2U#ZBA,_
M.\B9]\&OBM.AZV3Y;%-JT?7X<H[.]DZIPS\_(FH\-!:5UKGE;E9KC1Q'@AZ[
MC)(&_3G:\=O;0DE>OM>[P*%M;(G"CT2>U4#XX:N.6#P:A5UVZFQFH]LW__$_
M9K_]XFM.J1'Z#J?=1)2WO7*9L&N<VR><ZS1Z_?[3X=R=&;@J%JUZ=V>PXPS\
MDN;U*->7M@^U.;E6)%NW0V-K]:N2WG8/*>_#".\*BF_-)9<0=:WZ\PRO]SX\
MY[&N]X$TRIWF0^]DG&!((ZAP,6]E&JP#PH.9DW?5.;[M)A]22.V\E?'ZEN#0
M0\BK/>195F-T7YZUIU)G+R_)&MQ3;]@AV;$??.*=B@%GC"$0]M<QAVWMP]W#
MNT%G[ZWV[_R&>NWOP\;=>;;P9CD;Y)GI"6:O6VL).WY%5J_6$1X%TF]+IN4S
M4PK,]A/Z56NM8)LKJCW?C^KYGFWP.]7N[Z)_U!J-=M0_6KN_'\!+T3.M';W>
MAU1/!IV=X4IK4LR(*]W:?G1+H:#N)B\$--PHQ9Q,?9"OP^,GC(I70^_.4?$'
M!-"N$'@U9+J-0;_]1*5[;:X>O(]6\W#WL^,9*#6EUI2J#(!&>S"L*?6>>L)/
M5#ZP5?5AH8#!M!ZY&I%6W+X=^2_4)I]ME&-WZH<^S;GQK_=RX$7Q-*)TFEM:
MDNLFU=SIOU@92/FGF2U7:FR]KG,U3U'3O:Y];&4MG91G$V73Y+#Q%)?/PJ>!
M'.._LUE#RPW+)BF )JM!,[PTI +-I&6PTVF\Q;EU(T]=P;A< #F+(P_>K0I[
MI6KJJ7:6]>UL+,]N0DAP92;W <G*376C$)RNE(;TSP2'WCE2S<&; ?0*$S4_
MA#[NYF(NL(.TZOFCZY)VM?;WCM1VDI6TOQ%^;/R! \80_4XB A#"]*0X=WE'
M3WW;0.OE$F),W\[FCQ\7YI@!("[D;,[SS*VVV:="=.SK&+M23S$<<S/'XCCJ
M&7?G\WF6(+5YFR*2)7EW,*#KF5@(-=M5O_U_D^*$MZ0T\F9E+NX%/FF\XT+F
MPB0*?!F\&2=?9Z?*1E5R?1Q<@ZZMQ@\D5<_Q.-BL(66QJX >5(OUUWPV10',
MD7BV23;*)$#VD'!]KH>(=*T1:2W$BD-FQ-R0 DQ &Y@>=M-*)A)(S<4ZP*PW
M#!4V4^N'AH9-X4TB+@T.0A8G8KR.Q#A$IA$ER5&6N,^%@-\)!3._/0VQ-T8#
M7K.7<SO>JKIT/@2.'LXF0Y6D(HTI!6:O'J5+9MQU1,(N!/H+]HL Q-"C<@AC
M!& I8%M,'0M0+&#UZ!@0FWIA((9P+35@"6R-YF,3WGTG>/(.2^43/9V>\<6X
M%)^W'LCYZ(KC1HQYR>H,'48APQP/0QU:8V2"6*U/?8S".;:60KZ++8W\F'OQ
M BL= ZYE?:?PT8QK937]L*81^%F_^991!F/IS<5A9N4MZ=8#<^P$$38_7!B?
MTMA/7)^5II4Y9V_AB4K5JS@[\^'&%3W' OY.NPR.?2S@OPM]?NV<R(&U9W,B
MUTZ&_#[8^0DUCO63O'/XG"JV>6BX(<L5VS2VF,0CUM=N.]:@LEKXT7L=C$:M
M7M^\3ZN#;J\U'(X>OGN U>KUODVK@^XSWVR[U>\.]FBSO>UZ4SQL#?N31D^K
M/:;9H;[[=A?/K T(V F@_23RI\-7DO]V] V[,^PR9G^OW3:>H$])KEXL+?5]
M0=9\",;Q+('W"G7(>'U26HV97P'<=S+&78%E^TPYN65^CZR\U,NN@=Y+"2>:
M99>=W$EP?Q>%UFHP_%?55.]*V72]QA9K/*M2+^W@+28(J'C<UU36[%I.U=?V
M!*HZXJYD1:T37T/+M%[L?1U;C77[A'7=1L>\:Y5NC7,USGW-V0X)Z8[V&-^^
M\UK=0_CCL:_G*<[YX[>PC?:I-G"-XGB7 M3OK4[L?FK878'Q2+4:7^<G>X:W
M?Q]U:$?OOK[>K]<\ZJO=GZN]D\[R"!>[API-M2:WTWJ,2O *QU_92_,NI=[W
M<F!^-R^H-[EVD\^JS=#[-:.:ZFD(^]R9GJKH][Z#4HUS^X1S5 ]>XUR-<X]J
M+H E.+RSP;!#^'878V\?[3G+>NS;^6XLMOU0(-<W27AFW6N'C='@"9NCUC&Q
MK7I9-ZS171N.UY?TR)?4:?2']VSR5U_28UW2X&GR379>NNO*R3 *Y6:,JI\L
M/UD#]FD ^WTY-/.F2-OULGG\SNI/"IY#TVJ,[A%CNQ_;SHZZ7R;SD]Y0=]@P
M']=Y6]_2/>BH;S;:_9J.=OB&3&OPV->S\]KI]S@:(5I)'J@'(A3<4IU[.J5V
M)EWJ >WL[^UR>Z-&KU-/>_YN[_>P-VST1_T[9_'7=[L'=SL:[=2][J'NLA\#
M5-94 $=)8GAQ-*WJ;E=G O_K$!27G<H$KE.\'TJF]1J69=9W^QW>;:_;Z SO
M.1BPOM_=O]_#T=V3K9ZUSK)[P:!]>?)9)5$56^@;A\J-=43-])]9%I5UUQ3B
M.O'CL65 I^[YL+.7<U]G8'U#CQ>6:K0[CTY".Z\H[5G/PNHVCN33>2EQ",W2
M=)9G93NLZ7$Y;-\]'EL;A7MPL>30Z=9W^QW>;:_;Z)J#O9WR6N/6#N/6G0)@
M>^],JH;!,RX<6S^,[9ND[^PVA7R#9K+;06*/C+WOZFH/K>$=7.GUE>[!E<*-
MUI3Z_5WKO=JH?K,KK1TYCZ&6G<NY0<X<K&K':8VQG,@P\:\E?WR,\T2K73Q;
M:K!J6$T',,"-4AS)2-CQ%93SA(U'JH%XY\8C#P*:72&EAW>"?15<=KRM3DT5
MSYHJ>KU&S[Q[IYB:,+[*)?1L:6//R*/7;0S:O;UUPG[M[>R?B_:;4.ONX>57
M.'"? "=VQ+W[$\U2_]<V$^S5)P0-JXP,3S?1?H5!6,5Y9N^71E'<?LC'/-3&
M(_PI#1>P+8SF1BP=0$0P_A9ZM@;YJ.<3"?_#6=/3B&9-R_*L:0,G\K8T#+;^
MB6G<B,3XH=OJ&'"LP(_"AG$S\>$!_-R%E>81+83;&H<^EHI@1PN]M5@F:4#U
MKU1.@D^Z,@!;-5[@8_COF8QA-P B1QJ1#<#F>A,#Z!/LV"B-#3&&36+C7^/&
MGT_HHYF(YR&E)1IGK\^/&]SBS9GX\AI?ANN>GK_"/<MD'H74<^-DXH?"F*5Q
MD@I82VW\=S](#8TBQ_I-+6-'T>2.N%]JH?RJHH7R;IUN^[,4VD%GI=7&C8PE
M(NM0(^OVI-$ 63H%K((O #%^Z+?,.Z]AMHQ+PF^>9X[X_8.9$PY1S"SV <(
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MF,U8(4:)V5@%9G,Y\1,&?@5S%;E\@2TIGH[J#'%J.%\:Q[S=62QA 88-H@0
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M/M^CATTW'N><A,>:HA>Z80X\PN7?(=SX9EO242J2>H/8M!>DSW;N[E1$E_^
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M7]B+U%,%=)EVW;,KE>E_&NICD[.=*C@D<Y> "@97D< ESDC=W#@5Z28*?L_
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M,U>>]@)D&+.0N()2GS#JQ=:*Q1:O'"4W:8PD606EO@L+_]GMW5KW#N';36[
MO>!(J8=ZMGBP-\O6(NR.YP\\GLE5"LIBOCH \T_3W.&IVZF2]>U5!>/NI F7
M@$UM)$)I,99KG4BD$A )61ZNA"8BF0<B03*2@4A$_%W$01;/RJG2A9G;TBL$
MZK&+ ZY;Y C@(F:^9<KERB]*S!OLI4UC[U'BO9PJMU#BW39NQC8:%2HR:?;4
M%&0NC[=8FFEG!UW8N(- C5=028_T?O)> ]6(U(0"!15X\4!^/)0;2I 0\@,%
MY+]#*2.HAT%PS)(BSB.G>*'VZ[9O3AQ$XYWB6(/)56;U&$-%B>&6;GE9.M,>
MVLQI%C0)9F/A#'=A3V1/I)G;)M&Q,0P=TVZ/GUXG,,FRWC'#A52?=?B>C,-N
M8]<6>I&@+9< Y=,*-3='708S@5NW  ?=,J6[ 9G[S$+LMFLLIM=IMJH!4 )0
MVZX+\AN >Z?9\B_&L)%DQ:C^ECNT4JP&>@]$1*$'&&]]J9GO,9<ETA]((0__
M=G=<U^K>4Z<#9:C=.<SK(K[NKVUSFB#82T?+A%%M3C9[HR(#2]5_K;54R;FP
M=T'+-=S8AMB$"S=!FY;J-9WJ2^?\[! <:]HP)OTE]Q?R$^4R)Z?CD&$$7M6;
MWDI(QU=]]\=0_WO-+$%Z0L CS2VKP)XT#.BENCXQ.'EA\_IU;)6+=)DIU])P
M)TB590IPW6P01DBX%M:RS59J8EO>%2"H$F$F)+/8]7M&Q(O3<C)+6QRE7N^=
M$\<1;!^S--5'J(F8+<4J>Z:,F1&AV!0"":;XATJA89.I4EMV+J ZP& ,K7:A
M \<,3=!&^Z%Q-S=R,S?0?FA[7XC93;Q0MLV1Y*Z&U*!$BBJI7UNT[O)0H[#F
MAI*5B(#36\GJ8F-GE1-RQ?!8(!$>L>PPHFP 3'\ Y@I;IH246$4I%@[]S2SO
MJYN=CK']2%!./=MVATSK'81ZQ#G0?P1TK3O@OJ:1M;UW)4U$-X&PZ+9X% "$
M*'%=$]&M&9URR0%@*;)H2.T/M%9+D-L;F2HDIN<8Z,@M E3$5&$AC*6HR0/I
MZURAI8#]@*&5VG-@@7:(>?*<6 >&,08C(8,.!;HA<%:-:H]$F63A :IX(X5T
M2>:"=<JO4<5>8ZK04!"@%D8G73\'H!C7R%Z%:M4)*!7E<%'+NGS4+B$'\V>,
MA)!<A\!=SW$,]?&G*^"G%\YW3%Z2W*(8P-C@EA@H-Z69>H4Y;\ $8_DQ&D[?
M+?1!!#L"U$,]ZP*V=FR1*+6(=$&5>8S=?&>I@,("7N>\6V$?-O.TB^E0THD3
M(*&ZAL42K7N+_3A0=FYANJ2L&IZI1ZW5ULV6HHF_U%)"0F=:Z0*C-3)A/[@%
M*C5(])2^8](Q1""(J!*8[D5<G?8+&), DQW:)SAM#[52UM^(I2F59;NT%FJ$
MU<G8S*[M73J_!>X[#(A *@6ITY$BD[E1;2S-\G*N1'S)K1C+\R0.SEM]\2AB
MZ^&+&@=?Z?UI7D!]75R.4IZG/%QZ]1DJ</9HR[=,HQ&P%5T?5Z30/-/?R +*
M@*%EB3?8)Y. V4H^S0]IN2NH0^=KO+ 2B!_]N&^)-M.HEM-9$+K2;48*[ U%
M&,!0Y<,LFLA9/$M-V\RS<C/AQ/M#2XG7]S!8T'GS =IM_@/;./SN]!^%UWTP
MLGB.K.QTK>'O_#=N2^6: 6!Z"UK?YN:5?D?>^1$_X =9F[+N$=5V)1SI=*%"
M]@7]EGD#_\Z03,O;X,&?H;7PN;?GG4_5V//;SD2Q32;MPQX^%'6+7L(0'A?B
M8J;$HQ#6_FQCZ917E44XEQ^@_]>&SN?>JXV:ZF!@$"V87!&V"H@%M9D^1LIU
M0<TZG>66[96))Y%ZK: R3HL<NL&^VI77E,IK#IY;>0T\SWE\O_QXL]A\Z&0#
M@7!X#_76)%>OY1_>:*-@HFWCUU&"2X<_>E-^'[P /?IA$/-+\'WT,:_ \7&[
MUSF 19AF^O]#>3&O3QO79W\:SG]V>-3N'ATU?MQI^XV?+7JL?]#NGCSLL8L_
M.^P^TF!/EGKL/JXOK;'>13@W?WW1>V$/,L:_7W<\'[, \CSSU9.YKW8G=_#E
M^4-4W77:\*=O)-LAC0KJ\'=2A^_+ZM"(SPH+5#-KR!FL:<YSNJM#Z13HJ%":
M7?VD6+Q!'>@Y>6@A>#*^[=IGN-E^U(P;A>"YKIR_BB0TAME6%)%Q%(:Q6I.(
M_*&T@P'&TV?I;O-VYKW\2ITT7T&#/>[7>6K0S]73==]R+'U$.MXV*)5?'F_^
M[KPQ%K91$S]J^?V#>I7ZPY8 /EUQ*18II_LDM*K@=D?YYSC*+_WCUL%1_]7&
MG>.5KYSA4*EMO7+XEO'.L4? XDO&+$9WM<6H%<3-.Y 0W/*[;U;4KO6;_Z@*
MM/+*1@MQMTV/LDT_ITDZF$FH]OMU1,V"/.O#5W\ UFED/?-M.NJU.GU_?;OT
M@TP(6NR3C=$5]3X[Z(KS!)+4T.DX0;W1(NWQ_E]%=!/$F J"2/\%HX,@":0_
M7U5[L^EGH>!>F!80(99);JUO4+^RR_L&/WZ!-D7 ZU<&_> U89<6A#6?;G_6
M;&/N)'4GJ<NM3/^@U3\ZW(GJ XV(?<QFKII/1?; C0!&U">TOR?BO44("I@F
MHB(FCA>5FLDY?1%O@]S[Y:C=-:W55T-0# &>E(-9-<DBO2!Z*@*F^Z7;:7?D
ML0O$L'L __>8:'U32"GE_97RI8MTB(B3S'!&PAHQS^+Y>95H4<![:0%HE'\5
M03:E_HH()Q$X%+YB,I6^\V9]'039;RK3D_/^<?H%OLUM YW/PZRXDJJA(4!@
MJ,K];0!5( !FC&C_D+8(^X>GHU&NMUYO=A#"";241%"$C"<B0DIZIZDC]N7=
M&P0@ UB.E^0&%/F+WSZ1D0._7*BLM8UK / S;.9+Q7P&MC8LP=;P25W[*&IE
MYB58W6>?Z!S0/!=T91Q9EA9\SDF[0XJ5'_8HF*U'/Y1&0@O4/>M$PR<+-(-_
MW.ZOK!K\1:J!MCU.<]K.?M^^0!@2N<)#O_Z@W3-OQZ)_ M.#M%PE>HI,ZQZ0
M8,#8_A[%A<4-ME@.0-+GA,"MY;]'"#J.$  *\\%2<'#LJ-KOD8)NVZ_JU@V[
MH!YZ,\\G!H+G<1<7/+&H9F*.M.CM#8&E)HG&T"JYT(*%0%QL"4;5M9EE)$+F
M(M,?R.E"O3P"<NOPY\N:=J7(\3,Y1*Y!-ZJ9'*IMY_PL;<XM>PJ>W,+_@>OR
MRU'/JLT'7V>@?X^Z[4/SH(0*E(98C6WZ?DIQ)Y0^88O:=/B-"W'AX],OOWN?
MN#(;7_!+Q[EJM9J8?Z*Z@Q*J?/ZIMUBY-JTK9(K"O[Z(^D._>]SK=8.CT?!
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MT%PDB/-YY,9REE#9^HPP/U4VBPP,J-Y$"7&"_S2)5WNT%#*D3Y599;( YDG
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MN%!TPX[7#8]*0U&36.AV>CW:BM+0C;RP#M.OD+?B/F26(0<VS>H!,JU5N!=
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M#R\HE=SPNZ\A;I-XI\45N$O^B2"I^ \66H7$6\SX=&0IC. &X>:UW)V6B+4
MS9$#HP$W/HP#@/]2\5<<W.8%<9F@=:POA;?18.#=M+U+0"GJ?TM;4-+7;GG
M2QS$^A_.H*[IC[3M^:^[_M[P9J]SU.GV]=_U1+^M_-->YP1G!-D9Z,X[_WL/
MT-OUOS[N=8[I3H18J/57"[*$Q/QG"XMC@0::^_42@NW3+!H"1DO[R ;;?:E=
M!'W?)O9S*"#5>_P_:?:-@82XX&A)HSL,%KV".H.;*'6Z>EU*T9_?>3F@*[7;
M>1F\$K^]= $3^Y-VC_S.8*\/AMRXB*\DR)8I=!V<GE^.?2QU7D5.(0>L%\8W
M+%<=^_;LM[TB 00Y..G:3.=RV=JIYE#O,K4@)$ /A<$XN&(+E&%:%BM2@C<%
M6NZR1,UR+@-#I) VU!-SJKLG]EC#BV%K2FA%:S,-$>1N0]]\D 'SHD]%]21=
M6CGXJ/_GBB.$OP?Y% W+N.9@[YW^[;^\E_!LACC4/H21!Z]:4AF71N@S7\R"
M!&6JI?5#J&?M7>J%"O1+/X*\Q=X[O>;7P9_XL[<J^1/@L.:/+_F5'U40>I]Q
M]:/12& .K]#-)C\#K"N*I<;PW8GYKK,VG[/H!AS&V@EH8QH)1_4YQ+WX0]MC
M6,UD6=*T&X_<:L+10C(W3@WM$^09*,2C!_--#B#M'V']856@KS7C]J>5T4J)
M)/S@6GIH%+& <0'\+Z_#2%A$Q&+E 7</9,2 <T_" (O-23_PSS'LI)VW')A
MJ"26P?7-.L%5!?K Y-KE*P#$BV&*8"I/!NJ\40'J=Y!%^OUAI=Q(V]<RO ''
M(<KSG:G2G,V3<9+F*8>NA%2.ATQ6.]]C<B9*2M\(<NE4G_)7S^13.62T)W,?
ML[ZC,Y?K%SVZXA- -KY,_P-B%G,N5HR([XPUE$2.S/:/4^9E#J,< @OXJ_DY
MI4*I<"2U7O"<275EV<>?&( ['AY[!O1_3O608MXE04I7#J,4[4 !3&0)-X5V
MC]?)'E@9.@YR)L^N$YG*$9*';*M)Y))4.1UBG3\?E'14R0C*(SVH(*/ZRH!K
M^^>LGM]GH-!6LUU\O]\[IJWEF^PT&\Y6?\C149T)@P3/:9!1@^HH0]K)[S1K
M&E489PBU\9 $8U)9P&5)7'Q\;%'__)\@*:#PRN]*7"( -9R%[OI:!6,7^$L
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MD*EA_T4?J--#]&?@Y. RR<$Y-X>/Y,Q^?PZ)"APB7Q-@)<B9KN3_XHCP2_-
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MFJX[:RY,Q9KJE"_C9KL*FA %Q_CS3\TPP?!O/]--.76,FR[:0H//A]^^X.X
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M^P.@GKSVNQ+X?2Z83F?[P5??/Y_L10CYHAF<CIOXC[/F'-\U^M6/^K$'1IO
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M+ O*UJ'3$N!^^'U=:J\FP>8!O&Y%M@3$JC[?$B#WR=?;0,&+"-2Q=FKZ>0]
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M@Z/KOKQ*!+432<R$68-FBE&*%.)21NZ=<#QY:P7:'#&:>6'6=6%T$HO]H[2
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M;?+4^KQ1@;-%+WY6W*@I] [][L4\OJ[7>/CM2W]2]W,T2VJ061@6.4D02ZR
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MEDXZS*N<R_GIFCC%=K/COFH&DWM1H_?-& =TG98'D4)V*""92K/JG#)"EXX
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MJ)R1N]1H$B)ZO"EQ2:-%W"RN18@[+WD)ZE]7IG.4O5ET<Q;8I(+\I'_ J!=
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M+[O/+]9/7/&\_F9)\Y+@N_:&W6MI9/CN)*L=G,+_\6+'"&_PV^4/EI^73EY
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M =8J.DR4[$+ ;8+D04GC)D9V&;N7$-EY<8\Z8;T]NCH_J@ZGJ\I45K^=I6%
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MQ$3H(6S7T\) JLVG/DY[BJVZ?F*MMAWGF@!NQJB.01R8+X]616P4'J ZH@5
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M&H'-TC1!/L4)]+CN.HFP#TE" RAY2*CG12BTZS9R4N+4IK16O;:EY+D[W;L
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M*&$R(D;UC0X]?&I$5LW56CGPJU;/DI^V8#,CG[Y@#,PLQCA8$\8A@YVRP9:
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MH@A&21)#E% ?DC AD/N8RB!F7LJ,LOV./']J;D^M(JAT!*V29NQP#,%N1G"
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MPA=L[^WGC?XL<UG0N1)P*9ZR/-,;^KH[5].U;X9Y$$54Q!"'5,=-H4 MIY&
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M1XS8+\C(ENU^06:W]([+7>\1YZ(-2'@G<YEF5?+0QL("D90':225AQ7J_=<
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M"_WMU=9;AB6Y'74S.GN[L1QZ!;<QC!WA0'5]NE78S\K$K>']M;(2#.)3##,
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M;LB#(01[80ZF]_4\/-X, ]NH*U\?4TMQFU<E&RFOUGAI0#@-I?9#?34[B%A
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M8NX 5[>'ZN<H-.ZYNP/H]H[F73RSY[*OZANUJA7! IR(F%"H*%.Y;I)@2)(
MPY1C+TU)B!FRRH#<?OS4V*]I.V=08,($.\.576]$!B8I<S#LUVL';7:[2-L6
M,>[*[*!Y>\NQPU?U^VQ7S=K>O:Y^_/=,%NI!CZ\W\INR5Z?3)BBD?AQ%4&(:
M0N13"6D2I9#X@H0<,X\$U.9S-A,[M<]\W0\2K)2M-E4_7_ZU5^ZR(?IFA. >
MTX&)XAPXK:G##AVGE&(H>E2JL8-CEX(L[^Z9^TR+XC7+'^[E\Z+0?2:?%B_Y
M<B5OO7/=;(@F*&5^'!.8$"^"B,9"T5.20(JP2%*1IBQ(K>J2V\F?&EFUZH-:
M;\L46TOLS1AJ0$0'IJI6XX:N/DFJU:QVJMWO2O>$R6TRKJ4.X^;F]@-H+U6W
MYV/LZ^A]:()3_N.%*D'%_+46.4LBZ4L4(HBIWE&*U4^4(@2Y5 X5\@A!.#3M
M775$QM1HJ543K/0$M:+F+:N.H=E-0HXP&IAH[.&Q*EEX H#>Q0N//7>T,H8G
M#-LL:'CJTI[)J_7!9?EQ4=Q+W3R;+U\*78Q">1^!1U(.B=0MJ2+U$\.8P "C
MQ$O#B/A$]CC$.B9OHH=7[VGYJ#,0*ITM$U./(6OF=)P%U$@IJ(V*55SLEI(.
M<TY/P. VT?28L'&S2T^8O)=2>NKZ?LRPX2Q6#09TG:BF;+0DS,>(8"A9@B#2
MS:PQIR$D,2<^(@FB=K6ZCXN:FANPZ4%7J@*M:\_RW!T(FW&$&]P&9HF^D%E3
MQ6DTG))%A[A1Z>*TV;N$87!'[WYL;1ASL\"6@@68^@DD5!"(9!! G 0A1"E*
MN4B(CSF>?9,%6UBT7=N68?.J;TH:T&G8"+:W[JFV Z#A#L4YH S\_6^E'@RP
MZW#,=-<]SG:DC-W([+"1![J5';FP1T[9=D?L3XM\^:A7'?ERY@>^3 3Q82!B
M]5E["8$LI!*B)(@"(804'C7[K+L%3>_;;I0#G1G\-E!V?^#NX!GX*]_I;W\!
M6J#N70%ED:OE!+"1,K/Z 6>7A'42C\Z4J^-WCY=@==*"K72JTU?W\V]6S[W.
M^>))WBS*<A92G1X0QS A0JV%!&40,Q*J"<1C(A!^D.+8I@;, 1E6BZ 1\F:U
M3G4UPD99Z_2 0T":>3IGPC,:"];J@1^T@L?S@ZV]G0[SG?H[A^2,ZO%T&+KK
M\W1=>N9W7O%'6S'FM:U/E.*$Q#H7* U$HKP?CT(:)QCZ88"D1$$<HLAF^Z-;
MW-2V0+X\+HIE'= _KZ+3YZW"/3G@,,B6=' V=&/[1RM=!R@(98;*,(1Q6.3;
M<$>G^4=II/NN'NNH=R]EELNR5(LSEN75?+E5E+0J19I*)4?407+7N?J\9+EL
MTL!I7H>\LKF\RI?J[YLYXG>RN.3JKD+*ZM>SF(G8(UQ RI17@D(_T&NS"'HD
M8FG "!(I-JXN-:KJTV.ZKLH@RP58/DI0ROE<?]95*9#'Q5PA4_:L#3+N>V*P
M\)SLZ ],UJW=8,/PW2+1&[9?@"9V>&5^6UM#1P6V"*BK*@QVRF_<Z8JM#0[U
MGR;[QEBLP"?[YHRTJI_H&V2W;? F@]BY%3&N1N-M;[P)TEM;)F^C@:L$[&K#
MNYE\:_7N%_/YQT6A^US/.([#E! $F9?Z$*%(0NPC!H4O>9(P'GFQ4;A:3_E3
M<VN.I!5OVO#_MGSTJ[8#-(98'F_;#I/9BF] \ ?V*@; W4&*MQ%Z V=\=^OP
MQ@G@1@"=S@<W>TS_&-V/6<GI_+\D+3ZJWY0SPD/.([7XXU0JTL,R@92'$611
MX,N4"FI8LJM#QM2(;16$6NL)M**@TM0^2'<7SFYR<@32P 34 Y]>4;I'$#@[
M2G?WN:-'Z1XQ[%"4[K%+>[;/TE[3.UUI2/EGNJ!$O01C)(P8C2D,U+<.$0TQ
MQ![WH)<*/PI$Q(+$RK$Y+&9JG_EFW26^H:=E-ZS#D)HY(><#-?"G?K(VU6?U
MUNO89N=%9+JA<=O$ZK"H<;M5=9J[UY:J^^I^Y+ 5]%N5#)WK\/A+OLR^57T.
M#E631+&7>E(Y!7% N6[YF4(BXP3JL^S40Y*EE-M01Q\EID8L]U=?OM[_\O[K
M+_?7GW\&EY\_@/NKF\NO5Q_ Y?NOUW^]_GIM6^FSU]"84=#0@ ],4%OJ5[M<
MC0%@;<'P)3[/ =$IE?529%2B.P>J71H\ZUE]*V@=K"K31-GZ+! ,AQZ,4XH@
M"ED,J<]2';",&$YCSX^MV+!3VM1H;Z<<$UR78[*MA]4%L1FK.0-N8/HZCMD
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M_[ON1+E\I,KCV+JI7Q$PVW$S/$<;;C3>RGUW.!#V)W#]X'1[)F>IP[BG=/T
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MI7KXX.80BW PZ#G(Q$Y/+4W!DZ*1_1!/?RSJ6).0.&>$1D"0+ 2(X SD*:$
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M0, K+NR4#?ME,E-!O(+O6?YHW"OB@[]H\O\:K!G0Z+?UEIJ'BR8CW)W2TAM
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M-C8AVA!;WL1L)7;;-N+N MA,&#J#S;.PVT*LG;M[ZCIRCT[9!H@X;H;=->/
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M8/8QW#<\#HKAK<*. >Q$&1?3R><Z'Z5*'[^>\\]JB@E)TB1,) :8YXENR4Z
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M/\B3;PK+<<>\\0@]M-[_F,[>MKM(7RV^KGB]9R).\HC&2F"%1.HT]EQWO*$
M<Q@EJ<0IQ$;-$D]/-39YI8G=:84>7"W^=A$HBO]FH6%UXVN@O3I#S;,,Z@2L
MCW>N&SD+5=09@@-IGOT^/3O]T@B33G6R>X3AM$<C3K:41;,W[*NG/BV)+B7P
M^/Y"%[,)2G"8(<P!QV$($ YC0"(6 IQ$49I*QF)(3:NF;HT\-DE9$Q=4U)G7
M2-V&JUL2G@6"9\%GR+]5)=2#O/:N@+H]VF"53P\RT:YX>OB!?D;9;M&\S6WJ
M6'*6I!QDNC03XED,L+*Z ,]9CD2.2<:MKB@<FVALV_)00<J>K7*.8FMF4KE
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M0=5:,%FAY%0VF<T\J'BR F-70MF]W"//ON[^^R#8XGD^U6Z3;].94*;(7$G
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MV+:!W7II1-NE(LQ/2]>#/+MMW;H]Q; M6@^RM]>*]?!3;LMGP:9.$$QPS(4
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M!VG.Q:4_'S"M>/0, RO-,0('=*]=<95L2MJ;H$5RV]^;/7KE:N6%#9]T;B[
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M8K82=C-'1@,OJ Q9,*)81(AK+Q;-IC++Z-PK8:6HX\ LWM^"O]OA<=!:XFP
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M %0MFUGF[=VS-!T88#YI]/4U1$FDY1SW@:!)8C9S54YJ?)W.)>_3UEK=Y8Z
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M]9$'?HRDVY,,SG[ :IC!R*'Q-89BK&RY)5+Y3 (RD8 -3-%(M8_=:E^ZOW/
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M!6?W==A_HI8HP5;#H$L*E>2K3\6* &XK1[C]=M4_OUD_<-N:0+:TVMQ=*><
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M8&3;$V]:F!D7,+?4&5.^E%P]02O*U &2*TTX%4!9_1*1;#1KMCEOWWL/"34
MZTH%MRC'GQK1ZH3_O>%BS^3^#[E+",(<T?+EA!@RSN1H1'E/E,V?3$%7UMW%
M(EMYOVY=UJLZH-X48,U(^(N?D(*)CM4S[;.HR](TS#2FWGX[0H.0:\W2FP1R
MBE<@0JC!KBV M6YJ-!J.]02@;4K?*JB2&YV28AU+K!N%54?'6)\XQDU!\"PY
M%[%+C(&!5<L,W\]I-CC/KH40>M<+-A)AQ+Q"*D3 FQX,>.3=A.GE_H!#4&)!
M'NX!Y6I/4PW_6\<7:Y8@7,F$)-+QPE$IJYM9"'*%683E_0()M$@!HEN)I8]
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M; K%8%ULIR\P1I5&"\Y^8&\@/L+D_YC@"R(?G#>P*5+NX= 0Q1B)'%-9]^#
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M8&,36N?^)0S6DUA*5%COFP'"$NLM+W:-I8/8['B39 Y[K#HL0*-0WAD7"[R
MC;(55;B($K0:-I28+/:YYW;T34H6VJ*(=3.4R@JP3^4NB>X8=-;X&AMKMGVO
M@G@/SX)YB]MJ3;:5@G1+#$DK%9VBWE UZ6]4M#A-B?:<,F)5?S^Y JDI:9,[
M+BFWW"EYV]*_SK%9=6:"6A9&A8.R^576+)UQY=F,E_V;P?F-]ZY_<P,+N#%^
MTI:E+VJ]X-*1URA=WPD\#C%ZZ#:8J;?/@UI4Z-0->I-Y;(*H'3?4GLZPH1!&
M@MB,UC$B#"RJ!/2=.YLU@>G_G9)"AE=/BPU&[FB*<7)XSNT6SX#SJ@9I&L@;
M,")<G," QEB.$K_0!=%L325'N<:<7C;28>:NUX^B+WZX$YNFYL.%]E9O4E^1
M&GB/3U:QS@P9(L>WK+\<ID8G0'7Y= "1E@_^CY\KK9DV]K2T$+!0BS'HK(AB
MVRF\4*[%XH:L"RJN$YX7*#"CB?RH/P)2E^10KEMM$TA$%@0B2^3QQ:1=,P1,
M:\%R20UZJW*93QT_10:@#R&E\KD/XTE@DT/M.,:I!RX@2?C5)U&-)=MWT&HV
MM<*.M9T CI4K:;LQ:H"'!AC +ZSYD>-MIL)$Z:74Q>P;UJKN]M)[72JNFZ$_
M<!9*"X<*$C^G+-Q&B,(#V6.9_31V;42 %KM RT^$#1F%>'9#$6TP<VA?P?!J
M4BN0TD(+2Y"HL)^IVVI,%]!R'"EUI\F(\[B!7-$(,+@5(,!KKD!_J=!)<D(^
M#%O"V@QR@T^XPI1J7<^E[Y>,HD$.(TNLK_-/,1.QU$6@# HF1Q&%SN64_0S)
MJ.$\R!F>*9?J&9?%R*3B+'6:29@;L$F^O!B!LL+$K72028[#1_BF.HT#/K'X
M+$0XRI29*)R$6$,?Z!7FW]*[M'5Z?<N0OYKJSN(1QG 8M[FQS*=]>KQ;-BK"
M0$]JN NFRR/J#C.80V=W:F*F"2[/JDM5QUTF"-TRAWB!%F;(LMPG=V$A0NWR
M4VYI=]AB3SB5_1=-=]?%HT$_:74DU1<5X$L:J^N]2A!L52HDEJ<EQ)PISLAH
M9V"/RKIPBXI=I<F89V.W:?;W;K#,;:%";DD6@YZ:^;MTB3N'HB228T=VZ( H
M%U1SR,V@<>^E-PM'YX=9.X]42Q [V'8;-;YM:-,0SM-M:/.[A#:7\(\5[7IA
MY9ER0DOD@T92.T<.;PW$5(PY%Z4 WIZ5Y $Y1[ALTH)"<511<$@.]!CF@QC9
MY_5^ C6HD#[*G08--=*M6'6Y0DRB)-O41ZTUS S:";UF&N#>8)IBJ@G)-WY?
MO($&9H> 91AN0H%&G\@XL*(,UQ=(34D@'XPH[&<3>C6/"%2;RIPO89Z4NHR*
M3.AB*4N<D_1C'F>HN,U-R,D)UCAQMB<L7CH64\GE0+1_B[ZHN+5&A3-DE_:V
MR=>(U@Z^;8Q!SM+]M%9I\_J;"A)ECDU0(JG#S*7(+E=IL>\^(20\XG2B/*6F
M,AIOU)R'Y&I9>E;HV+ K5J(@7->/2:CCNSS;VGMOL+;0/@L=LQ,QL0:>0H=!
MZ.HF0^J6DRWI@W/</0#-Q\KY*"F\.:PU# TOHCUV,5]A#3A1''"\*2W.V?TJ
M+AV:V,T^2F661=+D*I!T)X)G7C4%;I&A[]%P4;+3YT(%L@2^B)-XCZ$,-.C'
M/!AS%?HF,+6-KP862L>]L34LHIHZTI!VT91ZH\N_SDSV(&8)&OYG5D45P4Y,
M/:'AS74.2W.4O&)7\0PB!+2>UU5*WQKE.#K#Z71QNI! *4,T&PIO/ML9-*B;
M;6;(P10[%CJU3=.;O1_^P(UR)@5W3G7A/$H9TO;&1%]+E5?T<TSG)JK$HJV:
MC>4?09OX!UL; [ONUEO.1F(MWP_VLS )3<<'.O'U1,4EG 3HN1BAP APP"TJ
M$*J56XEP2!:YG*@BE_Q)HK/NZ%S/L,QSK),?3?A,:RIP*6H3.UIVZ7GO&OPI
M,3!SU$JG<5,<;:U+-"+!\$XH;$S8JH9?6+)S:4IXP)T&J/(WL>["G[TD.9;P
M>O![J(CJ,9U542"XELZC(\*Z++W16:>\1%XDYE_?%G!%8)BS5:-A?KL ?G&.
ME;S[;[>8F+_V2/_FEN[MZ]*]2/Q7<ARFNA[_BA%WM<QUHP&F:>*'I"X1W%^[
MV-SVK5I.P3$T/NFBZP"('^T+=CL@*WIOTF@YGAY7.YI0*GO-8PV3R:<<D&*'
MG]LC ZLJ)\!ZFK"OZ'DN6ZPHU21F<:2D-]NN!&75%17XX4?M(RC/TLD 3Y0M
MR&Q6A>W)&O^\E17L ,>+;1J[QTH'![@,DH 364 L,RZW8_5/5D62/-M+1GNS
MQ,=ZRGRSLVM%:XGF"9/NDJX? UTY!P6.^>[LO']S=G'N7;SV;MX,O/YO5X,!
M\M0M)_UK..F-TS&D#(;=6#.IW;'(6@,C8"UW81+IND.+)9W$ZJV*T&HA/RIZ
M2Q%;77@Y SD2"%G:08?NP?[+<_O+*?]"W_=>[M9\R?5I^KE)8M"#ZG26-/R$
MWN0GQINLS;;:HRK%#S7H!T:G<1-F\1:+;D7DLIHD^NE)+#WM^\7Z$3%.I7=0
M>+:5 Y7 H(4_J7DBEW4<LA[4:J8E.DI#G963@B2$RRI+7U]OY_@M77/A-5Y/
MLE2R[ZT I3:F>(H<3BK<Y),_J'@QG8\I1R/TK=\5B2@DNK?A.,,RGFW#<3]@
M.(X/;;=TYHJ4:9WN57#$6I,YD\>&G(:RAI.Y#(PWB_I#5GJ*%?$_RN2:SD2H
M30:=,L;-RDJQH@UV9[80//& 3H!+Q<:0Q#$:"V6IT"D'/:@4$H%LJ]W;/0M:
MA$^82:[R68:UNZAF$6;]Q?P)_>\=_KH\, 9$@H]@ VGX=#G $J9V5'?,K#0D
MASR7S!"AF7:.RIM%4I"])=);+LR6J+&(P_]HB"-PIP")SLAN^*R4<$(Z>)YL
M$3N6^/@,M(M=F/"RM: )$SS:3KR2!2$,7EJQ3A"1$\$!@$5L0"8VX@):&:.L
MBA>O/H/;A=YJG+0V^>& E<K7#64L1R&GU%+9 6P*V#@4 F_"+#<;3XOL>,?-
M@%$(FE$@S-K/0VKSM)?/W,G: +Y=U439$5Q69%S9B9HEY*W'C#VJ6<W:3X.2
M41 ^O8--Q2MUVB2SN4S_F^/W;AG M&+::1>SW!IV*T.X5SN<.JVB34-I+LN,
MJ)][A0D=,5'%[%3MC5(LN>M=8S!4_Z0!JQF.W0#OH0D08S!$1(&R,KAC8PFI
MA9I'/UZ4&#1+PP)S\;1[ /3_&?V4;-Y"/X7M+:KC&!VST;"V^3\E&8$2._5#
M0EK8$C6,ZBRC&!)E@*2NQE ,:O1A=W3C2[;&Z3)%7- %)KH*JQ]K-4$Q$J0,
MK1(J3)&6'_R:FR.>6A:6O<[574AAF]C=V=5&;;!-<X%[=/J"4V]*1+I$%IN2
MT@O()MVI3%<;7B^Q?6)7;Y1WY.W<VW%Y]QN;K+1]9UHHQUR)!=MS&J;&'=C<
M] *^?P-G;]-WJGW0SV*CGG4/O)TS6*-I#'8<NPXV?3]:"*4S3.VYM_/^>H !
MTO/^NP$SM)NK_NG@7?_J?S:>I<DV;4SEH/3VX:1PZJ^W<RU])?W%[I_0*ZKM
M>S)JSYX<=?</:YMR[.V\+@**EQQ7W=T<Q?ZH78K]0V7Z:C7]]^2DO$]M=\!2
M& \.Z+6DJ5HQ4_(N3/+4M#M(.&LV+!H@U!I^ZMBTT/T+<"0W3DV>U5JL6KN>
MZS%:SL5T7L#VF]7 *VG[+].EM>DXMGB'O+UN1R/RG3L=CPHX?@'?NA>)6J"M
MACFW>XC"*577U7<J;"RCM)>\H?E(41Z8^RO>$_A?/ZC5RK%6L/7OSFX&I]Z'
M_M55__SF7Z1'G)V#&G%^]OKLA%%8F\(A6P:Z>JM/P@>*=V6+Y2[Y'PYJ\7P+
MM5@EU*(U.F7[G$IN[0X^M[J@;YA15JQ&;(_RJ  #$#2,A966K+J>K]-.I=]0
MF1^;*=D.#'!K:LN%N>7*2J7#DGG,4/!ROI,S:PQ=ZX)X6@2?Q1C?M^6&W+>A
M F/<>! K2X<$- LS[FA!C:RL.J%GY+RNQ<:E!A0WPK:"5"0DHOX6HR(,A@NF
M*SASA,*I+[&-,7U/#\/-<E C$*15+S6(L7_MG5UKT")MK:GL8C6*B]?>N\'5
MR1OXT']U]E9'@MR?7Y_=G ^NK[W7%U=P#BY)07K_MG_E7;Z_NKRX'IB<"09J
MZF.WP$0]3, C]$*(W>>P"W )OGDK,?V]2-0K<!%ZC$))KNK%G>*;=]P-6N,C
M\K2ATMP\-' MG7CKS+>HSZT_4V4R3C/FX-0&TW?[/)IG&!?78"@V9]R&EY)B
MH;9:*[4DH:J (NHPAH4SC*A>TK]S+A=HL\4KO3SD)ZG\L$A677*JRH15X<AU
MNH3+*Z2YP?330@_L>8+VNRY,VX" XF3C-*,XNDB_,>S7]K8;+6S4)0KV3N"$
M$O.O5#.P]5BIOT;(MZ1^,I-&#RDQ^F]TJ[=],UO8^.K>S30]5?A %KG2'<Z4
M-B)WCCQ8.^[(W^: 2"LLN7ZHN=]OT5,-55CB[M7*(T8G9R^8UEU#N>DTT\*^
M.R*NX.^'IC^:4_U95SLAH"^Z/4UQN]+>+2WEI&M$"$<AICJT3O$;'0/:\.T_
M:M_V8R5GR2WQ@-N396#*Z6)9W]E,1F76X#("9#*LTQ=,PCG9+IRM:*Y=*3J4
M8A8<M7FLL1.$NX^%"B+=[W@^D7J8))6%6:^ 7R7HTF?#(<V'B0HT!#3YH432
M<?OHJ\9>1KF*PY33[6_C9+XW2>9D#99YPU=W'VC#]JP)VKT"4-FBW%>&<@_U
M3BRP/QK5-U-3XGI4I%*.9*FR.8<>N7T=%JN1P+63A;15&:@?";,Z"FEB5Q7*
ME=$N1% *A:*JM* 11D5XT5K2!0"#LVGP:V> +VYMHD<*E9FJ*E0(2O;1M23(
MIPEO04I&QXN2-,678H]!A\M*F)ZJ>(^N$U7S): [0H.6T;M&Q<U<[T+A6S;>
MLJ(+;->[P=_#\MDH%QGMV  M^4!,C+9C,HTH5FQQXAOL<6BA1[;6; B[Z!#I
MN"33L1M*#3U(I^4BKZC(ENOZV^I/\T3=-J/@J:CH$$,%'>Z9$5(JB%]IG$)/
MX_8;W+'AWSG"N1E'GX R3 []5$:C/7OI!E-/^_R=M6157;;';:%L*NEJEX?M
MI%DJ4F>X6[GQDBG90+HL5K.L-/J+ W*Q8$/*6VG2)^^H"Z4#&&%08ZVP#]%=
M:4#$;.GVEQX5J\646I&&J<E5),F2RM*KI"4*-\_:1MNM%K>_#;?_5>'VE<.,
MSO[?JD%&]^"4-\8,^D[0H@>P_9X;HS#U'YL<F^PF28LD.>33&(1"<&)P)X%/
MIMQSBQ3),.-,>AO$G"9.9R&M97"1NBGB&Q2"'YV_L:JD,T @,1G>8BY+C4W0
M<09SV2G @X1F8)<=*$'#(:(N;3 W#:?8_=7)C-=*/796'B=P_P:A?+^3O?U0
M0JM42P)^&R=SL+_&4E?KQ7J$MI]-8P$EZO%E.\\P> 1(T"0Z'&A@3.&495.E
M2:\Q;>OXX5BJ.Z: [1)X:L/(VJ_+Y>Y=S:-<EQ%K3Q1U$=<*=KIR<?#N[/ID
M\/9M_WQP\?[:N[RZ^/WL^NSB?"L+_B*7V$FBN TM-0Y9+=P>\]=- 3IE(=[V
M9'%A4RQ71W[5DE!H-%)M6"[ +VB HHX^UVF)%GI ,I4-?GZ;C/N=S5"W%@S5
M'HRPW@ZU+-%_LY*"74]1R -Y;.SNM-#%-,*<DIUCG6W"98>F@NL[P1;AGRSY
MG!+#^"5HATF:@2U&/18Z158'>05P4'@<@O1@_GP,L1/(G$N4)YR28EM5$IA/
MI"ALC7K(#ZT4-+$,HM:J[G,DDR4S6J85[?S9J%:K\6&,".>].H+]/20GNO!>
MA4G'.XO]AH5>D>?BZ*GW!FP,^,6[SD J--2K7,W,/H1Q',[DV'MWVO&N#F^\
MPS]ZWLY)_[Q_VM]MRR3[>*IT= 2H\)WJPBK*&9:0[7>]-SD*SW:3IG.B"FU]
M'<[4^QAE7AIR&;D_<H6^TY:0A<^]CCV88P9<7 D.GEW)4==[_\?>_B']OO_D
MZ$M$](K6^=J?2! R_X&UAA<!.>0=]/AU3M[L/=O??V+6?N?ZP]G-'X,K,$Q.
M&P[HFMHB+0O/ZW3X;5C^.RRX5KQ-HL:)T]\>VTTG:NH6G%ZI6:C;.$@1ZQ /
M>_/<ZIZE8+XI)::]CNBL8?/0^'](:\2L:K8=2ZIBD"O3[VE9$76.9*%I8L=S
MHF1.YUIU6V3"N O<-1DQ&TOH+;1A,''IRG;SM(VP&0L!^[GL!/"&;G'ZWWN_
M<NVG7;HOIB0MP1UFN3*%%W1/!+> W](2!!L.CVPA8C\5(SG.A0J6;ZR!$FCV
MJDNR$'M."VQ*BBUQ XD[2062J1=GZE&O4(8^Z8M-;]A 9(+K.:<AO*U0V# )
M!M]P&F@A K\4BUE*!L6>[YB>BPDW2W30?V.&7G/*71YEE'$]GR0$DAYB;)_O
MXHX;47@K2\5-1Q3G-(\'<VO79JCJ=I+D=3(>IAE64DE36PE&>J?\&E:D=+QR
MA\BL0>H4 :FAI!(QDI)+",B7ISH7(2@&=F*6RQ<+'O89&?7C 5=Z+;&8-Q"X
M4CK8O6?[A@=JAK>W2HX7MH?C'76?/,>%  ;D@_D2R"GE?F*8PW%<8T=C%0";
MH80A6S(*@^4QLZ]OE%%MVZ 6[5"ORRL18BT CCR8JM*Z,\8H1RW! %V\ L+@
MI/AD$X)!HME)TBC18D(##WG[OB5HU;H=;,\6]I[I>GX(<J?:*M%"8Y/9TL=>
M\"A;TR17OF2D^TS2*E*/L8H(_P;\<=MVZ:Y-FZ0Y85H-Z)>\,DZG3Y&#(@8<
M<E%F?BMX$]K0 )DT*5LOR*S$JQ[]:G*X5ND@:_/Z3)(YZ+=JE<NCJRE5M?")
MFYW+S2RHM(<([BAAH>B$2"E!4^08>'?9*JTR#UWD!O3[$MCL/B/'0;D5'6H%
M&R[DF;('P4OB:).3:]J7'H%.0[?;L::&*BU5VU/>[TLDO&H8Y[J,C*GTJ>G+
M8BT64H#M2Y*KVCV@:,'XIU2X;%U<JF5=*/K4FLLDMZVV(JU3G018A,V(P>ZD
MGB!GF/$[A#97G9.U"BIN!,LA0%?[)*CE.";)<[$X[DS&\EJXE==*OA+NBV),
M&JJ 5.!V'1@.?D8 =X>9F[D0'\WZ0!Y;;LQ/F,@HZ&)_4_R 3=<"$Z&Q$.YZ
M?SSA3:4:8S,R?$(2.6W/C/NOW&K.P9E?%H>:>L51%W+G%9K[YME*NI_K$(=Q
M9JX7(/2C3+^WHHU=F.F"%)19"1/@H%.U%PU7ZTN7M'0=RM+>6=.&MZ1P@R%]
M%$U^S"Q]U-)PI9&/X4L[57U=R)7-&#5%A.G.U';XXWTH1]DN6=&^L9YY*ON7
MP,XZ?+;YC8;<M$YWMXHQ]J9E<:5E'A$E,LT,O6LP,Y2MB=)E$6E=+$._9(3W
MYG#0EI7[/D^\#P(A+:OEGC"-.4T#38T2?EA' KG-,_E?=>=IDRD(=HFIMR$*
MHI34K!&##,O+?6GPL3"/YJI2.@=;EXE#FF183<&>:G/9'.H\;A=UU@O_=U=H
M3E$1PHIH,;W.B_ FV2A!+I>G9X<CBGMH9U9A6J#26:)]3.S"03+LHA[)L4[:
M<B)Q!>/&+WT_R>.,Y7@RTDWE6060=QH5[$8ZX R0"-&%%UQ;"\A5Q7)AFPI2
M"V3*,&-)0,WCL0@"O5'Q#F!<#7.5TLMN$-=^TJYS\1LY8W [WXJYKJ_15\,P
M4VWHPO;F[-KK_W8U&&";+N_Z3?_M6^_5P#L[OQE<75X-L&X]II.>7)Q?WUR]
M'V#A>J]_@@V^^N<G ^_#V<T;&&3@O>U_N,8,5 ?A5X[A@>V681@2]!-?KT>U
M)F"UVEM1%ZHX ^S:8C<7WL^V'!RV"!;7*"(?<Q6F0<C'+TS3G"!%J%7Q<.M'
MZTNPQ>PAF>49U3L)1V!N8 *2B>5F*B$ +&:-E@N;L.I=KU91Z2R1I51@0 %/
MRG1Y+X=S<H9!85$;4!=E*2HLFS*4V5QJOJ:UP\I,.EQR,!*F%LI2'7P*&C(:
M,Z N$!-L&+OK =/W!2-8'&ZO[Y7Z7FX27K\=7]BI0@AO%;G/6UBM613'E_1M
ML"X8OH9<704D52S$XBK'1H8PBQ.@_#"*PL)<<-A 4986%M02]<E$3(=2\=U3
ML %@X)U+7,&.]YKJ?.QZ.WB;QL>=G9QH5-PNVP7N3&<BEI%;0'5JBS5F$ZH:
MKB].L#H0(ONHX 3Z_&U+$AE)/ZO6.W_ Q=;$-AFI; #?>P]=-L?T3_LU;/"(
M.J1[A?@M5XR[N"J>A11 :B+?3DW9[2MRM1_[PJ9ES#;P;P7IP3;P_U<%_NLB
M946;/$IRE2$;W.D=E1+3E'7.%BY\'UD0\!PKGUWVI5!5-D?6/5AX"MU#J(^^
M<Q+UT5LZ%W;#B=DL 6'$DHE8Y<D),XY.$^M-L06W0M[;82\'Y\R!H<@M'NI<
MQ!52VA'BO&''3*#T0YV/N'$YVU>"RY\!^V6N#"9)+JLK:'D@)TMLBHYRXZRJ
M[N8[05@9+@D;)<95YJYU499"!' 20X)[4*IC[)).JFT>-GE@Y5%B=[T!FOR7
M)>-)* MA+$PA8SG9871SA9B2*=VQVQP=;$/TM-/2M6E/Y+1BVE^R"YSJV+(*
M72@]-:6MT^P#0'UFCB#@NH>!B5][U\647 W&FUN9A'4;%.>BP;E0.@UUW9+G
M4=:=N1I ]2@23Z2I4>,;D [91+>_&4Y#JKTGHY%AP"5+SC"*&;?WP/"=CS*#
MG!TZQ6P9GIU<06 0+0H'N^4B=@7X+<B[0OZ@HA5@Z0X*'DJ?"JRM'YM>YC9Y
MVBZWR6NJ@_A.?)1@Q*VXHH:;XE0+]^&A_.1C27P.,Y/7PG$O6H7 -/C1].=>
M0W@>)#DT(]$L2T,\?$#+>3R"PTB?T$^I?=Z^R 2(Q&0VD46YIZGXB/K,'5NW
MBP2]EUGJ'F;=L,H1KQT;?:1ZI,:,%ZKCJ3#).CHVE&(90+^H\8K.E@X&UOQ(
M<% >Z_K@.:5VE@%5!=*M+94<Z])16HK"Q,-;285:_5MX=.J4K,(M2G*$H T9
MODV^C:*P["@"IH'%7&%%J930#'$C]'@[!B4D"/*,""RC .SJ SI7:=5I>5*N
M8"*&Z'5@93).XCTGYV56XHQNV%?O(C,S+" [_<):FVWF <_:Q0/>2(%?I2OV
MD0)Y3/1,C"A)4:L &DNE[G& *BV<$ZDH"8'=;T!JH2G,I:3VS1'\2*NQ4O>S
MPA*>%LDGB/BTDP[/.PDA>BIF;^K,AK);;I-A+,_;19,#4,!@XQH6>C7654D>
MR>DP"<A^974'9TK:L 5\V%K<VAE+BA<6!)(!?G3:+9.YG\>F/'>GTA@F9>GD
MC(W\6!O3BCMX:8!#I^1L-8^N9AX;8 0'"G1GC\TAXZ( [*KIN'=,<"P@F( C
M?ZM&$P@S%0*Z  &[8)AE\0 *'!$:1SOEDS)YY3%5PJ?^X$YB.1$\@WFP4Y6$
MX48$6A(4'?IBY'JK2:XU5?*8Y*Y):+8! %C"!I@.5X6!;(MGWU?;-41=,#)2
M.XR)($&UCBCXWV'V*&.JYT[:-SHIL0XL(UPU<D_?1] P?:N.ACHW,Z2LR'C4
M*H'3_[*AWG<1QN.8R^?;Z!D/[@/>Q7G@1""F@.! DC&+Q9*%V9]>AF1%;LQM
M8*A@+(?;P-!WR0B]_P0T/&'IV"W/63@[1R )]2?^\&9P-;AXW>'XS#*@-IGO
M\A.UF=.\C90(&6C_)>BD^(N+98B](.=N,^@S"<?HHL0ZQPL#\W;J*6+[G!S-
M-$X:^0]%R;EO#JH-O2/OPL^2(0*C#_9[QXVU^C)&')CCKD!31K**Q"R5+\P?
M+]'%$8G%BS"F9:&;7I8W#V3G2RH5[HM([Q_M&_]<T%]WGVDP [+( O-D_7.7
M?GJ<!?7?CKI/CGI+?]WO?NUOQ\^??M6=]\[UN'OT=/G/7SO97O?X^.A/'_6@
M>]Q;FX6%80\?MK"/B<"8R(".TYF(__'H\)&YP5!TG&  Q@[WPU[9N%S/[2V:
MX[\XF'WR>F4NC4*@=O*3V:JJ*5I>;)G=\H4P;[7OD=.D)9?JK:AH;CVNG/B5
MCWRRBDL_<P37AJ9.01A3P96_AJ0:WI\UY_:L@-8C0*5@56+=S];:D^2KQ5]
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M+. _DVP:_?J_4$L! A0#%     @ 4T"I5#9];]5E"   Y"T  !L
M     ( !     '-E<VXM,#,S,3(P,C)X,3!Q97@S,3$Q+FAT;5!+ 0(4 Q0
M   ( %- J50I1FJ:/@@  ( M   ;              "  9X(  !S97-N+3 S
M,S$R,#(R>#$P<65X,S$R,2YH=&U02P$"% ,4    " !30*E4GI7AO04%  !;
M&   &P              @ $5$0  <V5S;BTP,S,Q,C R,G@Q,'%E>#,R,3$N
M:'1M4$L! A0#%     @ 4T"I5,5+)(+B!   0A@  !L              ( !
M4Q8  '-E<VXM,#,S,3(P,C)X,3!Q97@S,C(Q+FAT;5!+ 0(4 Q0    ( %-
MJ53_'@#EO.<! .OM$  1              "  6X;  !S97-N+3(P,C(P,S,Q
M+FAT;5!+ 0(4 Q0    ( %- J53;<4,::A0   W-   1              "
M 5D# @!S97-N+3(P,C(P,S,Q+GAS9%!+ 0(4 Q0    ( %- J50&!SV_2Q(
M #RD   5              "  ?(7 @!S97-N+3(P,C(P,S,Q7V-A;"YX;6Q0
M2P$"% ,4    " !30*E4._:K9PA8  "*M , %0              @ %P*@(
M<V5S;BTR,#(R,#,S,5]D968N>&UL4$L! A0#%     @ 4T"I5%SMX=I2U@
M#0P) !4              ( !JX(" '-E<VXM,C R,C S,S%?;&%B+GAM;%!+
M 0(4 Q0    ( %- J50UU!!5S((  *[6!0 5              "  3!9 P!S
M97-N+3(P,C(P,S,Q7W!R92YX;6Q02P$"% ,4    " !30*E44S4,I* [  !5
MT $ '@              @ $OW , <V5S;BUE>#$P,7AZ=7)I8VAL:6-E;G-E
<86<N:'1M4$L%!@     +  L ^@(   L8!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
